{"docstore/data": {"2553057e-9a75-4883-a326-74d477110ea3": {"__data__": {"id_": "2553057e-9a75-4883-a326-74d477110ea3", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n ", "original_text": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d177c2c-1f0b-4001-89b8-425faa236d85", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.  ", "original_text": "Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.  "}, "hash": "2179d5db322bb6e06987effec48a94f70e73b31e434f0bd74323f88ee424d877", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d177c2c-1f0b-4001-89b8-425faa236d85": {"__data__": {"id_": "3d177c2c-1f0b-4001-89b8-425faa236d85", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.  ", "original_text": "Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2553057e-9a75-4883-a326-74d477110ea3", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n ", "original_text": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "207d60e4a1256a8492d8c05256c1a781f19960698aab2dfc5843adc45096b7de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f13c8f6-b8d5-4c7f-bddd-d8388ca24d60", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n ", "original_text": "This is Kevin Moran, Vice President of Investor Relations. "}, "hash": "9ae8ac5f3fe5127fe5a3cf90026cfa7787cda20aa4365d559bbd8651947f41d5", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.  ", "start_char_idx": 48, "end_char_idx": 144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f13c8f6-b8d5-4c7f-bddd-d8388ca24d60": {"__data__": {"id_": "2f13c8f6-b8d5-4c7f-bddd-d8388ca24d60", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n ", "original_text": "This is Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d177c2c-1f0b-4001-89b8-425faa236d85", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.  ", "original_text": "Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4058dd6b44c9c90aaca844dcf442444a69d2f59e7c3991e4edb2f4e3bd2161c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb8cc38c-12a3-4cd5-be6d-9791abf746fc", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.  ", "original_text": "Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n "}, "hash": "dc4cd7c28f2405c8ce8b9d3d9cc1e9d9ca08c70ff508f7342e1ccbd1d8a61687", "class_name": "RelatedNodeInfo"}}, "text": "This is Kevin Moran, Vice President of Investor Relations. ", "start_char_idx": 144, "end_char_idx": 203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb8cc38c-12a3-4cd5-be6d-9791abf746fc": {"__data__": {"id_": "cb8cc38c-12a3-4cd5-be6d-9791abf746fc", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.  ", "original_text": "Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f13c8f6-b8d5-4c7f-bddd-d8388ca24d60", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n ", "original_text": "This is Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a294ee47c4dbd51d6af0a40432bf8cfc56e2debc3e0b2e074e7d7c87fd873ad9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dc59d3a-6986-4cf2-bb92-90ad4e22ad05", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n ", "original_text": "You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.  "}, "hash": "cbad19768a0fea692e73565ed9a94a402313fe461aa8640679cd38910c8f3b88", "class_name": "RelatedNodeInfo"}}, "text": "Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n ", "start_char_idx": 203, "end_char_idx": 320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dc59d3a-6986-4cf2-bb92-90ad4e22ad05": {"__data__": {"id_": "2dc59d3a-6986-4cf2-bb92-90ad4e22ad05", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n ", "original_text": "You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb8cc38c-12a3-4cd5-be6d-9791abf746fc", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.  ", "original_text": "Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "431ee8ca81a8b252db531c496f1a099f8ebaeca011fb665901f71a694b25ab84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "332e3b3d-6b6b-4c16-a6d0-9d162aa8bdd0", "node_type": "1", "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "original_text": "Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n "}, "hash": "e22029673bea048de896eb5f00ee9d8506e153c823dcd44c4cf674e5235898a0", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.  ", "start_char_idx": 320, "end_char_idx": 433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "332e3b3d-6b6b-4c16-a6d0-9d162aa8bdd0": {"__data__": {"id_": "332e3b3d-6b6b-4c16-a6d0-9d162aa8bdd0", "embedding": null, "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "original_text": "Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dc59d3a-6986-4cf2-bb92-90ad4e22ad05", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n ", "original_text": "You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22ee7dbf0484be270c70d114e55ec1643bf1181e092a83f7a4d57c4136534a2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94128a65-ab91-42ef-9478-f16acd98a297", "node_type": "1", "metadata": {"window": "Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements.  "}, "hash": "3a96685b6e50c8e282846047af896978a0622c08cf3862c9f667691875c31aac", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n ", "start_char_idx": 433, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94128a65-ab91-42ef-9478-f16acd98a297": {"__data__": {"id_": "94128a65-ab91-42ef-9478-f16acd98a297", "embedding": null, "metadata": {"window": "Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "332e3b3d-6b6b-4c16-a6d0-9d162aa8bdd0", "node_type": "1", "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "original_text": "Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ca9dd92625a55b48333149e561590c9a7adc2d681faaef2ea1fc8d0cb78dc41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81d63427-dfe2-4b92-891c-a8476aa1fb8a", "node_type": "1", "metadata": {"window": "You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n ", "original_text": "The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n "}, "hash": "b29098a4a057a2a299613f913fa4bf9b7247d5a4962b7d0ab97f9daba7fea79b", "class_name": "RelatedNodeInfo"}}, "text": "During the call, we will be making forward -looking statements.  ", "start_char_idx": 542, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81d63427-dfe2-4b92-891c-a8476aa1fb8a": {"__data__": {"id_": "81d63427-dfe2-4b92-891c-a8476aa1fb8a", "embedding": null, "metadata": {"window": "You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n ", "original_text": "The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94128a65-ab91-42ef-9478-f16acd98a297", "node_type": "1", "metadata": {"window": "Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n  You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5930a104642c8ea7d23b65d3cc1fd9b3e0515c2dc2dd3b35c3839a2ba6df6460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f03a76e-2e72-467d-b8ce-bee41ab22fd2", "node_type": "1", "metadata": {"window": "Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n ", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n "}, "hash": "22e699e95e3f571df440c6e673f31a9e6774093f9b4138f0922f415710fe61b4", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n ", "start_char_idx": 607, "end_char_idx": 786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f03a76e-2e72-467d-b8ce-bee41ab22fd2": {"__data__": {"id_": "4f03a76e-2e72-467d-b8ce-bee41ab22fd2", "embedding": null, "metadata": {"window": "Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n ", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81d63427-dfe2-4b92-891c-a8476aa1fb8a", "node_type": "1", "metadata": {"window": "You can find today's press release and presentation on the IR section of our website at \nir.cardinalhealth.com.   Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n ", "original_text": "The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3eb199a9d905898382591c8a35268f2084a44b561546858cfa6f90d20de8f5c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20cbafa4-e967-4467-9f0c-908a90f98eeb", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. "}, "hash": "f565a83b04e58591b175daae09888d4a68fad2232063f894314437576e344712", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "start_char_idx": 786, "end_char_idx": 954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20cbafa4-e967-4467-9f0c-908a90f98eeb": {"__data__": {"id_": "20cbafa4-e967-4467-9f0c-908a90f98eeb", "embedding": null, "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f03a76e-2e72-467d-b8ce-bee41ab22fd2", "node_type": "1", "metadata": {"window": "Joining me today is Mike Kaufmann, Chief Executive Officer, and Jason Hollar, \nChief Financial Officer.  \n \n  During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n ", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3af61b2788e88c3b866d66815ef66d04707ac6c030c1164cd4cc9bc01b9360a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d3540b0-c9c1-4ad6-892f-68f78f54cf04", "node_type": "1", "metadata": {"window": "The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n "}, "hash": "d2c9428a322e117ca9802f4ec8c8a16663a70d70c09b5f81a9d96b05b9e0dc45", "class_name": "RelatedNodeInfo"}}, "text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "start_char_idx": 954, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d3540b0-c9c1-4ad6-892f-68f78f54cf04": {"__data__": {"id_": "3d3540b0-c9c1-4ad6-892f-68f78f54cf04", "embedding": null, "metadata": {"window": "The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20cbafa4-e967-4467-9f0c-908a90f98eeb", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ccfbfa6b89af552ec76034eb598abbac49f5f27e42e336e0d1acdb1221c8827", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dbf84d6-74ad-4feb-a47f-02332a62401f", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n "}, "hash": "c55e1e010b412774d1007b7435f1b03384e5355f0b22e9287dd3ab7042dd539f", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n ", "start_char_idx": 1092, "end_char_idx": 1220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dbf84d6-74ad-4feb-a47f-02332a62401f": {"__data__": {"id_": "3dbf84d6-74ad-4feb-a47f-02332a62401f", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d3540b0-c9c1-4ad6-892f-68f78f54cf04", "node_type": "1", "metadata": {"window": "The matters addressed in these  \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  \n \n  Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41285e36d8312c483fc3d818995df7eb3c2263e60b1f27c3b83bebd1c2ab612a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c97c48db-2936-44da-8d31-f829ef3e63b0", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n ", "original_text": "With that, I will now turn the call over to Mike.  \n \n"}, "hash": "ca843377eb076d370ac8ef2524935ded648ccf98b8ddb57400b5617cc4795b0f", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n ", "start_char_idx": 1220, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c97c48db-2936-44da-8d31-f829ef3e63b0": {"__data__": {"id_": "c97c48db-2936-44da-8d31-f829ef3e63b0", "embedding": null, "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n ", "original_text": "With that, I will now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dbf84d6-74ad-4feb-a47f-02332a62401f", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the beginning of our \npresentation for a description of these risks and uncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "987072885fc006d479cb5426b562e6f626cd2ffd23b08a7641b9303db27fc8e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b2f1848-4dfe-4e86-84dc-13784103c386", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.  "}, "hash": "d4fb5e77911e800521d12dba79f9feea37e747b4644a9a6adb93b3fa199642b2", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call over to Mike.  \n \n", "start_char_idx": 1381, "end_char_idx": 1435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b2f1848-4dfe-4e86-84dc-13784103c386": {"__data__": {"id_": "0b2f1848-4dfe-4e86-84dc-13784103c386", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c97c48db-2936-44da-8d31-f829ef3e63b0", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n ", "original_text": "With that, I will now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8d0a32515716a3841c911d4ede2a2bd3ea80fb8a82a84919590754f4e41d3d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0520f4a0-408d-4ca0-a732-1e0b1b2ed924", "node_type": "1", "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.  ", "original_text": "I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n"}, "hash": "826a4c1665f213b06a32ec4ef586c3a25ea7b885ff70e50094908c432b24798c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.  ", "start_char_idx": 1435, "end_char_idx": 1508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0520f4a0-408d-4ca0-a732-1e0b1b2ed924": {"__data__": {"id_": "0520f4a0-408d-4ca0-a732-1e0b1b2ed924", "embedding": null, "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.  ", "original_text": "I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b2f1848-4dfe-4e86-84dc-13784103c386", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant \nperiods can be found  in the schedule s attached to our press release.  \n \n  During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "834b9eb0eff6a233821cbc16234d0d954ea1d047663e197847b6bacb9f7f7350", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04d5bcf0-b6de-4469-b155-bfdd4b861b40", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.  ", "original_text": "I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n "}, "hash": "4df6d1afae8636c38c5313a55a65a8c5513b1ff0530766ab6cdf50906ea1dad5", "class_name": "RelatedNodeInfo"}}, "text": "I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n", "start_char_idx": 1508, "end_char_idx": 1641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04d5bcf0-b6de-4469-b155-bfdd4b861b40": {"__data__": {"id_": "04d5bcf0-b6de-4469-b155-bfdd4b861b40", "embedding": null, "metadata": {"window": "With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.  ", "original_text": "I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0520f4a0-408d-4ca0-a732-1e0b1b2ed924", "node_type": "1", "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion so that we can try and give everyone an opportunity.  \n \n  With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.  ", "original_text": "I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa9e1c845009581667db1de852655ff6842b62fb2acd2e5b23aa6bb3a52351f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13d355ca-64c0-4f55-8179-3bca87b26645", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n ", "original_text": "Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n "}, "hash": "a95335ef6e697b1094e32861b6464e8b2face41e47ecb38b3d5f80027510dbae", "class_name": "RelatedNodeInfo"}}, "text": "I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n ", "start_char_idx": 1641, "end_char_idx": 1748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13d355ca-64c0-4f55-8179-3bca87b26645": {"__data__": {"id_": "13d355ca-64c0-4f55-8179-3bca87b26645", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n ", "original_text": "Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04d5bcf0-b6de-4469-b155-bfdd4b861b40", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.  ", "original_text": "I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4baed72afc6b41150a9dd093efff3ffc8993b8b6c1bf2bca53267f2013108e45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "468fcdd1-16cd-4d6d-9c82-01e191f8aead", "node_type": "1", "metadata": {"window": "I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.  "}, "hash": "1c3e3a72bef85d86e756e9768fbad65e4c69764f4a66e58d25139de701d89bf7", "class_name": "RelatedNodeInfo"}}, "text": "Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n ", "start_char_idx": 1748, "end_char_idx": 1935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "468fcdd1-16cd-4d6d-9c82-01e191f8aead": {"__data__": {"id_": "468fcdd1-16cd-4d6d-9c82-01e191f8aead", "embedding": null, "metadata": {"window": "I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13d355ca-64c0-4f55-8179-3bca87b26645", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning to everyone joining us.   I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n ", "original_text": "Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbafd9b017f75fba399ec54cf1a317ba9797748fb8825ee1e0a51d1a5aceef9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d239d995-8b72-4d03-a34b-221645003780", "node_type": "1", "metadata": {"window": "I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.  "}, "hash": "69af05cb628e03e5afa8b27f55a56baa3479e683cae5f560ec55be637d036d39", "class_name": "RelatedNodeInfo"}}, "text": "Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.  ", "start_char_idx": 1935, "end_char_idx": 2052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d239d995-8b72-4d03-a34b-221645003780": {"__data__": {"id_": "d239d995-8b72-4d03-a34b-221645003780", "embedding": null, "metadata": {"window": "I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "468fcdd1-16cd-4d6d-9c82-01e191f8aead", "node_type": "1", "metadata": {"window": "I'll begin with a few high \nlevel thoughts on our first quarter then have Jason review our results and updated fiscal '21 outlook.  \n I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9e7b32c32d2c5d74913b3cb45c41d4145f78a0ed70d5aed1fddba9b8f01bf03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02555899-8709-4fc0-8e27-a904aef8bd82", "node_type": "1", "metadata": {"window": "Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "We saw significan t year -over-year \ngrowth.  \n \n "}, "hash": "cd02adec9529e52e0eb53a83062c745467a09d207b680e06fc7329e1894c78fe", "class_name": "RelatedNodeInfo"}}, "text": "These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.  ", "start_char_idx": 2052, "end_char_idx": 2192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02555899-8709-4fc0-8e27-a904aef8bd82": {"__data__": {"id_": "02555899-8709-4fc0-8e27-a904aef8bd82", "embedding": null, "metadata": {"window": "Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "We saw significan t year -over-year \ngrowth.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d239d995-8b72-4d03-a34b-221645003780", "node_type": "1", "metadata": {"window": "I'll close with an update on strategic action s we are taking to carry our positive momentum forward.  \n \n  Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.  ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bb1e196752a2b49d9410fad705927fc049dbfd029977bb06c21b47761fc240b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cdbc185-6356-4814-ad8c-abf3719216b8", "node_type": "1", "metadata": {"window": "Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n "}, "hash": "d3c647bf4c80c54b985ff45e895d93291207add89d93d10c0295f2f60647035e", "class_name": "RelatedNodeInfo"}}, "text": "We saw significan t year -over-year \ngrowth.  \n \n ", "start_char_idx": 2192, "end_char_idx": 2242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cdbc185-6356-4814-ad8c-abf3719216b8": {"__data__": {"id_": "1cdbc185-6356-4814-ad8c-abf3719216b8", "embedding": null, "metadata": {"window": "Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7129f0f1e011c7d734c67f7d13943d721e5dc26edbabed2fcfb73bbcfa8ffde6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02555899-8709-4fc0-8e27-a904aef8bd82", "node_type": "1", "metadata": {"window": "Our strong first quarter results were due to great execution on key strategic priorities and \nadditional aggressive cost controls in response to the uncertainties from the pandemic.  \n \n  Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "We saw significan t year -over-year \ngrowth.  \n \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ef059ea1f2494fc1c7358ea5a4eac18bea27f9f4ea8366e24f0bf795f9856f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4001bef-1faa-4490-8674-88dd49a058ee", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  ", "original_text": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.  "}, "hash": "25ceaffe492509459139b32963b08371785577c6b73405e259918b50dd4ba584", "class_name": "RelatedNodeInfo"}}, "text": "And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "start_char_idx": 2242, "end_char_idx": 2406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4001bef-1faa-4490-8674-88dd49a058ee": {"__data__": {"id_": "a4001bef-1faa-4490-8674-88dd49a058ee", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  ", "original_text": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cdbc185-6356-4814-ad8c-abf3719216b8", "node_type": "1", "metadata": {"window": "Regarding COVID -19, we saw continued utilization improvement in the quarter, particularly in \nelective procedures.   These dynamics, along with the disciplined execution I mentioned, contributed \nto better than expected performance in our medical segment.   We saw significan t year -over-year \ngrowth.  \n \n  And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "original_text": "And in pharma we continue to be encouraged by the resilience of our business, which grew in \nthe first quarter, despite volume softness related to the pandemic.  \n ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bc0e4d37bacc648d4ee8451181740aceec1d786fcc96f93ecc88f6c2bac8c54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bae68ad-40da-40c5-a50c-ff447fdf5b5d", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n ", "original_text": "Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n "}, "hash": "82386a4e84ef4fee0a45c9c66916556f2bedb338c3a1ed79a0b4847b87c18fe3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.  ", "start_char_idx": 0, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bae68ad-40da-40c5-a50c-ff447fdf5b5d": {"__data__": {"id_": "4bae68ad-40da-40c5-a50c-ff447fdf5b5d", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n ", "original_text": "Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4001bef-1faa-4490-8674-88dd49a058ee", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  ", "original_text": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f656743964f17f192c383fcb40b270127604b2cb2bb30f5cfd7afb746364be88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cea47fce-df81-44ba-85ad-27b3b85abebd", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n ", "original_text": "With that, I'll now turn it over to Jason.  \n \n"}, "hash": "1526870b5d4120db6f310d437897489fef8a0f024d88e8bd9bfd856f929192c5", "class_name": "RelatedNodeInfo"}}, "text": "Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n ", "start_char_idx": 199, "end_char_idx": 402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cea47fce-df81-44ba-85ad-27b3b85abebd": {"__data__": {"id_": "cea47fce-df81-44ba-85ad-27b3b85abebd", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n ", "original_text": "With that, I'll now turn it over to Jason.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bae68ad-40da-40c5-a50c-ff447fdf5b5d", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n ", "original_text": "Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86c229ba4e392433094c8a1ac92d7f4f2e69ca4497e72129ecd32992d372566e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5a7d44d-9e44-43d9-8146-82fee1816dba", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning everyone.  "}, "hash": "fa24932fc9b1adbb8f723268ac328902e7c11010f3ab3424f5f6cfebd30c5d35", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll now turn it over to Jason.  \n \n", "start_char_idx": 402, "end_char_idx": 449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5a7d44d-9e44-43d9-8146-82fee1816dba": {"__data__": {"id_": "f5a7d44d-9e44-43d9-8146-82fee1816dba", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning everyone.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cea47fce-df81-44ba-85ad-27b3b85abebd", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n ", "original_text": "With that, I'll now turn it over to Jason.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b9405e266262ed64c146b74b6708a0fabc37bfc467736c9b44806529ce69e0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc35820c-ce63-4d85-8e7f-e4ff0a423ffe", "node_type": "1", "metadata": {"window": "Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n ", "original_text": "I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n "}, "hash": "658424c7d4d950efd3e2ea2e0739908e8326549f0b7038ad8ad29ef49555be1d", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Mike, and good morning everyone.  ", "start_char_idx": 449, "end_char_idx": 506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc35820c-ce63-4d85-8e7f-e4ff0a423ffe": {"__data__": {"id_": "dc35820c-ce63-4d85-8e7f-e4ff0a423ffe", "embedding": null, "metadata": {"window": "Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n ", "original_text": "I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5a7d44d-9e44-43d9-8146-82fee1816dba", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.  ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning everyone.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e11eb725fc99dea2d7005ebe39f2aa29b295c826eb0e0718618ab6b8b99a77da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e44a36e-1297-4f96-8b6d-3e6f61d48c38", "node_type": "1", "metadata": {"window": "With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n ", "original_text": "Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n "}, "hash": "d14ecd5c2233728db29b104f835903242538543d2788c89a2b0d48f63eee67f0", "class_name": "RelatedNodeInfo"}}, "text": "I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n ", "start_char_idx": 506, "end_char_idx": 597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e44a36e-1297-4f96-8b6d-3e6f61d48c38": {"__data__": {"id_": "9e44a36e-1297-4f96-8b6d-3e6f61d48c38", "embedding": null, "metadata": {"window": "With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n ", "original_text": "Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc35820c-ce63-4d85-8e7f-e4ff0a423ffe", "node_type": "1", "metadata": {"window": "Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n ", "original_text": "I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f23b4b911d5446ae9b25b3f74b991275bbc84fd0fd25d285b0a9d9d5d2a61993", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f7b168e-b369-4849-97b5-7cebb47a324b", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n ", "original_text": "Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.  "}, "hash": "ffea2ee4aa8c289a3f5e08d171990c2f55a05a78a8daec2304d3b69ecf13dc3f", "class_name": "RelatedNodeInfo"}}, "text": "Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n ", "start_char_idx": 597, "end_char_idx": 754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f7b168e-b369-4849-97b5-7cebb47a324b": {"__data__": {"id_": "8f7b168e-b369-4849-97b5-7cebb47a324b", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n ", "original_text": "Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e44a36e-1297-4f96-8b6d-3e6f61d48c38", "node_type": "1", "metadata": {"window": "With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n ", "original_text": "Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd70ea17328345161b43bd03dc0ef1eeb1168add3cbc13cd85ee0c222b1a1bcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f052e21-65fa-435e-b8fc-448186084662", "node_type": "1", "metadata": {"window": "I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n ", "original_text": "Total gross margin grew 2% to $1.7 billion.  \n \n "}, "hash": "08ff96bdbfaabc94e3b9bcab1becb30da358c2ad7cc23882d6b9322defdfaab4", "class_name": "RelatedNodeInfo"}}, "text": "Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.  ", "start_char_idx": 754, "end_char_idx": 874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f052e21-65fa-435e-b8fc-448186084662": {"__data__": {"id_": "2f052e21-65fa-435e-b8fc-448186084662", "embedding": null, "metadata": {"window": "I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n ", "original_text": "Total gross margin grew 2% to $1.7 billion.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f7b168e-b369-4849-97b5-7cebb47a324b", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Mike, and good morning everyone.   I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n ", "original_text": "Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cef10485e31aebd0cd8b8e8a256c902889d28f8cb2c59b9d47f84e5d45fa44ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68f85312-726a-4673-9eb0-8ee2e5a2f79a", "node_type": "1", "metadata": {"window": "Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.  ", "original_text": "Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n "}, "hash": "910f35f0c472f5390d14a66b9345acaffe7eb1fd19c2b1937fa9547a6e03f914", "class_name": "RelatedNodeInfo"}}, "text": "Total gross margin grew 2% to $1.7 billion.  \n \n ", "start_char_idx": 874, "end_char_idx": 923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68f85312-726a-4673-9eb0-8ee2e5a2f79a": {"__data__": {"id_": "68f85312-726a-4673-9eb0-8ee2e5a2f79a", "embedding": null, "metadata": {"window": "Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.  ", "original_text": "Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f052e21-65fa-435e-b8fc-448186084662", "node_type": "1", "metadata": {"window": "I will review our first quarter performance \nand updated expectations for fiscal '21.  \n \n  Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n ", "original_text": "Total gross margin grew 2% to $1.7 billion.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f8892f66412148eaeeaf6c6d9fb62ed70a4b2cca91bcebbbfd087d38d7471e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "341294fd-3e6b-498a-bca7-0fafb433c230", "node_type": "1", "metadata": {"window": "Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n ", "original_text": "Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n "}, "hash": "4e944ea19d3ac783e6cd856a64fa1f7bf46867619eaaa6d8d992a8889760889f", "class_name": "RelatedNodeInfo"}}, "text": "Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n ", "start_char_idx": 923, "end_char_idx": 1065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "341294fd-3e6b-498a-bca7-0fafb433c230": {"__data__": {"id_": "341294fd-3e6b-498a-bca7-0fafb433c230", "embedding": null, "metadata": {"window": "Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n ", "original_text": "Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68f85312-726a-4673-9eb0-8ee2e5a2f79a", "node_type": "1", "metadata": {"window": "Beginnin g with consolidated company results, our first quarter EPS came in at $1.51 growing \n19% versus the prior year and exceeding our expectations.  \n \n  Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.  ", "original_text": "Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "807ef615b4894a915bd357d4d6fc7ca147c5cbf86c354782975f7872f014b4a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4faeab45-6e19-4a72-914e-dc0fb88a29db", "node_type": "1", "metadata": {"window": "Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n ", "original_text": "Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n "}, "hash": "0dd20336c70df208e71180a8c9d2729e02d740524bed463a66d597f2117607b6", "class_name": "RelatedNodeInfo"}}, "text": "Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n ", "start_char_idx": 1065, "end_char_idx": 1177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4faeab45-6e19-4a72-914e-dc0fb88a29db": {"__data__": {"id_": "4faeab45-6e19-4a72-914e-dc0fb88a29db", "embedding": null, "metadata": {"window": "Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n ", "original_text": "Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "341294fd-3e6b-498a-bca7-0fafb433c230", "node_type": "1", "metadata": {"window": "Total first quarter revenue increased 5% to $39.1 billion, driven primarily by sales growth from \nexisting custom ers.   Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n ", "original_text": "Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3305cf7ac612e19c21a25d1bcb63e66d58e5f7ca581a8065f0d52c3d31437427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f086f2e6-8f35-4133-96eb-ff626e854d5c", "node_type": "1", "metadata": {"window": "Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.  ", "original_text": "Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.  "}, "hash": "fa2552dbb65fd0a681e269d548c83f7ee14b7b8013a00f3e5419b78160d27748", "class_name": "RelatedNodeInfo"}}, "text": "Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n ", "start_char_idx": 1177, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f086f2e6-8f35-4133-96eb-ff626e854d5c": {"__data__": {"id_": "f086f2e6-8f35-4133-96eb-ff626e854d5c", "embedding": null, "metadata": {"window": "Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.  ", "original_text": "Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4faeab45-6e19-4a72-914e-dc0fb88a29db", "node_type": "1", "metadata": {"window": "Total gross margin grew 2% to $1.7 billion.  \n \n  Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n ", "original_text": "Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34166a0ce5e1b3158ad70eecd14587e93b646d60bde3fb8eab8006adea09e60d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be0914d9-88c9-4121-bb72-fc0ca44814fb", "node_type": "1", "metadata": {"window": "Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n ", "original_text": "Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n "}, "hash": "dc72cb9a9781efa58ac3d35b8fca92f43db7263c221302fef564ea0081d65e10", "class_name": "RelatedNodeInfo"}}, "text": "Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.  ", "start_char_idx": 1431, "end_char_idx": 1534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be0914d9-88c9-4121-bb72-fc0ca44814fb": {"__data__": {"id_": "be0914d9-88c9-4121-bb72-fc0ca44814fb", "embedding": null, "metadata": {"window": "Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n ", "original_text": "Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f086f2e6-8f35-4133-96eb-ff626e854d5c", "node_type": "1", "metadata": {"window": "Despite higher revenue, SG&A was flat at $1.1 billion, demonstrating our enterprise -wide \ncommitment to disciplined expense management.  \n \n  Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.  ", "original_text": "Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c03a4f7c2a0d4795e7e00b8aa152122b4ee1c9dd438742e5e5f7948e8ce7f07f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd18ae82-9dae-4137-86ab-f4bd0cb7753f", "node_type": "1", "metadata": {"window": "Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n ", "original_text": "Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n "}, "hash": "8cab164837f54b82ee81be404f2aef248c60a3c10fe01e4c092b318fc5bc22b4", "class_name": "RelatedNodeInfo"}}, "text": "Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n ", "start_char_idx": 1534, "end_char_idx": 1728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd18ae82-9dae-4137-86ab-f4bd0cb7753f": {"__data__": {"id_": "cd18ae82-9dae-4137-86ab-f4bd0cb7753f", "embedding": null, "metadata": {"window": "Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n ", "original_text": "Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be0914d9-88c9-4121-bb72-fc0ca44814fb", "node_type": "1", "metadata": {"window": "Total operating earnings grew 7% to $618 million, driven primarily by strong medical segment \nperformance.  \n \n  Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n ", "original_text": "Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "268461b880ad2ba74914cd30e136f8fe262b782df9aa6b5f107f7d1739efccd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81b5d8ce-4618-4ed6-82cf-46b5e92f96c2", "node_type": "1", "metadata": {"window": "Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n ", "original_text": "We generated operating cash f low of $270 million during the quarter.  "}, "hash": "df26bcb2455e4465a06c9920eaef32516502d490a312fd38785b9cbd659ede46", "class_name": "RelatedNodeInfo"}}, "text": "Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n ", "start_char_idx": 1728, "end_char_idx": 1885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81b5d8ce-4618-4ed6-82cf-46b5e92f96c2": {"__data__": {"id_": "81b5d8ce-4618-4ed6-82cf-46b5e92f96c2", "embedding": null, "metadata": {"window": "Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n ", "original_text": "We generated operating cash f low of $270 million during the quarter.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd18ae82-9dae-4137-86ab-f4bd0cb7753f", "node_type": "1", "metadata": {"window": "Interest and other expense decreased 52% versus the prior year to $38 million, driven by lower \ninterest expense as a result of our ongoing commitment to reduce debt as well as multiple other \nfavorable items, such as  FX and deferred compensation.  \n \n  Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n ", "original_text": "Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6a9311c0475e12816af6640d7a999f75252f6bf5a4ebee0632a0cae3c722aeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ea71a39-231a-4a1a-8451-e77579c3cffe", "node_type": "1", "metadata": {"window": "Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n "}, "hash": "ffee8235c788dd89d42133afd50342763e4d8ec2a2d9aabcacdccd1f53efa733", "class_name": "RelatedNodeInfo"}}, "text": "We generated operating cash f low of $270 million during the quarter.  ", "start_char_idx": 1885, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ea71a39-231a-4a1a-8451-e77579c3cffe": {"__data__": {"id_": "2ea71a39-231a-4a1a-8451-e77579c3cffe", "embedding": null, "metadata": {"window": "Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81b5d8ce-4618-4ed6-82cf-46b5e92f96c2", "node_type": "1", "metadata": {"window": "Our effective tax rate for the quarter was 23%, which includes a few small favorable discrete \nitems.   Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n ", "original_text": "We generated operating cash f low of $270 million during the quarter.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b09ecbd41ceddb27e03a5e8251019bbe1443f51ea69e7d7dd7f2f2a65d37e1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e286e1c-fa5f-4818-add4-7ab92b4a9a52", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n "}, "hash": "597e306fc49a75c3465064dcbfb26bc47583e7d322a9ef7fdcb0115be1ced9dd", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n ", "start_char_idx": 1956, "end_char_idx": 2054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e286e1c-fa5f-4818-add4-7ab92b4a9a52": {"__data__": {"id_": "8e286e1c-fa5f-4818-add4-7ab92b4a9a52", "embedding": null, "metadata": {"window": "Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ea71a39-231a-4a1a-8451-e77579c3cffe", "node_type": "1", "metadata": {"window": "Although discrete adjustments may cause our quarterly tax rate to deviate from our guidance \nrange of 24% to 26%, at this time we still believe this range is appropriate for the full year.  \n \n  Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cded00b4dc33e29cf4d6c97cc3254fbd15f24746377e9b11136803bd9c89a485", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44ef3ae3-ec68-4e71-b2c9-9168b2053585", "node_type": "1", "metadata": {"window": "We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n "}, "hash": "40891c8456b5cc0f24c5d678ce66f7d53f22bbfc99ac6fa941df50af65dfe5ec", "class_name": "RelatedNodeInfo"}}, "text": "We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n ", "start_char_idx": 2054, "end_char_idx": 2182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44ef3ae3-ec68-4e71-b2c9-9168b2053585": {"__data__": {"id_": "44ef3ae3-ec68-4e71-b2c9-9168b2053585", "embedding": null, "metadata": {"window": "We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e286e1c-fa5f-4818-add4-7ab92b4a9a52", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding were 295 million, about 2 million fewer shares than the \nprior year, reflecting the repurchases completed last year.  \n \n  We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f200422af00a6d003fd4cd38b844d7b5327f2ab98a43dd720e4318e0f27dc726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "503cb4c3-a98e-486b-adda-e78d7df31eac", "node_type": "1", "metadata": {"window": "As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n "}, "hash": "74c904405e765b14e07a86af54df0e0931673268cbb38981ab3a3b190a06e9db", "class_name": "RelatedNodeInfo"}}, "text": "Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n ", "start_char_idx": 2182, "end_char_idx": 2376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "503cb4c3-a98e-486b-adda-e78d7df31eac": {"__data__": {"id_": "503cb4c3-a98e-486b-adda-e78d7df31eac", "embedding": null, "metadata": {"window": "As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b9dfa0cb6dae283f538dc06521fbf2983747ce7fda288a7bee436960e37ed37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44ef3ae3-ec68-4e71-b2c9-9168b2053585", "node_type": "1", "metadata": {"window": "We generated operating cash f low of $270 million during the quarter.   As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a301e6b3d3cc39fa319b65bc3f12247003aca29de31051634b2eb1979e3abf1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5772d814-021c-450e-a227-77a126e8d8da", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n ", "original_text": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n"}, "hash": "4c19de1c07cd427dfc23272cbc9d9518393c5a48cade3d3fa8ecd30e7be35a5b", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "start_char_idx": 2376, "end_char_idx": 2496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5772d814-021c-450e-a227-77a126e8d8da": {"__data__": {"id_": "5772d814-021c-450e-a227-77a126e8d8da", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n ", "original_text": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "503cb4c3-a98e-486b-adda-e78d7df31eac", "node_type": "1", "metadata": {"window": "As a reminder, the day \nof week in which the quarter ends, affects point in time cash flows.  \n \n  We ended the first quarter with a cash balance of $2.7 billion and no outstanding borrowings \nunder our credit facilities.  \n \n  Now turning to the segments, beginning with medical on Slide 6, medical revenue increased \n1% in the first quarter to $4 billion, driven by sales growth in our at -Home Solutions business.  \n \n  Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "original_text": "Segment profit increased 36% to $230 million, driven by cost sav ings, including global \nmanufacturing efficiencies.  \n ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f475d6e3314a665ffd75384f747f7ae14a5bf913ec252e7312f21397f1f30d07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ba668b2-e5a4-46c7-a048-d03b7902f02b", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.  ", "original_text": "First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n "}, "hash": "95350ec81d4d492321e1fe3cb9ce5956dc63a5198b9ffc447b8a31d98536f727", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n", "start_char_idx": 0, "end_char_idx": 116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ba668b2-e5a4-46c7-a048-d03b7902f02b": {"__data__": {"id_": "2ba668b2-e5a4-46c7-a048-d03b7902f02b", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.  ", "original_text": "First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5772d814-021c-450e-a227-77a126e8d8da", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n ", "original_text": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7ecd8f3dd83119226e6aab0b26f0d64e149f5b451f6ca096dedfad8cbfeb5c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b4ea6d-c196-4d82-8cdd-8ceb64e0353d", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n ", "original_text": "Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n "}, "hash": "07fa10157eb595f9eb3530983000ba3f0ca6fc11346511a9c04df36567301e39", "class_name": "RelatedNodeInfo"}}, "text": "First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n ", "start_char_idx": 116, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75b4ea6d-c196-4d82-8cdd-8ceb64e0353d": {"__data__": {"id_": "75b4ea6d-c196-4d82-8cdd-8ceb64e0353d", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n ", "original_text": "Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ba668b2-e5a4-46c7-a048-d03b7902f02b", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.  ", "original_text": "First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "729ade19c22332df472d7f4f63e4444571849e082aa8d227a3252adceb51164a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2db8bcdc-058f-4a34-95ef-d2d390139b0f", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.  ", "original_text": "Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n "}, "hash": "2270bee45859950722a8096d5daafc55e2d74b1f93ced54aed4aae9f6eff12a3", "class_name": "RelatedNodeInfo"}}, "text": "Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n ", "start_char_idx": 243, "end_char_idx": 467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2db8bcdc-058f-4a34-95ef-d2d390139b0f": {"__data__": {"id_": "2db8bcdc-058f-4a34-95ef-d2d390139b0f", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.  ", "original_text": "Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b4ea6d-c196-4d82-8cdd-8ceb64e0353d", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n ", "original_text": "Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76527b6db9672f1351e62994984079f8abec7d3e1201cc3754d1ea56485132f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9218e891-ef4f-4464-a3c3-6b30734bce56", "node_type": "1", "metadata": {"window": "First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n ", "original_text": "And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.  "}, "hash": "a133be356e1d6acc4b5dbcd626f2f759ca2fe6d4ce7ca14fdb91249f761dad27", "class_name": "RelatedNodeInfo"}}, "text": "Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n ", "start_char_idx": 467, "end_char_idx": 691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9218e891-ef4f-4464-a3c3-6b30734bce56": {"__data__": {"id_": "9218e891-ef4f-4464-a3c3-6b30734bce56", "embedding": null, "metadata": {"window": "First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n ", "original_text": "And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2db8bcdc-058f-4a34-95ef-d2d390139b0f", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.  ", "original_text": "Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "504881a287201500bc9987e0c57d023a26e8020f92ac9e21ffa3817a7838c06d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9067a12-4afc-43c1-91a3-1fe484218092", "node_type": "1", "metadata": {"window": "Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.  ", "original_text": "These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n "}, "hash": "db873b2651053c42ff270da2d8113b7b10f0a2e44321545e314d4d0639b3bf9a", "class_name": "RelatedNodeInfo"}}, "text": "And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.  ", "start_char_idx": 691, "end_char_idx": 822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9067a12-4afc-43c1-91a3-1fe484218092": {"__data__": {"id_": "f9067a12-4afc-43c1-91a3-1fe484218092", "embedding": null, "metadata": {"window": "Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.  ", "original_text": "These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9218e891-ef4f-4464-a3c3-6b30734bce56", "node_type": "1", "metadata": {"window": "First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n ", "original_text": "And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37df1f631a1c147abdd58ad4413056b1fe9160c489d0cf63a874599ec8140ba4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "599e79dc-fa86-4c3a-883b-8ec7bedfe130", "node_type": "1", "metadata": {"window": "Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n ", "original_text": "As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.  "}, "hash": "7d9bc3c8d8128e8ab150cc8379b59abf17f1625a99ee818d84034723d33efb3d", "class_name": "RelatedNodeInfo"}}, "text": "These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n ", "start_char_idx": 822, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "599e79dc-fa86-4c3a-883b-8ec7bedfe130": {"__data__": {"id_": "599e79dc-fa86-4c3a-883b-8ec7bedfe130", "embedding": null, "metadata": {"window": "Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n ", "original_text": "As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9067a12-4afc-43c1-91a3-1fe484218092", "node_type": "1", "metadata": {"window": "Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.  ", "original_text": "These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55b057656c275d6a0a56cd46949271d91baa88402f27c0839aaf9d2cfe7ca6d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e6e2578-5c88-404d-b637-e0267bcbc912", "node_type": "1", "metadata": {"window": "And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n ", "original_text": "To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n "}, "hash": "70378e7dc57f52a8492794f519421f21fd750bedc525ee8cf8fda08134afdac0", "class_name": "RelatedNodeInfo"}}, "text": "As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.  ", "start_char_idx": 915, "end_char_idx": 1099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e6e2578-5c88-404d-b637-e0267bcbc912": {"__data__": {"id_": "6e6e2578-5c88-404d-b637-e0267bcbc912", "embedding": null, "metadata": {"window": "And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n ", "original_text": "To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "599e79dc-fa86-4c3a-883b-8ec7bedfe130", "node_type": "1", "metadata": {"window": "Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n  And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n ", "original_text": "As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b05a05ddadd43ebbd5838a04175c2cbef763c554194a6eab66a2669f7623276", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6669fb65-e6e8-440b-9386-a7fd110a285f", "node_type": "1", "metadata": {"window": "These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.  ", "original_text": "PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.  "}, "hash": "97f1ad2eadbc4161b29ad47fe42c6eadc433480e5b31a9fba9a7e9dda05b8aae", "class_name": "RelatedNodeInfo"}}, "text": "To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n ", "start_char_idx": 1099, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6669fb65-e6e8-440b-9386-a7fd110a285f": {"__data__": {"id_": "6669fb65-e6e8-440b-9386-a7fd110a285f", "embedding": null, "metadata": {"window": "These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.  ", "original_text": "PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e6e2578-5c88-404d-b637-e0267bcbc912", "node_type": "1", "metadata": {"window": "And finally, as Mike mentioned, our team delivered strong expe nse management in response \nto uncertainties related to COVID -19.   These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n ", "original_text": "To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca1b13101b9a1c2dd64f1469535598c1ab7ea3faf201130ffbb1bb2d7f4f5b0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f76c634-2d95-467f-b0c5-73d513a6a56c", "node_type": "1", "metadata": {"window": "As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n ", "original_text": "I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n "}, "hash": "3a2f70d82ac8e5dac796b74f865c7ce95e58a51926057997764fd532318417a6", "class_name": "RelatedNodeInfo"}}, "text": "PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.  ", "start_char_idx": 1252, "end_char_idx": 1378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f76c634-2d95-467f-b0c5-73d513a6a56c": {"__data__": {"id_": "5f76c634-2d95-467f-b0c5-73d513a6a56c", "embedding": null, "metadata": {"window": "As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n ", "original_text": "I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6669fb65-e6e8-440b-9386-a7fd110a285f", "node_type": "1", "metadata": {"window": "These measures position us to operate and invest in the \nbusiness for continued growth.  \n \n  As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.  ", "original_text": "PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "522ef0195e62e0123ecbb8d09ff3af762e7911abbab0bcce62ed3c1af566ee6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8d6e949-0588-45fe-9046-940e60f06be1", "node_type": "1", "metadata": {"window": "To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n ", "original_text": "Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n "}, "hash": "6ff69dc2f32309ecd40d4cf000c90eed3484e821645d07d8474bc44f7c6ae415", "class_name": "RelatedNodeInfo"}}, "text": "I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n ", "start_char_idx": 1378, "end_char_idx": 1506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8d6e949-0588-45fe-9046-940e60f06be1": {"__data__": {"id_": "f8d6e949-0588-45fe-9046-940e60f06be1", "embedding": null, "metadata": {"window": "To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n ", "original_text": "Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f76c634-2d95-467f-b0c5-73d513a6a56c", "node_type": "1", "metadata": {"window": "As we have previously discussed, we continue to incur significantly higher procurement costs \nfor cert ain PPE product categories due to global supply challenges during the pandemic.   To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n ", "original_text": "I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "958e4fd26277195305afc049b0f907ed4450a5f96e65c6fc2ac0637d5b633357", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43efa39c-4bb4-4c84-a578-7e5f924d4de9", "node_type": "1", "metadata": {"window": "PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n ", "original_text": "Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.  "}, "hash": "d505f3553e8e0a604d37854615af60c37b6c9130bb51a98d74ccbf316dcc1a22", "class_name": "RelatedNodeInfo"}}, "text": "Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n ", "start_char_idx": 1506, "end_char_idx": 1695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43efa39c-4bb4-4c84-a578-7e5f924d4de9": {"__data__": {"id_": "43efa39c-4bb4-4c84-a578-7e5f924d4de9", "embedding": null, "metadata": {"window": "PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n ", "original_text": "Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8d6e949-0588-45fe-9046-940e60f06be1", "node_type": "1", "metadata": {"window": "To help \nmitigate these cost increases, we implemented price increases on select PPE products with the goal \nof maintaining neutral margin dollars.  \n \n  PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n ", "original_text": "Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2395bbaa4fd72dcd4213391ff294d927313445001b7a44e151a873e17913fa81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aa968f2-515a-441c-8984-3bbe713f6ab2", "node_type": "1", "metadata": {"window": "I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.  ", "original_text": "Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n "}, "hash": "6caef0e864f4a3828b677f9551ee62daf10dbdba2b171500f02808244641b5eb", "class_name": "RelatedNodeInfo"}}, "text": "Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.  ", "start_char_idx": 1695, "end_char_idx": 1849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aa968f2-515a-441c-8984-3bbe713f6ab2": {"__data__": {"id_": "1aa968f2-515a-441c-8984-3bbe713f6ab2", "embedding": null, "metadata": {"window": "I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.  ", "original_text": "Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43efa39c-4bb4-4c84-a578-7e5f924d4de9", "node_type": "1", "metadata": {"window": "PPE cost increases and corr esponding mitigation efforts did not have a material net impact on \nour results for the quarter.   I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n ", "original_text": "Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c31fb388b0449d7dcfe579ed28bfede38f31d35655dce0153cbe2939895c2ede", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5124f9db-9207-4f08-94ec-787470c1ec72", "node_type": "1", "metadata": {"window": "Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n ", "original_text": "During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n "}, "hash": "f24ada0e7156e6074ba82e66f313ec9689324f453034df4ef4b3e981c2b5b244", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n ", "start_char_idx": 1849, "end_char_idx": 1934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5124f9db-9207-4f08-94ec-787470c1ec72": {"__data__": {"id_": "5124f9db-9207-4f08-94ec-787470c1ec72", "embedding": null, "metadata": {"window": "Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n ", "original_text": "During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aa968f2-515a-441c-8984-3bbe713f6ab2", "node_type": "1", "metadata": {"window": "I will discuss the potential effects of these dynamics in the segment for the \nfull year when I share updated assumptions.  \n \n  Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.  ", "original_text": "Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bf5ac14b0e8c3d3ba8851afa5f7951520da08a81e657a2d166bbaa51636239e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1073cae1-05d4-4525-9991-9ee2519dc4ef", "node_type": "1", "metadata": {"window": "Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.  ", "original_text": "Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n "}, "hash": "4f4939a25d551cb1960b5703d18b81d83507a64754156d952a1f9f3e15123ccb", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n ", "start_char_idx": 1934, "end_char_idx": 2106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1073cae1-05d4-4525-9991-9ee2519dc4ef": {"__data__": {"id_": "1073cae1-05d4-4525-9991-9ee2519dc4ef", "embedding": null, "metadata": {"window": "Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.  ", "original_text": "Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5124f9db-9207-4f08-94ec-787470c1ec72", "node_type": "1", "metadata": {"window": "Now transitioning to the pharma seg ment on Slide 5, revenue increased 5% to $35.1 billion, \ndriven by sales growth from pharmaceutical distribution and specialty solutions customers.  \n \n  Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n ", "original_text": "During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "290decee0d30be7bac09311688405b9b9f4ba638c2ae89aeda5296d616ba5396", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e465efda-9c7c-4ac1-9ce9-c91e2e357642", "node_type": "1", "metadata": {"window": "Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.  "}, "hash": "1f9889f6ac80c614927a4db550a85eba9058f9946a1be7601ff98f0e8791b455", "class_name": "RelatedNodeInfo"}}, "text": "Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n ", "start_char_idx": 2106, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e465efda-9c7c-4ac1-9ce9-c91e2e357642": {"__data__": {"id_": "e465efda-9c7c-4ac1-9ce9-c91e2e357642", "embedding": null, "metadata": {"window": "Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1073cae1-05d4-4525-9991-9ee2519dc4ef", "node_type": "1", "metadata": {"window": "Despite expected COVID -19 related volume declines, segment profit increased 1% to $402 \nmillion, driven by a  higher contribution from brand sales mix.   Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.  ", "original_text": "Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a90996fd50f70fba2d3c2cc5f6fe75855c6480702ba987732399bae3ee61396", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88e86fee-b6c9-4b70-9676-ffbb6fc3f95e", "node_type": "1", "metadata": {"window": "During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n "}, "hash": "f4070085dd5424d36f32e65315acfa95d2592f830eab5159fafce90bdcd4619b", "class_name": "RelatedNodeInfo"}}, "text": "Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.  ", "start_char_idx": 2227, "end_char_idx": 2350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88e86fee-b6c9-4b70-9676-ffbb6fc3f95e": {"__data__": {"id_": "88e86fee-b6c9-4b70-9676-ffbb6fc3f95e", "embedding": null, "metadata": {"window": "During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e465efda-9c7c-4ac1-9ce9-c91e2e357642", "node_type": "1", "metadata": {"window": "Additionally, the pharma team remained \nfocused on diligent expense management.  \n \n  During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "165aa8e27545ea1c8c80dcaaf67286301e5d3da2c1590772917961b18cd35cde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7e40522-8958-4b01-a792-990660fbc840", "node_type": "1", "metadata": {"window": "Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.  "}, "hash": "0a8f31335c9ff033d20aeb0a804309ed57d9268dfcb1570de4dc0b303984d338", "class_name": "RelatedNodeInfo"}}, "text": "We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n ", "start_char_idx": 2350, "end_char_idx": 2516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7e40522-8958-4b01-a792-990660fbc840": {"__data__": {"id_": "f7e40522-8958-4b01-a792-990660fbc840", "embedding": null, "metadata": {"window": "Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88e86fee-b6c9-4b70-9676-ffbb6fc3f95e", "node_type": "1", "metadata": {"window": "During the quarter we saw improving pharmaceutical demand, enabling us to finish generally \nin line with our COVID -19 expectations for this point in the fiscal year.  \n \n  Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01a83f5cc4d3427543c944a2239719e6445a2bf700621504d6a143b30f36fda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6fa5d49-088d-4a7b-9976-bad1f278a594", "node_type": "1", "metadata": {"window": "Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "Finally we're encouraged to see another quarter of consistent market "}, "hash": "e016e21d8f6c209559fe21ae02171f81373db6b607ee6c98a0ce2d00f666d202", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.  ", "start_char_idx": 2516, "end_char_idx": 2629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6fa5d49-088d-4a7b-9976-bad1f278a594": {"__data__": {"id_": "d6fa5d49-088d-4a7b-9976-bad1f278a594", "embedding": null, "metadata": {"window": "Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "Finally we're encouraged to see another quarter of consistent market ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1233a304-658b-4c6a-abdf-b127304b6fd0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f208fd9458459a8329fa085e09c79509eb5059a00ff2ba0e4130b395823cea9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7e40522-8958-4b01-a792-990660fbc840", "node_type": "1", "metadata": {"window": "Our specialty solutions business also demonstrated improvement in the quarter, resulting in \nstrong overall growth.  \n \n  Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.  ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60e52e651060b501d051dc6cfe2e8f0e5a6d82ea6662d8d8c124e7a61ef3880b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "639bbde2-c738-444a-8dbe-d060890b320f", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n ", "original_text": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n "}, "hash": "3772f16e1f6d464ee931f46cc5b94be66a48237fe219fc3fc2e7475b5abcea81", "class_name": "RelatedNodeInfo"}}, "text": "Finally we're encouraged to see another quarter of consistent market ", "start_char_idx": 2629, "end_char_idx": 2698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "639bbde2-c738-444a-8dbe-d060890b320f": {"__data__": {"id_": "639bbde2-c738-444a-8dbe-d060890b320f", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n ", "original_text": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6fa5d49-088d-4a7b-9976-bad1f278a594", "node_type": "1", "metadata": {"window": "Our nuclear business, as expected, was down year -over-year, but experienced significant \nvolume recovery in the quarter.   We've mentioned nuclear has been particularly affected by the \npandemic due to the mix of higher margin products and the business' higher fixed cost structures.  \n \n  We continue to believe we are well positioned to capture long -term value in the \nradiopharmaceutical industry.   Finally we're encouraged to see another quarter of consistent market ", "original_text": "Finally we're encouraged to see another quarter of consistent market ", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef7c80c7169af6c2ac952e57e053971295f606316684c457583d50bcd181c365", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da12aa00-b95d-431b-a641-e05a502f0a2c", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.  ", "original_text": "Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.  "}, "hash": "3844849e493439983497b6a2635652a10121de3e064181966aa039b66bdbb04e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n ", "start_char_idx": 0, "end_char_idx": 138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da12aa00-b95d-431b-a641-e05a502f0a2c": {"__data__": {"id_": "da12aa00-b95d-431b-a641-e05a502f0a2c", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.  ", "original_text": "Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "639bbde2-c738-444a-8dbe-d060890b320f", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n ", "original_text": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97fae181c25a55c50dfd34610ce51437ed8f59b40b271069c2bbc9bfaab4cfd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b94add0-aa17-476c-9fb1-b5c025f1288e", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n ", "original_text": "As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.  "}, "hash": "091acf077c9a270fc9225ce1511bc96c1ac8e12e318f767472f63e9ce59d6608", "class_name": "RelatedNodeInfo"}}, "text": "Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.  ", "start_char_idx": 138, "end_char_idx": 205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b94add0-aa17-476c-9fb1-b5c025f1288e": {"__data__": {"id_": "7b94add0-aa17-476c-9fb1-b5c025f1288e", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n ", "original_text": "As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da12aa00-b95d-431b-a641-e05a502f0a2c", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.  ", "original_text": "Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae4c4cfcff427211dcdc8df7e4b424010c675f9b80227134d5441c91c52d7c9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc57783d-41a1-4d40-a6da-0dcaaf8780df", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.  ", "original_text": "We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n "}, "hash": "8124d6148b6bb73760b0d511885745e78c3f65de70da42f1e0b08de972a2ad4b", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.  ", "start_char_idx": 205, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc57783d-41a1-4d40-a6da-0dcaaf8780df": {"__data__": {"id_": "bc57783d-41a1-4d40-a6da-0dcaaf8780df", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.  ", "original_text": "We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b94add0-aa17-476c-9fb1-b5c025f1288e", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n ", "original_text": "As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3b4e720c8529c32c1c99358db790f50e610c47489e745de8742e91c8d3539f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09b52429-9f70-410e-a0b3-e304293a6976", "node_type": "1", "metadata": {"window": "Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n ", "original_text": "This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.  "}, "hash": "1c824aed2b81c3530214b8f632e74e982ab5b9dc65c357f621de9c218fdc471a", "class_name": "RelatedNodeInfo"}}, "text": "We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n ", "start_char_idx": 401, "end_char_idx": 491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09b52429-9f70-410e-a0b3-e304293a6976": {"__data__": {"id_": "09b52429-9f70-410e-a0b3-e304293a6976", "embedding": null, "metadata": {"window": "Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n ", "original_text": "This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc57783d-41a1-4d40-a6da-0dcaaf8780df", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.  ", "original_text": "We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8003097df08c2967e059935c14c99900d79ba47bca0e40e0fbb0d47289fc0c19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeceb55f-9b49-49ae-97e5-9125a4c80952", "node_type": "1", "metadata": {"window": "As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.  ", "original_text": "Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n "}, "hash": "1b0f7cd27e0add990e1e612f14e4b9895eaf5ca03836634b938fd0bb615bca00", "class_name": "RelatedNodeInfo"}}, "text": "This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.  ", "start_char_idx": 491, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeceb55f-9b49-49ae-97e5-9125a4c80952": {"__data__": {"id_": "eeceb55f-9b49-49ae-97e5-9125a4c80952", "embedding": null, "metadata": {"window": "As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.  ", "original_text": "Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09b52429-9f70-410e-a0b3-e304293a6976", "node_type": "1", "metadata": {"window": "Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n ", "original_text": "This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77fb2543f59688970445a54436322d7129f238fdff34b26f11585ee5406334d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9e26fdb-d961-4e79-93e2-2ee6b912589a", "node_type": "1", "metadata": {"window": "We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n ", "original_text": "With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.  "}, "hash": "3015728fc817bff231919c7377bfbe1388e97396219ba86f7f365fbc97b24b04", "class_name": "RelatedNodeInfo"}}, "text": "Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n ", "start_char_idx": 600, "end_char_idx": 831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9e26fdb-d961-4e79-93e2-2ee6b912589a": {"__data__": {"id_": "e9e26fdb-d961-4e79-93e2-2ee6b912589a", "embedding": null, "metadata": {"window": "We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n ", "original_text": "With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeceb55f-9b49-49ae-97e5-9125a4c80952", "node_type": "1", "metadata": {"window": "As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.  ", "original_text": "Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b49ca2bb1e7f1f55e84aee0cc0bb0758799f7ae3a5967ea85e0e0a2289cc03ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3c4b89a-5b57-4986-ba77-6101a5268d57", "node_type": "1", "metadata": {"window": "This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n ", "original_text": "To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n "}, "hash": "ace842076ba964fae3f4373ab30b3fdcadf961ca7975a17dcff1630641e59b73", "class_name": "RelatedNodeInfo"}}, "text": "With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.  ", "start_char_idx": 831, "end_char_idx": 965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3c4b89a-5b57-4986-ba77-6101a5268d57": {"__data__": {"id_": "f3c4b89a-5b57-4986-ba77-6101a5268d57", "embedding": null, "metadata": {"window": "This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n ", "original_text": "To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9e26fdb-d961-4e79-93e2-2ee6b912589a", "node_type": "1", "metadata": {"window": "We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n  This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n ", "original_text": "With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c9a4ecb74ab6471f03d0c6709b538ca6a578aa84ba27c990361a154b86580c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29074658-658a-4ed6-a243-f37252aec5b0", "node_type": "1", "metadata": {"window": "Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n", "original_text": "And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.  "}, "hash": "95036bd7b24678f4d277f3b5423351da67777d8100680117ff829612c6118390", "class_name": "RelatedNodeInfo"}}, "text": "To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n ", "start_char_idx": 965, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29074658-658a-4ed6-a243-f37252aec5b0": {"__data__": {"id_": "29074658-658a-4ed6-a243-f37252aec5b0", "embedding": null, "metadata": {"window": "Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n", "original_text": "And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3c4b89a-5b57-4986-ba77-6101a5268d57", "node_type": "1", "metadata": {"window": "This increased EPS guidance is driven by an improved outlook for our medical segment, \ndepicted on Slide 9.   Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n ", "original_text": "To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c4ac0e0cea7e82867b64ac9389161cbcc2e0d0321e458ba38117485988bb33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4efe0a6-d8de-4c76-80fc-ba2c79ffda42", "node_type": "1", "metadata": {"window": "With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n ", "original_text": "Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n "}, "hash": "817e2dc915223de7d36adb4b461b980b1561e4ca1d4053c615ee636601ab20e6", "class_name": "RelatedNodeInfo"}}, "text": "And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.  ", "start_char_idx": 1077, "end_char_idx": 1231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4efe0a6-d8de-4c76-80fc-ba2c79ffda42": {"__data__": {"id_": "f4efe0a6-d8de-4c76-80fc-ba2c79ffda42", "embedding": null, "metadata": {"window": "With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n ", "original_text": "Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29074658-658a-4ed6-a243-f37252aec5b0", "node_type": "1", "metadata": {"window": "Because of our strong execution on cost savings, including increased global \nmanuf acturing efficiencies and the lower impact of COVID -19 related volume declines, we now \nexpect low double digit profit growth in the segment.  \n \n  With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n", "original_text": "And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d090187c6dcad91060cce09cc5edcc642de9a9d3e87ec1ea0c6091556d01bade", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e0b654d-999f-4ca8-bab7-a53669cd1168", "node_type": "1", "metadata": {"window": "To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.  ", "original_text": "As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n "}, "hash": "e03d845f1eb450d36d4d473521bd142aee367739225a7f9df45db54d52a2c9a7", "class_name": "RelatedNodeInfo"}}, "text": "Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n ", "start_char_idx": 1231, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e0b654d-999f-4ca8-bab7-a53669cd1168": {"__data__": {"id_": "1e0b654d-999f-4ca8-bab7-a53669cd1168", "embedding": null, "metadata": {"window": "To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.  ", "original_text": "As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4efe0a6-d8de-4c76-80fc-ba2c79ffda42", "node_type": "1", "metadata": {"window": "With one quarter of additional insight, we are updating our segment revenue growth to mid to \nhigh single digits f or the full year.   To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n ", "original_text": "Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8bc729a083d287b9a3d9cfa70eae4729c1f86ce2aa45dd68e8f0cc0aadc6bb27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4696571d-c8db-4c53-8996-e2254467a960", "node_type": "1", "metadata": {"window": "And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n ", "original_text": "With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n"}, "hash": "46e42b32a628d436ab0d23af4d30cb850f707496139bf0f24407cc21dd1ee92d", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n ", "start_char_idx": 1342, "end_char_idx": 1493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4696571d-c8db-4c53-8996-e2254467a960": {"__data__": {"id_": "4696571d-c8db-4c53-8996-e2254467a960", "embedding": null, "metadata": {"window": "And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n ", "original_text": "With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e0b654d-999f-4ca8-bab7-a53669cd1168", "node_type": "1", "metadata": {"window": "To be clear, the increase in our revenue guidance relates to better \nclarity on the impact of PPE pricing.  \n \n  And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.  ", "original_text": "As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85582cf34a079d58decd2a029d416af71df563b67ad9e062f64710d04f0e44cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19fe9cc0-06c8-4bc4-85a5-ae9dafbb85fd", "node_type": "1", "metadata": {"window": "Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.  ", "original_text": "However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n "}, "hash": "ff6ddf705a7fcbc001714b1f3aa5e27c2ebc3674f8514b2834653d4046d08262", "class_name": "RelatedNodeInfo"}}, "text": "With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n", "start_char_idx": 1493, "end_char_idx": 1683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19fe9cc0-06c8-4bc4-85a5-ae9dafbb85fd": {"__data__": {"id_": "19fe9cc0-06c8-4bc4-85a5-ae9dafbb85fd", "embedding": null, "metadata": {"window": "Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.  ", "original_text": "However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4696571d-c8db-4c53-8996-e2254467a960", "node_type": "1", "metadata": {"window": "And we expect this increased revenue to be more than offset by the higher cost of procuring \nPPE products, which will adversely im pact our margin rate.   Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n ", "original_text": "With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "085b308e4fd820f67b8fae4a6b771ca1321525c54188a124e426a3f0ad071166", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b8e61ee-24e1-4cf4-ab1c-ce15c08e14ae", "node_type": "1", "metadata": {"window": "As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n ", "original_text": "At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.  "}, "hash": "6db72e9f599341a4d1d1d19cc8bdd6b5656d8579df248e2b26c45c8e21972e28", "class_name": "RelatedNodeInfo"}}, "text": "However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n ", "start_char_idx": 1683, "end_char_idx": 1887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b8e61ee-24e1-4cf4-ab1c-ce15c08e14ae": {"__data__": {"id_": "2b8e61ee-24e1-4cf4-ab1c-ce15c08e14ae", "embedding": null, "metadata": {"window": "As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n ", "original_text": "At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19fe9cc0-06c8-4bc4-85a5-ae9dafbb85fd", "node_type": "1", "metadata": {"window": "Mike will provide more color on our PPE \nsupply assurance efforts for our customers later in his remarks.  \n \n  As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.  ", "original_text": "However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d88ea81c6045508e5fe93c281d09a97dd69bf7ca0e5aa5f2eb72f9f6abc4e167", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15033c9f-2366-4ec7-b1a3-6c887340c131", "node_type": "1", "metadata": {"window": "With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.  ", "original_text": "This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n "}, "hash": "c2fc2455173a79f36019bee49438bd6abb2e7ce822fb134c0257d55686f6d4d0", "class_name": "RelatedNodeInfo"}}, "text": "At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.  ", "start_char_idx": 1887, "end_char_idx": 2046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15033c9f-2366-4ec7-b1a3-6c887340c131": {"__data__": {"id_": "15033c9f-2366-4ec7-b1a3-6c887340c131", "embedding": null, "metadata": {"window": "With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.  ", "original_text": "This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b8e61ee-24e1-4cf4-ab1c-ce15c08e14ae", "node_type": "1", "metadata": {"window": "As it relates to the pharma segment, we are reiterating our assumptions of mid -single digit \nrevenue growth and low single digi t profit growth.  \n \n  With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n ", "original_text": "At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "246b5e6ca819d606dcf9bbc1b78741a6fde1a3cf8a95fa72bc37f018aa5dc8fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1244a6a7-fd05-4271-93da-8f7e57aa6190", "node_type": "1", "metadata": {"window": "However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.  "}, "hash": "138277f42b7fc8ad10f63430a2cab8e3e538faaa45cfd5e62f2a8302f149e128", "class_name": "RelatedNodeInfo"}}, "text": "This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n ", "start_char_idx": 2046, "end_char_idx": 2237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1244a6a7-fd05-4271-93da-8f7e57aa6190": {"__data__": {"id_": "1244a6a7-fd05-4271-93da-8f7e57aa6190", "embedding": null, "metadata": {"window": "However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15033c9f-2366-4ec7-b1a3-6c887340c131", "node_type": "1", "metadata": {"window": "With respect to our enterprise COVID -19 assumptions, we are not assuming that the virus \ntriggers another wave of widespread reductions in elective procedures or physician office visits.  \n However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.  ", "original_text": "This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9edafb21ad7ac7bb57f310f4f26fe150ea11892557957b726e0dda28c8c1292a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05af0c4b-f01a-499e-9661-2a5f38f5e3fe", "node_type": "1", "metadata": {"window": "At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n "}, "hash": "599e78d3c295f21b027222aadb51d072160540efecb5bc06603d949c3ffd517f", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.  ", "start_char_idx": 2237, "end_char_idx": 2402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05af0c4b-f01a-499e-9661-2a5f38f5e3fe": {"__data__": {"id_": "05af0c4b-f01a-499e-9661-2a5f38f5e3fe", "embedding": null, "metadata": {"window": "At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1244a6a7-fd05-4271-93da-8f7e57aa6190", "node_type": "1", "metadata": {"window": "However we are closely monitoring virus trends, pa tient utilization and the health of the global \neconomy, including unemployment trends, all of which currently have varying degrees of uncertainty.  \n \n  At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ebf3cdd99618a6c0abf981e2c7a38d84b2a4293d1c8824d0fe22bff2cff2534", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6d19bd1-2b52-49ab-a90d-b9a75d799045", "node_type": "1", "metadata": {"window": "This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Now I want to mention a notable item included in our GAAP results.  "}, "hash": "3dcb3197af796e5ad24e6d5e80d23071a78f68184a7978b081a2653358c76252", "class_name": "RelatedNodeInfo"}}, "text": "Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n ", "start_char_idx": 2402, "end_char_idx": 2590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6d19bd1-2b52-49ab-a90d-b9a75d799045": {"__data__": {"id_": "d6d19bd1-2b52-49ab-a90d-b9a75d799045", "embedding": null, "metadata": {"window": "This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Now I want to mention a notable item included in our GAAP results.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05af0c4b-f01a-499e-9661-2a5f38f5e3fe", "node_type": "1", "metadata": {"window": "At this time we anticipate the total net impact of COVID -19 in the second quarter to be \nrelatively consiste nt to what we experienced in the first quarter.   This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "367ae7b52cc1b4a9c714f7115d1792f5a7e9d33ac08da6b98910357cf0c7f6cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc0a792-4a27-444a-a581-9282deaa5413", "node_type": "1", "metadata": {"window": "We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n "}, "hash": "78823b5f2c1957b0c421812af69c1b573d669647072707ae32ef3ef4c2d66e7f", "class_name": "RelatedNodeInfo"}}, "text": "Now I want to mention a notable item included in our GAAP results.  ", "start_char_idx": 2590, "end_char_idx": 2658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc0a792-4a27-444a-a581-9282deaa5413": {"__data__": {"id_": "dfc0a792-4a27-444a-a581-9282deaa5413", "embedding": null, "metadata": {"window": "We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "95e67101-a75f-4bb1-90db-77c354a480c5", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7e51babc115bc8010619cbe22855394cfa46e372ddfe9432af4c00af9fae73f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6d19bd1-2b52-49ab-a90d-b9a75d799045", "node_type": "1", "metadata": {"window": "This is primarily due to the improved \nutilization environment, offset by cost absorption on our self -manufactured products and the \npreviously mentioned higher costs of procuring PPE.  \n \n  We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Now I want to mention a notable item included in our GAAP results.  ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05cb083d2107fd9f92415e222c004d43795a8e5ffab78ea187af9d6d29522c68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cce90874-e40e-47f8-a1f8-12e6745124c1", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.  ", "original_text": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.  "}, "hash": "39641a236ed13febf6a97cd49a9257cf772aa65d145947814c4808b18064581b", "class_name": "RelatedNodeInfo"}}, "text": "Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "start_char_idx": 2658, "end_char_idx": 2925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cce90874-e40e-47f8-a1f8-12e6745124c1": {"__data__": {"id_": "cce90874-e40e-47f8-a1f8-12e6745124c1", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.  ", "original_text": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc0a792-4a27-444a-a581-9282deaa5413", "node_type": "1", "metadata": {"window": "We continue to expect a lower total COVID -19 impact in the second half of the year, and we \nassume utilization will exit the year at or near pre -pandemic levels.   Furthermore we continue to \nexplore opportunities to mitigate these impacts on our business through cost controls and  more \npermanent improvements to our operational cost structure.  \n \n  Now I want to mention a notable item included in our GAAP results.   Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "original_text": "Recall that in the first \nquarter of fiscal '20, we accrued $5.6 billion pre -tax related to an agreement in principle among st a \nleadership group of State Attorney's general to resolve pending and future opioid litigation claims by \nstates, cities and counties.  \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "367ecb72c71ae530ebd54ab5f78f548f6791d01f8578ee5167fba3239763fa1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4616da42-fb11-44c1-b33e-2bb6bf87d3c7", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet. ", "original_text": "The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n "}, "hash": "dcbb8048ee207a93a762c25ee1592f62273d8d79951c2fd877702721539e0980", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.  ", "start_char_idx": 0, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4616da42-fb11-44c1-b33e-2bb6bf87d3c7": {"__data__": {"id_": "4616da42-fb11-44c1-b33e-2bb6bf87d3c7", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet. ", "original_text": "The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cce90874-e40e-47f8-a1f8-12e6745124c1", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.  ", "original_text": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d14bb1cf110e94bdd0e80edfb8735176abfc131ea5a8c1512f9b76383d3a883", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0df23b67-9ffc-4cd4-a02d-fc5be94c2f34", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.  ", "original_text": "Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n "}, "hash": "d350101281796d42f64639b6fafae24bada8b3e44fcbcbab47142f18f1c41788", "class_name": "RelatedNodeInfo"}}, "text": "The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n ", "start_char_idx": 199, "end_char_idx": 359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0df23b67-9ffc-4cd4-a02d-fc5be94c2f34": {"__data__": {"id_": "0df23b67-9ffc-4cd4-a02d-fc5be94c2f34", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.  ", "original_text": "Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4616da42-fb11-44c1-b33e-2bb6bf87d3c7", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet. ", "original_text": "The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e27b0cfc59f69b89f7f352caeb9e042b9c7d6c35d097a53b1d7c5bf6d23a9b28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4e3b061-b484-48a8-beb6-e83237bf2f50", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n ", "original_text": "First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.  "}, "hash": "cb4ed4719b4a7435dd96d7e096cd2ec943c1fc3d292676421f298448b2c4f786", "class_name": "RelatedNodeInfo"}}, "text": "Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n ", "start_char_idx": 359, "end_char_idx": 537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4e3b061-b484-48a8-beb6-e83237bf2f50": {"__data__": {"id_": "b4e3b061-b484-48a8-beb6-e83237bf2f50", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n ", "original_text": "First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0df23b67-9ffc-4cd4-a02d-fc5be94c2f34", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.  ", "original_text": "Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f584aba97d9442fb0af24f1d0f8faf322f21ce43bcf3f3e390cd5e15b96f44e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6229201-76ea-43c4-88a1-ba8b12608d65", "node_type": "1", "metadata": {"window": "The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n", "original_text": "Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet. "}, "hash": "87e8e39c5d1966ac9cc41b6a59ca5401a9040711f12d7feba8954b7ae4dc29fb", "class_name": "RelatedNodeInfo"}}, "text": "First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.  ", "start_char_idx": 537, "end_char_idx": 655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6229201-76ea-43c4-88a1-ba8b12608d65": {"__data__": {"id_": "a6229201-76ea-43c4-88a1-ba8b12608d65", "embedding": null, "metadata": {"window": "The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n", "original_text": "Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet. ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4e3b061-b484-48a8-beb6-e83237bf2f50", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n ", "original_text": "First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfb4de34c5e2137bb85d559306847a7886571760e47760375e1287c9d63c34ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96354ca1-349b-4d78-8f32-3024cb0584c4", "node_type": "1", "metadata": {"window": "Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.  "}, "hash": "843b9771fafa3e745cb8a1743b2746de78f94b76e16ae61e256585102c1160cd", "class_name": "RelatedNodeInfo"}}, "text": "Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet. ", "start_char_idx": 655, "end_char_idx": 756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96354ca1-349b-4d78-8f32-3024cb0584c4": {"__data__": {"id_": "96354ca1-349b-4d78-8f32-3024cb0584c4", "embedding": null, "metadata": {"window": "Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6229201-76ea-43c4-88a1-ba8b12608d65", "node_type": "1", "metadata": {"window": "The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n", "original_text": "Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet. ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2439672a114303c25c8624da6ad55cef7bd868e4b27d2f91fb64b0675b9c7e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa6c671b-95da-45a3-bde0-6c83e7b67b6e", "node_type": "1", "metadata": {"window": "First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n ", "original_text": "We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n "}, "hash": "e420aeede100fc237cb5bf6cbf905d150fdbe7ec569b2f25129740e5f95e7f98", "class_name": "RelatedNodeInfo"}}, "text": "And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.  ", "start_char_idx": 756, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa6c671b-95da-45a3-bde0-6c83e7b67b6e": {"__data__": {"id_": "fa6c671b-95da-45a3-bde0-6c83e7b67b6e", "embedding": null, "metadata": {"window": "First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n ", "original_text": "We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96354ca1-349b-4d78-8f32-3024cb0584c4", "node_type": "1", "metadata": {"window": "Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8745e5bedcfaaafcef737ced003bebbd3c511a734362f3efd371339c29d91117", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b1952b-516d-42bc-9aae-ad8f1e5f2921", "node_type": "1", "metadata": {"window": "Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.  ", "original_text": "I'll now turn it back over to Mike.  \n \n"}, "hash": "3175bd9f65d3a8097c239a08616135c0e268f60cd1ad71dbb761895e3d27edbc", "class_name": "RelatedNodeInfo"}}, "text": "We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n ", "start_char_idx": 853, "end_char_idx": 1002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75b1952b-516d-42bc-9aae-ad8f1e5f2921": {"__data__": {"id_": "75b1952b-516d-42bc-9aae-ad8f1e5f2921", "embedding": null, "metadata": {"window": "Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.  ", "original_text": "I'll now turn it back over to Mike.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa6c671b-95da-45a3-bde0-6c83e7b67b6e", "node_type": "1", "metadata": {"window": "First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.   Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n ", "original_text": "We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d26c8b7d05de62466eea3aeaecec83d0908f6458b4da90203bfe2acda33704be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ab87a29-63f5-417e-a8a2-b1de9946b30a", "node_type": "1", "metadata": {"window": "And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n ", "original_text": "Mike Kaufmann:  Thanks, Jason.  "}, "hash": "cc38616734bf03b7ce3ba473ed71c47a9409e4de4661a7a38ed6689ff43ece07", "class_name": "RelatedNodeInfo"}}, "text": "I'll now turn it back over to Mike.  \n \n", "start_char_idx": 1002, "end_char_idx": 1042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ab87a29-63f5-417e-a8a2-b1de9946b30a": {"__data__": {"id_": "0ab87a29-63f5-417e-a8a2-b1de9946b30a", "embedding": null, "metadata": {"window": "And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n ", "original_text": "Mike Kaufmann:  Thanks, Jason.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b1952b-516d-42bc-9aae-ad8f1e5f2921", "node_type": "1", "metadata": {"window": "Second, we are focused on taking appropriate action to maintain our \ninvestment grade balance sheet.  And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.  ", "original_text": "I'll now turn it back over to Mike.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49847ceccb11f6b68efc18ccf024764c529415f8670bbd0a328692368d62cd22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8858d96c-ca77-4cfd-99ef-e7cf11a2c1d6", "node_type": "1", "metadata": {"window": "We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.  ", "original_text": "We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n "}, "hash": "59e8db23e046c136b6b4a866ab0f22d937d74a8550134cea65a43615f193be37", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Jason.  ", "start_char_idx": 1042, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8858d96c-ca77-4cfd-99ef-e7cf11a2c1d6": {"__data__": {"id_": "8858d96c-ca77-4cfd-99ef-e7cf11a2c1d6", "embedding": null, "metadata": {"window": "We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.  ", "original_text": "We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ab87a29-63f5-417e-a8a2-b1de9946b30a", "node_type": "1", "metadata": {"window": "And third, we are committed to returning cash to shareholders, \nprimarily through our dividend.   We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n ", "original_text": "Mike Kaufmann:  Thanks, Jason.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82ed6134d9d08a9383e92e2752c36396eaf5cbfc697960487529a76e08960d19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b7d7afd-2966-49a7-ae61-8a2d7b1c14bb", "node_type": "1", "metadata": {"window": "I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n ", "original_text": "To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.  "}, "hash": "f4654ecdc3237811c872c90e23169a15dff2be75de1d509377f62120dc4380d9", "class_name": "RelatedNodeInfo"}}, "text": "We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n ", "start_char_idx": 1074, "end_char_idx": 1213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b7d7afd-2966-49a7-ae61-8a2d7b1c14bb": {"__data__": {"id_": "4b7d7afd-2966-49a7-ae61-8a2d7b1c14bb", "embedding": null, "metadata": {"window": "I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n ", "original_text": "To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8858d96c-ca77-4cfd-99ef-e7cf11a2c1d6", "node_type": "1", "metadata": {"window": "We believe this prioritization of capital best positions us to both \nmaintain flexibility and to generate significant value over the long term.  \n \n  I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.  ", "original_text": "We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e97904a216bc79679562fa820451f224cde2cf3ab95cc16b58ca8398433706b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8feeaceb-de1a-4400-ae08-0c8c0396ef8e", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.  ", "original_text": "I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n "}, "hash": "e7165ccbdc6788543c037591e48891b84c450f28fc58248dc8e4e7fa9c58b44f", "class_name": "RelatedNodeInfo"}}, "text": "To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.  ", "start_char_idx": 1213, "end_char_idx": 1340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8feeaceb-de1a-4400-ae08-0c8c0396ef8e": {"__data__": {"id_": "8feeaceb-de1a-4400-ae08-0c8c0396ef8e", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.  ", "original_text": "I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b7d7afd-2966-49a7-ae61-8a2d7b1c14bb", "node_type": "1", "metadata": {"window": "I'll now turn it back over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n ", "original_text": "To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9581fb468ab91c30285e0471ea97e41e1826ac3f49f60a1d7915395e1bbe51af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51d1da03-1880-41e4-870d-b4a29ddf729e", "node_type": "1", "metadata": {"window": "We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n ", "original_text": "First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.  "}, "hash": "7434d082e808b2e6973a8303d14556bf5e4ae9ada4677dd480dd50be902196ab", "class_name": "RelatedNodeInfo"}}, "text": "I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n ", "start_char_idx": 1340, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51d1da03-1880-41e4-870d-b4a29ddf729e": {"__data__": {"id_": "51d1da03-1880-41e4-870d-b4a29ddf729e", "embedding": null, "metadata": {"window": "We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n ", "original_text": "First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8feeaceb-de1a-4400-ae08-0c8c0396ef8e", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Jason.   We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.  ", "original_text": "I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c4d037c4ae9c222983dadcf7e0c08cac89ad82a722c17376363cf31e7b5adfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1607c3e-9cca-4b95-b17f-7b1828a6cb8a", "node_type": "1", "metadata": {"window": "To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n ", "original_text": "These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n "}, "hash": "3c40cc3e21577ef3797eb79cca82a9ca379d3becdc39173c751148c3f91186bf", "class_name": "RelatedNodeInfo"}}, "text": "First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.  ", "start_char_idx": 1509, "end_char_idx": 1652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1607c3e-9cca-4b95-b17f-7b1828a6cb8a": {"__data__": {"id_": "c1607c3e-9cca-4b95-b17f-7b1828a6cb8a", "embedding": null, "metadata": {"window": "To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n ", "original_text": "These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51d1da03-1880-41e4-870d-b4a29ddf729e", "node_type": "1", "metadata": {"window": "We aspire to be health care's most trusted partner by delivering \nproducts and solutions that improve t he lives of people every day.  \n \n  To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n ", "original_text": "First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e2f4ef4842322821bdca23147c0904dbf34f0caf26e56ae206af5f89c35acd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "336749ed-4751-44d1-a990-724a6a4f1069", "node_type": "1", "metadata": {"window": "I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.  ", "original_text": "For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.  "}, "hash": "19d05b72c0fbcda757522bb9562c96a61bdf1173529b935c0a937ee71dc42dc1", "class_name": "RelatedNodeInfo"}}, "text": "These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n ", "start_char_idx": 1652, "end_char_idx": 1780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "336749ed-4751-44d1-a990-724a6a4f1069": {"__data__": {"id_": "336749ed-4751-44d1-a990-724a6a4f1069", "embedding": null, "metadata": {"window": "I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.  ", "original_text": "For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1607c3e-9cca-4b95-b17f-7b1828a6cb8a", "node_type": "1", "metadata": {"window": "To achieve this mission, we leverage our scale and expertise to excel in our traditional spaces \nand expand into adjacencies.   I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n ", "original_text": "These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23bc049177cc5d1d15eeb67567560da5fff15ee5b566dfbd5b97182e483b84e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55bf3ded-e792-4123-9373-05e6ae4acdc8", "node_type": "1", "metadata": {"window": "First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n ", "original_text": "Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n "}, "hash": "708ebaba8284ad4535648e928d84c1fac62a8c0310ca3dc7bab1f3e744948da9", "class_name": "RelatedNodeInfo"}}, "text": "For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.  ", "start_char_idx": 1780, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55bf3ded-e792-4123-9373-05e6ae4acdc8": {"__data__": {"id_": "55bf3ded-e792-4123-9373-05e6ae4acdc8", "embedding": null, "metadata": {"window": "First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n ", "original_text": "Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "336749ed-4751-44d1-a990-724a6a4f1069", "node_type": "1", "metadata": {"window": "I'll share how we are doing both, while simultaneously addressing the \nchallenges of the ongoing pa ndemic through targeted investments in pursuit of this mission.  \n \n  First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.  ", "original_text": "For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2707b0fa63615a2b592804ab362f3dadd02c9d76e0502752ab748aa5c6f6cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed9db687-2cf8-4819-890e-441b50527efc", "node_type": "1", "metadata": {"window": "These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.  ", "original_text": "In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n "}, "hash": "1f59118bc04fd5a3642826b47dc14636dbf185327c1bee5ea0a3a846272e056f", "class_name": "RelatedNodeInfo"}}, "text": "Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n ", "start_char_idx": 2005, "end_char_idx": 2184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed9db687-2cf8-4819-890e-441b50527efc": {"__data__": {"id_": "ed9db687-2cf8-4819-890e-441b50527efc", "embedding": null, "metadata": {"window": "These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.  ", "original_text": "In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55bf3ded-e792-4123-9373-05e6ae4acdc8", "node_type": "1", "metadata": {"window": "First, we are enhancing our IT infrastructure in key areas to increase capabilities, simplify \nprocesses and improve the customer experience.   These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n ", "original_text": "Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04fbf0ad265b1d626dae6e5d2e35e7526aeb2c2df9a3e5aef7971f14a7efe89d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0991d865-ffa1-4532-9443-db7e8f0551eb", "node_type": "1", "metadata": {"window": "For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.  "}, "hash": "7e0f286148965480a9157b995fc86151e09c004b66586d0553931e98b1290433", "class_name": "RelatedNodeInfo"}}, "text": "In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n ", "start_char_idx": 2184, "end_char_idx": 2326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0991d865-ffa1-4532-9443-db7e8f0551eb": {"__data__": {"id_": "0991d865-ffa1-4532-9443-db7e8f0551eb", "embedding": null, "metadata": {"window": "For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed9db687-2cf8-4819-890e-441b50527efc", "node_type": "1", "metadata": {"window": "These multiyear initiatives will generate signif icant \nbenefits in the future, some of which we are beginning to realize.  \n \n  For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.  ", "original_text": "In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb297bbb755928a355c19edc8386fe69b94fa89374f830c3e8d355c7d03f6b50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46e20b61-5060-4c61-937f-4132ab6a7aae", "node_type": "1", "metadata": {"window": "Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n "}, "hash": "052861a938e985569b9ba71c604cd4e8ef975e6d6f05b5acbbba4f7f97a92676", "class_name": "RelatedNodeInfo"}}, "text": "We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.  ", "start_char_idx": 2326, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46e20b61-5060-4c61-937f-4132ab6a7aae": {"__data__": {"id_": "46e20b61-5060-4c61-937f-4132ab6a7aae", "embedding": null, "metadata": {"window": "Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0991d865-ffa1-4532-9443-db7e8f0551eb", "node_type": "1", "metadata": {"window": "For example in our pharmaceutical distribution business, our teams are preparing to deploy the \nnext iteration of our technology platform enhancements, creating greater operational e fficiencies and \nbetter data visibility.   Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5dd2e65dbfe1e2cd1c8376bd686e999ea90568f6304dd2e45e22d6dcce993e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bf8b295-4777-494b-ae35-6d516ff38c94", "node_type": "1", "metadata": {"window": "In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.  "}, "hash": "a6433fc1097ec6b2e9d7bd20776b715641dcf4884bbe78b15ea87641ae6be731", "class_name": "RelatedNodeInfo"}}, "text": "For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n ", "start_char_idx": 2476, "end_char_idx": 2730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bf8b295-4777-494b-ae35-6d516ff38c94": {"__data__": {"id_": "8bf8b295-4777-494b-ae35-6d516ff38c94", "embedding": null, "metadata": {"window": "In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46e20b61-5060-4c61-937f-4132ab6a7aae", "node_type": "1", "metadata": {"window": "Also, initiatives in our corporate functions will harness the potential of AI and \nmachine learning to enable stronger insights, both for our business and for our customers.  \n \n  In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83887b37af0c28855110d78186e928df087aca641f8fcb0250e92c4b3c3d495a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a7d0677-cbd0-496b-8d1e-d9dd1c65e512", "node_type": "1", "metadata": {"window": "We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n "}, "hash": "7983f8511482aa082c13dd30048100aeebb2a49ad85274b35d03dc0f9e2d69f0", "class_name": "RelatedNodeInfo"}}, "text": "Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.  ", "start_char_idx": 2730, "end_char_idx": 2847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a7d0677-cbd0-496b-8d1e-d9dd1c65e512": {"__data__": {"id_": "4a7d0677-cbd0-496b-8d1e-d9dd1c65e512", "embedding": null, "metadata": {"window": "We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5266e613c6649d635704174434c7acd4dc9fedfda0188802127cb4bb9c16b369", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bf8b295-4777-494b-ae35-6d516ff38c94", "node_type": "1", "metadata": {"window": "In medical our work to streamline our gl obal supply chain network and processes continues, \nand we are seeing significant efficiencies.  \n \n  We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e9e38f01393175bde3c460628aa137061d8805fac4335af94a2526d04462723", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acf4c530-b1d3-40f7-bc8a-da910acd57a0", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.  ", "original_text": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n "}, "hash": "b4f7e434e3b91861572427a52590adf72467e9424a4d29e2c9197c5a1ac057ee", "class_name": "RelatedNodeInfo"}}, "text": "Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "start_char_idx": 2847, "end_char_idx": 3027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acf4c530-b1d3-40f7-bc8a-da910acd57a0": {"__data__": {"id_": "acf4c530-b1d3-40f7-bc8a-da910acd57a0", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.  ", "original_text": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a7d0677-cbd0-496b-8d1e-d9dd1c65e512", "node_type": "1", "metadata": {"window": "We are also strategically investing to expand in high growth areas to support new technologies \nand therapies and to drive innovative care delivery.   For exampl e in specialty, we are developing \npartnerships and making thoughtful investments that combine the technology, scale and expertise of \nour business with new innovations in cell and gene therapy, biosimilars and value -based care \nmodels.  \n \n  Our 3PL continues it s strong growth with the recent launches in traditional markets, as well as \nemerging markets.   Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "original_text": "Also we recently made an investment in Vineti, the first commercial cloud -based \nplatform to integrate logistics, manufacturing and clinical data for cell and gen e therapies.  \n ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a97ff069d6c1e3f9d8b97919e6d851a3d2e6e717777def6c8d3c49c22572dc6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1c600cd-86a6-4fcd-86c6-a2cdf0c7b25d", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.  ", "original_text": "We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.  "}, "hash": "76131c935714e45eaa61ddc00920a0c0bdd5678747c04b8e13abbf014902b4e8", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n ", "start_char_idx": 0, "end_char_idx": 241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1c600cd-86a6-4fcd-86c6-a2cdf0c7b25d": {"__data__": {"id_": "e1c600cd-86a6-4fcd-86c6-a2cdf0c7b25d", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.  ", "original_text": "We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acf4c530-b1d3-40f7-bc8a-da910acd57a0", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.  ", "original_text": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "094b0fab4fd2dc3b7a52c2cc093d848030c656c327d9a4acc83397586fc85ce7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b46bc18e-472a-4a77-b44b-999a852f1bfd", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n ", "original_text": "We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n "}, "hash": "436c2d94a51712332df36df1929748df423de485a69083d27f57a81c7a2e5230", "class_name": "RelatedNodeInfo"}}, "text": "We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.  ", "start_char_idx": 241, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b46bc18e-472a-4a77-b44b-999a852f1bfd": {"__data__": {"id_": "b46bc18e-472a-4a77-b44b-999a852f1bfd", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n ", "original_text": "We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1c600cd-86a6-4fcd-86c6-a2cdf0c7b25d", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.  ", "original_text": "We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73b7960c0ec8d45b16d7328243261d56db075c2e4e768da19d8b8f3f3ad34c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cdca9ba-7e5a-49ce-ab60-caede40f68aa", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.  ", "original_text": "These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.  "}, "hash": "0bb4fc7e3dd6443552a80a8c4a9f99449985beeab08f0b131fd7807d185f7e34", "class_name": "RelatedNodeInfo"}}, "text": "We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n ", "start_char_idx": 371, "end_char_idx": 617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cdca9ba-7e5a-49ce-ab60-caede40f68aa": {"__data__": {"id_": "5cdca9ba-7e5a-49ce-ab60-caede40f68aa", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.  ", "original_text": "These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b46bc18e-472a-4a77-b44b-999a852f1bfd", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n ", "original_text": "We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3d904af8fcf79aecaf57a9b62c0f07fda5125a0ead0c78a31246780e6456005", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "980294e3-431b-44c3-b2ce-fe4807172267", "node_type": "1", "metadata": {"window": "We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n ", "original_text": "Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.  "}, "hash": "ee98cedc1007adf6466eb98acd4b18f3c0fbeea70c920ba832e0a06fa4c19e75", "class_name": "RelatedNodeInfo"}}, "text": "These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.  ", "start_char_idx": 617, "end_char_idx": 736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "980294e3-431b-44c3-b2ce-fe4807172267": {"__data__": {"id_": "980294e3-431b-44c3-b2ce-fe4807172267", "embedding": null, "metadata": {"window": "We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n ", "original_text": "Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cdca9ba-7e5a-49ce-ab60-caede40f68aa", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.  ", "original_text": "These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1737fd8f363aa7f979f826dbac33102c430bf5cf73af1753fab7522323e9ef40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87931d02-335c-42db-9601-06c551e37dee", "node_type": "1", "metadata": {"window": "We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n ", "original_text": "While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n "}, "hash": "0cf95fd038e4df550631bba5f3b490ffa43552f112dee08ea9f4fa8cb8d011bd", "class_name": "RelatedNodeInfo"}}, "text": "Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.  ", "start_char_idx": 736, "end_char_idx": 886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87931d02-335c-42db-9601-06c551e37dee": {"__data__": {"id_": "87931d02-335c-42db-9601-06c551e37dee", "embedding": null, "metadata": {"window": "We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n ", "original_text": "While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "980294e3-431b-44c3-b2ce-fe4807172267", "node_type": "1", "metadata": {"window": "We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n ", "original_text": "Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd06d99640a1a6e083cfce1ee16b25ce4d8971ea8e4c7c63ef53b0f21155c218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66335f33-bc7d-4111-8a9a-847897b30481", "node_type": "1", "metadata": {"window": "These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n", "original_text": "In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.  "}, "hash": "9c9b19d8acb97bf2ba7ed214b51c31d2ce7b7f8483f81f4d46d908775f5aeaca", "class_name": "RelatedNodeInfo"}}, "text": "While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n ", "start_char_idx": 886, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66335f33-bc7d-4111-8a9a-847897b30481": {"__data__": {"id_": "66335f33-bc7d-4111-8a9a-847897b30481", "embedding": null, "metadata": {"window": "These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n", "original_text": "In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87931d02-335c-42db-9601-06c551e37dee", "node_type": "1", "metadata": {"window": "We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n ", "original_text": "While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d23313b4218dc1c3ac695300081878901b89f20f9a21ae020f1ae70d586d57fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2f49dab-af55-4ada-b0e4-73415f0a6d41", "node_type": "1", "metadata": {"window": "Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n ", "original_text": "For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n "}, "hash": "93072ab74eabcc1bc581b94922cefea843dcdd6f097ba067223a48ca98625445", "class_name": "RelatedNodeInfo"}}, "text": "In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.  ", "start_char_idx": 998, "end_char_idx": 1110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2f49dab-af55-4ada-b0e4-73415f0a6d41": {"__data__": {"id_": "e2f49dab-af55-4ada-b0e4-73415f0a6d41", "embedding": null, "metadata": {"window": "Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n ", "original_text": "For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66335f33-bc7d-4111-8a9a-847897b30481", "node_type": "1", "metadata": {"window": "These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.   Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n", "original_text": "In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35ec91f5b3f09857fb2b60d8a3d791beb023da1d2e5a26d177823bc3ee5afbe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55503605-18c2-474d-aa20-a119f5e2eb46", "node_type": "1", "metadata": {"window": "While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.  ", "original_text": "The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n "}, "hash": "0775207738423b2acc8a28cac36de57f3ad853fd3c87868189a367b925780555", "class_name": "RelatedNodeInfo"}}, "text": "For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n ", "start_char_idx": 1110, "end_char_idx": 1273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55503605-18c2-474d-aa20-a119f5e2eb46": {"__data__": {"id_": "55503605-18c2-474d-aa20-a119f5e2eb46", "embedding": null, "metadata": {"window": "While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.  ", "original_text": "The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2f49dab-af55-4ada-b0e4-73415f0a6d41", "node_type": "1", "metadata": {"window": "Across the company, we are working diligent ly to meet our customers' current \nneeds while also looking ahead to what they might need in the future.   While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n ", "original_text": "For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5a0655182a5147f3ae4a5983c34b9a4653e7ed4adb66bc4956a69b83c392449", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6f76547-f46e-4e4e-ab6a-de53a1384069", "node_type": "1", "metadata": {"window": "In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n ", "original_text": "In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n"}, "hash": "2c987c604bfea871ac2867f229bc997dc1d37306d30d94ca548c91350db53d51", "class_name": "RelatedNodeInfo"}}, "text": "The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n ", "start_char_idx": 1273, "end_char_idx": 1469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6f76547-f46e-4e4e-ab6a-de53a1384069": {"__data__": {"id_": "f6f76547-f46e-4e4e-ab6a-de53a1384069", "embedding": null, "metadata": {"window": "In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n ", "original_text": "In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55503605-18c2-474d-aa20-a119f5e2eb46", "node_type": "1", "metadata": {"window": "While doing all of this, we \nremain highly focused on our internal and external responses to the pandemic.  \n \n  In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.  ", "original_text": "The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6daf854e56a68192a85b77503efdaaff8ab6accf9d4a855931ffcf158ad1aaf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc09c02a-8256-4e3b-836c-d6d065c1e0d9", "node_type": "1", "metadata": {"window": "For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n ", "original_text": "And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n "}, "hash": "73dc1338fdb7e57ba31774c686312e1172135e7a1c5881b35f3b8eeb70303120", "class_name": "RelatedNodeInfo"}}, "text": "In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n", "start_char_idx": 1469, "end_char_idx": 1663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc09c02a-8256-4e3b-836c-d6d065c1e0d9": {"__data__": {"id_": "dc09c02a-8256-4e3b-836c-d6d065c1e0d9", "embedding": null, "metadata": {"window": "For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n ", "original_text": "And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6f76547-f46e-4e4e-ab6a-de53a1384069", "node_type": "1", "metadata": {"window": "In medical we implemented multiple measures  to address ongoing supply challenges for PPE \nproduct categories.   For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n ", "original_text": "In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a746ca738578f3baebcef20f10c6ffc030ac0cc3eb22b88a75ec4fe4c514313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b19c9f3-c3c5-4bb7-8e9c-c504a901d137", "node_type": "1", "metadata": {"window": "The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n", "original_text": "As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.  "}, "hash": "43fc9861adfaf8134e20f315da98456989961e2fb2ae3ba8ea71e2cf700da6f8", "class_name": "RelatedNodeInfo"}}, "text": "And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n ", "start_char_idx": 1663, "end_char_idx": 1818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b19c9f3-c3c5-4bb7-8e9c-c504a901d137": {"__data__": {"id_": "4b19c9f3-c3c5-4bb7-8e9c-c504a901d137", "embedding": null, "metadata": {"window": "The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n", "original_text": "As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc09c02a-8256-4e3b-836c-d6d065c1e0d9", "node_type": "1", "metadata": {"window": "For example, we established our supply assurance program to provide \nconsistent, long -range supply for our products, including exam gloves, gowns and masks.  \n \n  The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n ", "original_text": "And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6caf7840d022d88db156556b4eba6cb990e6abecbcc4faf0dec032dd8cf6e6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "564ed94c-9e0c-4a66-9899-f6e9ab802976", "node_type": "1", "metadata": {"window": "In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.  ", "original_text": "I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n "}, "hash": "a8d136ab87943a11986a9ceda2ecc004012d02127af464071fc31fadf6083ddb", "class_name": "RelatedNodeInfo"}}, "text": "As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.  ", "start_char_idx": 1818, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "564ed94c-9e0c-4a66-9899-f6e9ab802976": {"__data__": {"id_": "564ed94c-9e0c-4a66-9899-f6e9ab802976", "embedding": null, "metadata": {"window": "In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.  ", "original_text": "I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b19c9f3-c3c5-4bb7-8e9c-c504a901d137", "node_type": "1", "metadata": {"window": "The program has been positively received, and this collaboration with our customers will \nenable us to collectively navigate supply volatility and deliver critical products for patient care.  \n \n  In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n", "original_text": "As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f83c54066e82813173ee69fec113dbc97da4d777781e838282ac84844ce3ab1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f4d8b6a-9c71-4477-b1e8-48860c36a312", "node_type": "1", "metadata": {"window": "And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.  ", "original_text": "We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n "}, "hash": "bf22b373cbe8c702b5206b410388e85aaae49451242e521bd4b7ae93305bfa46", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n ", "start_char_idx": 1980, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f4d8b6a-9c71-4477-b1e8-48860c36a312": {"__data__": {"id_": "9f4d8b6a-9c71-4477-b1e8-48860c36a312", "embedding": null, "metadata": {"window": "And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.  ", "original_text": "We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "564ed94c-9e0c-4a66-9899-f6e9ab802976", "node_type": "1", "metadata": {"window": "In pharma we are constantly monitoring evolving treatment patterns, collaborating wit h the \nteam at Red Oak to ensure supply and focusing on delivering the industry's highest service levels.  \n And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.  ", "original_text": "I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc6e759d4cd65f1f38906e1e54d7a4f3d8fcec273460eb77f3d8a48032758d70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd4d2f16-208e-47d5-af01-a64978644e09", "node_type": "1", "metadata": {"window": "As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n ", "original_text": "With that I'll pause to open it up for questions.  \n \n"}, "hash": "e2952dcb31b37cd89be7553fe5add0f1d1fcf0f7ca7e91d70adae143b1f7e573", "class_name": "RelatedNodeInfo"}}, "text": "We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n ", "start_char_idx": 2111, "end_char_idx": 2279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd4d2f16-208e-47d5-af01-a64978644e09": {"__data__": {"id_": "cd4d2f16-208e-47d5-af01-a64978644e09", "embedding": null, "metadata": {"window": "As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n ", "original_text": "With that I'll pause to open it up for questions.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f4d8b6a-9c71-4477-b1e8-48860c36a312", "node_type": "1", "metadata": {"window": "And across the company, we continue to aggressively control our expenses to ensure we deliver on \nall of our commitments and create long -term value.  \n \n  As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.  ", "original_text": "We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35872ef6be3635796fa169bc83dad140e92d56e105dcde9797a2400fa5f0db7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5fb5d17-2c39-4173-a05b-7613b3bdc82e", "node_type": "1", "metadata": {"window": "I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?  ", "original_text": "Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.  "}, "hash": "f09215b35248d640fd1d5d833b48f6b7d92c73b744e9f83dc24042e604c6474f", "class_name": "RelatedNodeInfo"}}, "text": "With that I'll pause to open it up for questions.  \n \n", "start_char_idx": 2279, "end_char_idx": 2333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5fb5d17-2c39-4173-a05b-7613b3bdc82e": {"__data__": {"id_": "f5fb5d17-2c39-4173-a05b-7613b3bdc82e", "embedding": null, "metadata": {"window": "I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?  ", "original_text": "Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd4d2f16-208e-47d5-af01-a64978644e09", "node_type": "1", "metadata": {"window": "As I said earlier, we aspire to be health care's most trusted partner and create the greatest \nvalue for our customers, shareholders, communities and employees.   I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n ", "original_text": "With that I'll pause to open it up for questions.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41e877239656e832cd287df7df1e371f5dbcca44a4db337cff9e6c9eaaa054f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1134da6e-4e18-4447-8859-a613f448b045", "node_type": "1", "metadata": {"window": "We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "Congratulations on the good quarter.  "}, "hash": "a6d09ea2d9aade7d14691f5c01d19bf28a15c71db78d833300e439eaa81c971d", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.  ", "start_char_idx": 2333, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1134da6e-4e18-4447-8859-a613f448b045": {"__data__": {"id_": "1134da6e-4e18-4447-8859-a613f448b045", "embedding": null, "metadata": {"window": "We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "Congratulations on the good quarter.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5fb5d17-2c39-4173-a05b-7613b3bdc82e", "node_type": "1", "metadata": {"window": "I want to thank our employees \naround the globe for their integrity, adaptability and persistent  dedication to this mission.  \n \n  We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?  ", "original_text": "Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2547d7d30e02004e7cd6d6616bb25cfb1d5af56006cd0313567ef2eaff13dd58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aa5ec17-5700-4e74-a32a-eef33e9f8793", "node_type": "1", "metadata": {"window": "With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n "}, "hash": "25ea795bd9e70bcefe4b19034af8f37564a0494aa6424fcaf212fffefbe65add", "class_name": "RelatedNodeInfo"}}, "text": "Congratulations on the good quarter.  ", "start_char_idx": 2399, "end_char_idx": 2437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aa5ec17-5700-4e74-a32a-eef33e9f8793": {"__data__": {"id_": "9aa5ec17-5700-4e74-a32a-eef33e9f8793", "embedding": null, "metadata": {"window": "With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1134da6e-4e18-4447-8859-a613f448b045", "node_type": "1", "metadata": {"window": "We are confronting today's challenges and developing tomorrow's solutions with the tenacity, \nagility and innovation that makes Cardinal Health essential to care.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "Congratulations on the good quarter.  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50d8899e13c04ecee6b252c32516499043e8c8c17b1ec633e2b44a904d89a7b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14285215-cfa7-412d-8a0f-5fe857747f62", "node_type": "1", "metadata": {"window": "Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?  "}, "hash": "c3d8bcb44695dd43cc95fd3fe00026776a50f53462b1ae7084ba33e3362c83da", "class_name": "RelatedNodeInfo"}}, "text": "Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n ", "start_char_idx": 2437, "end_char_idx": 2692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14285215-cfa7-412d-8a0f-5fe857747f62": {"__data__": {"id_": "14285215-cfa7-412d-8a0f-5fe857747f62", "embedding": null, "metadata": {"window": "Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aa5ec17-5700-4e74-a32a-eef33e9f8793", "node_type": "1", "metadata": {"window": "With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5950f39aa10b551d2e46a818b9da5678bc2c88b50b2db00a41f485c97a41a822", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4015eeda-f065-428d-8a3c-26eb644e97be", "node_type": "1", "metadata": {"window": "Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the "}, "hash": "a9daa2b357c8c1d0d1cd79d5d44d242554a64aec1970230344a9634b62889cee", "class_name": "RelatedNodeInfo"}}, "text": "If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?  ", "start_char_idx": 2692, "end_char_idx": 2833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4015eeda-f065-428d-8a3c-26eb644e97be": {"__data__": {"id_": "4015eeda-f065-428d-8a3c-26eb644e97be", "embedding": null, "metadata": {"window": "Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96878c1c-63fe-489a-a010-49bb089f92ba", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128e001494dd27a8a74090eddbf460acd3fa945aa40811a4207e9f7e34c3c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14285215-cfa7-412d-8a0f-5fe857747f62", "node_type": "1", "metadata": {"window": "Operator:  Operator Instructions  \n \nMike Cherny:  Good morning.   Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?  ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72f20fb40727e3de2b1164d5e28bece772758dea738cfccfa4c0fd7d89009ad2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79e9e2fa-396c-4d1a-9dfc-5a98f2dbb278", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n ", "original_text": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n"}, "hash": "53d0676d3cbd4c0a4781ff26ab2ef79f230121ab5f109eda0cc22a9b56b7b2aa", "class_name": "RelatedNodeInfo"}}, "text": "And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "start_char_idx": 2833, "end_char_idx": 2990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79e9e2fa-396c-4d1a-9dfc-5a98f2dbb278": {"__data__": {"id_": "79e9e2fa-396c-4d1a-9dfc-5a98f2dbb278", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n ", "original_text": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4015eeda-f065-428d-8a3c-26eb644e97be", "node_type": "1", "metadata": {"window": "Congratulations on the good quarter.   Yes, I guess, I don't know if this \nis a question for Mike or Jason, but I just wanted to dive in a little bit to the medical performance in \nthe quarter and the stren gth that you saw, especially against the backdrop with some of the PPE \ndynamics.  \n \n  If you can even parse it a little further, was there anything that was more short -term in nature in \nterms of what you saw in the quarter?   And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "original_text": "And as you think about the risk we ighting of the various \ndifferent tailwinds, headwinds you have tied to the guidance increase, where do you think are the ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8282edb5e1aa05d41ae1e68a1bb740854f5cdb3787607c202f41e0e222993e6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33e489ea-d46f-4ad9-96f5-cded31d34c49", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n ", "original_text": "Mike Kaufmann:  Yes, thanks for the question.  "}, "hash": "f32d8a8391e00f86cecfc79ceca22ade63f80bdd70002b5b8df1101b98d2f569", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n", "start_char_idx": 0, "end_char_idx": 223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33e489ea-d46f-4ad9-96f5-cded31d34c49": {"__data__": {"id_": "33e489ea-d46f-4ad9-96f5-cded31d34c49", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n ", "original_text": "Mike Kaufmann:  Yes, thanks for the question.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79e9e2fa-396c-4d1a-9dfc-5a98f2dbb278", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n ", "original_text": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3ec0ce90d53d12324e043d67259babf286bf391a037801705a05a8e9322a753", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ddc3da3-19b0-4715-a592-fbdb832d2d2d", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.  ", "original_text": "I'll start and then I'll turn it over to Jason.  "}, "hash": "f86b303f9356f82b98ff7d6f08823755333e35ba348ae74701387b14e6fc7092", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, thanks for the question.  ", "start_char_idx": 223, "end_char_idx": 270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ddc3da3-19b0-4715-a592-fbdb832d2d2d": {"__data__": {"id_": "5ddc3da3-19b0-4715-a592-fbdb832d2d2d", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.  ", "original_text": "I'll start and then I'll turn it over to Jason.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33e489ea-d46f-4ad9-96f5-cded31d34c49", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n ", "original_text": "Mike Kaufmann:  Yes, thanks for the question.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d1c46c212b5d1fbc3cc2877f1462d7df64c95b53713445e23ca9d30fcb63079", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6600a5c5-640d-4a28-b997-6dc9fac60f69", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n", "original_text": "First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n "}, "hash": "9106adcfaa918966a931b8c89911b367fe9cb690d43a825906b3cbf9bac6ad30", "class_name": "RelatedNodeInfo"}}, "text": "I'll start and then I'll turn it over to Jason.  ", "start_char_idx": 270, "end_char_idx": 319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6600a5c5-640d-4a28-b997-6dc9fac60f69": {"__data__": {"id_": "6600a5c5-640d-4a28-b997-6dc9fac60f69", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n", "original_text": "First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ddc3da3-19b0-4715-a592-fbdb832d2d2d", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.  ", "original_text": "I'll start and then I'll turn it over to Jason.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55e095b1c1acdc8ab34f629577ba2d3038363a7c25c45f0b9fab40a9573c5f4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6fe9835-ebdd-4107-b7f8-fff83e9f6907", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.  ", "original_text": "The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n "}, "hash": "2645a1600a16af37585f3f3b99d06556f23342e909539c9568ef17cf872155ec", "class_name": "RelatedNodeInfo"}}, "text": "First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n ", "start_char_idx": 319, "end_char_idx": 441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6fe9835-ebdd-4107-b7f8-fff83e9f6907": {"__data__": {"id_": "d6fe9835-ebdd-4107-b7f8-fff83e9f6907", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.  ", "original_text": "The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6600a5c5-640d-4a28-b997-6dc9fac60f69", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n", "original_text": "First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59b84fdddcdeedc8b12f4e52e623999ec7382d3859c8400da3aaa59982aa963b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0095e074-aa17-4851-9bf0-16af8583a376", "node_type": "1", "metadata": {"window": "I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.  ", "original_text": "So a lot of really good progress with Steve and his team.  "}, "hash": "8cf9ff8ad861db68a1df95d8eee82acb6f26c8e19cd5cbc43661a6f21b0148f7", "class_name": "RelatedNodeInfo"}}, "text": "The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n ", "start_char_idx": 441, "end_char_idx": 782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0095e074-aa17-4851-9bf0-16af8583a376": {"__data__": {"id_": "0095e074-aa17-4851-9bf0-16af8583a376", "embedding": null, "metadata": {"window": "I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.  ", "original_text": "So a lot of really good progress with Steve and his team.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6fe9835-ebdd-4107-b7f8-fff83e9f6907", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.  ", "original_text": "The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd5f290e4d6f493925da11e998906be673d4d93b934e7212d8889294a94996e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20292e99-b9e8-444b-87aa-4b7c6ef651c2", "node_type": "1", "metadata": {"window": "First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.  ", "original_text": "But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n"}, "hash": "df070380369cf33ecd14e9f6a37c711dfdce68be489a99d3408306336cc33132", "class_name": "RelatedNodeInfo"}}, "text": "So a lot of really good progress with Steve and his team.  ", "start_char_idx": 782, "end_char_idx": 841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20292e99-b9e8-444b-87aa-4b7c6ef651c2": {"__data__": {"id_": "20292e99-b9e8-444b-87aa-4b7c6ef651c2", "embedding": null, "metadata": {"window": "First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.  ", "original_text": "But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0095e074-aa17-4851-9bf0-16af8583a376", "node_type": "1", "metadata": {"window": "I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.  ", "original_text": "So a lot of really good progress with Steve and his team.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0383557ada1d1aa0336a01926bfce44eddf16413767f70070ab9071c318c94dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afdc40a0-2acd-4f22-9eb4-23a9b59a0b30", "node_type": "1", "metadata": {"window": "The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n ", "original_text": "Jason Hollar:  Sure.  "}, "hash": "9bdd950cf8dcda774ec4ecc4d670577d29e3015d488a284ff60d25a0bd0ee39b", "class_name": "RelatedNodeInfo"}}, "text": "But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n", "start_char_idx": 841, "end_char_idx": 969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afdc40a0-2acd-4f22-9eb4-23a9b59a0b30": {"__data__": {"id_": "afdc40a0-2acd-4f22-9eb4-23a9b59a0b30", "embedding": null, "metadata": {"window": "The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20292e99-b9e8-444b-87aa-4b7c6ef651c2", "node_type": "1", "metadata": {"window": "First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n  The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.  ", "original_text": "But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "301413225934af7739b164a760e7f5444e9c85ebb9f29ee31c9d01123b2fe7a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fea7dfea-602d-42f0-a86a-3c67d71dcdb6", "node_type": "1", "metadata": {"window": "So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.  ", "original_text": "Thanks, Mike.  "}, "hash": "6e37f64de68692472dab1d68054062e18b93713514c3e3a123ff228b9e2e6fee", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure.  ", "start_char_idx": 969, "end_char_idx": 991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fea7dfea-602d-42f0-a86a-3c67d71dcdb6": {"__data__": {"id_": "fea7dfea-602d-42f0-a86a-3c67d71dcdb6", "embedding": null, "metadata": {"window": "So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.  ", "original_text": "Thanks, Mike.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afdc40a0-2acd-4f22-9eb4-23a9b59a0b30", "node_type": "1", "metadata": {"window": "The team did a really good job this quarter of staying not only focused on driving expenses for \nthe quarter in relation to the uncertainty of the pandemic but also, continuing to get after the longer -\nterm expense initiatives we had and  working on a lot of the other strategic initiatives we talked about, \nlike our commercial work.  \n \n  So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d018477daf912369c293cc1a3c027f90c6175268cde3ddc76dee04c285a8cdc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4529007f-78a4-42a9-9e6a-1a65394f5383", "node_type": "1", "metadata": {"window": "But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.  ", "original_text": "Yes, first of all, we should start with the COVID impacts.  "}, "hash": "39bebee709cb18b34b26739856da268641ad75021206783b25634c9cce396d9b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Mike.  ", "start_char_idx": 991, "end_char_idx": 1006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4529007f-78a4-42a9-9e6a-1a65394f5383": {"__data__": {"id_": "4529007f-78a4-42a9-9e6a-1a65394f5383", "embedding": null, "metadata": {"window": "But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.  ", "original_text": "Yes, first of all, we should start with the COVID impacts.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fea7dfea-602d-42f0-a86a-3c67d71dcdb6", "node_type": "1", "metadata": {"window": "So a lot of really good progress with Steve and his team.   But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.  ", "original_text": "Thanks, Mike.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8734ecdd25869372c77e19e9d9bbd6840b8205627bd9cd977be5ed4892272c64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01771693-41da-42cb-a7d7-eb8582cb6b77", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.  ", "original_text": "And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n "}, "hash": "9f241dbcf3f282f43d29f3e62effa096b1fbb2110e689b39d02fa3ea210601a6", "class_name": "RelatedNodeInfo"}}, "text": "Yes, first of all, we should start with the COVID impacts.  ", "start_char_idx": 1006, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01771693-41da-42cb-a7d7-eb8582cb6b77": {"__data__": {"id_": "01771693-41da-42cb-a7d7-eb8582cb6b77", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.  ", "original_text": "And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4529007f-78a4-42a9-9e6a-1a65394f5383", "node_type": "1", "metadata": {"window": "But I am going to turn it over to \nJason, so he can give you a little bit more of some of the color you would like to hear.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.  ", "original_text": "Yes, first of all, we should start with the COVID impacts.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08946320f3201f25ab1b607858b947c812767e720c96c20a58686db0aa508250", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a21cfb1-3485-464f-a999-7d769f1c9c6b", "node_type": "1", "metadata": {"window": "Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n ", "original_text": "Of course, there 's a lot going on within that.  "}, "hash": "70f4581e9f09f36d748b21812f42bdc908012752f867fcc8560472eb9fbdbc57", "class_name": "RelatedNodeInfo"}}, "text": "And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n ", "start_char_idx": 1066, "end_char_idx": 1189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a21cfb1-3485-464f-a999-7d769f1c9c6b": {"__data__": {"id_": "5a21cfb1-3485-464f-a999-7d769f1c9c6b", "embedding": null, "metadata": {"window": "Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n ", "original_text": "Of course, there 's a lot going on within that.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01771693-41da-42cb-a7d7-eb8582cb6b77", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.  ", "original_text": "And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5d6373c32350b92128c40ca3bc78dd59c0892002364bc91f7b111b71852d47d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "919c2e7c-94fd-41f6-be0b-f5d74273931f", "node_type": "1", "metadata": {"window": "Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.  ", "original_text": "So there is still a headwind year -over-year as it \nrelates to the lower elective volume.  "}, "hash": "cfccedc12faba191cd05ae9ce5595f57edc1fe634c865e210529453298520181", "class_name": "RelatedNodeInfo"}}, "text": "Of course, there 's a lot going on within that.  ", "start_char_idx": 1189, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "919c2e7c-94fd-41f6-be0b-f5d74273931f": {"__data__": {"id_": "919c2e7c-94fd-41f6-be0b-f5d74273931f", "embedding": null, "metadata": {"window": "Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.  ", "original_text": "So there is still a headwind year -over-year as it \nrelates to the lower elective volume.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a21cfb1-3485-464f-a999-7d769f1c9c6b", "node_type": "1", "metadata": {"window": "Thanks, Mike.   Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n ", "original_text": "Of course, there 's a lot going on within that.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169657348de82ede0700c8e8255a0dbd659734e88cfe374084a01134e61a6e7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "228d19a2-5ecd-4efc-aa3e-097bf17ab12f", "node_type": "1", "metadata": {"window": "And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n ", "original_text": "However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.  "}, "hash": "e0476d1150e8e33a26418222e34024788fa7d5a93813c70938507511b2a170ea", "class_name": "RelatedNodeInfo"}}, "text": "So there is still a headwind year -over-year as it \nrelates to the lower elective volume.  ", "start_char_idx": 1238, "end_char_idx": 1329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "228d19a2-5ecd-4efc-aa3e-097bf17ab12f": {"__data__": {"id_": "228d19a2-5ecd-4efc-aa3e-097bf17ab12f", "embedding": null, "metadata": {"window": "And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n ", "original_text": "However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "919c2e7c-94fd-41f6-be0b-f5d74273931f", "node_type": "1", "metadata": {"window": "Yes, first of all, we should start with the COVID impacts.   And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.  ", "original_text": "So there is still a headwind year -over-year as it \nrelates to the lower elective volume.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70ce55d1c7eedfcb00516726f2e506339434e194962b4fb93f21c8570798f8c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "107e9590-764a-4972-aaf0-0c5015acab24", "node_type": "1", "metadata": {"window": "Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.  ", "original_text": "So all \nthose items came together in a way that effectively offset one another.  \n \n "}, "hash": "9c4e588c5dd0ce17b693d30560a11642f4b9ac59174721fa25471cc1166bad71", "class_name": "RelatedNodeInfo"}}, "text": "However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.  ", "start_char_idx": 1329, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "107e9590-764a-4972-aaf0-0c5015acab24": {"__data__": {"id_": "107e9590-764a-4972-aaf0-0c5015acab24", "embedding": null, "metadata": {"window": "Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.  ", "original_text": "So all \nthose items came together in a way that effectively offset one another.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "228d19a2-5ecd-4efc-aa3e-097bf17ab12f", "node_type": "1", "metadata": {"window": "And the \nkey point is that within the quarter, there was a relatively minimal impact on the business on a net \nbasis.  \n \n  Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n ", "original_text": "However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1dfc1b02dde0a65add2a99c7c41b9c66b1989426260818f74c647c9555a09175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38927753-5255-450b-9612-1d9165ba4a23", "node_type": "1", "metadata": {"window": "So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n ", "original_text": "Another key point that you referenced, and I didn't reference here, is PPE.  "}, "hash": "deceb050d6f91f7b89f206dc76020b2dc1202d4a3cf5f71c4bac811d00a1a182", "class_name": "RelatedNodeInfo"}}, "text": "So all \nthose items came together in a way that effectively offset one another.  \n \n ", "start_char_idx": 1484, "end_char_idx": 1569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38927753-5255-450b-9612-1d9165ba4a23": {"__data__": {"id_": "38927753-5255-450b-9612-1d9165ba4a23", "embedding": null, "metadata": {"window": "So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n ", "original_text": "Another key point that you referenced, and I didn't reference here, is PPE.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "107e9590-764a-4972-aaf0-0c5015acab24", "node_type": "1", "metadata": {"window": "Of course, there 's a lot going on within that.   So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.  ", "original_text": "So all \nthose items came together in a way that effectively offset one another.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b05831ae505bcb923dc36694f3d989663f10ba25a0b04deeb4f5cb6b71de7894", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57aa9b66-6b57-401a-96e4-21bfa56d9d5a", "node_type": "1", "metadata": {"window": "However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.  ", "original_text": "For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n "}, "hash": "e84988f74fe4afc63ecbdc7fd43369603d148697d2e307ea967f9156bd028317", "class_name": "RelatedNodeInfo"}}, "text": "Another key point that you referenced, and I didn't reference here, is PPE.  ", "start_char_idx": 1569, "end_char_idx": 1646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57aa9b66-6b57-401a-96e4-21bfa56d9d5a": {"__data__": {"id_": "57aa9b66-6b57-401a-96e4-21bfa56d9d5a", "embedding": null, "metadata": {"window": "However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.  ", "original_text": "For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38927753-5255-450b-9612-1d9165ba4a23", "node_type": "1", "metadata": {"window": "So there is still a headwind year -over-year as it \nrelates to the lower elective volume.   However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n ", "original_text": "Another key point that you referenced, and I didn't reference here, is PPE.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a0e72951a15f4fd102022dd20d22c3bb20c37fd647b71e1a8b58c8d1642a449", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22531a03-2104-485f-a2cd-3bb4e85c471e", "node_type": "1", "metadata": {"window": "So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n ", "original_text": "So for the first quarter that all kind of offset.  "}, "hash": "1e4d73e77aa782316e1a996127066d691432f9f91d891444bfab8e0a7e8313d0", "class_name": "RelatedNodeInfo"}}, "text": "For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n ", "start_char_idx": 1646, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22531a03-2104-485f-a2cd-3bb4e85c471e": {"__data__": {"id_": "22531a03-2104-485f-a2cd-3bb4e85c471e", "embedding": null, "metadata": {"window": "So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n ", "original_text": "So for the first quarter that all kind of offset.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57aa9b66-6b57-401a-96e4-21bfa56d9d5a", "node_type": "1", "metadata": {"window": "However, that was offset in part by some of those COVID \nspecific costs that Mike had referenced, but also increased volume in our lab t esting business.   So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.  ", "original_text": "For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf90af28145a81b685ab1d9407eb9a2b79fb82bdce351b6d9519b01fa977fb6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d85dbb8-1a5b-4913-af1b-9da406f36748", "node_type": "1", "metadata": {"window": "Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.  ", "original_text": "I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n "}, "hash": "fd8a034234de7b6b819fc22ffa0f80ecc48fd9fe09054a08278508cda9d37edb", "class_name": "RelatedNodeInfo"}}, "text": "So for the first quarter that all kind of offset.  ", "start_char_idx": 1799, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d85dbb8-1a5b-4913-af1b-9da406f36748": {"__data__": {"id_": "0d85dbb8-1a5b-4913-af1b-9da406f36748", "embedding": null, "metadata": {"window": "Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.  ", "original_text": "I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22531a03-2104-485f-a2cd-3bb4e85c471e", "node_type": "1", "metadata": {"window": "So all \nthose items came together in a way that effectively offset one another.  \n \n  Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n ", "original_text": "So for the first quarter that all kind of offset.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4196d804ddd2dc7fb2a0b235c6d7bc3a914bd2a0ce4b6f3596394f4a27beba03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a77d7f2-9ecf-4b35-938c-ece5c879480a", "node_type": "1", "metadata": {"window": "For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n ", "original_text": "As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.  "}, "hash": "32eecceb4a501c789a60ec5346c8eb703ea7e5f6fdffc3815251a95db2548d45", "class_name": "RelatedNodeInfo"}}, "text": "I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n ", "start_char_idx": 1850, "end_char_idx": 2025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a77d7f2-9ecf-4b35-938c-ece5c879480a": {"__data__": {"id_": "5a77d7f2-9ecf-4b35-938c-ece5c879480a", "embedding": null, "metadata": {"window": "For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n ", "original_text": "As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d85dbb8-1a5b-4913-af1b-9da406f36748", "node_type": "1", "metadata": {"window": "Another key point that you referenced, and I didn't reference here, is PPE.   For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.  ", "original_text": "I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f95dbdd1d500ac9452ba7a28006601509c8e91368bda5a6f2f497b1540941b93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee2de254-486f-4498-89ea-8c04c4229aea", "node_type": "1", "metadata": {"window": "So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.  ", "original_text": "So that \nwas very much consi stent with our expectations.  \n \n "}, "hash": "8f838baca4a79f385f3b086c1491707bf2028219f2fbee92944f4eb585ac1a09", "class_name": "RelatedNodeInfo"}}, "text": "As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.  ", "start_char_idx": 2025, "end_char_idx": 2219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee2de254-486f-4498-89ea-8c04c4229aea": {"__data__": {"id_": "ee2de254-486f-4498-89ea-8c04c4229aea", "embedding": null, "metadata": {"window": "So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.  ", "original_text": "So that \nwas very much consi stent with our expectations.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a77d7f2-9ecf-4b35-938c-ece5c879480a", "node_type": "1", "metadata": {"window": "For the quarter, we \nsaw that the increased costs that we did recognize were miti gated through price increases that also \nhappened in the quarter.  \n \n  So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n ", "original_text": "As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1f96134f894b73574eeea74dcfd4430f11d7be6282078e047768c560563c40b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d21b9620-cd26-4d34-8300-d7f018294301", "node_type": "1", "metadata": {"window": "I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.  "}, "hash": "90f3676baa5f0fac20e365d3e8b992ed64b2adc907716295077f428c585a5593", "class_name": "RelatedNodeInfo"}}, "text": "So that \nwas very much consi stent with our expectations.  \n \n ", "start_char_idx": 2219, "end_char_idx": 2282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d21b9620-cd26-4d34-8300-d7f018294301": {"__data__": {"id_": "d21b9620-cd26-4d34-8300-d7f018294301", "embedding": null, "metadata": {"window": "I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee2de254-486f-4498-89ea-8c04c4229aea", "node_type": "1", "metadata": {"window": "So for the first quarter that all kind of offset.   I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.  ", "original_text": "So that \nwas very much consi stent with our expectations.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eacadd3908c80e0b8eae760d1b72160a744b4a32ed580f4318a18ef74366eaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "168ce4c9-ba9d-4467-b16c-24c7fe96061b", "node_type": "1", "metadata": {"window": "As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n "}, "hash": "5546f6676b8d1d5233f412c31eaf7e8e15eabe8fb029f57dadbb4f81b8f96257", "class_name": "RelatedNodeInfo"}}, "text": "But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.  ", "start_char_idx": 2282, "end_char_idx": 2428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "168ce4c9-ba9d-4467-b16c-24c7fe96061b": {"__data__": {"id_": "168ce4c9-ba9d-4467-b16c-24c7fe96061b", "embedding": null, "metadata": {"window": "As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d21b9620-cd26-4d34-8300-d7f018294301", "node_type": "1", "metadata": {"window": "I'll come back to that point in a second but for the \nrest of the performance within medical, for the segment, for the quarter, there were also additional \ncost savings.  \n \n  As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f4a0e16a0d6a3c9b2adba9447ce295ff3ac3edf7605c150ad5ff94990a48506", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a713cb1-34c3-4137-8e6f-b7834a77db56", "node_type": "1", "metadata": {"window": "So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.  "}, "hash": "7e9a09f2d962801c85b50fe41984cf4c19164fff1f89af93fd399b4b0fa7bcb8", "class_name": "RelatedNodeInfo"}}, "text": "And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n ", "start_char_idx": 2428, "end_char_idx": 2566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a713cb1-34c3-4137-8e6f-b7834a77db56": {"__data__": {"id_": "7a713cb1-34c3-4137-8e6f-b7834a77db56", "embedding": null, "metadata": {"window": "So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "168ce4c9-ba9d-4467-b16c-24c7fe96061b", "node_type": "1", "metadata": {"window": "As Mike indicated, this was led by the ongoing multi -year effort into building healthier future \ninitiative that was really getting after global manufacturing and supply chain transformation.   So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e2200cebc43dd426e58b82b2c0c3a01b8c2cc836a7b56cdfb343ed9edab2ec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52706fb1-58f4-48f8-8a86-5d301d160f71", "node_type": "1", "metadata": {"window": "But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "So we have a good balance included within our guidance for all \nthose items.  \n "}, "hash": "bdade13ef1d605667dd27967165af5a0dd292f03233502fd32636c728d31d4d2", "class_name": "RelatedNodeInfo"}}, "text": "That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.  ", "start_char_idx": 2566, "end_char_idx": 2694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52706fb1-58f4-48f8-8a86-5d301d160f71": {"__data__": {"id_": "52706fb1-58f4-48f8-8a86-5d301d160f71", "embedding": null, "metadata": {"window": "But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "So we have a good balance included within our guidance for all \nthose items.  \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c726332ff0109363063b779e3e958830d3ab3206177cc356ff920fe9dae93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a713cb1-34c3-4137-8e6f-b7834a77db56", "node_type": "1", "metadata": {"window": "So that \nwas very much consi stent with our expectations.  \n \n  But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.  ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2eaa099eae4bef80b8f68a7a6d4cd7d43a5ec5eb4c446b37a4b6718f51b0f96b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2199d210-8890-4d09-9dc1-851ecb8fd171", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.  ", "original_text": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n "}, "hash": "4223d4154b1fd016e6a0c646e46327d5d0325e9da5c4f2809ca6b0a646ac8c29", "class_name": "RelatedNodeInfo"}}, "text": "So we have a good balance included within our guidance for all \nthose items.  \n ", "start_char_idx": 2694, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2199d210-8890-4d09-9dc1-851ecb8fd171": {"__data__": {"id_": "2199d210-8890-4d09-9dc1-851ecb8fd171", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.  ", "original_text": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52706fb1-58f4-48f8-8a86-5d301d160f71", "node_type": "1", "metadata": {"window": "But as Mike highlighted, there were also some additional aggressive cost controls that we put \nin place due to the uncertainties in the quarter.   And we saw some really great flow through of those \nactions in terms of delaying some open positions and managing third party spend.  \n \n  That may be a bit more temporary in nature and is something that we'll continue to work to see \nif we can make more permanent.   So we have a good balance included within our guidance for all \nthose items.  \n ", "original_text": "So we have a good balance included within our guidance for all \nthose items.  \n ", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62a22d5d660539d3f00dc3db0bb3956cbd463d036e1f13b23c801afe4ce22396", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fe48257-8615-4d1f-abd3-587290841f8d", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n ", "original_text": "We have procured these higher cost PPE inven tory items, but it's in transit.  "}, "hash": "4fa177cc2a02b8cc6d0c0e783cde3fcb0928fb3efe2cedb5e6dafa4a84ae81d8", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n ", "start_char_idx": 0, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fe48257-8615-4d1f-abd3-587290841f8d": {"__data__": {"id_": "3fe48257-8615-4d1f-abd3-587290841f8d", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n ", "original_text": "We have procured these higher cost PPE inven tory items, but it's in transit.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2199d210-8890-4d09-9dc1-851ecb8fd171", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.  ", "original_text": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26bccef7a37c4fd1229ec4d184d46a1c143f0903cbe69bfe1e3616ab80b1b796", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "326d4427-95cd-4dce-8022-c5bac9e9a803", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.  ", "original_text": "A lot of that \nvolume is in transit.  "}, "hash": "c495c9cdf48de24e692fdac3b60aa88a801ce3e5244e23527bc0a4116b4fbb32", "class_name": "RelatedNodeInfo"}}, "text": "We have procured these higher cost PPE inven tory items, but it's in transit.  ", "start_char_idx": 233, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "326d4427-95cd-4dce-8022-c5bac9e9a803": {"__data__": {"id_": "326d4427-95cd-4dce-8022-c5bac9e9a803", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.  ", "original_text": "A lot of that \nvolume is in transit.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fe48257-8615-4d1f-abd3-587290841f8d", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n ", "original_text": "We have procured these higher cost PPE inven tory items, but it's in transit.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25a3f443307babda3f3e4779f3508e1b0a1ffd059d85515598878d88487061fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ff9b0d4-2927-4da0-b9dd-9098a1c6119c", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.  ", "original_text": "So we know that we will be incurring those costs.  "}, "hash": "944bfe1731e42401572547541c008006503bc4600703321c75eab7a221f49459", "class_name": "RelatedNodeInfo"}}, "text": "A lot of that \nvolume is in transit.  ", "start_char_idx": 312, "end_char_idx": 350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ff9b0d4-2927-4da0-b9dd-9098a1c6119c": {"__data__": {"id_": "7ff9b0d4-2927-4da0-b9dd-9098a1c6119c", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.  ", "original_text": "So we know that we will be incurring those costs.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "326d4427-95cd-4dce-8022-c5bac9e9a803", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.  ", "original_text": "A lot of that \nvolume is in transit.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c290ef8acdcb1d79dcfd4f163b06c5a477d535aed2562c0a4e26f3fd4e48ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "782e5dd5-f2d5-4637-8d57-4484e5441752", "node_type": "1", "metadata": {"window": "We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n ", "original_text": "A lot of it's already on our \nbalance sheet and our inventory.  \n \n "}, "hash": "e777134c6fe49de98aed6fcec986e422179c5dc45905d98fd1b50340121a8044", "class_name": "RelatedNodeInfo"}}, "text": "So we know that we will be incurring those costs.  ", "start_char_idx": 350, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "782e5dd5-f2d5-4637-8d57-4484e5441752": {"__data__": {"id_": "782e5dd5-f2d5-4637-8d57-4484e5441752", "embedding": null, "metadata": {"window": "We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n ", "original_text": "A lot of it's already on our \nbalance sheet and our inventory.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ff9b0d4-2927-4da0-b9dd-9098a1c6119c", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.  ", "original_text": "So we know that we will be incurring those costs.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb6d66aa992bec64ce68c8ce6b9238e3bbad97d72d5e1e9bd74e38c1e8ec4d11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e10fe546-f601-43e8-9547-8750e8f8f027", "node_type": "1", "metadata": {"window": "A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n ", "original_text": "And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.  "}, "hash": "4b68f66a47751f5fb79bca88d90044eb0aa9c42d35ca12206fb6e03ec65043af", "class_name": "RelatedNodeInfo"}}, "text": "A lot of it's already on our \nbalance sheet and our inventory.  \n \n ", "start_char_idx": 401, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e10fe546-f601-43e8-9547-8750e8f8f027": {"__data__": {"id_": "e10fe546-f601-43e8-9547-8750e8f8f027", "embedding": null, "metadata": {"window": "A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n ", "original_text": "And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "782e5dd5-f2d5-4637-8d57-4484e5441752", "node_type": "1", "metadata": {"window": "We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n ", "original_text": "A lot of it's already on our \nbalance sheet and our inventory.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdd8e557a6e198c0df33b233ccd1256a982d9d56a8ac9fec6f9aca2835d7f19c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fc8e2b2-a762-4432-9e9c-bb36c16fa5ca", "node_type": "1", "metadata": {"window": "So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.  ", "original_text": "And, of course, we're also raising prices, consistent with that.  "}, "hash": "7456f7ce208918a5fa26fb3e8a74229e4433a6958de494222ff4dd1b45045185", "class_name": "RelatedNodeInfo"}}, "text": "And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.  ", "start_char_idx": 469, "end_char_idx": 586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fc8e2b2-a762-4432-9e9c-bb36c16fa5ca": {"__data__": {"id_": "3fc8e2b2-a762-4432-9e9c-bb36c16fa5ca", "embedding": null, "metadata": {"window": "So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.  ", "original_text": "And, of course, we're also raising prices, consistent with that.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e10fe546-f601-43e8-9547-8750e8f8f027", "node_type": "1", "metadata": {"window": "A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n ", "original_text": "And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71c42cbeaaaf9a91ba036b7f28f76dbab37b9e8b3c6a175f28f6e2df1428eeeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05bac6d9-a8f9-4209-89a6-ee29542b71a8", "node_type": "1", "metadata": {"window": "A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n", "original_text": "However there \nare some timing elements that don't line up perfectly between the two.  \n \n "}, "hash": "bc74c9376fde182b67844077e9bde3ff33dc18bc2eb681df0585907125f57daf", "class_name": "RelatedNodeInfo"}}, "text": "And, of course, we're also raising prices, consistent with that.  ", "start_char_idx": 586, "end_char_idx": 652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05bac6d9-a8f9-4209-89a6-ee29542b71a8": {"__data__": {"id_": "05bac6d9-a8f9-4209-89a6-ee29542b71a8", "embedding": null, "metadata": {"window": "A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n", "original_text": "However there \nare some timing elements that don't line up perfectly between the two.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fc8e2b2-a762-4432-9e9c-bb36c16fa5ca", "node_type": "1", "metadata": {"window": "So we know that we will be incurring those costs.   A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.  ", "original_text": "And, of course, we're also raising prices, consistent with that.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71f5fb462f1394f6fccda79c1252b0506072a0fca713a71225fca6484e231709", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce84c58b-6f24-48eb-bc91-ce4f5f7c48b2", "node_type": "1", "metadata": {"window": "And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.  ", "original_text": "So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n "}, "hash": "b1a6ca527377759532c32f94589bbfa2956e1750d69058104204dc8c171d4dd9", "class_name": "RelatedNodeInfo"}}, "text": "However there \nare some timing elements that don't line up perfectly between the two.  \n \n ", "start_char_idx": 652, "end_char_idx": 743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce84c58b-6f24-48eb-bc91-ce4f5f7c48b2": {"__data__": {"id_": "ce84c58b-6f24-48eb-bc91-ce4f5f7c48b2", "embedding": null, "metadata": {"window": "And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.  ", "original_text": "So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05bac6d9-a8f9-4209-89a6-ee29542b71a8", "node_type": "1", "metadata": {"window": "A lot of it's already on our \nbalance sheet and our inventory.  \n \n  And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n", "original_text": "However there \nare some timing elements that don't line up perfectly between the two.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cfc20c709803237d85b8832e9195e721f5ec70d42a3b903148072d717a77fc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "400d773c-803d-4114-aa87-c24896bdd27d", "node_type": "1", "metadata": {"window": "And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n", "original_text": "Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.  "}, "hash": "9f8cd47807c793cdc7e47a7d7c2024e91b85b0e987a9acb0891132f30711e975", "class_name": "RelatedNodeInfo"}}, "text": "So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n ", "start_char_idx": 743, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "400d773c-803d-4114-aa87-c24896bdd27d": {"__data__": {"id_": "400d773c-803d-4114-aa87-c24896bdd27d", "embedding": null, "metadata": {"window": "And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n", "original_text": "Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce84c58b-6f24-48eb-bc91-ce4f5f7c48b2", "node_type": "1", "metadata": {"window": "And we will recognize that higher cost in the second and perhaps third  and fourth quarter as \nwe sell those items.   And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.  ", "original_text": "So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a28a4582c5f55e9e694bda8084d2c1be87baa28356595f3710c9b9dc732fdacc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "538d26ea-92f3-49ed-a9b3-779c672baf6e", "node_type": "1", "metadata": {"window": "However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n", "original_text": "But I would not call tha t \nsignificant.  \n \n"}, "hash": "5bb6abe5a9f89f8e3c654d332712ac33d91c3783f4320d29e2919f8a3f52307c", "class_name": "RelatedNodeInfo"}}, "text": "Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.  ", "start_char_idx": 863, "end_char_idx": 1039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "538d26ea-92f3-49ed-a9b3-779c672baf6e": {"__data__": {"id_": "538d26ea-92f3-49ed-a9b3-779c672baf6e", "embedding": null, "metadata": {"window": "However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n", "original_text": "But I would not call tha t \nsignificant.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "400d773c-803d-4114-aa87-c24896bdd27d", "node_type": "1", "metadata": {"window": "And, of course, we're also raising prices, consistent with that.   However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n", "original_text": "Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b0a64d9949490b4f4026bdb0c2b40ce9de381be9261ea6c31f3145d3b245a5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16edbd6e-2394-4d30-803a-ab4ee2310210", "node_type": "1", "metadata": {"window": "So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes. ", "original_text": "Michael Cherny:  Great.  "}, "hash": "202971d852ad1684314e76302fc3dbd238206584494ae22caddfabe6aea4729c", "class_name": "RelatedNodeInfo"}}, "text": "But I would not call tha t \nsignificant.  \n \n", "start_char_idx": 1039, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16edbd6e-2394-4d30-803a-ab4ee2310210": {"__data__": {"id_": "16edbd6e-2394-4d30-803a-ab4ee2310210", "embedding": null, "metadata": {"window": "So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes. ", "original_text": "Michael Cherny:  Great.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "538d26ea-92f3-49ed-a9b3-779c672baf6e", "node_type": "1", "metadata": {"window": "However there \nare some timing elements that don't line up perfectly between the two.  \n \n  So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n", "original_text": "But I would not call tha t \nsignificant.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8025394cc4c670b3882b5ea9b397621ea2d8b2f5a1120b1e7e38b74a5b80eb0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73f0232a-1cd1-4529-af24-fd87eb8d0930", "node_type": "1", "metadata": {"window": "Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.  ", "original_text": "Thanks.  \n \n"}, "hash": "6a25ad5256e0052f5d749e1248b49bd74863c73527423d3a6357fdb729afbb6d", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:  Great.  ", "start_char_idx": 1084, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73f0232a-1cd1-4529-af24-fd87eb8d0930": {"__data__": {"id_": "73f0232a-1cd1-4529-af24-fd87eb8d0930", "embedding": null, "metadata": {"window": "Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.  ", "original_text": "Thanks.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16edbd6e-2394-4d30-803a-ab4ee2310210", "node_type": "1", "metadata": {"window": "So that's the one element from Q1 to Q2 for the medical bu siness that we would see a bit of \nadditional headwind.  \n \n  Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes. ", "original_text": "Michael Cherny:  Great.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e41a47600542d76bde3896320342f07c55ceb9212ea9ebcb99c86bdaa52c615", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc6eea4a-1d86-434a-82a9-19632fdd8268", "node_type": "1", "metadata": {"window": "But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n ", "original_text": "Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n"}, "hash": "60fedf04bedd3a33d126305257ea190dbd4e0599c07e06c40d5661c1b27b07fa", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1109, "end_char_idx": 1121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc6eea4a-1d86-434a-82a9-19632fdd8268": {"__data__": {"id_": "fc6eea4a-1d86-434a-82a9-19632fdd8268", "embedding": null, "metadata": {"window": "But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n ", "original_text": "Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73f0232a-1cd1-4529-af24-fd87eb8d0930", "node_type": "1", "metadata": {"window": "Now on the flipside, we would expect in the pharma business, there is a little bit of lesser of a \nheadwind from Q1 to Q2 as that environment is a little bit more normalized.   But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.  ", "original_text": "Thanks.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be2e271ab97a7c5ec7430c733fa962f7eea656a5cc267678dc4c6b8391a5fa4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70a9db09-ee43-44c5-9203-70d08a7a7b49", "node_type": "1", "metadata": {"window": "Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?  ", "original_text": "Steven Valiquette:  Yes. "}, "hash": "6acb92c6f8c533025e7f8b6959aaf9da3f2cba5631a34cf8579d4c6afcfe12d3", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n", "start_char_idx": 1121, "end_char_idx": 1200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70a9db09-ee43-44c5-9203-70d08a7a7b49": {"__data__": {"id_": "70a9db09-ee43-44c5-9203-70d08a7a7b49", "embedding": null, "metadata": {"window": "Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?  ", "original_text": "Steven Valiquette:  Yes. ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc6eea4a-1d86-434a-82a9-19632fdd8268", "node_type": "1", "metadata": {"window": "But I would not call tha t \nsignificant.  \n \n Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n ", "original_text": "Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1a7f01f71cb53839519d25ae3d955ae1383e21e971987a877f6b85fcb334566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffeb1023-396a-4cf0-8456-342887f55d31", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?  ", "original_text": "Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.  "}, "hash": "91958531aad7a07e6d1e55973db0ef50ec747793be12d23afaf544ea2b25ec13", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:  Yes. ", "start_char_idx": 1200, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffeb1023-396a-4cf0-8456-342887f55d31": {"__data__": {"id_": "ffeb1023-396a-4cf0-8456-342887f55d31", "embedding": null, "metadata": {"window": "Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?  ", "original_text": "Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70a9db09-ee43-44c5-9203-70d08a7a7b49", "node_type": "1", "metadata": {"window": "Michael Cherny:  Great.   Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?  ", "original_text": "Steven Valiquette:  Yes. ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b77cd4b14242850f427d5aaa5ac133d096d23e3186819a9f32a02a4cfc9a3187", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "317d9bef-5324-4d5f-b672-b6c47f0b24b0", "node_type": "1", "metadata": {"window": "Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.  ", "original_text": "You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n "}, "hash": "6517beb01ee93f63ca69c030f4433b5891cf90810f69f50a004f7a620d22b554", "class_name": "RelatedNodeInfo"}}, "text": "Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.  ", "start_char_idx": 1225, "end_char_idx": 1319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "317d9bef-5324-4d5f-b672-b6c47f0b24b0": {"__data__": {"id_": "317d9bef-5324-4d5f-b672-b6c47f0b24b0", "embedding": null, "metadata": {"window": "Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.  ", "original_text": "You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffeb1023-396a-4cf0-8456-342887f55d31", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?  ", "original_text": "Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fb63a3cdabf98bdc843b51af665a1266b071a3d4ff1feebabc22a718b425288", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56f693a0-83d0-48dc-afec-7c090ccc97f6", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n", "original_text": "So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?  "}, "hash": "c0c093c60e34c50ef4d75b105909ab7439a2aa423e80f38e4f3c4b59956d8abc", "class_name": "RelatedNodeInfo"}}, "text": "You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n ", "start_char_idx": 1319, "end_char_idx": 1544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56f693a0-83d0-48dc-afec-7c090ccc97f6": {"__data__": {"id_": "56f693a0-83d0-48dc-afec-7c090ccc97f6", "embedding": null, "metadata": {"window": "Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n", "original_text": "So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "317d9bef-5324-4d5f-b672-b6c47f0b24b0", "node_type": "1", "metadata": {"window": "Operator:  We'll now take a question from Steven Valiquette with Barclays.  \n \n Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.  ", "original_text": "You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14ccc69ffb1448bd6abe5607ea03bd834755ea1d8f63d03016f8761be7eca087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7513eb88-4a01-4ab6-93ac-e8e6929778bd", "node_type": "1", "metadata": {"window": "Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.  ", "original_text": "Is it pretty comprehensive or will there still be \nother cases?  "}, "hash": "86143304098340422d34c086dcff4d58441f14d3df4f90e1dc584e88cefe5d87", "class_name": "RelatedNodeInfo"}}, "text": "So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?  ", "start_char_idx": 1544, "end_char_idx": 1697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7513eb88-4a01-4ab6-93ac-e8e6929778bd": {"__data__": {"id_": "7513eb88-4a01-4ab6-93ac-e8e6929778bd", "embedding": null, "metadata": {"window": "Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.  ", "original_text": "Is it pretty comprehensive or will there still be \nother cases?  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56f693a0-83d0-48dc-afec-7c090ccc97f6", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Yes.  Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n", "original_text": "So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d85ab4f11eaaaecb577bc3b79c916cfa0a9c820c5f543ac34bec3813d02b0772", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c201eb5-1bd0-45da-a406-2e9ad40fd25c", "node_type": "1", "metadata": {"window": "You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.  ", "original_text": "Just some more color around that.  "}, "hash": "0f2c991c2b5e1b1fc89ea853fb24cbdc34b2816b81455137718e564bc1e9e571", "class_name": "RelatedNodeInfo"}}, "text": "Is it pretty comprehensive or will there still be \nother cases?  ", "start_char_idx": 1697, "end_char_idx": 1762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c201eb5-1bd0-45da-a406-2e9ad40fd25c": {"__data__": {"id_": "3c201eb5-1bd0-45da-a406-2e9ad40fd25c", "embedding": null, "metadata": {"window": "You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.  ", "original_text": "Just some more color around that.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7513eb88-4a01-4ab6-93ac-e8e6929778bd", "node_type": "1", "metadata": {"window": "Hey, I just wanted to mention sort of on the open litigation and the extra \ncharge you took.   You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.  ", "original_text": "Is it pretty comprehensive or will there still be \nother cases?  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8bc597266d14bb8e8979cda54de39665f34c9068b8764fdf925fb3c8a57d834", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebff9453-7059-4503-8f62-3462f7b21d39", "node_type": "1", "metadata": {"window": "So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.  ", "original_text": "Thanks.  \n \n"}, "hash": "8310b0d58f7f3221bd88136c42339d59dc8922dffa4181f40b63244f9b492b16", "class_name": "RelatedNodeInfo"}}, "text": "Just some more color around that.  ", "start_char_idx": 1762, "end_char_idx": 1797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebff9453-7059-4503-8f62-3462f7b21d39": {"__data__": {"id_": "ebff9453-7059-4503-8f62-3462f7b21d39", "embedding": null, "metadata": {"window": "So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.  ", "original_text": "Thanks.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c201eb5-1bd0-45da-a406-2e9ad40fd25c", "node_type": "1", "metadata": {"window": "You know, on e of your peers also took a charge this morning and they made a \npoint in the press release that included not only the states but also the counties and municipalities \nand other government entities as well.  \n \n  So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.  ", "original_text": "Just some more color around that.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06854cf69b3571198e2ea536c4d9e2d87bc33897abd479c72318bb842d20e5e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4d5dfc9-c2f9-4196-9af1-9a1fd302e1b5", "node_type": "1", "metadata": {"window": "Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.  ", "original_text": "Mike Kaufmann:  Sure.  "}, "hash": "4122f74780481c13b2834a08b9dbd22862e930ccf9dea37db7d5c9b970b329f4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1109, "end_char_idx": 1121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4d5dfc9-c2f9-4196-9af1-9a1fd302e1b5": {"__data__": {"id_": "c4d5dfc9-c2f9-4196-9af1-9a1fd302e1b5", "embedding": null, "metadata": {"window": "Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.  ", "original_text": "Mike Kaufmann:  Sure.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebff9453-7059-4503-8f62-3462f7b21d39", "node_type": "1", "metadata": {"window": "So I'm just curious with your total, you know, ch arge that you have now, do you - what percent \nof your total liability do you think that would cover?   Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.  ", "original_text": "Thanks.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "144392d09f4e3203a852504d3b742cb9a3412b858bc712d41c27d9ce81415958", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa0b1047-5dec-4da5-8339-ee88481e3820", "node_type": "1", "metadata": {"window": "Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n ", "original_text": "Thanks Steve.  "}, "hash": "666538d244c5ac4f53046b45fc5bdc4d6abbc8093755614395b92952d31258b1", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Sure.  ", "start_char_idx": 1809, "end_char_idx": 1832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa0b1047-5dec-4da5-8339-ee88481e3820": {"__data__": {"id_": "aa0b1047-5dec-4da5-8339-ee88481e3820", "embedding": null, "metadata": {"window": "Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n ", "original_text": "Thanks Steve.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4d5dfc9-c2f9-4196-9af1-9a1fd302e1b5", "node_type": "1", "metadata": {"window": "Is it pretty comprehensive or will there still be \nother cases?   Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.  ", "original_text": "Mike Kaufmann:  Sure.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "569283658c779de8e2f60dbb393bb62b0a4c9b611dbae2a517f56a0fbc3bea76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "392c4f53-1e98-4bf5-99cd-8f88d5df46c8", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.  ", "original_text": "I'll giv e you a little bit of color here.  "}, "hash": "ea3ff8d8d3dd623ee309f94ae656ffcd766f852f9c263e93711a755a1f20b58a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks Steve.  ", "start_char_idx": 1832, "end_char_idx": 1847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "392c4f53-1e98-4bf5-99cd-8f88d5df46c8": {"__data__": {"id_": "392c4f53-1e98-4bf5-99cd-8f88d5df46c8", "embedding": null, "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.  ", "original_text": "I'll giv e you a little bit of color here.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa0b1047-5dec-4da5-8339-ee88481e3820", "node_type": "1", "metadata": {"window": "Just some more color around that.   Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n ", "original_text": "Thanks Steve.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4097c83cfd1bbb615c5f0d54cfd1d0dd2092c73c8b437f3d44c8a88ec7b615d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81fdefd5-b0e0-46cb-95b5-7b48558c8f83", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.  ", "original_text": "Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.  "}, "hash": "05a306f682274d21826151d156470022e4920d8c095c35e266cba324657a88b0", "class_name": "RelatedNodeInfo"}}, "text": "I'll giv e you a little bit of color here.  ", "start_char_idx": 1847, "end_char_idx": 1891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81fdefd5-b0e0-46cb-95b5-7b48558c8f83": {"__data__": {"id_": "81fdefd5-b0e0-46cb-95b5-7b48558c8f83", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.  ", "original_text": "Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "392c4f53-1e98-4bf5-99cd-8f88d5df46c8", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.  ", "original_text": "I'll giv e you a little bit of color here.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "483a2e3c3cc4d8749a74467675ba0e2a7d9948562b313b2e098a550dd32b7297", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4b47b46-cadc-4948-90a7-cee40b093446", "node_type": "1", "metadata": {"window": "Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.  ", "original_text": "So that accrual represents our assumption around that.  \n \n "}, "hash": "a519ea7985198cddfab012ab68573a5091a0f7bd3bf6f3fc4ba5ec1ac48f63c3", "class_name": "RelatedNodeInfo"}}, "text": "Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.  ", "start_char_idx": 1891, "end_char_idx": 2044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4b47b46-cadc-4948-90a7-cee40b093446": {"__data__": {"id_": "d4b47b46-cadc-4948-90a7-cee40b093446", "embedding": null, "metadata": {"window": "Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.  ", "original_text": "So that accrual represents our assumption around that.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81fdefd5-b0e0-46cb-95b5-7b48558c8f83", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.   Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.  ", "original_text": "Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d13064fda325dbde9a47a6043cc56a06bad10b0e2604ebe663ffa972184dbdb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd115ace-6499-4d0a-815e-f59d38d638b7", "node_type": "1", "metadata": {"window": "I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.  ", "original_text": "What's not in there, is any private party plaintiff cases.  "}, "hash": "a0941e74af65381b7fe7387e4bdf7015bc18e9c99861b4a53b26b73c02904867", "class_name": "RelatedNodeInfo"}}, "text": "So that accrual represents our assumption around that.  \n \n ", "start_char_idx": 2044, "end_char_idx": 2104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd115ace-6499-4d0a-815e-f59d38d638b7": {"__data__": {"id_": "fd115ace-6499-4d0a-815e-f59d38d638b7", "embedding": null, "metadata": {"window": "I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.  ", "original_text": "What's not in there, is any private party plaintiff cases.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4b47b46-cadc-4948-90a7-cee40b093446", "node_type": "1", "metadata": {"window": "Thanks Steve.   I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.  ", "original_text": "So that accrual represents our assumption around that.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d787cea082e6fe3d930696e78231635bb7a1cf287826d6cda27ba4f1dee7d755", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db60c987-a5d6-44b0-a4c9-1f964f1cc87c", "node_type": "1", "metadata": {"window": "Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n", "original_text": "You know individual or some other non -\npolitical subdivision or state.  "}, "hash": "403ffbfb1e209641f9dd753effcd2869d4c4ded9030a2b1317677c70d140ae67", "class_name": "RelatedNodeInfo"}}, "text": "What's not in there, is any private party plaintiff cases.  ", "start_char_idx": 2104, "end_char_idx": 2164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db60c987-a5d6-44b0-a4c9-1f964f1cc87c": {"__data__": {"id_": "db60c987-a5d6-44b0-a4c9-1f964f1cc87c", "embedding": null, "metadata": {"window": "Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n", "original_text": "You know individual or some other non -\npolitical subdivision or state.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd115ace-6499-4d0a-815e-f59d38d638b7", "node_type": "1", "metadata": {"window": "I'll giv e you a little bit of color here.   Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.  ", "original_text": "What's not in there, is any private party plaintiff cases.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e069f0e91212a339d7c502149354491d96ddbbf0eaf3111be0142c302d96bcbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab7bc12c-d297-498d-ab48-b22d197a6fe4", "node_type": "1", "metadata": {"window": "So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.  ", "original_text": "Those are still out there.  "}, "hash": "24282f9c168144f965bd35b305e4adfff79b2a08971a3f924c59be61eceec0b4", "class_name": "RelatedNodeInfo"}}, "text": "You know individual or some other non -\npolitical subdivision or state.  ", "start_char_idx": 2164, "end_char_idx": 2237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab7bc12c-d297-498d-ab48-b22d197a6fe4": {"__data__": {"id_": "ab7bc12c-d297-498d-ab48-b22d197a6fe4", "embedding": null, "metadata": {"window": "So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.  ", "original_text": "Those are still out there.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db60c987-a5d6-44b0-a4c9-1f964f1cc87c", "node_type": "1", "metadata": {"window": "Our view has always \nbeen that it is a global settlement that takes into account all of the states as well as the political \nsubdivisions in the state.   So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n", "original_text": "You know individual or some other non -\npolitical subdivision or state.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4887c97e86643b6418a1d422db3e89575be8b789d679e011151e787848aa108a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4d7a7f5-53d5-41ad-a98e-4dafd2774f75", "node_type": "1", "metadata": {"window": "What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.  ", "original_text": "We intend to defend ourselves vigorously \nagainst those.  "}, "hash": "1f8d26ca9a4b6a4ccbbe06100474eb2a562acfb43b6c377dad8fa84c149261b2", "class_name": "RelatedNodeInfo"}}, "text": "Those are still out there.  ", "start_char_idx": 2237, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4d7a7f5-53d5-41ad-a98e-4dafd2774f75": {"__data__": {"id_": "d4d7a7f5-53d5-41ad-a98e-4dafd2774f75", "embedding": null, "metadata": {"window": "What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.  ", "original_text": "We intend to defend ourselves vigorously \nagainst those.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab7bc12c-d297-498d-ab48-b22d197a6fe4", "node_type": "1", "metadata": {"window": "So that accrual represents our assumption around that.  \n \n  What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.  ", "original_text": "Those are still out there.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b5ba7ca2d56c9f86735ab47d2a8f840a2640f31f05e0f1b4eb712b49922bb3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e449cfb5-3cfb-4346-9dad-9de6703b4406", "node_type": "1", "metadata": {"window": "You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.  ", "original_text": "But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n"}, "hash": "d7c08a3df66ba5cf3e3f429903a2f1cab5b183f26e6b0691fe2f91d657641f70", "class_name": "RelatedNodeInfo"}}, "text": "We intend to defend ourselves vigorously \nagainst those.  ", "start_char_idx": 2265, "end_char_idx": 2323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e449cfb5-3cfb-4346-9dad-9de6703b4406": {"__data__": {"id_": "e449cfb5-3cfb-4346-9dad-9de6703b4406", "embedding": null, "metadata": {"window": "You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.  ", "original_text": "But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4d7a7f5-53d5-41ad-a98e-4dafd2774f75", "node_type": "1", "metadata": {"window": "What's not in there, is any private party plaintiff cases.   You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.  ", "original_text": "We intend to defend ourselves vigorously \nagainst those.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0bcb84f611b0cf114d37509cf29413ac23b0e05f1b689e21235e67f4967c058", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc7a5024-66d3-42a9-8db7-a868bb91a14d", "node_type": "1", "metadata": {"window": "Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.  ", "original_text": "Steven Valiquette:  Okay.  "}, "hash": "fdfa6cd6338af1b78d0419eea110315b0687d47dcd55555c4a0498d5c401e165", "class_name": "RelatedNodeInfo"}}, "text": "But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n", "start_char_idx": 2323, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc7a5024-66d3-42a9-8db7-a868bb91a14d": {"__data__": {"id_": "bc7a5024-66d3-42a9-8db7-a868bb91a14d", "embedding": null, "metadata": {"window": "Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.  ", "original_text": "Steven Valiquette:  Okay.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e449cfb5-3cfb-4346-9dad-9de6703b4406", "node_type": "1", "metadata": {"window": "You know individual or some other non -\npolitical subdivision or state.   Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.  ", "original_text": "But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f367fc6d30910720660d88d5215c8cf639975b5093340ce74b480d50a941dc77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e27533af-ac15-42ab-8cbe-33ae576c42a3", "node_type": "1", "metadata": {"window": "We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.  "}, "hash": "41a3e19b6a1f39293ea6b3840c56d08a5a5cb990bb37cdc53fab98b63ee4bcdb", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:  Okay.  ", "start_char_idx": 2417, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e27533af-ac15-42ab-8cbe-33ae576c42a3": {"__data__": {"id_": "e27533af-ac15-42ab-8cbe-33ae576c42a3", "embedding": null, "metadata": {"window": "We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc7a5024-66d3-42a9-8db7-a868bb91a14d", "node_type": "1", "metadata": {"window": "Those are still out there.   We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.  ", "original_text": "Steven Valiquette:  Okay.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bec0f53c7394658ab4ceb4eb1100915fcdb9bc5e4810b126f96e5dae20d23614", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e80b2cf-30d8-4c13-9f30-b35eb9758340", "node_type": "1", "metadata": {"window": "But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Obviously this fiscal first quarter was very strong.  "}, "hash": "188262862db58ea4c3e8b4c42920d6cdc68a84f4215aaa9ae55490e068579e40", "class_name": "RelatedNodeInfo"}}, "text": "And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.  ", "start_char_idx": 2444, "end_char_idx": 2548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e80b2cf-30d8-4c13-9f30-b35eb9758340": {"__data__": {"id_": "5e80b2cf-30d8-4c13-9f30-b35eb9758340", "embedding": null, "metadata": {"window": "But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Obviously this fiscal first quarter was very strong.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e27533af-ac15-42ab-8cbe-33ae576c42a3", "node_type": "1", "metadata": {"window": "We intend to defend ourselves vigorously \nagainst those.   But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ee13d252577865ebcc207ee4dac3f6b0b8dc52e54a403ff5475466f78e8c832", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b3cfbeb-1f5e-4b09-bdfa-7ce78c362b78", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.  "}, "hash": "220ebed23330af61929ebfd1f2a2f5c91eb6589426599a3487b8a91f08a4db23", "class_name": "RelatedNodeInfo"}}, "text": "Obviously this fiscal first quarter was very strong.  ", "start_char_idx": 2548, "end_char_idx": 2602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b3cfbeb-1f5e-4b09-bdfa-7ce78c362b78": {"__data__": {"id_": "7b3cfbeb-1f5e-4b09-bdfa-7ce78c362b78", "embedding": null, "metadata": {"window": "Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e80b2cf-30d8-4c13-9f30-b35eb9758340", "node_type": "1", "metadata": {"window": "But that accrual takes into account all, both the s tates and the political subdivisions.  \n \n Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Obviously this fiscal first quarter was very strong.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "472c164a36caf372ec905564c4dd3b9b794c7db5ec6fdd0916aff4d2de457c6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "152e0039-1537-4407-9554-331381edd576", "node_type": "1", "metadata": {"window": "And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Thanks.  \n "}, "hash": "aef13b0c3cb687543c4b86294682263d2f7569860d0788dafa675fcbcbb36546", "class_name": "RelatedNodeInfo"}}, "text": "Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.  ", "start_char_idx": 2602, "end_char_idx": 2707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "152e0039-1537-4407-9554-331381edd576": {"__data__": {"id_": "152e0039-1537-4407-9554-331381edd576", "embedding": null, "metadata": {"window": "And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Thanks.  \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f15eb638-dc76-451b-b633-c7320a38a86b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7f90a5c0ed8889646f2fbe3989396ed45ebd689588a0e7df8cd169c6625e6c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b3cfbeb-1f5e-4b09-bdfa-7ce78c362b78", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Okay.   And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.  ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77d0195398af76a36267d901b4efc4a02d5d3638e13efbee95915380fccf4886", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1bf31ad-6172-4e89-aeaf-553592302a31", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.  ", "original_text": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.  "}, "hash": "3c855dd4cb7d907f98dcb656e5b7960877daa7297218fd2e2a2e0bcb7b842daf", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1109, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1bf31ad-6172-4e89-aeaf-553592302a31": {"__data__": {"id_": "d1bf31ad-6172-4e89-aeaf-553592302a31", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.  ", "original_text": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "152e0039-1537-4407-9554-331381edd576", "node_type": "1", "metadata": {"window": "And also a few questions just from investors on the run rate of medical \nprofits on a quarterly basis.   Obviously this fiscal first quarter was very strong.   Any additional \nthoughts on, you k now, kind of quarterly run rates from here might be helpful as well.   Thanks.  \n ", "original_text": "Thanks.  \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25f354d049e4c6886ffc5e831f6cdb972a7a4bb58ae4617249605f938cc0a07f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1bcf065-b4dc-4ee3-b06b-807a0035f697", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n ", "original_text": "But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n "}, "hash": "4118fbef6b4f2b87f989c43da4e2c46e80ef7b25535b7a28678a02a74bd76bbc", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.  ", "start_char_idx": 0, "end_char_idx": 258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1bcf065-b4dc-4ee3-b06b-807a0035f697": {"__data__": {"id_": "f1bcf065-b4dc-4ee3-b06b-807a0035f697", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n ", "original_text": "But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1bf31ad-6172-4e89-aeaf-553592302a31", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.  ", "original_text": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8b131e02e4725fc9a1aa0c8d528982a2229b2cb8ae24c96133b6ada9e3430ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84a785eb-0e16-404e-868b-93870cb5dfd9", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.  ", "original_text": "And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n "}, "hash": "6c1cff13603f175993735095c229204d392ba194ef6efa949efee37b60aa50a5", "class_name": "RelatedNodeInfo"}}, "text": "But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n ", "start_char_idx": 258, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84a785eb-0e16-404e-868b-93870cb5dfd9": {"__data__": {"id_": "84a785eb-0e16-404e-868b-93870cb5dfd9", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.  ", "original_text": "And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1bcf065-b4dc-4ee3-b06b-807a0035f697", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n ", "original_text": "But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad46266012d3a6aef182fb84add37489e08187e2c44fd78310242a0286e34e3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08a6f515-ec1a-4d55-873a-87bdaefd3ac8", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n", "original_text": "Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.  "}, "hash": "b1fafd0635d7ef7108e05f6bd9d5064dfe040ca6b7ae0fddbbbf83ebea0aeab3", "class_name": "RelatedNodeInfo"}}, "text": "And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n ", "start_char_idx": 368, "end_char_idx": 554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08a6f515-ec1a-4d55-873a-87bdaefd3ac8": {"__data__": {"id_": "08a6f515-ec1a-4d55-873a-87bdaefd3ac8", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n", "original_text": "Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84a785eb-0e16-404e-868b-93870cb5dfd9", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.  ", "original_text": "And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bea8dc5c73a3f20406bc6f623ce76acf725fb7fc151d9d1580ef9254612477a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6feed95b-467a-4ea9-ac9b-2fc040103f82", "node_type": "1", "metadata": {"window": "But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.  ", "original_text": "But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n "}, "hash": "6f1dd4e7300d05b8dac15a256b06358730600757f667d1f6223475ce0d27963f", "class_name": "RelatedNodeInfo"}}, "text": "Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.  ", "start_char_idx": 554, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6feed95b-467a-4ea9-ac9b-2fc040103f82": {"__data__": {"id_": "6feed95b-467a-4ea9-ac9b-2fc040103f82", "embedding": null, "metadata": {"window": "But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.  ", "original_text": "But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08a6f515-ec1a-4d55-873a-87bdaefd3ac8", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n", "original_text": "Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49cb4af463f07c007a95a938b39318da966359e9e9aeebed7327e3584e559e4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87ee05bb-6279-45e8-be46-de6b28ecb920", "node_type": "1", "metadata": {"window": "And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n ", "original_text": "We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.  "}, "hash": "887bcc6bf8984f0f27d34c1531948e8fc0cb406114d939b60ea42147b376c670", "class_name": "RelatedNodeInfo"}}, "text": "But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n ", "start_char_idx": 706, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87ee05bb-6279-45e8-be46-de6b28ecb920": {"__data__": {"id_": "87ee05bb-6279-45e8-be46-de6b28ecb920", "embedding": null, "metadata": {"window": "And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n ", "original_text": "We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6feed95b-467a-4ea9-ac9b-2fc040103f82", "node_type": "1", "metadata": {"window": "But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.  ", "original_text": "But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e379b322a766f10e34069c2667507202956be78160f4734cb63fcf3ac7777b08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6a4cae3-b8a8-49ef-94ec-8f0a057e5768", "node_type": "1", "metadata": {"window": "Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.  ", "original_text": "But we need a little bit more time to work that through.  \n \n"}, "hash": "bc78bd0b74c2dae5210f376aca084bbe8503d59b4681eaa1121ced0d68a57fce", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.  ", "start_char_idx": 863, "end_char_idx": 1091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6a4cae3-b8a8-49ef-94ec-8f0a057e5768": {"__data__": {"id_": "f6a4cae3-b8a8-49ef-94ec-8f0a057e5768", "embedding": null, "metadata": {"window": "Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.  ", "original_text": "But we need a little bit more time to work that through.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87ee05bb-6279-45e8-be46-de6b28ecb920", "node_type": "1", "metadata": {"window": "And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n ", "original_text": "We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e581e717ddb25b8d64afb79140ac5c3df720f1d21291baa49eeb92d4c35a990f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d025279-9312-4c1d-8cf0-6f068f610076", "node_type": "1", "metadata": {"window": "But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.  ", "original_text": "Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.  "}, "hash": "b82f9078c46f99aab1957e0947720403018a08fd77800c7bd18846709a75fd67", "class_name": "RelatedNodeInfo"}}, "text": "But we need a little bit more time to work that through.  \n \n", "start_char_idx": 1091, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d025279-9312-4c1d-8cf0-6f068f610076": {"__data__": {"id_": "3d025279-9312-4c1d-8cf0-6f068f610076", "embedding": null, "metadata": {"window": "But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.  ", "original_text": "Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6a4cae3-b8a8-49ef-94ec-8f0a057e5768", "node_type": "1", "metadata": {"window": "Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.   But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.  ", "original_text": "But we need a little bit more time to work that through.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "418a59eb3082a7f1e9c67880604eac0bcf3804e3242e54f996aafe5080486f7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfe39b14-d909-4995-8df5-32d01c8c8788", "node_type": "1", "metadata": {"window": "We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.  ", "original_text": "And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n "}, "hash": "e58d27aa34d530873bde3fb84eef3ddc5a2a2d1248eaaeac1ca4e21052f5ba5a", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.  ", "start_char_idx": 1152, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfe39b14-d909-4995-8df5-32d01c8c8788": {"__data__": {"id_": "cfe39b14-d909-4995-8df5-32d01c8c8788", "embedding": null, "metadata": {"window": "We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.  ", "original_text": "And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d025279-9312-4c1d-8cf0-6f068f610076", "node_type": "1", "metadata": {"window": "But other ele ments were very specific to the \npandemic and we're really tightly managing our costs and then perhaps in a little bit of a shorter term.  \n \n  We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.  ", "original_text": "Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdfee43d3eb25f04a5c30c5411db61bd87ec47044d6b7833ea9381184a058eb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "706c6462-b6f0-47ab-9ed5-d4e67807c037", "node_type": "1", "metadata": {"window": "But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.  ", "original_text": "So a lot of the upward trajectory already has occurred in the first quarter.  "}, "hash": "0d8ad04ef817b4dfb32a60fe405200071c270536a3096e43e8d39ddcdf440a09", "class_name": "RelatedNodeInfo"}}, "text": "And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n ", "start_char_idx": 1325, "end_char_idx": 1403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "706c6462-b6f0-47ab-9ed5-d4e67807c037": {"__data__": {"id_": "706c6462-b6f0-47ab-9ed5-d4e67807c037", "embedding": null, "metadata": {"window": "But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.  ", "original_text": "So a lot of the upward trajectory already has occurred in the first quarter.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfe39b14-d909-4995-8df5-32d01c8c8788", "node_type": "1", "metadata": {"window": "We'll continue to evaluate those initiatives and see if we can make them more permanent by \nchanging the way in which we do on certain things, which is very consistent with our building healthier \nfuture initiatives elsewhere.   But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.  ", "original_text": "And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d97c2a4d724c14fb87c53d8882837b4bcb97a84510b8852ab46c5eaa79175b34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fef52fe-6b92-47b4-8872-91498a17c889", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n", "original_text": "So you wouldn't see \nthat sequential.  "}, "hash": "2a5dc18fb27176d347ae312161522ca02e37082ff712a367ecdda3c71a7ee32f", "class_name": "RelatedNodeInfo"}}, "text": "So a lot of the upward trajectory already has occurred in the first quarter.  ", "start_char_idx": 1403, "end_char_idx": 1481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fef52fe-6b92-47b4-8872-91498a17c889": {"__data__": {"id_": "4fef52fe-6b92-47b4-8872-91498a17c889", "embedding": null, "metadata": {"window": "Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n", "original_text": "So you wouldn't see \nthat sequential.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "706c6462-b6f0-47ab-9ed5-d4e67807c037", "node_type": "1", "metadata": {"window": "But we need a little bit more time to work that through.  \n \n Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.  ", "original_text": "So a lot of the upward trajectory already has occurred in the first quarter.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cad352569db5c9414f33e4bb1361d595899a8d8fe22a29c009d70ccfe59573be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b94e1883-c671-4d4a-a096-4df1c5a24d9a", "node_type": "1", "metadata": {"window": "And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n", "original_text": "It is not as big as maybe it was historically when we were first thinking about this.  "}, "hash": "48197d3aaf80d925a497fb9de55bf7eeaffa96b501e6925ed314b2f00a52036f", "class_name": "RelatedNodeInfo"}}, "text": "So you wouldn't see \nthat sequential.  ", "start_char_idx": 1481, "end_char_idx": 1520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b94e1883-c671-4d4a-a096-4df1c5a24d9a": {"__data__": {"id_": "b94e1883-c671-4d4a-a096-4df1c5a24d9a", "embedding": null, "metadata": {"window": "And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n", "original_text": "It is not as big as maybe it was historically when we were first thinking about this.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fef52fe-6b92-47b4-8872-91498a17c889", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  The only other thing I would add is that we did exit the quarter roughly mid-single \ndigits down on electives and so that was better than our expectations.   And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n", "original_text": "So you wouldn't see \nthat sequential.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73e8fc2b5e95ceae615a7affe7a8af275cbe511211fdc9db114d3a50bff0dc13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3eb804f-0f21-4cdd-9756-e789f6d0b377", "node_type": "1", "metadata": {"window": "So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi. ", "original_text": "So \nI think that's one component also to keep in mind.  "}, "hash": "cb0755383f4e5335f8ea0170a1bbc143a312e815cb1cd3d19f74ab046308e084", "class_name": "RelatedNodeInfo"}}, "text": "It is not as big as maybe it was historically when we were first thinking about this.  ", "start_char_idx": 1520, "end_char_idx": 1607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3eb804f-0f21-4cdd-9756-e789f6d0b377": {"__data__": {"id_": "d3eb804f-0f21-4cdd-9756-e789f6d0b377", "embedding": null, "metadata": {"window": "So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi. ", "original_text": "So \nI think that's one component also to keep in mind.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b94e1883-c671-4d4a-a096-4df1c5a24d9a", "node_type": "1", "metadata": {"window": "And as Jason said, we expect \nto finish the year near pre -COVID levels.  \n \n  So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n", "original_text": "It is not as big as maybe it was historically when we were first thinking about this.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62bf2992118393ad8ffa921ba86194be7e671f209e5463916ab80acb7c0a5586", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8e57fd3-e2ea-442f-9242-ffb4a87d8a10", "node_type": "1", "metadata": {"window": "So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.  ", "original_text": "Next question, please.  \n \n"}, "hash": "c9739f1c229c6dcb9d0fb45e07b2065ba9b9adc3f62b668f6460776a34231000", "class_name": "RelatedNodeInfo"}}, "text": "So \nI think that's one component also to keep in mind.  ", "start_char_idx": 1607, "end_char_idx": 1663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8e57fd3-e2ea-442f-9242-ffb4a87d8a10": {"__data__": {"id_": "b8e57fd3-e2ea-442f-9242-ffb4a87d8a10", "embedding": null, "metadata": {"window": "So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.  ", "original_text": "Next question, please.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3eb804f-0f21-4cdd-9756-e789f6d0b377", "node_type": "1", "metadata": {"window": "So a lot of the upward trajectory already has occurred in the first quarter.   So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi. ", "original_text": "So \nI think that's one component also to keep in mind.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "614bef2eaa72fd4f4c04e457c421d53d85f026eec1db788dedf54097779d3eee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfc10a99-1064-4cc5-aad9-5a83ac42082e", "node_type": "1", "metadata": {"window": "It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n", "original_text": "Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n"}, "hash": "964ea335746b0ad1a3b13d8ca82de5f175b37b08e8b4a680eaebda6575a09b56", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n \n", "start_char_idx": 1663, "end_char_idx": 1690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfc10a99-1064-4cc5-aad9-5a83ac42082e": {"__data__": {"id_": "cfc10a99-1064-4cc5-aad9-5a83ac42082e", "embedding": null, "metadata": {"window": "It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n", "original_text": "Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8e57fd3-e2ea-442f-9242-ffb4a87d8a10", "node_type": "1", "metadata": {"window": "So you wouldn't see \nthat sequential.   It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.  ", "original_text": "Next question, please.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee8be7e2ee5be4768278974203b9c7ef3612d567de65b01754bd091167a917ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "668f8cf4-6a69-479c-98cb-454e774545d0", "node_type": "1", "metadata": {"window": "So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.  ", "original_text": "Adam Heussner:  Hi. "}, "hash": "c64acd0ecd92d69760aa3053093def3c35876bcc2c0ca3e504efdd3df69993e3", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n", "start_char_idx": 1690, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "668f8cf4-6a69-479c-98cb-454e774545d0": {"__data__": {"id_": "668f8cf4-6a69-479c-98cb-454e774545d0", "embedding": null, "metadata": {"window": "So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.  ", "original_text": "Adam Heussner:  Hi. ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfc10a99-1064-4cc5-aad9-5a83ac42082e", "node_type": "1", "metadata": {"window": "It is not as big as maybe it was historically when we were first thinking about this.   So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n", "original_text": "Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83da3f32149f4aee1a35596580c84ac602c5f774f471953b75cb1fecda1c5509", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08944901-1bbe-4797-bdfc-08ae5ed539c1", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.  ", "original_text": "In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.  "}, "hash": "cdbbce80562d87a7560cfb4dcbc529fa05d7aeea7c594181e25cc65b83c4d3fc", "class_name": "RelatedNodeInfo"}}, "text": "Adam Heussner:  Hi. ", "start_char_idx": 1776, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08944901-1bbe-4797-bdfc-08ae5ed539c1": {"__data__": {"id_": "08944901-1bbe-4797-bdfc-08ae5ed539c1", "embedding": null, "metadata": {"window": "Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.  ", "original_text": "In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "668f8cf4-6a69-479c-98cb-454e774545d0", "node_type": "1", "metadata": {"window": "So \nI think that's one component also to keep in mind.   Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.  ", "original_text": "Adam Heussner:  Hi. ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "413558b700fdcd460f847494af13782acc92360b29602512346bb04d02fd85f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9cd71c6-2b65-4880-a434-4985814d71a4", "node_type": "1", "metadata": {"window": "Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n ", "original_text": "Thanks.  \n \n"}, "hash": "eb9d50c50addfddea41003c4622a8d174c1ce5c212b18876b211666578e7807d", "class_name": "RelatedNodeInfo"}}, "text": "In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.  ", "start_char_idx": 1796, "end_char_idx": 2003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9cd71c6-2b65-4880-a434-4985814d71a4": {"__data__": {"id_": "e9cd71c6-2b65-4880-a434-4985814d71a4", "embedding": null, "metadata": {"window": "Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n ", "original_text": "Thanks.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08944901-1bbe-4797-bdfc-08ae5ed539c1", "node_type": "1", "metadata": {"window": "Next question, please.  \n \n Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.  ", "original_text": "In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6dab837f781f6c9c5e06793e1c22f36fe9138079267b378ccafb86fd6657799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75dc8694-6a23-402f-b53a-9e25f3f0a1f6", "node_type": "1", "metadata": {"window": "Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.  ", "original_text": "Jason Hollar:   Yes.  "}, "hash": "8752f5e481ea4dbfa60f060f52a598ad76eed2e6ee962f255ce387ecbdde74af", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 2003, "end_char_idx": 2015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75dc8694-6a23-402f-b53a-9e25f3f0a1f6": {"__data__": {"id_": "75dc8694-6a23-402f-b53a-9e25f3f0a1f6", "embedding": null, "metadata": {"window": "Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.  ", "original_text": "Jason Hollar:   Yes.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9cd71c6-2b65-4880-a434-4985814d71a4", "node_type": "1", "metadata": {"window": "Operator:  And our next question will come from Adam Heussner from Credit Suisse.  \n \n Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n ", "original_text": "Thanks.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5788ff34865b71dc7e56da17fb7cb24fa6f7510993db5836b80887fd701db5d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39911401-345e-4e20-8fde-3976e2e66029", "node_type": "1", "metadata": {"window": "In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.  ", "original_text": "So as I think about the - let's just step back and think about the raise for the full \nyear guidance.  "}, "hash": "37638f4f368aa485412b25069160c819a0cd7a26d2b9fb3a96d09f14d68a530c", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Yes.  ", "start_char_idx": 2015, "end_char_idx": 2037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39911401-345e-4e20-8fde-3976e2e66029": {"__data__": {"id_": "39911401-345e-4e20-8fde-3976e2e66029", "embedding": null, "metadata": {"window": "In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.  ", "original_text": "So as I think about the - let's just step back and think about the raise for the full \nyear guidance.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75dc8694-6a23-402f-b53a-9e25f3f0a1f6", "node_type": "1", "metadata": {"window": "Adam Heussner:  Hi.  In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.  ", "original_text": "Jason Hollar:   Yes.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "972adb9d9c07543cc2dc110c1c9360faf6cbf5ee88b21992501e108e5963bce5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7386ec5-7b42-4a29-801d-fb630a5850fd", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n ", "original_text": "That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n "}, "hash": "b5a08c033b4d4bec24ff7cce8382dd037b13cc01d7be52055ecfe917520f0402", "class_name": "RelatedNodeInfo"}}, "text": "So as I think about the - let's just step back and think about the raise for the full \nyear guidance.  ", "start_char_idx": 2037, "end_char_idx": 2140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7386ec5-7b42-4a29-801d-fb630a5850fd": {"__data__": {"id_": "b7386ec5-7b42-4a29-801d-fb630a5850fd", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n ", "original_text": "That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39911401-345e-4e20-8fde-3976e2e66029", "node_type": "1", "metadata": {"window": "In terms of the cost savings which were partially contributing to the EPS raise, \njust curious of how much of the improvement there had already been planned versus if you expedited \nthose cost initiatives.   Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.  ", "original_text": "So as I think about the - let's just step back and think about the raise for the full \nyear guidance.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "514e6f86bfac8352d87b7343d57ccaaad4a87e9ee6aabe9fe984e4ad5e9f95de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69614c16-e5e7-4757-9622-127a14aa5749", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.  ", "original_text": "And so within that, we had two key compone nts.  "}, "hash": "f4134af48070c1ebb1a1a0cf99d1809d97d97962b36676afb3df4c0f3871c945", "class_name": "RelatedNodeInfo"}}, "text": "That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n ", "start_char_idx": 2140, "end_char_idx": 2248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69614c16-e5e7-4757-9622-127a14aa5749": {"__data__": {"id_": "69614c16-e5e7-4757-9622-127a14aa5749", "embedding": null, "metadata": {"window": "Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.  ", "original_text": "And so within that, we had two key compone nts.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7386ec5-7b42-4a29-801d-fb630a5850fd", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n ", "original_text": "That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53840deb789393473f478d12c60a8bb2daafa87c867f3799ca99938fdf8d6edd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b5098c-adbf-4c4f-aa81-50e3270bca1c", "node_type": "1", "metadata": {"window": "So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.  ", "original_text": "First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.  "}, "hash": "242274e4dcf0cd7f5a378eb873edc33f12dd99db65fa00b8fe71240e97998dd3", "class_name": "RelatedNodeInfo"}}, "text": "And so within that, we had two key compone nts.  ", "start_char_idx": 2248, "end_char_idx": 2297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75b5098c-adbf-4c4f-aa81-50e3270bca1c": {"__data__": {"id_": "75b5098c-adbf-4c4f-aa81-50e3270bca1c", "embedding": null, "metadata": {"window": "So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.  ", "original_text": "First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69614c16-e5e7-4757-9622-127a14aa5749", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yes.   So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.  ", "original_text": "And so within that, we had two key compone nts.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07c4a1fa673a61d7b7f12edd9966986114f5ed85a48999994c3ae632ac30be74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5a1ef6d-4628-428f-a8a3-505cb49fcd2f", "node_type": "1", "metadata": {"window": "That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n", "original_text": "And that is the most \nmeaningful impact.  \n \n "}, "hash": "53ab99c5557b9222a71d7aa67ad352a553e1d9a096b06718c1dc0a284c8efa24", "class_name": "RelatedNodeInfo"}}, "text": "First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.  ", "start_char_idx": 2297, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5a1ef6d-4628-428f-a8a3-505cb49fcd2f": {"__data__": {"id_": "a5a1ef6d-4628-428f-a8a3-505cb49fcd2f", "embedding": null, "metadata": {"window": "That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n", "original_text": "And that is the most \nmeaningful impact.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b5098c-adbf-4c4f-aa81-50e3270bca1c", "node_type": "1", "metadata": {"window": "So as I think about the - let's just step back and think about the raise for the full \nyear guidance.   That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.  ", "original_text": "First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06d47da013030c5fad8bc1fd46c6245b0776daee2c54b8a4b4dcbe004da756ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "175ad5f6-0682-4999-8c84-718741d462f5", "node_type": "1", "metadata": {"window": "And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.  ", "original_text": "But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.  "}, "hash": "22bd2006d46fe5427012635677012ffc806cd05b87e4f88a2097c70e14f0b433", "class_name": "RelatedNodeInfo"}}, "text": "And that is the most \nmeaningful impact.  \n \n ", "start_char_idx": 2417, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "175ad5f6-0682-4999-8c84-718741d462f5": {"__data__": {"id_": "175ad5f6-0682-4999-8c84-718741d462f5", "embedding": null, "metadata": {"window": "And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.  ", "original_text": "But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5a1ef6d-4628-428f-a8a3-505cb49fcd2f", "node_type": "1", "metadata": {"window": "That is entirely due to the medical performance and you saw that we raised the \noutlook there as well.  \n \n  And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n", "original_text": "And that is the most \nmeaningful impact.  \n \n ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47c902fc6f24eabd88189858aea97408d3bce5719b824451c090ada8e39fcf5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ceca0f69-f08d-4f93-840e-6e0fcdd16557", "node_type": "1", "metadata": {"window": "First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "So, you know, both go into it.  "}, "hash": "6f0c59aab86e0c1f26f8b01ef08fa0511bce984b496e7163132f53e8409201d1", "class_name": "RelatedNodeInfo"}}, "text": "But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.  ", "start_char_idx": 2463, "end_char_idx": 2582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ceca0f69-f08d-4f93-840e-6e0fcdd16557": {"__data__": {"id_": "ceca0f69-f08d-4f93-840e-6e0fcdd16557", "embedding": null, "metadata": {"window": "First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "So, you know, both go into it.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "175ad5f6-0682-4999-8c84-718741d462f5", "node_type": "1", "metadata": {"window": "And so within that, we had two key compone nts.   First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.  ", "original_text": "But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2676773d3c8b39135edf935c315d81c4c567e5ec7a372579517d783953e5ba31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8195483c-0a2f-48dd-a378-6eac470f0e72", "node_type": "1", "metadata": {"window": "And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n"}, "hash": "a60f98fd3ccf4ecfb116df0c25300faf2321e9c979c32fe8b6071391e1b01d62", "class_name": "RelatedNodeInfo"}}, "text": "So, you know, both go into it.  ", "start_char_idx": 2582, "end_char_idx": 2614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8195483c-0a2f-48dd-a378-6eac470f0e72": {"__data__": {"id_": "8195483c-0a2f-48dd-a378-6eac470f0e72", "embedding": null, "metadata": {"window": "And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ceca0f69-f08d-4f93-840e-6e0fcdd16557", "node_type": "1", "metadata": {"window": "First of all COVID is better, less of a \nheadwind than what we had anticipated although still a headwind for the year.   And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "So, you know, both go into it.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f013156b40e711aa93890f1475b29351faef8c335fe15a8c131c1d775aee68c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41088301-30a4-481d-8b3d-8a522e567e85", "node_type": "1", "metadata": {"window": "But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.  "}, "hash": "bd9233cc4aba04dd601df3ef9fbf566979cb9c3bc1c4ca4afd3f2bffb130cc35", "class_name": "RelatedNodeInfo"}}, "text": "But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n", "start_char_idx": 2614, "end_char_idx": 2732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41088301-30a4-481d-8b3d-8a522e567e85": {"__data__": {"id_": "41088301-30a4-481d-8b3d-8a522e567e85", "embedding": null, "metadata": {"window": "But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8195483c-0a2f-48dd-a378-6eac470f0e72", "node_type": "1", "metadata": {"window": "And that is the most \nmeaningful impact.  \n \n  But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edb5ea8bc30bd6377c503b265455c689189df38f6984b3234618021011085711", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6009caef-dede-4a04-8d7a-a18fafa78785", "node_type": "1", "metadata": {"window": "So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "And so \nsome of our other components of our business performed very strong too.  "}, "hash": "226195decbac59b56e08ac404475531a8efd43d8ea5006c1d401a69023536deb", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.  ", "start_char_idx": 2732, "end_char_idx": 2922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6009caef-dede-4a04-8d7a-a18fafa78785": {"__data__": {"id_": "6009caef-dede-4a04-8d7a-a18fafa78785", "embedding": null, "metadata": {"window": "So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "And so \nsome of our other components of our business performed very strong too.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c15e9dc3d9fbeb5fab4192e002bf7901490b58810e92d4f86f17f7c29a4162c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41088301-30a4-481d-8b3d-8a522e567e85", "node_type": "1", "metadata": {"window": "But also significant within that, not insignificant, is the underlying cost reductions th at we've \nbeen referencing.   So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d44c3b909edea16125f3f295dd193180a60b22760b04466a392dc63c07ef1138", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f4dca8e-d7e0-4067-930d-ef0b9b993ef5", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n", "original_text": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n "}, "hash": "ea27d8a201c7da257061ef2e50586e16cfabb74bd794530a0d77b9e6248142cf", "class_name": "RelatedNodeInfo"}}, "text": "And so \nsome of our other components of our business performed very strong too.  ", "start_char_idx": 2922, "end_char_idx": 3003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f4dca8e-d7e0-4067-930d-ef0b9b993ef5": {"__data__": {"id_": "5f4dca8e-d7e0-4067-930d-ef0b9b993ef5", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n", "original_text": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6009caef-dede-4a04-8d7a-a18fafa78785", "node_type": "1", "metadata": {"window": "So, you know, both go into it.   But I would say COVID is a little bit more of a benefit \nthere versus the cost savings but still very meaningful.  \n \n Mike Kaufmann:  And then I would just add, we've also seen really good performance  of our lab \nbusiness in the first quarter that we would expect to continue through the rest of the year.   And so \nsome of our other components of our business performed very strong too.  ", "original_text": "And so \nsome of our other components of our business performed very strong too.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e367be095d9487d20d46e57b15c49f92241d48e2d3aed555f0eaaf23e0b4218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5b30864-646c-4c4b-ac6d-960fd3ca5431", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n", "original_text": "That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.  "}, "hash": "6a961da44ca804f0e30bc2ea509c2c83ae0e21994c3c49830c3750b0e61e4e61", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n ", "start_char_idx": 0, "end_char_idx": 241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5b30864-646c-4c4b-ac6d-960fd3ca5431": {"__data__": {"id_": "c5b30864-646c-4c4b-ac6d-960fd3ca5431", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n", "original_text": "That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f4dca8e-d7e0-4067-930d-ef0b9b993ef5", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n", "original_text": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b5d23466384ed7172518f244850077077ac1e19ceefba172acf6f5308aa3191", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "734e0d3c-b8c4-451e-b2e4-37b56dee3b66", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n", "original_text": "So we'll continue to have some fluctuations there.  "}, "hash": "93a8b40e76dd32800a0f165079ea71cd146734e009277c8e901a36969fce9331", "class_name": "RelatedNodeInfo"}}, "text": "That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.  ", "start_char_idx": 241, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "734e0d3c-b8c4-451e-b2e4-37b56dee3b66": {"__data__": {"id_": "734e0d3c-b8c4-451e-b2e4-37b56dee3b66", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n", "original_text": "So we'll continue to have some fluctuations there.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5b30864-646c-4c4b-ac6d-960fd3ca5431", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n", "original_text": "That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a6c6d8dd7b0aa5b5310d6c02553ffafc1a64b6cc9a732f9c4bb1a5ef9798aa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "174fb136-eb98-43c3-a076-c1d801b8af87", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.  ", "original_text": "But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n"}, "hash": "9f2cb0dd85e744691e7fe789220426c2e95610f113407641088804d600b48501", "class_name": "RelatedNodeInfo"}}, "text": "So we'll continue to have some fluctuations there.  ", "start_char_idx": 357, "end_char_idx": 409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "174fb136-eb98-43c3-a076-c1d801b8af87": {"__data__": {"id_": "174fb136-eb98-43c3-a076-c1d801b8af87", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.  ", "original_text": "But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "734e0d3c-b8c4-451e-b2e4-37b56dee3b66", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n", "original_text": "So we'll continue to have some fluctuations there.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc13429d6d0ccddfc899e6af39d4cb2c7a8763e49f3c8d53e4d2488035bfc616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f729f5a-86dc-444c-bbe5-784d7fa77c02", "node_type": "1", "metadata": {"window": "That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.  ", "original_text": "Adam Heussner:  Thanks.  \n \n"}, "hash": "8f715c3efc9b99e25c22f0b0cdb834249f41895f1fee10b09c30c124ab927420", "class_name": "RelatedNodeInfo"}}, "text": "But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n", "start_char_idx": 409, "end_char_idx": 572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f729f5a-86dc-444c-bbe5-784d7fa77c02": {"__data__": {"id_": "4f729f5a-86dc-444c-bbe5-784d7fa77c02", "embedding": null, "metadata": {"window": "That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.  ", "original_text": "Adam Heussner:  Thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "174fb136-eb98-43c3-a076-c1d801b8af87", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.  ", "original_text": "But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "869c27e74aeae30d3190824616c2293ee55507b2b558c71c471c1349d616cb2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93483ed4-6648-4019-a431-1cacf77dcf8a", "node_type": "1", "metadata": {"window": "So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n", "original_text": "Operator:  Now we'll move to Adam Noble with UBS.  \n \n"}, "hash": "5205686518d38c441cd0ec3e1fd38e3a71b424a8803c73b24b5cc3b481630385", "class_name": "RelatedNodeInfo"}}, "text": "Adam Heussner:  Thanks.  \n \n", "start_char_idx": 572, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93483ed4-6648-4019-a431-1cacf77dcf8a": {"__data__": {"id_": "93483ed4-6648-4019-a431-1cacf77dcf8a", "embedding": null, "metadata": {"window": "So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n", "original_text": "Operator:  Now we'll move to Adam Noble with UBS.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f729f5a-86dc-444c-bbe5-784d7fa77c02", "node_type": "1", "metadata": {"window": "That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.  ", "original_text": "Adam Heussner:  Thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9870676f5babf575ebc5e4f8718bc594fba1fa25bba5c29688280089e9f324b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "142f5614-f5a8-4fc6-a814-927e814e87c3", "node_type": "1", "metadata": {"window": "But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n", "original_text": "Adam Noble:  Great, thanks for the question.  "}, "hash": "d625f5313e7dece4e2c22ff4b009eb79e1912fd0fde36afa4f79c3696a73cc45", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Now we'll move to Adam Noble with UBS.  \n \n", "start_char_idx": 600, "end_char_idx": 654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "142f5614-f5a8-4fc6-a814-927e814e87c3": {"__data__": {"id_": "142f5614-f5a8-4fc6-a814-927e814e87c3", "embedding": null, "metadata": {"window": "But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n", "original_text": "Adam Noble:  Great, thanks for the question.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93483ed4-6648-4019-a431-1cacf77dcf8a", "node_type": "1", "metadata": {"window": "So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n", "original_text": "Operator:  Now we'll move to Adam Noble with UBS.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0274a0803b4b1c70bd80f00978b29e12922b3dc885e364b7a5b3b439dc2eebb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48eb11bb-9dd5-453d-a19e-e19924838840", "node_type": "1", "metadata": {"window": "Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I just wanted to go back to the lab business.  "}, "hash": "8a4f2c158d867b5cf64fe2d2bb4be5cedda383bb5feb57e55911a6f9b20e5a28", "class_name": "RelatedNodeInfo"}}, "text": "Adam Noble:  Great, thanks for the question.  ", "start_char_idx": 654, "end_char_idx": 700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48eb11bb-9dd5-453d-a19e-e19924838840": {"__data__": {"id_": "48eb11bb-9dd5-453d-a19e-e19924838840", "embedding": null, "metadata": {"window": "Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I just wanted to go back to the lab business.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "142f5614-f5a8-4fc6-a814-927e814e87c3", "node_type": "1", "metadata": {"window": "But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n", "original_text": "Adam Noble:  Great, thanks for the question.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30990b8954f3586d20faa48751efeed1908e34eb83f4f61e0d6db23f5e7a1372", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2363fd63-c463-489f-88fc-3ee37a98b99f", "node_type": "1", "metadata": {"window": "Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.  ", "original_text": "Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n"}, "hash": "632db53e8a79eb4d2c753d1ef420b76c329ab315dbe7ae6f103116a6595bb171", "class_name": "RelatedNodeInfo"}}, "text": "I just wanted to go back to the lab business.  ", "start_char_idx": 700, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2363fd63-c463-489f-88fc-3ee37a98b99f": {"__data__": {"id_": "2363fd63-c463-489f-88fc-3ee37a98b99f", "embedding": null, "metadata": {"window": "Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.  ", "original_text": "Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48eb11bb-9dd5-453d-a19e-e19924838840", "node_type": "1", "metadata": {"window": "Adam Heussner:  Thanks.  \n \n Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I just wanted to go back to the lab business.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb47bed4d7443306700fa01c418c0cb0d56a0647b553729637a81d87ec3e1dcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "005c668d-04e3-4614-87ee-a3a406b0b57d", "node_type": "1", "metadata": {"window": "Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n ", "original_text": "Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n"}, "hash": "367dcf5605f2f9015c145975ce8796097b4c1a98efdae4336f00b93d9970f424", "class_name": "RelatedNodeInfo"}}, "text": "Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n", "start_char_idx": 747, "end_char_idx": 855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "005c668d-04e3-4614-87ee-a3a406b0b57d": {"__data__": {"id_": "005c668d-04e3-4614-87ee-a3a406b0b57d", "embedding": null, "metadata": {"window": "Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n ", "original_text": "Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2363fd63-c463-489f-88fc-3ee37a98b99f", "node_type": "1", "metadata": {"window": "Operator:  Now we'll move to Adam Noble with UBS.  \n \n Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.  ", "original_text": "Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27f318ea7a585fe4d10e094a34e3fbf66b60ab67ec28cf644421254408f18f7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8fe0524-dd80-42c1-9d61-ffc8158543f7", "node_type": "1", "metadata": {"window": "I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "6cc2c030ec76430a2de9a8d919a1e4cc00cf727e63980051540c440a082fc8b2", "class_name": "RelatedNodeInfo"}}, "text": "Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n", "start_char_idx": 855, "end_char_idx": 1020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8fe0524-dd80-42c1-9d61-ffc8158543f7": {"__data__": {"id_": "b8fe0524-dd80-42c1-9d61-ffc8158543f7", "embedding": null, "metadata": {"window": "I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "005c668d-04e3-4614-87ee-a3a406b0b57d", "node_type": "1", "metadata": {"window": "Adam Noble:  Great, thanks for the question.   I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n ", "original_text": "Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4beeb9a94abc627161ae95eafab08b3a11ad4fbf3dedc13d30c0a6b012e3f7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dcb51e0-c35a-4905-981e-2839ba4a2ae2", "node_type": "1", "metadata": {"window": "Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.  ", "original_text": "Our lab business has been a business that we've had for a really long time.  "}, "hash": "5a193307ac6ac21d3ea3c6d4401bba9d5f3ea0efac08878f13b51c136456778e", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 1020, "end_char_idx": 1042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dcb51e0-c35a-4905-981e-2839ba4a2ae2": {"__data__": {"id_": "4dcb51e0-c35a-4905-981e-2839ba4a2ae2", "embedding": null, "metadata": {"window": "Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.  ", "original_text": "Our lab business has been a business that we've had for a really long time.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8fe0524-dd80-42c1-9d61-ffc8158543f7", "node_type": "1", "metadata": {"window": "I just wanted to go back to the lab business.   Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d5e0ab5734ce2f5fcaba6660bc680472b923cc8d83d2dc5106591cdce8e4b64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4eed7b2d-2550-4b33-bb59-c199653725ec", "node_type": "1", "metadata": {"window": "Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n ", "original_text": "It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n "}, "hash": "a2f2576404e2bcfab8d387893b146a86ec8bea6d8428bc6f7b866e509342d915", "class_name": "RelatedNodeInfo"}}, "text": "Our lab business has been a business that we've had for a really long time.  ", "start_char_idx": 1042, "end_char_idx": 1119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4eed7b2d-2550-4b33-bb59-c199653725ec": {"__data__": {"id_": "4eed7b2d-2550-4b33-bb59-c199653725ec", "embedding": null, "metadata": {"window": "Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n ", "original_text": "It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dcb51e0-c35a-4905-981e-2839ba4a2ae2", "node_type": "1", "metadata": {"window": "Just \ncurious if you guys can kind of size how big a business that is within the overall medical segment?  \n Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.  ", "original_text": "Our lab business has been a business that we've had for a really long time.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c19f398613631e5a5c0a0f7aff41d5929ed686e78f4ad923a21ed2de8cf45f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a468c4ad-8994-476f-8c49-ecd592f67e4d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n ", "original_text": "Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n"}, "hash": "0c6d80b62197fcf8db0b36d3dbf7b5cdb64308c6c16e055840e9fa7d332e26b9", "class_name": "RelatedNodeInfo"}}, "text": "It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n ", "start_char_idx": 1119, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a468c4ad-8994-476f-8c49-ecd592f67e4d": {"__data__": {"id_": "a468c4ad-8994-476f-8c49-ecd592f67e4d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n ", "original_text": "Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4eed7b2d-2550-4b33-bb59-c199653725ec", "node_type": "1", "metadata": {"window": "Then just curiou s, is that mainly the hospital channel or do you have a significant presence with \noutpatient labs and other areas of the lab testing universe?  \n \n Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n ", "original_text": "It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27c7b8832ef13212cf9a0948f864bed3d85b52dfa9af19deb1302533454ea9d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "411062d7-8277-4cd2-b0d6-ff0b9ee9b9bb", "node_type": "1", "metadata": {"window": "Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.  ", "original_text": "So those are who we are supplying.  "}, "hash": "4e3342ee6f789cfc1e9ac6554c26de5f7c73395e007b27ea35802e4b70a8a59f", "class_name": "RelatedNodeInfo"}}, "text": "Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n", "start_char_idx": 1218, "end_char_idx": 1316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "411062d7-8277-4cd2-b0d6-ff0b9ee9b9bb": {"__data__": {"id_": "411062d7-8277-4cd2-b0d6-ff0b9ee9b9bb", "embedding": null, "metadata": {"window": "Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.  ", "original_text": "So those are who we are supplying.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a468c4ad-8994-476f-8c49-ecd592f67e4d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n ", "original_text": "Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a072ec48cc17fc8093f2242a1da0d92d7c3e4262117a18be8588523b1cf49923", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d22ce52a-11c9-4755-b161-4b444c80858b", "node_type": "1", "metadata": {"window": "It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n ", "original_text": "We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n "}, "hash": "8b2b2ace3ca87585e01d92e96997e32e69fdc3eeca3a7cfce69f40d4146d5f13", "class_name": "RelatedNodeInfo"}}, "text": "So those are who we are supplying.  ", "start_char_idx": 1316, "end_char_idx": 1352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d22ce52a-11c9-4755-b161-4b444c80858b": {"__data__": {"id_": "d22ce52a-11c9-4755-b161-4b444c80858b", "embedding": null, "metadata": {"window": "It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n ", "original_text": "We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "411062d7-8277-4cd2-b0d6-ff0b9ee9b9bb", "node_type": "1", "metadata": {"window": "Our lab business has been a business that we've had for a really long time.   It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.  ", "original_text": "So those are who we are supplying.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21075877c1fba612ce95f037ca01d69cea8b4ed3926373b22cd508bfec73c56d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c739590-7b2d-426b-8e27-811a82806ff9", "node_type": "1", "metadata": {"window": "Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.  ", "original_text": "And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n "}, "hash": "5ec970741df29fa4f35ac779979ccb2d8f63af0e9a5e9fe1f4db130531cd28b0", "class_name": "RelatedNodeInfo"}}, "text": "We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n ", "start_char_idx": 1352, "end_char_idx": 1511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c739590-7b2d-426b-8e27-811a82806ff9": {"__data__": {"id_": "5c739590-7b2d-426b-8e27-811a82806ff9", "embedding": null, "metadata": {"window": "Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.  ", "original_text": "And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d22ce52a-11c9-4755-b161-4b444c80858b", "node_type": "1", "metadata": {"window": "It \nhas been a  consistent grower for us, both on the top and bottom line for a lot of years.  \n \n  Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n ", "original_text": "We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7bb95792a68a79d31269a01cda05738681dd0a474b468f25154841e886227a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27043ca3-ae5c-4fd8-a517-5f507cf49092", "node_type": "1", "metadata": {"window": "So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n", "original_text": "They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.  "}, "hash": "daa5ec7c26a45659c2837d5ba25b7fea998d599c1c98716da9bbe8cda3483bfb", "class_name": "RelatedNodeInfo"}}, "text": "And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n ", "start_char_idx": 1511, "end_char_idx": 1714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27043ca3-ae5c-4fd8-a517-5f507cf49092": {"__data__": {"id_": "27043ca3-ae5c-4fd8-a517-5f507cf49092", "embedding": null, "metadata": {"window": "So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n", "original_text": "They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c739590-7b2d-426b-8e27-811a82806ff9", "node_type": "1", "metadata": {"window": "Its main customers are basically the outpatient labs and other hospital lab type of businesses.  \n So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.  ", "original_text": "And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f684c22aa3c0931adfca3d6f976182fca12ce70346230bea350d4b1774f2dc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8b58df8-7408-467a-b0b3-2dff384fb988", "node_type": "1", "metadata": {"window": "We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.  ", "original_text": "So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n "}, "hash": "2ea75f87b33481402bbb5590dfebce586a61d7c36d7faf62360346cf2b35fd49", "class_name": "RelatedNodeInfo"}}, "text": "They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.  ", "start_char_idx": 1714, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8b58df8-7408-467a-b0b3-2dff384fb988": {"__data__": {"id_": "f8b58df8-7408-467a-b0b3-2dff384fb988", "embedding": null, "metadata": {"window": "We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.  ", "original_text": "So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27043ca3-ae5c-4fd8-a517-5f507cf49092", "node_type": "1", "metadata": {"window": "So those are who we are supplying.   We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n", "original_text": "They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6860d6b17d904eeeef9c1bcc39d99e77b16b07a1e554f13a876ee557abde1ec4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54dd4a26-8718-445f-abbc-6d0e5e1295e0", "node_type": "1", "metadata": {"window": "And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.  ", "original_text": "And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.  "}, "hash": "6494c645236d50b073c06cbfdd5507ba4d61f2e3e37b36d6417a5329bd4d72e2", "class_name": "RelatedNodeInfo"}}, "text": "So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n ", "start_char_idx": 1851, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54dd4a26-8718-445f-abbc-6d0e5e1295e0": {"__data__": {"id_": "54dd4a26-8718-445f-abbc-6d0e5e1295e0", "embedding": null, "metadata": {"window": "And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.  ", "original_text": "And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8b58df8-7408-467a-b0b3-2dff384fb988", "node_type": "1", "metadata": {"window": "We have a very robust product line, some o f which is our self -\nmanufactured or sourced items as well as we work with all of the national brand players.  \n \n  And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.  ", "original_text": "So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f50a9a297b039b661049da2ed673fb6e33706c7fa43ae690ab98cf4f4351ab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9193c411-95c7-47c0-926f-4bfa80d95397", "node_type": "1", "metadata": {"window": "They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n ", "original_text": "But really strong performance by the lab business.  \n \n"}, "hash": "18b42507ac726dbf4c15df2621436da5659382ceabe631f2af286ad89c68e679", "class_name": "RelatedNodeInfo"}}, "text": "And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.  ", "start_char_idx": 1970, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9193c411-95c7-47c0-926f-4bfa80d95397": {"__data__": {"id_": "9193c411-95c7-47c0-926f-4bfa80d95397", "embedding": null, "metadata": {"window": "They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n ", "original_text": "But really strong performance by the lab business.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54dd4a26-8718-445f-abbc-6d0e5e1295e0", "node_type": "1", "metadata": {"window": "And so while it has always been a business that has performed well and grown nicely for us, \nwith the increase in COVID testing, that business has  had some, you know, additional growth this \nyear.  \n \n  They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.  ", "original_text": "And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1e9745c38f08bfb088fa33038a9c39dcab3b9a6fed88aba814b5bc4ff14eb1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35faad6b-b88d-48fe-b996-4f6a814182ab", "node_type": "1", "metadata": {"window": "So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "Adam Noble:  Got you.  "}, "hash": "76a94a4a1e73f04fee742d7e70c60e00bc15cb55b5f7683baca63e450044ad85", "class_name": "RelatedNodeInfo"}}, "text": "But really strong performance by the lab business.  \n \n", "start_char_idx": 2107, "end_char_idx": 2162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35faad6b-b88d-48fe-b996-4f6a814182ab": {"__data__": {"id_": "35faad6b-b88d-48fe-b996-4f6a814182ab", "embedding": null, "metadata": {"window": "So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "Adam Noble:  Got you.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9193c411-95c7-47c0-926f-4bfa80d95397", "node_type": "1", "metadata": {"window": "They've also been a real leader in getting reagents out, testing equipment, working with folks \non helping on the swab supply early on.   So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n ", "original_text": "But really strong performance by the lab business.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a8c9c5a1e53ceb52f0cbdbf2333d7aa3e3f97644f5f56f7b210ded7a5029f16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5b57186-1ac2-4771-a653-87604d5f5cde", "node_type": "1", "metadata": {"window": "And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "That's super helpful.  "}, "hash": "9ea31e38df647ed9328030b6812d986675e66ad5c05b8f00f0f540484c4690c4", "class_name": "RelatedNodeInfo"}}, "text": "Adam Noble:  Got you.  ", "start_char_idx": 2162, "end_char_idx": 2185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5b57186-1ac2-4771-a653-87604d5f5cde": {"__data__": {"id_": "a5b57186-1ac2-4771-a653-87604d5f5cde", "embedding": null, "metadata": {"window": "And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "That's super helpful.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35faad6b-b88d-48fe-b996-4f6a814182ab", "node_type": "1", "metadata": {"window": "So it's a business we're really proud of the team there and \ncontinue  to feel good about their growth this year.  \n \n  And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "Adam Noble:  Got you.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76dfd81a63f70318fd35b139144e7396aa217809493a49b584ffd2e375a59481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bde680a8-eaef-46fb-a72e-9c818966ae87", "node_type": "1", "metadata": {"window": "But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n "}, "hash": "51cb83b6df425b11ed8823bfbd2a72422d08bd618c2647e53a3de014ee09d66e", "class_name": "RelatedNodeInfo"}}, "text": "That's super helpful.  ", "start_char_idx": 2185, "end_char_idx": 2208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bde680a8-eaef-46fb-a72e-9c818966ae87": {"__data__": {"id_": "bde680a8-eaef-46fb-a72e-9c818966ae87", "embedding": null, "metadata": {"window": "But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5b57186-1ac2-4771-a653-87604d5f5cde", "node_type": "1", "metadata": {"window": "And we actually are evaluating how much of that might continue on going forward as we \ncontinue to look at that business going forward.   But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "That's super helpful.  ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09dd36a956817ff44ac71e4a4ed4fbcb2fc7d72407537e9f32435a186ad66960", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28ccd561-e427-4571-8f71-752e516aed31", "node_type": "1", "metadata": {"window": "Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n "}, "hash": "d544fb9d5ed088db2e70a7527ba3063713a4260ef0bedbdc2ba90d6383e5cb13", "class_name": "RelatedNodeInfo"}}, "text": "With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n ", "start_char_idx": 2208, "end_char_idx": 2402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28ccd561-e427-4571-8f71-752e516aed31": {"__data__": {"id_": "28ccd561-e427-4571-8f71-752e516aed31", "embedding": null, "metadata": {"window": "Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efd6bb26-986a-4d51-93b1-55e299b81335", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aafdb1d9cde48f649f488d453fa737dfd46650a8c2d98a342d3c6f1fe975c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bde680a8-eaef-46fb-a72e-9c818966ae87", "node_type": "1", "metadata": {"window": "But really strong performance by the lab business.  \n \n Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f62b220afcfa6bb76871274a66d036df36bd54633a91e137427c1f4e0292cd10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10fd6086-9752-4af2-82e1-2e332da96d37", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.  ", "original_text": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.  "}, "hash": "34b47066940df4ed055af60c6f9f2492ac9b675b1aaa105dd38c9bf3a240bc32", "class_name": "RelatedNodeInfo"}}, "text": "And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "start_char_idx": 2402, "end_char_idx": 2682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10fd6086-9752-4af2-82e1-2e332da96d37": {"__data__": {"id_": "10fd6086-9752-4af2-82e1-2e332da96d37", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.  ", "original_text": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28ccd561-e427-4571-8f71-752e516aed31", "node_type": "1", "metadata": {"window": "Adam Noble:  Got you.   That's super helpful.   With regards to the medical business overall, I'm just \ncurious if you could talk about the recovery and utilization there between the US as well as some of \nyour international footprints.  \n \n  And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "original_text": "And, you know, your comments around not exp ecting to see a real drop in elective procedures, \nprobably most likely in the US in COVID, I'm just curious, given some of the lockdowns that have \nrecently been implemented in Europe, whether there is any heightened concern there?  \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db4fffee97fd708fbf38f427931d6e80931ca566430c0e91e8c64ad695c4c1df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18a65ffb-1d13-4747-9cfd-bcc09e065f5d", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n ", "original_text": "I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.  "}, "hash": "df9211f4e1f2b0341da65d560595965a5e2b57298a68095902f1b39c198b3322", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.  ", "start_char_idx": 0, "end_char_idx": 65, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18a65ffb-1d13-4747-9cfd-bcc09e065f5d": {"__data__": {"id_": "18a65ffb-1d13-4747-9cfd-bcc09e065f5d", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n ", "original_text": "I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10fd6086-9752-4af2-82e1-2e332da96d37", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.  ", "original_text": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3853f4fe7f75cb9c207566513b42a6e7661f2256c9a5f0fb6d5054e95c3a880c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bd89c31-1d87-415a-8839-e0b3047fe935", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.  ", "original_text": "It's hard to know how long, but I do think \nit will be choppy.  \n \n "}, "hash": "fd58d1360d4f5e64bf6e766bfbfe114329fa9d2e7c7681414ffa0ceada2bd185", "class_name": "RelatedNodeInfo"}}, "text": "I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.  ", "start_char_idx": 65, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bd89c31-1d87-415a-8839-e0b3047fe935": {"__data__": {"id_": "1bd89c31-1d87-415a-8839-e0b3047fe935", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.  ", "original_text": "It's hard to know how long, but I do think \nit will be choppy.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18a65ffb-1d13-4747-9cfd-bcc09e065f5d", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n ", "original_text": "I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32711e5765500b277be666dc459e3c7e88a1c13f70afd91ecfb9df0d6e300892", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "848bd998-e467-4627-ac0c-971702f44b46", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n ", "original_text": "We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.  "}, "hash": "643261d07febe1956ccc909723b77dc2c7f8079ba48842f381b86bbcc7cc4fce", "class_name": "RelatedNodeInfo"}}, "text": "It's hard to know how long, but I do think \nit will be choppy.  \n \n ", "start_char_idx": 193, "end_char_idx": 261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "848bd998-e467-4627-ac0c-971702f44b46": {"__data__": {"id_": "848bd998-e467-4627-ac0c-971702f44b46", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n ", "original_text": "We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bd89c31-1d87-415a-8839-e0b3047fe935", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.  ", "original_text": "It's hard to know how long, but I do think \nit will be choppy.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24d197e2812a1381b3af89bd43621ff1df55944222968204aad8e152a8ce8738", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "502e7132-aef7-4bdd-8884-52a33d324d5c", "node_type": "1", "metadata": {"window": "I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.  ", "original_text": "The majority of our product is going through our US channels.  \n \n "}, "hash": "ad466c2a65fefe1c70a7473606d7cec152ece44ac3f9601fb3c1f4c99ffc8cc4", "class_name": "RelatedNodeInfo"}}, "text": "We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.  ", "start_char_idx": 261, "end_char_idx": 375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "502e7132-aef7-4bdd-8884-52a33d324d5c": {"__data__": {"id_": "502e7132-aef7-4bdd-8884-52a33d324d5c", "embedding": null, "metadata": {"window": "I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.  ", "original_text": "The majority of our product is going through our US channels.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "848bd998-e467-4627-ac0c-971702f44b46", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n ", "original_text": "We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6070c02623b9883cc2bd3b4dad3ceeb3159750c102fa4f59f87c9bfef0aab53c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e837febb-4dcb-4667-b7b8-3ddb0ac4b6c3", "node_type": "1", "metadata": {"window": "It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.  ", "original_text": "And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.  "}, "hash": "002d2c0657d221163af19d6764bda5fe007405d7b256b8d49062c70a70948099", "class_name": "RelatedNodeInfo"}}, "text": "The majority of our product is going through our US channels.  \n \n ", "start_char_idx": 375, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e837febb-4dcb-4667-b7b8-3ddb0ac4b6c3": {"__data__": {"id_": "e837febb-4dcb-4667-b7b8-3ddb0ac4b6c3", "embedding": null, "metadata": {"window": "It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.  ", "original_text": "And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "502e7132-aef7-4bdd-8884-52a33d324d5c", "node_type": "1", "metadata": {"window": "I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.  ", "original_text": "The majority of our product is going through our US channels.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5bd38851b08a5facb1a216e98e0aa60b53dad98ab667f0d4d9d931160ea268d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79d43d4f-88dd-4937-bd49-375e14da41c8", "node_type": "1", "metadata": {"window": "We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n ", "original_text": "And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n "}, "hash": "fc1d4d915f4f82e2011b144105de0568f0c01ad77a933b0135d7f1b11032b34f", "class_name": "RelatedNodeInfo"}}, "text": "And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.  ", "start_char_idx": 442, "end_char_idx": 593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79d43d4f-88dd-4937-bd49-375e14da41c8": {"__data__": {"id_": "79d43d4f-88dd-4937-bd49-375e14da41c8", "embedding": null, "metadata": {"window": "We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n ", "original_text": "And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e837febb-4dcb-4667-b7b8-3ddb0ac4b6c3", "node_type": "1", "metadata": {"window": "It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.  ", "original_text": "And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adf53365579c7ab0ada7c41eba3af154ccb7d5907f7df2156ea15a1d695849d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a9f75b5-8358-4079-8913-424c15398830", "node_type": "1", "metadata": {"window": "The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.  ", "original_text": "But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.  "}, "hash": "b2369061f888c34441182fcd7af35cdae20790983f2eda74497f8214e963d5d3", "class_name": "RelatedNodeInfo"}}, "text": "And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n ", "start_char_idx": 593, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a9f75b5-8358-4079-8913-424c15398830": {"__data__": {"id_": "7a9f75b5-8358-4079-8913-424c15398830", "embedding": null, "metadata": {"window": "The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.  ", "original_text": "But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79d43d4f-88dd-4937-bd49-375e14da41c8", "node_type": "1", "metadata": {"window": "We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.   The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n ", "original_text": "And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff98ede025ce1efe3664e9781950852faa6c11a5f21767ec335e50c7a169b3ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67e5a6b9-1c1c-41b6-8d04-8fb08548e6d0", "node_type": "1", "metadata": {"window": "And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.  ", "original_text": "If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.  "}, "hash": "5c4a9811043c0cba85db82385ed9182665785c47568cd85ea1935329c2dd45d1", "class_name": "RelatedNodeInfo"}}, "text": "But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.  ", "start_char_idx": 739, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67e5a6b9-1c1c-41b6-8d04-8fb08548e6d0": {"__data__": {"id_": "67e5a6b9-1c1c-41b6-8d04-8fb08548e6d0", "embedding": null, "metadata": {"window": "And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.  ", "original_text": "If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a9f75b5-8358-4079-8913-424c15398830", "node_type": "1", "metadata": {"window": "The majority of our product is going through our US channels.  \n \n  And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.  ", "original_text": "But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2aa0a33d9861aac9b9b6be059a7bc7f988deaab32902ff59db5088dad331420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8ba5e9e-6d9b-41de-818a-b9ce34591aa8", "node_type": "1", "metadata": {"window": "And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n", "original_text": "But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n "}, "hash": "ef1f21ea7558c03500aede71871b2e72ef928c415ebd5d4909b04f9e9216bac2", "class_name": "RelatedNodeInfo"}}, "text": "If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.  ", "start_char_idx": 845, "end_char_idx": 954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8ba5e9e-6d9b-41de-818a-b9ce34591aa8": {"__data__": {"id_": "a8ba5e9e-6d9b-41de-818a-b9ce34591aa8", "embedding": null, "metadata": {"window": "And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n", "original_text": "But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67e5a6b9-1c1c-41b6-8d04-8fb08548e6d0", "node_type": "1", "metadata": {"window": "And as I said as it relates to electives, we exited Q1 down mid -single digits and expect to get \nat or near pre-COVID levels by the end of the year.   And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.  ", "original_text": "If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39780b00aa994bf9ee9882f2fdb7c37323b4600be7b6a7b7f92c70e385bbec3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b3e8dfc-e836-442b-aa1b-cb5bdf4ea61d", "node_type": "1", "metadata": {"window": "But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.  ", "original_text": "As far as in Europe, again, that is just product sales.  "}, "hash": "9b15f2b2e34c430420552b566aa53116aebb58af2eb54c61b8fafbdd1d648508", "class_name": "RelatedNodeInfo"}}, "text": "But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n ", "start_char_idx": 954, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b3e8dfc-e836-442b-aa1b-cb5bdf4ea61d": {"__data__": {"id_": "0b3e8dfc-e836-442b-aa1b-cb5bdf4ea61d", "embedding": null, "metadata": {"window": "But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.  ", "original_text": "As far as in Europe, again, that is just product sales.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8ba5e9e-6d9b-41de-818a-b9ce34591aa8", "node_type": "1", "metadata": {"window": "And while that's not a huge sequential growth, \nwe do expect it to be somewhat choppy and it's hard to exactly predict on a quarterly basis.  \n \n  But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n", "original_text": "But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d763426b546cbe89b9d37529b883d20a6733cb86b5cd3f1c5149bcd0579c131", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb8c48d5-8487-405c-a893-0ca7e709574b", "node_type": "1", "metadata": {"window": "If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n", "original_text": "We don't do distribution over there.  "}, "hash": "df5f9f4ada7cbf9a85bdce4dad254dfffbd4e6c38efc577a347e89199f5c7bf6", "class_name": "RelatedNodeInfo"}}, "text": "As far as in Europe, again, that is just product sales.  ", "start_char_idx": 1092, "end_char_idx": 1149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb8c48d5-8487-405c-a893-0ca7e709574b": {"__data__": {"id_": "cb8c48d5-8487-405c-a893-0ca7e709574b", "embedding": null, "metadata": {"window": "If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n", "original_text": "We don't do distribution over there.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b3e8dfc-e836-442b-aa1b-cb5bdf4ea61d", "node_type": "1", "metadata": {"window": "But we feel good about our current guidance as it relates - again assumi ng there is no major \nshutdown.   If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.  ", "original_text": "As far as in Europe, again, that is just product sales.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa4ec92b41d836bea6a0ce29bfe10abb3cba733bbc10be84371ebc85d6ed0ca5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ae81690-6ec1-42ee-b7f1-60f1179e2c97", "node_type": "1", "metadata": {"window": "But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n", "original_text": "And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n"}, "hash": "ff255cb3fd71a7fffd745db8ae2514bee5bbcd85648877de8fb9daa70734c644", "class_name": "RelatedNodeInfo"}}, "text": "We don't do distribution over there.  ", "start_char_idx": 1149, "end_char_idx": 1187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ae81690-6ec1-42ee-b7f1-60f1179e2c97": {"__data__": {"id_": "5ae81690-6ec1-42ee-b7f1-60f1179e2c97", "embedding": null, "metadata": {"window": "But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n", "original_text": "And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb8c48d5-8487-405c-a893-0ca7e709574b", "node_type": "1", "metadata": {"window": "If we had everybody shutting down again like in our Q4 that would create some different \ntypes of concerns.   But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n", "original_text": "We don't do distribution over there.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f651f91022ae3d3d1814513feed5d23fe27c7992e3be0b607c58595ca1fe38b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ce21810-6094-4ba7-b893-b11e34ba19ae", "node_type": "1", "metadata": {"window": "As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n", "original_text": "Adam Noble :  Great.  "}, "hash": "cd103c3d49dd3b6504affe266194c55037cc49aceb0477d83d2f2b9ba967ba4d", "class_name": "RelatedNodeInfo"}}, "text": "And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n", "start_char_idx": 1187, "end_char_idx": 1326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ce21810-6094-4ba7-b893-b11e34ba19ae": {"__data__": {"id_": "4ce21810-6094-4ba7-b893-b11e34ba19ae", "embedding": null, "metadata": {"window": "As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n", "original_text": "Adam Noble :  Great.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ae81690-6ec1-42ee-b7f1-60f1179e2c97", "node_type": "1", "metadata": {"window": "But as long as we just see spotty types of - lumpy type of shutdowns, we would \nexpect that - you know, we can manage  through that.  \n \n  As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n", "original_text": "And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b390d0a2f7ef51a8646d7057f07f34716b64a07265b2b0b8321f47897ebed74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7351732-92aa-4f52-b2af-c5d5a6f0f09e", "node_type": "1", "metadata": {"window": "We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.  ", "original_text": "Thanks for the questions.  \n \n"}, "hash": "e1c8ddcffadfec0e56bc25a275557719850b0c134f46d94e52751f8f1fb8b4eb", "class_name": "RelatedNodeInfo"}}, "text": "Adam Noble :  Great.  ", "start_char_idx": 1326, "end_char_idx": 1348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7351732-92aa-4f52-b2af-c5d5a6f0f09e": {"__data__": {"id_": "a7351732-92aa-4f52-b2af-c5d5a6f0f09e", "embedding": null, "metadata": {"window": "We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.  ", "original_text": "Thanks for the questions.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ce21810-6094-4ba7-b893-b11e34ba19ae", "node_type": "1", "metadata": {"window": "As far as in Europe, again, that is just product sales.   We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n", "original_text": "Adam Noble :  Great.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39ba428b1a365b634e0be0be00385294c554cb8edc8da917fcdfbf5de129c8a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55830972-b324-414a-92ae-1fac08b87b79", "node_type": "1", "metadata": {"window": "And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.  ", "original_text": "Mike Kaufmann:  Thanks.  \n \n"}, "hash": "1d7ac4010cea57794e93e9f6aff010c5073a05f7cca3105ee6ecef559979f29e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions.  \n \n", "start_char_idx": 1348, "end_char_idx": 1378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55830972-b324-414a-92ae-1fac08b87b79": {"__data__": {"id_": "55830972-b324-414a-92ae-1fac08b87b79", "embedding": null, "metadata": {"window": "And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.  ", "original_text": "Mike Kaufmann:  Thanks.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7351732-92aa-4f52-b2af-c5d5a6f0f09e", "node_type": "1", "metadata": {"window": "We don't do distribution over there.   And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.  ", "original_text": "Thanks for the questions.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5a85e9f181538066bc9794bf80a0968dad132fba5210920b7bf215f7a8a591c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64fab53c-d357-48f0-b1f3-bb97ec60938d", "node_type": "1", "metadata": {"window": "Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n ", "original_text": "Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n"}, "hash": "ddfea3591a2c287dc3d32e27e7eb712d38fefdfedaa01a44d846a3b1e2a8145d", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks.  \n \n", "start_char_idx": 1378, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64fab53c-d357-48f0-b1f3-bb97ec60938d": {"__data__": {"id_": "64fab53c-d357-48f0-b1f3-bb97ec60938d", "embedding": null, "metadata": {"window": "Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n ", "original_text": "Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55830972-b324-414a-92ae-1fac08b87b79", "node_type": "1", "metadata": {"window": "And \nour current guidance does assume against some choppiness over there and we're not looking for \nmajor shutdowns over there either.  \n \n Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.  ", "original_text": "Mike Kaufmann:  Thanks.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87df49dc4608f65592542257bbf410e6675f30f3490b6252372445c714d03f3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf5d5949-48ac-41e4-a4d2-5fda32eef62d", "node_type": "1", "metadata": {"window": "Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n", "original_text": "Lisa Gill:  Thanks very much.  "}, "hash": "3cffa1662532ed4df040d3049a2d8daca83f51550747963518b669be4f990182", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n", "start_char_idx": 1406, "end_char_idx": 1479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf5d5949-48ac-41e4-a4d2-5fda32eef62d": {"__data__": {"id_": "cf5d5949-48ac-41e4-a4d2-5fda32eef62d", "embedding": null, "metadata": {"window": "Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n", "original_text": "Lisa Gill:  Thanks very much.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64fab53c-d357-48f0-b1f3-bb97ec60938d", "node_type": "1", "metadata": {"window": "Adam Noble :  Great.   Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n ", "original_text": "Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "446729fb53d672fa0fb661a92f03d84b132123bbc95cea3c79019cc6ef72b180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "492db601-eb30-4567-a79c-d9581c409918", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n ", "original_text": "Good morning, Mike and Jason.  "}, "hash": "b0ac0e66d4bfbf5e069a467a6ab1304057373e6fe96c35a5d577d90dd29b08da", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Thanks very much.  ", "start_char_idx": 1479, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "492db601-eb30-4567-a79c-d9581c409918": {"__data__": {"id_": "492db601-eb30-4567-a79c-d9581c409918", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n ", "original_text": "Good morning, Mike and Jason.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf5d5949-48ac-41e4-a4d2-5fda32eef62d", "node_type": "1", "metadata": {"window": "Thanks for the questions.  \n \n Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n", "original_text": "Lisa Gill:  Thanks very much.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c0d8f4a1e20b776374884a77326889b8228bdeede6d6324dd1285ee34c6ab27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c74f8374-2175-4ffd-88d2-54bd55eba4e2", "node_type": "1", "metadata": {"window": "Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?  ", "original_text": "Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n "}, "hash": "65140682d4270143a355716e35206e9bc4fe4c8b2027882b2cf0e0c8e975dd2e", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, Mike and Jason.  ", "start_char_idx": 1510, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c74f8374-2175-4ffd-88d2-54bd55eba4e2": {"__data__": {"id_": "c74f8374-2175-4ffd-88d2-54bd55eba4e2", "embedding": null, "metadata": {"window": "Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?  ", "original_text": "Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "492db601-eb30-4567-a79c-d9581c409918", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks.  \n \n Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n ", "original_text": "Good morning, Mike and Jason.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d40d2f052a152a74810842109b400693b378c83a0c8c2181c3d6522631f3693f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f24601ce-4d23-4700-9217-c1d5ad57e9c9", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?  ", "original_text": "We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n"}, "hash": "cda6a7e92e06c710ae41495e51b1e321f3d2575e2addf9384132587732d454a0", "class_name": "RelatedNodeInfo"}}, "text": "Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n ", "start_char_idx": 1541, "end_char_idx": 1751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f24601ce-4d23-4700-9217-c1d5ad57e9c9": {"__data__": {"id_": "f24601ce-4d23-4700-9217-c1d5ad57e9c9", "embedding": null, "metadata": {"window": "Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?  ", "original_text": "We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c74f8374-2175-4ffd-88d2-54bd55eba4e2", "node_type": "1", "metadata": {"window": "Operator:  We will now take a question from Lisa Gill with JPMorgan.  \n \n Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?  ", "original_text": "Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f0ac4c3bff4d1734bcb9d95cc9d0964960085031a5bc9944c3338d0993fc8c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2e3c825-ab7c-4192-81a3-e0b5046bfdb5", "node_type": "1", "metadata": {"window": "Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n", "original_text": "So if you can talk about what trends you're seeing there.  \n \n "}, "hash": "e176e47df0a6987e9f6dce30912c97f773e40e7dc5df5231225a21addce0cabd", "class_name": "RelatedNodeInfo"}}, "text": "We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n", "start_char_idx": 1751, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2e3c825-ab7c-4192-81a3-e0b5046bfdb5": {"__data__": {"id_": "e2e3c825-ab7c-4192-81a3-e0b5046bfdb5", "embedding": null, "metadata": {"window": "Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n", "original_text": "So if you can talk about what trends you're seeing there.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f24601ce-4d23-4700-9217-c1d5ad57e9c9", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.   Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?  ", "original_text": "We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1150aa63d47cdc6acfbba43861beb4d329257a9503ca026ab8231c793ee94629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f7264cb-2c85-46ac-915f-d762756803f2", "node_type": "1", "metadata": {"window": "Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.  ", "original_text": "And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?  "}, "hash": "9d27ae5ac2d056b57d4f96d6d8848f70c548e3cbd5daa007d109e97cd805d73d", "class_name": "RelatedNodeInfo"}}, "text": "So if you can talk about what trends you're seeing there.  \n \n ", "start_char_idx": 1952, "end_char_idx": 2015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f7264cb-2c85-46ac-915f-d762756803f2": {"__data__": {"id_": "5f7264cb-2c85-46ac-915f-d762756803f2", "embedding": null, "metadata": {"window": "Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.  ", "original_text": "And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2e3c825-ab7c-4192-81a3-e0b5046bfdb5", "node_type": "1", "metadata": {"window": "Good morning, Mike and Jason.   Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n", "original_text": "So if you can talk about what trends you're seeing there.  \n \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1228ccf77285215e595415b36583c6de059c0a2109ed09fb519f468486665340", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3b1a0be-9159-4138-8dbd-d7282373e7f0", "node_type": "1", "metadata": {"window": "We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n", "original_text": "Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?  "}, "hash": "22cce5c448e144378a3784222a44fcd83f4c21d81fb72d00d46e80bda5eaa2ef", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?  ", "start_char_idx": 2015, "end_char_idx": 2200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3b1a0be-9159-4138-8dbd-d7282373e7f0": {"__data__": {"id_": "a3b1a0be-9159-4138-8dbd-d7282373e7f0", "embedding": null, "metadata": {"window": "We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n", "original_text": "Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f7264cb-2c85-46ac-915f-d762756803f2", "node_type": "1", "metadata": {"window": "Just as we think about the \npharmaceutical distribution busine ss on a go forward basis, Mike, can you talk about maybe what you \nsaw in the quarter around new prescription volume trends and expectations?  \n \n  We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.  ", "original_text": "And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "891501d6499abbb4c28cc250161faad18dc217c63f0b4e0f56d2c0560cfed6c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d1bf75c-d5ef-4dc4-b837-cde6de64ecd8", "node_type": "1", "metadata": {"window": "So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "And how do we think \nabout potential margin differentials?  \n \n"}, "hash": "8aaa548efabddac2b1e1f4c2781d6d69beaf2a83227d013dad8ba03dcc5ac292", "class_name": "RelatedNodeInfo"}}, "text": "Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?  ", "start_char_idx": 2200, "end_char_idx": 2294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d1bf75c-d5ef-4dc4-b837-cde6de64ecd8": {"__data__": {"id_": "1d1bf75c-d5ef-4dc4-b837-cde6de64ecd8", "embedding": null, "metadata": {"window": "So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "And how do we think \nabout potential margin differentials?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3b1a0be-9159-4138-8dbd-d7282373e7f0", "node_type": "1", "metadata": {"window": "We understand that people are starting to go back to the physician office but just looking at \nIQVIA data, it does n't look like trends for new prescriptions are back to what they were historically.  \n So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n", "original_text": "Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ea7a4544be54a72635dfa0f4ba69c3940f84fe50ded8c939ddffec0bde67288", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe5ba65-8aea-43f7-b5d4-3e2f28d3a852", "node_type": "1", "metadata": {"window": "And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.  "}, "hash": "1a5e7e8d6bc0e5eb75863b8282d1d8f7aec90140e14ffe1df51ec016e64244cd", "class_name": "RelatedNodeInfo"}}, "text": "And how do we think \nabout potential margin differentials?  \n \n", "start_char_idx": 2294, "end_char_idx": 2357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe5ba65-8aea-43f7-b5d4-3e2f28d3a852": {"__data__": {"id_": "6fe5ba65-8aea-43f7-b5d4-3e2f28d3a852", "embedding": null, "metadata": {"window": "And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d1bf75c-d5ef-4dc4-b837-cde6de64ecd8", "node_type": "1", "metadata": {"window": "So if you can talk about what trends you're seeing there.  \n \n  And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "And how do we think \nabout potential margin differentials?  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "debf9b37d664b841dedecea13fe3a68250e95d4d8fbd9397bbb6ff8c1ae5c269", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33b6c668-803e-4aeb-9bb5-6770b2c31dc2", "node_type": "1", "metadata": {"window": "Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n"}, "hash": "ab43a253789cd9913f3bdc582afd167f35a2e8a53e9baa52521008730788fe76", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.  ", "start_char_idx": 2357, "end_char_idx": 2453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33b6c668-803e-4aeb-9bb5-6770b2c31dc2": {"__data__": {"id_": "33b6c668-803e-4aeb-9bb5-6770b2c31dc2", "embedding": null, "metadata": {"window": "Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe5ba65-8aea-43f7-b5d4-3e2f28d3a852", "node_type": "1", "metadata": {"window": "And then secondly, when we think about your guidance and think about your pharmaceutical \ndistribution component , can you talk about your expectation for biosimilars in your numbers?   Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca3e9bffe90c46841a3c6255e49c19de078a29e801ae879a644ea79d25e7ffcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08521c34-9876-4e5e-9e80-4482df39a9fa", "node_type": "1", "metadata": {"window": "And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "And we've been successful working with the suppliers and our customers in this area.  \n "}, "hash": "4c04cf0d2e86e74409825f190c86b2966f204c833002c5b16e5af992b1267256", "class_name": "RelatedNodeInfo"}}, "text": "We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n", "start_char_idx": 2453, "end_char_idx": 2560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08521c34-9876-4e5e-9e80-4482df39a9fa": {"__data__": {"id_": "08521c34-9876-4e5e-9e80-4482df39a9fa", "embedding": null, "metadata": {"window": "And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "And we've been successful working with the suppliers and our customers in this area.  \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44e816c5af256782889f439a821b7e4b18d469868bbdc9ae363a96bc4bd1d2fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33b6c668-803e-4aeb-9bb5-6770b2c31dc2", "node_type": "1", "metadata": {"window": "Do you \nhave an expectation that that's going to be a positive for you for this fiscal year?   And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b340b15a82ef2c25604864d6ef4e05653f7404d04fc177b7e7c1407f21dc483", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c187c0d5-e62f-498b-a8ef-213e6dcb606f", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.  ", "original_text": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.  "}, "hash": "2c8577d133bfe2d2c7bbd141c5e6c1f617e72c3c0cb4fa09f77d3797774a407c", "class_name": "RelatedNodeInfo"}}, "text": "And we've been successful working with the suppliers and our customers in this area.  \n ", "start_char_idx": 2560, "end_char_idx": 2648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c187c0d5-e62f-498b-a8ef-213e6dcb606f": {"__data__": {"id_": "c187c0d5-e62f-498b-a8ef-213e6dcb606f", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.  ", "original_text": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08521c34-9876-4e5e-9e80-4482df39a9fa", "node_type": "1", "metadata": {"window": "And how do we think \nabout potential margin differentials?  \n \n Mike Kaufmann:  Yes, I'll just s tart with the biosimilars first and move on to the Rx trends.   We do \ncontinue to see biosimilars gain momentum with increased adoptions across multiple sites of care.  \n And we've been successful working with the suppliers and our customers in this area.  \n ", "original_text": "And we've been successful working with the suppliers and our customers in this area.  \n ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc4c316734d1ccefbe45939ff27f2a08f35d9ac97e0a122e0a0b0024ac1e46a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee780fef-b232-4dfa-9a0d-e3a961aad3ae", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n ", "original_text": "Generally biosimilar margins are similar to branded margins.  \n"}, "hash": "34c7ad4f22af13f2313325f85b076a8933f7ca92c523359fab2d03bd33706a66", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.  ", "start_char_idx": 0, "end_char_idx": 153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee780fef-b232-4dfa-9a0d-e3a961aad3ae": {"__data__": {"id_": "ee780fef-b232-4dfa-9a0d-e3a961aad3ae", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n ", "original_text": "Generally biosimilar margins are similar to branded margins.  \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c187c0d5-e62f-498b-a8ef-213e6dcb606f", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.  ", "original_text": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20bb6c429f87657b4a5270929fe23df2afbd66398e3ca43753e80c789cefb874", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a142a726-ded1-4aa4-966c-b75ae8e61fed", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.  ", "original_text": "It depends on the individual supplier and the product.  \n \n "}, "hash": "bc4d78a53d729ab01310d0079254138f3b7d2a1dfb4eee38555107014474ef3e", "class_name": "RelatedNodeInfo"}}, "text": "Generally biosimilar margins are similar to branded margins.  \n", "start_char_idx": 153, "end_char_idx": 216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a142a726-ded1-4aa4-966c-b75ae8e61fed": {"__data__": {"id_": "a142a726-ded1-4aa4-966c-b75ae8e61fed", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.  ", "original_text": "It depends on the individual supplier and the product.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee780fef-b232-4dfa-9a0d-e3a961aad3ae", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n ", "original_text": "Generally biosimilar margins are similar to branded margins.  \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34b216f7c7af605ee0b7ebc58cacb9e676acd7d844d779a6206f8ab3d6b8d297", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3d3e48b-7fde-43da-a46d-d4452d92ce37", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n ", "original_text": "There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.  "}, "hash": "ef0cba7662d0a826d6104fe60e9dcc81bd3ab0052af583bfccb118605f6f442f", "class_name": "RelatedNodeInfo"}}, "text": "It depends on the individual supplier and the product.  \n \n ", "start_char_idx": 216, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3d3e48b-7fde-43da-a46d-d4452d92ce37": {"__data__": {"id_": "e3d3e48b-7fde-43da-a46d-d4452d92ce37", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n ", "original_text": "There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a142a726-ded1-4aa4-966c-b75ae8e61fed", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.  ", "original_text": "It depends on the individual supplier and the product.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43b3922c579db19647abc60f02c2482d88b7bd2b97215cfee30ea60a737c5aa6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b03c4c3a-c305-469d-b285-e90f3cfdc9c7", "node_type": "1", "metadata": {"window": "Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n ", "original_text": "But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n "}, "hash": "ef5417d1d620692acb229209591b5c04b0ac54ef83d187654ec72a0e49f81284", "class_name": "RelatedNodeInfo"}}, "text": "There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.  ", "start_char_idx": 276, "end_char_idx": 413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b03c4c3a-c305-469d-b285-e90f3cfdc9c7": {"__data__": {"id_": "b03c4c3a-c305-469d-b285-e90f3cfdc9c7", "embedding": null, "metadata": {"window": "Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n ", "original_text": "But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3d3e48b-7fde-43da-a46d-d4452d92ce37", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n ", "original_text": "There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e103f6289ea639618d81deea4a71facbc41960c60b5cdc07caee84497335b50a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b026a08-23ef-4c5a-b80e-d49b6052ae91", "node_type": "1", "metadata": {"window": "It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.  ", "original_text": "And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.  "}, "hash": "0ce9ff4fa57e2d62652c322de1329853aa8546609cd9f462c86f44d5776b5d67", "class_name": "RelatedNodeInfo"}}, "text": "But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n ", "start_char_idx": 413, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b026a08-23ef-4c5a-b80e-d49b6052ae91": {"__data__": {"id_": "7b026a08-23ef-4c5a-b80e-d49b6052ae91", "embedding": null, "metadata": {"window": "It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.  ", "original_text": "And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b03c4c3a-c305-469d-b285-e90f3cfdc9c7", "node_type": "1", "metadata": {"window": "Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n ", "original_text": "But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0d364ccfcdfd1cc627241b7855a7a1952629b89c5fde368456cdf344e1a7ae4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09cc708e-d13a-4de8-bd10-96c99e6c8108", "node_type": "1", "metadata": {"window": "There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n ", "original_text": "So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n "}, "hash": "9284fe6002468065cf9b4ef72075a0a4b8247fd1a508a9082b9c37b6d709db4f", "class_name": "RelatedNodeInfo"}}, "text": "And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.  ", "start_char_idx": 594, "end_char_idx": 722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09cc708e-d13a-4de8-bd10-96c99e6c8108": {"__data__": {"id_": "09cc708e-d13a-4de8-bd10-96c99e6c8108", "embedding": null, "metadata": {"window": "There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n ", "original_text": "So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b026a08-23ef-4c5a-b80e-d49b6052ae91", "node_type": "1", "metadata": {"window": "It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.  ", "original_text": "And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "543c3c323806c0960363340c38c6df3cfd3014bb04caaf9b40c90078f46085f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce7b62b2-cb0c-4d7c-8648-3964b20f3b5e", "node_type": "1", "metadata": {"window": "But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.  ", "original_text": "And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n "}, "hash": "ee8cf2e814c46cab892ed5dccc7e68935eb2c9597f53cd168112a5dbbee7a9d9", "class_name": "RelatedNodeInfo"}}, "text": "So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n ", "start_char_idx": 722, "end_char_idx": 888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce7b62b2-cb0c-4d7c-8648-3964b20f3b5e": {"__data__": {"id_": "ce7b62b2-cb0c-4d7c-8648-3964b20f3b5e", "embedding": null, "metadata": {"window": "But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.  ", "original_text": "And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09cc708e-d13a-4de8-bd10-96c99e6c8108", "node_type": "1", "metadata": {"window": "There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.   But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n ", "original_text": "So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b9cf39cdeded322777d1c46f7e6156272571a1c5299f1c846c2d6337c218ad6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "540d116c-9002-4f50-a8f3-b1e7215c18bd", "node_type": "1", "metadata": {"window": "And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n", "original_text": "Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.  "}, "hash": "0234bef7e4a4f075ae345acf220ce94b9a7af659f094df653dacec61422f51c5", "class_name": "RelatedNodeInfo"}}, "text": "And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n ", "start_char_idx": 888, "end_char_idx": 1267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "540d116c-9002-4f50-a8f3-b1e7215c18bd": {"__data__": {"id_": "540d116c-9002-4f50-a8f3-b1e7215c18bd", "embedding": null, "metadata": {"window": "And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n", "original_text": "Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce7b62b2-cb0c-4d7c-8648-3964b20f3b5e", "node_type": "1", "metadata": {"window": "But generally, as I've said in the past, the real margin \nopportunity for us in biosimilars over the mid to long term, will be is if they have an interchangeable \ndesignation.  \n \n  And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.  ", "original_text": "And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f8d137de60aa7d2021d9af897d818d3f98117cd1dc3bb7039ba9e1a727bbf9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f432debc-bb6c-42c7-bcef-61ec1dc82a57", "node_type": "1", "metadata": {"window": "So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.  ", "original_text": "So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n "}, "hash": "a75a610ece5368c638cdb8ad262c0c2390df4cd7076d0afc290707169cd4243f", "class_name": "RelatedNodeInfo"}}, "text": "Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.  ", "start_char_idx": 1267, "end_char_idx": 1427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f432debc-bb6c-42c7-bcef-61ec1dc82a57": {"__data__": {"id_": "f432debc-bb6c-42c7-bcef-61ec1dc82a57", "embedding": null, "metadata": {"window": "So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.  ", "original_text": "So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "540d116c-9002-4f50-a8f3-b1e7215c18bd", "node_type": "1", "metadata": {"window": "And then I think that will increase the opportunities for us to really make more meaningful \ncontributions to our bottom line.   So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n", "original_text": "Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fbe63f5a508034542e5bae76926fb51847e542d27e71aeb4182adb670e6c163", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a02e310-14cc-4f49-bbf7-8642082b9cd4", "node_type": "1", "metadata": {"window": "And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n", "original_text": "As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.  "}, "hash": "1b7cfdf1a8e7be8eee35a2d817bb80d09b08b3198df4b925762514670efff65d", "class_name": "RelatedNodeInfo"}}, "text": "So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n ", "start_char_idx": 1427, "end_char_idx": 1611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a02e310-14cc-4f49-bbf7-8642082b9cd4": {"__data__": {"id_": "4a02e310-14cc-4f49-bbf7-8642082b9cd4", "embedding": null, "metadata": {"window": "And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n", "original_text": "As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f432debc-bb6c-42c7-bcef-61ec1dc82a57", "node_type": "1", "metadata": {"window": "So while we continue to be very excited about the future potential for \nbiosimil ars, they have really not, at this time, reached a level of materiality for us.  \n \n  And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.  ", "original_text": "So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "038128b871c6fc323114c4da2d5d6bb49b821011bcad4602f1b561a20b2e656e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a3a3fd8-3062-4ea1-af3f-30ba2766bf53", "node_type": "1", "metadata": {"window": "Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n", "original_text": "So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n"}, "hash": "b04a83c16027f01656d497933020b17fd66fb86d88caa2e8fb77df311cf44d87", "class_name": "RelatedNodeInfo"}}, "text": "As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.  ", "start_char_idx": 1611, "end_char_idx": 1804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a3a3fd8-3062-4ea1-af3f-30ba2766bf53": {"__data__": {"id_": "9a3a3fd8-3062-4ea1-af3f-30ba2766bf53", "embedding": null, "metadata": {"window": "Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n", "original_text": "So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a02e310-14cc-4f49-bbf7-8642082b9cd4", "node_type": "1", "metadata": {"window": "And then flipping to your other question around Rx trends, I think the first comment I would \nmake is the real resilience of the pharma segment in general, this is a business that it seems like \nwhenever we go through large challenges in the US, it's a business that continues to - while it may \nhave some headwind continues to be very resilient to the overall marketplace.  \n \n  Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n", "original_text": "As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b1e0d998f2fd418a4d7b5cb8cbda5a1fd4c96cb7502d3e18893b6bc3754c108", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c788372c-36a7-41d8-b831-ce95355cbdf6", "node_type": "1", "metadata": {"window": "So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi. ", "original_text": "Lisa Gill:  Okay, great.  "}, "hash": "8697f3680faa0bc67093e47f2c4f89fcbc9c30df2ce01390280a08391e4f78fa", "class_name": "RelatedNodeInfo"}}, "text": "So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n", "start_char_idx": 1804, "end_char_idx": 1964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c788372c-36a7-41d8-b831-ce95355cbdf6": {"__data__": {"id_": "c788372c-36a7-41d8-b831-ce95355cbdf6", "embedding": null, "metadata": {"window": "So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi. ", "original_text": "Lisa Gill:  Okay, great.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a3a3fd8-3062-4ea1-af3f-30ba2766bf53", "node_type": "1", "metadata": {"window": "Now we also know in our pharma segment that includes our nuclear business, which as Jason \nmentioned, was coming back nicely in the quarter and tracking well.   So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n", "original_text": "So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42babc6d2c93fb9d73328e11c0467ac41ec2a1004d766c67536d3fb9d55c05e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f617382-29a9-4b9e-94fc-0aacdb11b9a3", "node_type": "1", "metadata": {"window": "As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.  ", "original_text": "Thank you.  \n \n"}, "hash": "27f7a8c9b48c3523b6724a7427ebb8158e0beb46936e9fa86d0f2f24614f7104", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Okay, great.  ", "start_char_idx": 1964, "end_char_idx": 1990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f617382-29a9-4b9e-94fc-0aacdb11b9a3": {"__data__": {"id_": "5f617382-29a9-4b9e-94fc-0aacdb11b9a3", "embedding": null, "metadata": {"window": "As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.  ", "original_text": "Thank you.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c788372c-36a7-41d8-b831-ce95355cbdf6", "node_type": "1", "metadata": {"window": "So we're glad that we \nmaintained both the people and the resources and commitments there because we did see that \nbounce back still below prio r levels but bouncing back nicely.  \n \n  As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi. ", "original_text": "Lisa Gill:  Okay, great.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0eaf99b34ccef80d6547aef2480d2c68ead61d37602be66fc5dc4d6f6c475bac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0d18af2-1d3b-4aad-8506-16a4c1fa0011", "node_type": "1", "metadata": {"window": "So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?  ", "original_text": "Operator:  Now moving to Joseph Amato with Evercore.  \n \n"}, "hash": "aa06092883043f3e459876b91aaf67b876cca5fbfd104dcc1c404a35f9327b2a", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 1990, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0d18af2-1d3b-4aad-8506-16a4c1fa0011": {"__data__": {"id_": "c0d18af2-1d3b-4aad-8506-16a4c1fa0011", "embedding": null, "metadata": {"window": "So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?  ", "original_text": "Operator:  Now moving to Joseph Amato with Evercore.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f617382-29a9-4b9e-94fc-0aacdb11b9a3", "node_type": "1", "metadata": {"window": "As far as your comment around the IQVIA data, I actually would say that what we're seeing is \nthat our general business tracks pretty closely to it, around both new Rx's, generics, et cetera.   So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.  ", "original_text": "Thank you.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d01942ad39c1f024ae4914cdaf102939855ca8c784178a3eb3746c12ef179e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdbc3545-6f63-4a65-8344-289f47dbe258", "node_type": "1", "metadata": {"window": "Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n", "original_text": "Joseph Amato:  Hi. "}, "hash": "ae1db20e5d519830407fb25bc8c83a10dd2c871b29c747e58a40601548f84846", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Now moving to Joseph Amato with Evercore.  \n \n", "start_char_idx": 2005, "end_char_idx": 2062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdbc3545-6f63-4a65-8344-289f47dbe258": {"__data__": {"id_": "fdbc3545-6f63-4a65-8344-289f47dbe258", "embedding": null, "metadata": {"window": "Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n", "original_text": "Joseph Amato:  Hi. ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0d18af2-1d3b-4aad-8506-16a4c1fa0011", "node_type": "1", "metadata": {"window": "So \nwe're not really seeing any trends within our business that I would call out that are much different than \nwhat we're seeing in the overall IQVIA data.  \n \n Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?  ", "original_text": "Operator:  Now moving to Joseph Amato with Evercore.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "921cdddca941fcd8f6b60d6e102842f21a59e38f9dc7a6a7bdc669ff1ebca356", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eb0c9d3-129a-48f2-ac23-af546a9f7262", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.  ", "original_text": "Just a quick ques tion on Cardinal Health at -Home.  "}, "hash": "c791a77e2cd92e6ae15abc6d44d392cbb3dc8ee0f36b039e81a02833c0cf38a6", "class_name": "RelatedNodeInfo"}}, "text": "Joseph Amato:  Hi. ", "start_char_idx": 2062, "end_char_idx": 2081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eb0c9d3-129a-48f2-ac23-af546a9f7262": {"__data__": {"id_": "7eb0c9d3-129a-48f2-ac23-af546a9f7262", "embedding": null, "metadata": {"window": "Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.  ", "original_text": "Just a quick ques tion on Cardinal Health at -Home.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdbc3545-6f63-4a65-8344-289f47dbe258", "node_type": "1", "metadata": {"window": "Lisa Gill:  Okay, great.   Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n", "original_text": "Joseph Amato:  Hi. ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17ec0534c5ccc379c6dd7904a6c100a6789986260bf8d3795dbc3e5529807cb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf1a0140-3885-451d-b242-438a8a09342e", "node_type": "1", "metadata": {"window": "Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n ", "original_text": "Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?  "}, "hash": "d66a186d23cb9b966701ed77ef5a5a58ee7062fd4bf0e5fc92a16bd26e9cb24c", "class_name": "RelatedNodeInfo"}}, "text": "Just a quick ques tion on Cardinal Health at -Home.  ", "start_char_idx": 2081, "end_char_idx": 2134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf1a0140-3885-451d-b242-438a8a09342e": {"__data__": {"id_": "cf1a0140-3885-451d-b242-438a8a09342e", "embedding": null, "metadata": {"window": "Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n ", "original_text": "Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eb0c9d3-129a-48f2-ac23-af546a9f7262", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.  ", "original_text": "Just a quick ques tion on Cardinal Health at -Home.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df39712536aa74ab00c1881d60dd2f146d09fe0a20819b702c955332b9c95aa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25fa851c-5ec9-42b5-b3dc-ec119d4f3d4b", "node_type": "1", "metadata": {"window": "Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.  ", "original_text": "Thanks.  \n \n"}, "hash": "de6cd969fe82267dd85bee10ad0514699061355dcdffd0c022cf72313f713d5e", "class_name": "RelatedNodeInfo"}}, "text": "Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?  ", "start_char_idx": 2134, "end_char_idx": 2232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25fa851c-5ec9-42b5-b3dc-ec119d4f3d4b": {"__data__": {"id_": "25fa851c-5ec9-42b5-b3dc-ec119d4f3d4b", "embedding": null, "metadata": {"window": "Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.  ", "original_text": "Thanks.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf1a0140-3885-451d-b242-438a8a09342e", "node_type": "1", "metadata": {"window": "Operator:  Now moving to Joseph Amato with Evercore.  \n \n Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n ", "original_text": "Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9797f09bdbe703732e3dad0c639a20f317146425d33574e375cc6caf3e3502c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f45261b-47d8-4e28-a337-814f48f8c627", "node_type": "1", "metadata": {"window": "Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.  ", "original_text": "Mike Kaufmann:  Yes, this is a business we continue to be super excited about.  "}, "hash": "8dde9e616f04d445b8df74ce40670e96990b7e2301c445373cd7b3c5f1d9505e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 2232, "end_char_idx": 2244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f45261b-47d8-4e28-a337-814f48f8c627": {"__data__": {"id_": "6f45261b-47d8-4e28-a337-814f48f8c627", "embedding": null, "metadata": {"window": "Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.  ", "original_text": "Mike Kaufmann:  Yes, this is a business we continue to be super excited about.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25fa851c-5ec9-42b5-b3dc-ec119d4f3d4b", "node_type": "1", "metadata": {"window": "Joseph Amato:  Hi.  Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.  ", "original_text": "Thanks.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efb9976b8cf0b7d55051974595fbf1c3f7fe80fc26a0810a3b51063596e5faa6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "242da652-62b2-4400-92de-126d0250dba1", "node_type": "1", "metadata": {"window": "Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n ", "original_text": "As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n "}, "hash": "e56991ab14312b71547d1e66f39a92074efde2a63959e5210119e106db3cc001", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, this is a business we continue to be super excited about.  ", "start_char_idx": 2244, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "242da652-62b2-4400-92de-126d0250dba1": {"__data__": {"id_": "242da652-62b2-4400-92de-126d0250dba1", "embedding": null, "metadata": {"window": "Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n ", "original_text": "As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f45261b-47d8-4e28-a337-814f48f8c627", "node_type": "1", "metadata": {"window": "Just a quick ques tion on Cardinal Health at -Home.   Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.  ", "original_text": "Mike Kaufmann:  Yes, this is a business we continue to be super excited about.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "088e2e45c75f803cb9af5035467ff1fcbefef4a9cd1a5bee58cb2d278fcd5ad0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7984f3f0-af84-49e7-8070-f4341885acd2", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.  ", "original_text": "We are a leader in the space and we intend to stay that going forward.  "}, "hash": "7bf14ece8bf50647f50b26c4430837dc05fb72e38a4a145da4d50b5fd954b5e9", "class_name": "RelatedNodeInfo"}}, "text": "As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n ", "start_char_idx": 2324, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7984f3f0-af84-49e7-8070-f4341885acd2": {"__data__": {"id_": "7984f3f0-af84-49e7-8070-f4341885acd2", "embedding": null, "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.  ", "original_text": "We are a leader in the space and we intend to stay that going forward.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "242da652-62b2-4400-92de-126d0250dba1", "node_type": "1", "metadata": {"window": "Could you give us a sense for \nkind of how you see demand trending as you progress through 2021?   Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n ", "original_text": "As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b787d4cdca8f08874c29fcbd5a5754572078b4da7d99ba76828cdd25dbaf8faf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14372b84-8d5f-48ac-bf61-429c93925862", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.  ", "original_text": "And so we did see  very \nnice revenue trends in that business.  "}, "hash": "ff2476d0ae5e051c010d94c6b81018f59048ac86036d0cd67582366d4247cc94", "class_name": "RelatedNodeInfo"}}, "text": "We are a leader in the space and we intend to stay that going forward.  ", "start_char_idx": 2534, "end_char_idx": 2606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14372b84-8d5f-48ac-bf61-429c93925862": {"__data__": {"id_": "14372b84-8d5f-48ac-bf61-429c93925862", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.  ", "original_text": "And so we did see  very \nnice revenue trends in that business.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7984f3f0-af84-49e7-8070-f4341885acd2", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.  ", "original_text": "We are a leader in the space and we intend to stay that going forward.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac0200e6ac386bdaa3cfa5b353ffc30d9aa5fa215b60fd63a949ff051bee6d1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e03289af-e433-4d24-8a18-247c4e819448", "node_type": "1", "metadata": {"window": "As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n "}, "hash": "ce20875aab00ca45e0e139d2259f154a6ec76f04c5e010b3945b96c29ea83aa5", "class_name": "RelatedNodeInfo"}}, "text": "And so we did see  very \nnice revenue trends in that business.  ", "start_char_idx": 2606, "end_char_idx": 2670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e03289af-e433-4d24-8a18-247c4e819448": {"__data__": {"id_": "e03289af-e433-4d24-8a18-247c4e819448", "embedding": null, "metadata": {"window": "As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14372b84-8d5f-48ac-bf61-429c93925862", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, this is a business we continue to be super excited about.   As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.  ", "original_text": "And so we did see  very \nnice revenue trends in that business.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e13e458046a96278464d29e608681368c5a03462464836dc03b1183d445fe2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5d9a8bb-faec-45ef-b2b3-2696fc41d0ad", "node_type": "1", "metadata": {"window": "We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "So we remain excited about the team, our resources.  "}, "hash": "a9ff2c92811455cb19dbb8de6d299b15499332155b7544447b7f198dc7368bc1", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n ", "start_char_idx": 2670, "end_char_idx": 2828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5d9a8bb-faec-45ef-b2b3-2696fc41d0ad": {"__data__": {"id_": "a5d9a8bb-faec-45ef-b2b3-2696fc41d0ad", "embedding": null, "metadata": {"window": "We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "So we remain excited about the team, our resources.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e03289af-e433-4d24-8a18-247c4e819448", "node_type": "1", "metadata": {"window": "As we've said, a \ncouple of different  times, it's one of those areas that we've called out as one of our strategic growth \nareas with both specialty, our services businesses and Cardinal Health at -Home.  \n \n  We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f1d0a987f05411afdbc8056bb451cc93e2036e987c127cdd5515894a5a914fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93b5a1a2-c705-4553-a85b-59612dcbe693", "node_type": "1", "metadata": {"window": "And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "The p ipeline of opportunities we're \nworking on feels really good in that business.  "}, "hash": "a26dcf288add7c3c47085f6d72178a18d44581005d76cf8a90a562b12d8be161", "class_name": "RelatedNodeInfo"}}, "text": "So we remain excited about the team, our resources.  ", "start_char_idx": 2828, "end_char_idx": 2881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93b5a1a2-c705-4553-a85b-59612dcbe693": {"__data__": {"id_": "93b5a1a2-c705-4553-a85b-59612dcbe693", "embedding": null, "metadata": {"window": "And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "The p ipeline of opportunities we're \nworking on feels really good in that business.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5d9a8bb-faec-45ef-b2b3-2696fc41d0ad", "node_type": "1", "metadata": {"window": "We are a leader in the space and we intend to stay that going forward.   And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "So we remain excited about the team, our resources.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2a28ab287b7eec7cb77d81997b4c01e4442f7169d3b445482c4a0adbc1ec2ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d41eac65-9e1e-4da6-8d93-97039f0c0847", "node_type": "1", "metadata": {"window": "We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "Next question, please.  "}, "hash": "3129e1fc80a42419be4cace7abed41754b460ab2efcdc387c5856f7b170a84a8", "class_name": "RelatedNodeInfo"}}, "text": "The p ipeline of opportunities we're \nworking on feels really good in that business.  ", "start_char_idx": 2881, "end_char_idx": 2967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d41eac65-9e1e-4da6-8d93-97039f0c0847": {"__data__": {"id_": "d41eac65-9e1e-4da6-8d93-97039f0c0847", "embedding": null, "metadata": {"window": "We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "Next question, please.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11ca4a499f933639d5052da30ab28d8ad2b9b0dcf0f29892513ef72bcb1bff8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93b5a1a2-c705-4553-a85b-59612dcbe693", "node_type": "1", "metadata": {"window": "And so we did see  very \nnice revenue trends in that business.   We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "The p ipeline of opportunities we're \nworking on feels really good in that business.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c612f72f4335eacd41b86f08679ab92758d09e3c7cd4ae621a929b268e4a0c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc53abef-a3bc-4379-8dd1-b0e7625931d1", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.  ", "original_text": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.  "}, "hash": "a7b2392924f83f56b7b8cf80c6e5867a4eea274497edb5d718663054aa1d0199", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  ", "start_char_idx": 2967, "end_char_idx": 2991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc53abef-a3bc-4379-8dd1-b0e7625931d1": {"__data__": {"id_": "dc53abef-a3bc-4379-8dd1-b0e7625931d1", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.  ", "original_text": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d41eac65-9e1e-4da6-8d93-97039f0c0847", "node_type": "1", "metadata": {"window": "We continue to make investments in that business, specifically \nto continue to grow and have a very nice, both mid and long -term view of that business.  \n \n  So we remain excited about the team, our resources.   The p ipeline of opportunities we're \nworking on feels really good in that business.   Next question, please.  ", "original_text": "Next question, please.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "102ebaefcbc730c2d96c3399fafb56d913e5d7c7abaf024bbcb0ed60f4a1004c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc74bd7a-4e9f-4ec2-8ba2-22fb337f9b17", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.  ", "original_text": "And we'll hear from Eric Percher with Nephron \nResearch.  \n \n"}, "hash": "da2105019e6c04904acd3fc64000cd7d9e216c93378ccd099ba8f868b5ab3e82", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.  ", "start_char_idx": 0, "end_char_idx": 72, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc74bd7a-4e9f-4ec2-8ba2-22fb337f9b17": {"__data__": {"id_": "bc74bd7a-4e9f-4ec2-8ba2-22fb337f9b17", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.  ", "original_text": "And we'll hear from Eric Percher with Nephron \nResearch.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc53abef-a3bc-4379-8dd1-b0e7625931d1", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.  ", "original_text": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41a8175053f81ea18bdebddc199c3c3e9da9433899eb555e29a65e0298be7d90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb3b6212-de9e-4b65-afcc-bb9788f8a451", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n", "original_text": "Eric Percher:  Thank you.  "}, "hash": "95a619d557b5892228c7e3c9b48be60e05ed0be516e071d9f8b4269a95d1f947", "class_name": "RelatedNodeInfo"}}, "text": "And we'll hear from Eric Percher with Nephron \nResearch.  \n \n", "start_char_idx": 72, "end_char_idx": 133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb3b6212-de9e-4b65-afcc-bb9788f8a451": {"__data__": {"id_": "fb3b6212-de9e-4b65-afcc-bb9788f8a451", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n", "original_text": "Eric Percher:  Thank you.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc74bd7a-4e9f-4ec2-8ba2-22fb337f9b17", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.  ", "original_text": "And we'll hear from Eric Percher with Nephron \nResearch.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5e1f742975fe72c2dbdd42df5d990aebf373ef725a925a2564b1ccd7e27dd94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cbd1d7b-4570-4f80-a4e4-926f42d0d9c4", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.  ", "original_text": "I wanted to ask fo r a little bit more detail on the nuclear business.  "}, "hash": "0ee6ac1b27e8e4788ce06525c875e0046380b09b9c1de516cfdfb9fba46ac4c7", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thank you.  ", "start_char_idx": 133, "end_char_idx": 160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cbd1d7b-4570-4f80-a4e4-926f42d0d9c4": {"__data__": {"id_": "8cbd1d7b-4570-4f80-a4e4-926f42d0d9c4", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.  ", "original_text": "I wanted to ask fo r a little bit more detail on the nuclear business.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb3b6212-de9e-4b65-afcc-bb9788f8a451", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n", "original_text": "Eric Percher:  Thank you.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0277a48c8915f523427af7ee1f5aee3fec9eb22ca23fc27f974c2892e35ecc0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbe5ad37-a5cb-4788-940e-ca985e9f0b9d", "node_type": "1", "metadata": {"window": "And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.  ", "original_text": "And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.  "}, "hash": "ded174ccf283660129c67dcfbc4ede5c85a542c903e31f157128dd67fa8328be", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to ask fo r a little bit more detail on the nuclear business.  ", "start_char_idx": 160, "end_char_idx": 232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbe5ad37-a5cb-4788-940e-ca985e9f0b9d": {"__data__": {"id_": "bbe5ad37-a5cb-4788-940e-ca985e9f0b9d", "embedding": null, "metadata": {"window": "And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.  ", "original_text": "And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cbd1d7b-4570-4f80-a4e4-926f42d0d9c4", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.  ", "original_text": "I wanted to ask fo r a little bit more detail on the nuclear business.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd7563ef96dd49b62daeb18368b0f54cb102eff3e09cac00c22dbaba8687d396", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12e26e5b-c053-4ba5-b502-b2a808524502", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n ", "original_text": "And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n"}, "hash": "71c02f7b7f27a7ef32c3dc0fd589e145e3086408c30b67147f90ae6d655de97e", "class_name": "RelatedNodeInfo"}}, "text": "And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.  ", "start_char_idx": 232, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12e26e5b-c053-4ba5-b502-b2a808524502": {"__data__": {"id_": "12e26e5b-c053-4ba5-b502-b2a808524502", "embedding": null, "metadata": {"window": "Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n ", "original_text": "And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbe5ad37-a5cb-4788-940e-ca985e9f0b9d", "node_type": "1", "metadata": {"window": "And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.  ", "original_text": "And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65864f0b25150ccf8520d270a5a4e387b4ab765d81a31bb04b85517b8ccef3ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d970352b-ccf0-464e-85e0-08bf99c5025f", "node_type": "1", "metadata": {"window": "I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.  ", "original_text": "Mike Kaufmann:  Yes, that's a great question.  "}, "hash": "2042d307e1aef8e3c1c1b2fea03f86c252d8c61c39300bf55549e8cb86f6997e", "class_name": "RelatedNodeInfo"}}, "text": "And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n", "start_char_idx": 351, "end_char_idx": 495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d970352b-ccf0-464e-85e0-08bf99c5025f": {"__data__": {"id_": "d970352b-ccf0-464e-85e0-08bf99c5025f", "embedding": null, "metadata": {"window": "I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.  ", "original_text": "Mike Kaufmann:  Yes, that's a great question.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12e26e5b-c053-4ba5-b502-b2a808524502", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n ", "original_text": "And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "892c411ba9a4f7b2ce8d9df15b9a365688eed3894c3d529a8945e75e95099deb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2e1ec62-cf91-47e4-b82b-7d78ccf75ba4", "node_type": "1", "metadata": {"window": "And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n", "original_text": "We have seen a little bit of difference between \noncology coming back faster than cardiology.  "}, "hash": "7c293b9d430f92b934838da91e3d3e6ae47d1dc742f66cded2ade2dca27a8cd4", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, that's a great question.  ", "start_char_idx": 495, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2e1ec62-cf91-47e4-b82b-7d78ccf75ba4": {"__data__": {"id_": "a2e1ec62-cf91-47e4-b82b-7d78ccf75ba4", "embedding": null, "metadata": {"window": "And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n", "original_text": "We have seen a little bit of difference between \noncology coming back faster than cardiology.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d970352b-ccf0-464e-85e0-08bf99c5025f", "node_type": "1", "metadata": {"window": "I wanted to ask fo r a little bit more detail on the nuclear business.   And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.  ", "original_text": "Mike Kaufmann:  Yes, that's a great question.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f32cec265e2bac4ed79f45c323a52867d342de1225cabe4ef9fc8e84f38052bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2624fe0-c463-4dc3-a606-c4c4f7ec96de", "node_type": "1", "metadata": {"window": "And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n", "original_text": "So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n "}, "hash": "df3fc24543dce8045c7de91561045185789cad0d2b15088be89848961dbe2286", "class_name": "RelatedNodeInfo"}}, "text": "We have seen a little bit of difference between \noncology coming back faster than cardiology.  ", "start_char_idx": 542, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2624fe0-c463-4dc3-a606-c4c4f7ec96de": {"__data__": {"id_": "f2624fe0-c463-4dc3-a606-c4c4f7ec96de", "embedding": null, "metadata": {"window": "And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n", "original_text": "So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2e1ec62-cf91-47e4-b82b-7d78ccf75ba4", "node_type": "1", "metadata": {"window": "And I'm \ncurious to hear if some of that strength has been in specific areas across cardiology or neuro or \noncology.   And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n", "original_text": "We have seen a little bit of difference between \noncology coming back faster than cardiology.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a4d6bf0fb5bc17ee72604c197bfcfcdd67cc91f47a3ec5e9df3572462abe462", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80f22916-2dca-40ce-92bd-6d1a17dd0b10", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.  ", "original_text": "And really as we expected, it has bounced back nicely.  "}, "hash": "4e0263d03d996b168362ea5c9f543a3eed356b5475ded725cf8b8b85fe232539", "class_name": "RelatedNodeInfo"}}, "text": "So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n ", "start_char_idx": 637, "end_char_idx": 715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80f22916-2dca-40ce-92bd-6d1a17dd0b10": {"__data__": {"id_": "80f22916-2dca-40ce-92bd-6d1a17dd0b10", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.  ", "original_text": "And really as we expected, it has bounced back nicely.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2624fe0-c463-4dc3-a606-c4c4f7ec96de", "node_type": "1", "metadata": {"window": "And has that been a pretty good forward indicator for upticks in volume and maybe gett ing \nback to the new scripts you were talking about?  \n \n Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n", "original_text": "So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "060848ec00687fc6753080b3d717ab9b1c133715b271b04c7141dd6936ed81ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98938a9c-f69f-4cdd-903f-71983353c915", "node_type": "1", "metadata": {"window": "We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.  ", "original_text": "But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n"}, "hash": "b4c991d848244e9ae133294e1ea8761aa42d5c26de2e0d8c48c5ae8ef8895499", "class_name": "RelatedNodeInfo"}}, "text": "And really as we expected, it has bounced back nicely.  ", "start_char_idx": 715, "end_char_idx": 771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98938a9c-f69f-4cdd-903f-71983353c915": {"__data__": {"id_": "98938a9c-f69f-4cdd-903f-71983353c915", "embedding": null, "metadata": {"window": "We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.  ", "original_text": "But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80f22916-2dca-40ce-92bd-6d1a17dd0b10", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, that's a great question.   We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.  ", "original_text": "And really as we expected, it has bounced back nicely.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02435b31a374e00b806046002d656c64ea5839408d20d54ff5753cedd2554be1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "115e4179-db99-48b1-ba27-b04a6d612c0c", "node_type": "1", "metadata": {"window": "So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n ", "original_text": "Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n"}, "hash": "c15ba0c8aab165e381efd27ed24c45817b42bf0eba543531ecf14a370c6e39ec", "class_name": "RelatedNodeInfo"}}, "text": "But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n", "start_char_idx": 771, "end_char_idx": 1082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "115e4179-db99-48b1-ba27-b04a6d612c0c": {"__data__": {"id_": "115e4179-db99-48b1-ba27-b04a6d612c0c", "embedding": null, "metadata": {"window": "So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n ", "original_text": "Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98938a9c-f69f-4cdd-903f-71983353c915", "node_type": "1", "metadata": {"window": "We have seen a little bit of difference between \noncology coming back faster than cardiology.   So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.  ", "original_text": "But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fad794ef72f28e04b356fd2ff33cdf3eeb553d1d96b5ba16c33984c3b95fe6c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18de233e-14c1-4cbd-ad8f-744beb1ebe04", "node_type": "1", "metadata": {"window": "And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.  ", "original_text": "Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.  "}, "hash": "4ed654f90717a40a576effac053e21e8f34ba68485e34048b6d4eba14a952c15", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n", "start_char_idx": 1082, "end_char_idx": 1187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18de233e-14c1-4cbd-ad8f-744beb1ebe04": {"__data__": {"id_": "18de233e-14c1-4cbd-ad8f-744beb1ebe04", "embedding": null, "metadata": {"window": "And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.  ", "original_text": "Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "115e4179-db99-48b1-ba27-b04a6d612c0c", "node_type": "1", "metadata": {"window": "So we do a lot of work in both of those spaces in our \nnuclear business.  \n \n  And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n ", "original_text": "Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6e163da9ee5cb47bcf4fe0543a4fb20ae01582e855c6cb97242694d49323df8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1149bad5-2953-42e2-a5d2-09a40ac2c984", "node_type": "1", "metadata": {"window": "But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n ", "original_text": "And we took \nappropriate cost reductions.  "}, "hash": "143a821032a85def8c7783c88df2abfd3f1a2ade6b614397931a49f39faa9c1c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.  ", "start_char_idx": 1187, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1149bad5-2953-42e2-a5d2-09a40ac2c984": {"__data__": {"id_": "1149bad5-2953-42e2-a5d2-09a40ac2c984", "embedding": null, "metadata": {"window": "But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n ", "original_text": "And we took \nappropriate cost reductions.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18de233e-14c1-4cbd-ad8f-744beb1ebe04", "node_type": "1", "metadata": {"window": "And really as we expected, it has bounced back nicely.   But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.  ", "original_text": "Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b95f1953e80fd6931ce104f693753bf3fd7db2ff6afcc9363202174b5c2ca54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29904156-561d-48b8-9c7d-14e7504edb68", "node_type": "1", "metadata": {"window": "Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n ", "original_text": "But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n "}, "hash": "3c4905cc07049ba07a41f278427aeaa3bb33502f0778ed620b11a7cce9329de8", "class_name": "RelatedNodeInfo"}}, "text": "And we took \nappropriate cost reductions.  ", "start_char_idx": 1278, "end_char_idx": 1321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29904156-561d-48b8-9c7d-14e7504edb68": {"__data__": {"id_": "29904156-561d-48b8-9c7d-14e7504edb68", "embedding": null, "metadata": {"window": "Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n ", "original_text": "But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1149bad5-2953-42e2-a5d2-09a40ac2c984", "node_type": "1", "metadata": {"window": "But to your point, what we've seen \nboth in nuclear and in our specialty businesses that oncology has bounced back much faster than \nother ologies, whether it be cardiology, rheumatology, ne phrology, but particularly to nuclear, our \ncardiology business has bounced back a little bit slower than oncology.  \n \n Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n ", "original_text": "And we took \nappropriate cost reductions.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30e799122cec80b03ca27f0f7f1c7a8be5e3be06b1d69f2ed7847c05d8d43ccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebec3a23-144c-4acb-98f8-1fc11c4a4d52", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n", "original_text": "We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.  "}, "hash": "6a3c7980f8fa52de2f6c1f9ff28ffc59d9b00521977c66ada785fb8672d7a601", "class_name": "RelatedNodeInfo"}}, "text": "But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n ", "start_char_idx": 1321, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebec3a23-144c-4acb-98f8-1fc11c4a4d52": {"__data__": {"id_": "ebec3a23-144c-4acb-98f8-1fc11c4a4d52", "embedding": null, "metadata": {"window": "Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n", "original_text": "We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29904156-561d-48b8-9c7d-14e7504edb68", "node_type": "1", "metadata": {"window": "Eric Percher:  And with your cost reduction there, that may come back as you get back to full speed?  \n \n Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n ", "original_text": "But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ceff69ab9a9c9cf905577d8486180abdd045e495ab790f083ba2b96157691c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b050892-1e27-4c26-8861-e3777de8cfb5", "node_type": "1", "metadata": {"window": "And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n", "original_text": "The theragnostic area we think is a real good growth area for us.  \n \n "}, "hash": "77e9f69f21eef0d819bc32f52542417699a4a29aaa8929bd18c8f9c08c559c32", "class_name": "RelatedNodeInfo"}}, "text": "We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.  ", "start_char_idx": 1446, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b050892-1e27-4c26-8861-e3777de8cfb5": {"__data__": {"id_": "8b050892-1e27-4c26-8861-e3777de8cfb5", "embedding": null, "metadata": {"window": "And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n", "original_text": "The theragnostic area we think is a real good growth area for us.  \n \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebec3a23-144c-4acb-98f8-1fc11c4a4d52", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  You know, actually it' s a business that is a pretty fixed cost business.   And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n", "original_text": "We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "128a33ae2681c99a458de7e41c53014f57a435324246cf5c4ef21b4a369ce8b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "314ff37f-7ddf-4457-8937-4cc7d653527b", "node_type": "1", "metadata": {"window": "But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n", "original_text": "So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n "}, "hash": "8627096ed3c523e9ba525295d34b13673aa193fd4bdf049df3756466fb88d0f5", "class_name": "RelatedNodeInfo"}}, "text": "The theragnostic area we think is a real good growth area for us.  \n \n ", "start_char_idx": 1554, "end_char_idx": 1625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "314ff37f-7ddf-4457-8937-4cc7d653527b": {"__data__": {"id_": "314ff37f-7ddf-4457-8937-4cc7d653527b", "embedding": null, "metadata": {"window": "But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n", "original_text": "So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b050892-1e27-4c26-8861-e3777de8cfb5", "node_type": "1", "metadata": {"window": "And we took \nappropriate cost reductions.   But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n", "original_text": "The theragnostic area we think is a real good growth area for us.  \n \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5e1b85f48cc52b26b349d7e9d6be5c119c27e1155008fb05ab3b9c1aa93ceff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d8311d5-a03d-40e2-8f19-18247d794a5b", "node_type": "1", "metadata": {"window": "We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n"}, "hash": "29169b9371e5091baf37cd010ff653d7f25d3651c116547acae85e276f7d7533", "class_name": "RelatedNodeInfo"}}, "text": "So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n ", "start_char_idx": 1625, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d8311d5-a03d-40e2-8f19-18247d794a5b": {"__data__": {"id_": "7d8311d5-a03d-40e2-8f19-18247d794a5b", "embedding": null, "metadata": {"window": "We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "314ff37f-7ddf-4457-8937-4cc7d653527b", "node_type": "1", "metadata": {"window": "But I wouldn't say we took aggressive cost reductions because we really \nbelieved in that business over the long -term.  \n \n  We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n", "original_text": "So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9b779872bc55e055ee05382d07dd4cef2cf506af4f6695572d461cbb9715237", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63621525-573d-4bea-a05c-916450909efd", "node_type": "1", "metadata": {"window": "The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.  ", "original_text": "Eric Percher:  Thank you.  \n \n"}, "hash": "130b067e4a94a1ba3daab7cb6608dd4d774417d146b8aa94d72145695ba89bb5", "class_name": "RelatedNodeInfo"}}, "text": "And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n", "start_char_idx": 1952, "end_char_idx": 2051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63621525-573d-4bea-a05c-916450909efd": {"__data__": {"id_": "63621525-573d-4bea-a05c-916450909efd", "embedding": null, "metadata": {"window": "The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.  ", "original_text": "Eric Percher:  Thank you.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d8311d5-a03d-40e2-8f19-18247d794a5b", "node_type": "1", "metadata": {"window": "We think it has a very nice pipeline of projects we're working on with manufacturers for clinical \ntrials.   The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61b7591c0d759a14292af66264801f3ea3626b1b87092623592a2504077c014a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdc5a6fe-9499-47fe-8886-47f2aa41e0d6", "node_type": "1", "metadata": {"window": "So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.  ", "original_text": "Mike Kaufmann:  Next question.  \n \n"}, "hash": "74bcfb50353ecbb7bc0ded295cbde6b789bf54f06cca8181826e3fb9496690e1", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thank you.  \n \n", "start_char_idx": 2051, "end_char_idx": 2081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdc5a6fe-9499-47fe-8886-47f2aa41e0d6": {"__data__": {"id_": "cdc5a6fe-9499-47fe-8886-47f2aa41e0d6", "embedding": null, "metadata": {"window": "So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.  ", "original_text": "Mike Kaufmann:  Next question.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63621525-573d-4bea-a05c-916450909efd", "node_type": "1", "metadata": {"window": "The theragnostic area we think is a real good growth area for us.  \n \n  So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.  ", "original_text": "Eric Percher:  Thank you.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ccb9c83c89c19f8169e61c5e651041cf85cf005fdf43ab5b41780c731dfb13c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b6d8d9f-4c6c-498f-9f85-70b4f61d977c", "node_type": "1", "metadata": {"window": "And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.  ", "original_text": "Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n"}, "hash": "9196e2e6b8f0e5cb632f266e23fe46f1fa347f7001caf12d4aa50f71ea483f98", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Next question.  \n \n", "start_char_idx": 2081, "end_char_idx": 2116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b6d8d9f-4c6c-498f-9f85-70b4f61d977c": {"__data__": {"id_": "1b6d8d9f-4c6c-498f-9f85-70b4f61d977c", "embedding": null, "metadata": {"window": "And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.  ", "original_text": "Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdc5a6fe-9499-47fe-8886-47f2aa41e0d6", "node_type": "1", "metadata": {"window": "So we decided essentially, as we kind of talked about last quarter, just to hold on to our \npeople, because th e rest of our assets, being whether it's our manufacturing facilities with our \ncyclotrons or our individual pharmacies, which still needed to be staffed, we didn't make extra \naggressive cost reductions there.  \n \n  And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.  ", "original_text": "Mike Kaufmann:  Next question.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "419dfbf6ca6e62d81079f6db848a34cc79e2ab3c384e9d009f53591e2fab2382", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95433123-6936-498f-aa23-a05612bf5201", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?  ", "original_text": "Ricky Goldwasser:  Yes, hi.  "}, "hash": "010ff5353aed7b6ac81ae6c7f54b444a5559d74021ae172e5520af0aba96fd17", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n", "start_char_idx": 2116, "end_char_idx": 2206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95433123-6936-498f-aa23-a05612bf5201": {"__data__": {"id_": "95433123-6936-498f-aa23-a05612bf5201", "embedding": null, "metadata": {"window": "Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?  ", "original_text": "Ricky Goldwasser:  Yes, hi.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b6d8d9f-4c6c-498f-9f85-70b4f61d977c", "node_type": "1", "metadata": {"window": "And so it's nice to see it bounce back and de liver the type of results that we saw in our Q1.  \n \n Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.  ", "original_text": "Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03e390333931511e18baa7be4bb4b334a47cf03371b5a0c656623aaad3df79c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f3b0fbc-c0b5-45e9-9dbd-fc9bfc66a179", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "Good morning.  "}, "hash": "ed9231615ffcb766f69fbaaad1ec8cde0b15703d78ba4858acc1ae9a5086c992", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Yes, hi.  ", "start_char_idx": 2206, "end_char_idx": 2235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f3b0fbc-c0b5-45e9-9dbd-fc9bfc66a179": {"__data__": {"id_": "8f3b0fbc-c0b5-45e9-9dbd-fc9bfc66a179", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "Good morning.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95433123-6936-498f-aa23-a05612bf5201", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.  \n \n Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?  ", "original_text": "Ricky Goldwasser:  Yes, hi.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c1fa8786fe9453bd7101c21c6c26d486f0183c849c52c3418f998941ce12f07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "651a79aa-2cef-42c9-9b33-fa963e44c334", "node_type": "1", "metadata": {"window": "Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "One question related to specialty.  "}, "hash": "aa3865a5fe798694b171fe32cbdacacddf23abff6fa0da869d2967decb7227d7", "class_name": "RelatedNodeInfo"}}, "text": "Good morning.  ", "start_char_idx": 2235, "end_char_idx": 2250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "651a79aa-2cef-42c9-9b33-fa963e44c334": {"__data__": {"id_": "651a79aa-2cef-42c9-9b33-fa963e44c334", "embedding": null, "metadata": {"window": "Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "One question related to specialty.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f3b0fbc-c0b5-45e9-9dbd-fc9bfc66a179", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Next question.  \n \n Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "Good morning.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05b8be10d9c0d57570fbe521d45e50070385bb76eae3eb7872cd7cdaf47d016b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91ced30c-7e09-4605-a889-7b04923895be", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?  "}, "hash": "6aecc863376ff49d5290fd0d91fc607b4c06f64ea79a363c38af294ccd277069", "class_name": "RelatedNodeInfo"}}, "text": "One question related to specialty.  ", "start_char_idx": 2250, "end_char_idx": 2286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91ced30c-7e09-4605-a889-7b04923895be": {"__data__": {"id_": "91ced30c-7e09-4605-a889-7b04923895be", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "651a79aa-2cef-42c9-9b33-fa963e44c334", "node_type": "1", "metadata": {"window": "Operator:  And our next question will come from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "One question related to specialty.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41b60a195fd537d3cc366398bd98b1601043973152be56f08b3aa2adaf7294c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e6a7616-1852-4887-8062-7379ded08ed5", "node_type": "1", "metadata": {"window": "Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "Should we think \nabout it as going through core distribution, through specialty?  \n "}, "hash": "7ab6324f8f5bd51d2dbf0e2e256579b4aa10a53cacb16ce92ef0e06ade7154f2", "class_name": "RelatedNodeInfo"}}, "text": "You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?  ", "start_char_idx": 2286, "end_char_idx": 2487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e6a7616-1852-4887-8062-7379ded08ed5": {"__data__": {"id_": "6e6a7616-1852-4887-8062-7379ded08ed5", "embedding": null, "metadata": {"window": "Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "Should we think \nabout it as going through core distribution, through specialty?  \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e717350e45a808ea29d3d08c231cd24abe97e3b0db41d195f79d3146a9f436c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91ced30c-7e09-4605-a889-7b04923895be", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes, hi.   Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94760e65f51079c2f415396b9644c31102c9b142e865e3a7b85f6727ae07f185", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60fc38f5-5a2f-45d3-994b-a1aa8a049333", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n ", "original_text": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n"}, "hash": "590870b98e444315eed9042d8859793bd2edcb82e1a3f00b8738868995ba6136", "class_name": "RelatedNodeInfo"}}, "text": "Should we think \nabout it as going through core distribution, through specialty?  \n ", "start_char_idx": 2487, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60fc38f5-5a2f-45d3-994b-a1aa8a049333": {"__data__": {"id_": "60fc38f5-5a2f-45d3-994b-a1aa8a049333", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n ", "original_text": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e6a7616-1852-4887-8062-7379ded08ed5", "node_type": "1", "metadata": {"window": "Good morning.   One question related to specialty.   You know, obviously, \nthere was some big news on Biogen yesterday, and we're getting questions from investors on how \nshould we think about drugs like that as potential contributors to your business?   Should we think \nabout it as going through core distribution, through specialty?  \n ", "original_text": "Should we think \nabout it as going through core distribution, through specialty?  \n ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd0ddb494df6e4038778a306124a6f091b2880489192a85f5cf2da58a17de625", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f97dd12-6204-4427-a1dd-745ed9bfb51a", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "7519767ddcb26582bbd5502177ad36459d3beba96cb57e376a4c82602395c3bc", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n", "start_char_idx": 0, "end_char_idx": 169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f97dd12-6204-4427-a1dd-745ed9bfb51a": {"__data__": {"id_": "1f97dd12-6204-4427-a1dd-745ed9bfb51a", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60fc38f5-5a2f-45d3-994b-a1aa8a049333", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n ", "original_text": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eae3b3ddbcab4c39fd0c83426ff913a223c3a23ee34f76b25bacec7e6c9099b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7417b4fd-2cdf-46e5-afb5-dfce19501216", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n ", "original_text": "As far as the specialty products , I would say is this.  "}, "hash": "0a0fe0daa28af533092eb80ade8f08b7cce0cdb5c781e13a0e8ad50e45a84a2a", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 169, "end_char_idx": 191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7417b4fd-2cdf-46e5-afb5-dfce19501216": {"__data__": {"id_": "7417b4fd-2cdf-46e5-afb5-dfce19501216", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n ", "original_text": "As far as the specialty products , I would say is this.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f97dd12-6204-4427-a1dd-745ed9bfb51a", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19a19f79a56faf27038368e2a0b0ce9d69e74c5346977fa89084cc1ba4e1c569", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2687cd5-ed96-4490-b7d5-e1538c79f191", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n", "original_text": "What I really like about \nour position is we can manage both.  \n \n "}, "hash": "a17c77b08788d23958f300fca287baf62fe8c807171c2a3fa5fa49d0d459943e", "class_name": "RelatedNodeInfo"}}, "text": "As far as the specialty products , I would say is this.  ", "start_char_idx": 191, "end_char_idx": 248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2687cd5-ed96-4490-b7d5-e1538c79f191": {"__data__": {"id_": "a2687cd5-ed96-4490-b7d5-e1538c79f191", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n", "original_text": "What I really like about \nour position is we can manage both.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7417b4fd-2cdf-46e5-afb5-dfce19501216", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n ", "original_text": "As far as the specialty products , I would say is this.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30953eca4ad453927a66feaa1e68be8fbb95beddc1015e9b9a5b7e38c8f36be1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c8e036d-6e84-4b0f-8f9d-c04af802b870", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n ", "original_text": "We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.  "}, "hash": "ca5c786ffd03717aa929f7fc7a4e9cd440228a0821a0bf306f49207fdb4aee1a", "class_name": "RelatedNodeInfo"}}, "text": "What I really like about \nour position is we can manage both.  \n \n ", "start_char_idx": 248, "end_char_idx": 315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c8e036d-6e84-4b0f-8f9d-c04af802b870": {"__data__": {"id_": "9c8e036d-6e84-4b0f-8f9d-c04af802b870", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n ", "original_text": "We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2687cd5-ed96-4490-b7d5-e1538c79f191", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n", "original_text": "What I really like about \nour position is we can manage both.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ea100894d07f0371ba118bc1cdb4f9674dedc676cd5bc3d300b412f31b2817e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ffe1cad-101e-4862-a245-278db58af059", "node_type": "1", "metadata": {"window": "As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.  ", "original_text": "Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n "}, "hash": "fdc893c1945fe5ae15bff1a9cea3a963055b14d7da044e42766d8c685c89e923", "class_name": "RelatedNodeInfo"}}, "text": "We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.  ", "start_char_idx": 315, "end_char_idx": 419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ffe1cad-101e-4862-a245-278db58af059": {"__data__": {"id_": "7ffe1cad-101e-4862-a245-278db58af059", "embedding": null, "metadata": {"window": "As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.  ", "original_text": "Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c8e036d-6e84-4b0f-8f9d-c04af802b870", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n ", "original_text": "We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14261a190c2e2b41fd6e6b67e1f871b866e9e9d5a2fc0bde0478ef774b87226b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4aa8a53f-814d-4298-ac6e-f4c02776d0b3", "node_type": "1", "metadata": {"window": "What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n ", "original_text": "So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n"}, "hash": "98301c0faf3365e68105862f98243b8db3aa4787b95bacafc46e8e8f4f0b3390", "class_name": "RelatedNodeInfo"}}, "text": "Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n ", "start_char_idx": 419, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4aa8a53f-814d-4298-ac6e-f4c02776d0b3": {"__data__": {"id_": "4aa8a53f-814d-4298-ac6e-f4c02776d0b3", "embedding": null, "metadata": {"window": "What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n ", "original_text": "So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ffe1cad-101e-4862-a245-278db58af059", "node_type": "1", "metadata": {"window": "As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.  ", "original_text": "Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a3d7f210b67ecd40f68421e476ef196ae1b78b54134a2f6790b6867b83ff3a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55e7830e-5902-4dd5-88d0-ca0e325e43b6", "node_type": "1", "metadata": {"window": "We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.  ", "original_text": "And then also with our specialty business, they can go that way.  \n \n "}, "hash": "145eac4205e41920a3eb57b46b38c8c902a5f5e94172d761c99caa89b1c59f01", "class_name": "RelatedNodeInfo"}}, "text": "So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n", "start_char_idx": 531, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55e7830e-5902-4dd5-88d0-ca0e325e43b6": {"__data__": {"id_": "55e7830e-5902-4dd5-88d0-ca0e325e43b6", "embedding": null, "metadata": {"window": "We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.  ", "original_text": "And then also with our specialty business, they can go that way.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4aa8a53f-814d-4298-ac6e-f4c02776d0b3", "node_type": "1", "metadata": {"window": "What I really like about \nour position is we can manage both.  \n \n  We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n ", "original_text": "So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "640c64fdf58a41eb2b3c95fdc0356d8844fa96fdd48e30c2d5a6ef37bdc2588e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9e63d24-244a-4836-a2fa-e01cc2f54c2f", "node_type": "1", "metadata": {"window": "Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.  ", "original_text": "So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.  "}, "hash": "5d395eb71cabe0ca789b8d0a12dff15c2a464a5088e7f5864c0d5f8bb3db3c47", "class_name": "RelatedNodeInfo"}}, "text": "And then also with our specialty business, they can go that way.  \n \n ", "start_char_idx": 724, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9e63d24-244a-4836-a2fa-e01cc2f54c2f": {"__data__": {"id_": "b9e63d24-244a-4836-a2fa-e01cc2f54c2f", "embedding": null, "metadata": {"window": "Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.  ", "original_text": "So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55e7830e-5902-4dd5-88d0-ca0e325e43b6", "node_type": "1", "metadata": {"window": "We have the capabilities for a manufacturer to choose going through our pharma distribution \nbusiness.   Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.  ", "original_text": "And then also with our specialty business, they can go that way.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2579c86650148c4d4efdeb93971cdc33d3bcbd33ac5c8f3f2833ef04d93dd46b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5afa2743-a110-45f4-b65b-33f3a7ae48f4", "node_type": "1", "metadata": {"window": "So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n ", "original_text": "But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n "}, "hash": "4829368d7979838ba86158999024b66fe69f1e047c9ed0c2a3b64e8dd13e9687", "class_name": "RelatedNodeInfo"}}, "text": "So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.  ", "start_char_idx": 794, "end_char_idx": 929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5afa2743-a110-45f4-b65b-33f3a7ae48f4": {"__data__": {"id_": "5afa2743-a110-45f4-b65b-33f3a7ae48f4", "embedding": null, "metadata": {"window": "So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n ", "original_text": "But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9e63d24-244a-4836-a2fa-e01cc2f54c2f", "node_type": "1", "metadata": {"window": "Obviously we serve one of the largest chains, the largest grocery chain, the largest mail \norder, insurer.  \n \n  So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.  ", "original_text": "So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "400a13df51c6a0ed49c4dac333efb85c780f487951b941b5f0d257e3c97531ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8631960-1ab0-463a-9142-3f38c23f8243", "node_type": "1", "metadata": {"window": "And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.  ", "original_text": "And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.  "}, "hash": "405049887f8fc63ba44bc65ae614dc3a2ea0b8b1e60baaf1cedce6068a458592", "class_name": "RelatedNodeInfo"}}, "text": "But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n ", "start_char_idx": 929, "end_char_idx": 1076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8631960-1ab0-463a-9142-3f38c23f8243": {"__data__": {"id_": "c8631960-1ab0-463a-9142-3f38c23f8243", "embedding": null, "metadata": {"window": "And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.  ", "original_text": "And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5afa2743-a110-45f4-b65b-33f3a7ae48f4", "node_type": "1", "metadata": {"window": "So we've got a lot of strong customer base as well as a strong presence in the acute space \nthat our pharma distribution business has the reach to be able to manage specialty drugs that way.  \n And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n ", "original_text": "But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1795a6606e39da361cbc4f47ee6ff8b8378bd3ff77d86a58725ecba031f44de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3e7894e-c5bb-4618-983e-62300724676c", "node_type": "1", "metadata": {"window": "So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n ", "original_text": "So it's hard to specifically talk about any individual drugs.  "}, "hash": "60a5e33b3fcaadba720b4eff1916aae884450f05a822a88b8f32d88e25561900", "class_name": "RelatedNodeInfo"}}, "text": "And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.  ", "start_char_idx": 1076, "end_char_idx": 1204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3e7894e-c5bb-4618-983e-62300724676c": {"__data__": {"id_": "f3e7894e-c5bb-4618-983e-62300724676c", "embedding": null, "metadata": {"window": "So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n ", "original_text": "So it's hard to specifically talk about any individual drugs.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8631960-1ab0-463a-9142-3f38c23f8243", "node_type": "1", "metadata": {"window": "And then also with our specialty business, they can go that way.  \n \n  So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.  ", "original_text": "And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c357fb3224568ce0c515a4ab862fb40c15985f61dfca314a35f58b83268434fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7af4239e-9256-4a7d-bbb6-956e529b5361", "node_type": "1", "metadata": {"window": "But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n", "original_text": "W e \ndon't really like to do that.  \n \n "}, "hash": "a48598e902f32dca384e41fac5f18621188ea589eadd6d2252e6cf170163ec22", "class_name": "RelatedNodeInfo"}}, "text": "So it's hard to specifically talk about any individual drugs.  ", "start_char_idx": 1204, "end_char_idx": 1267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7af4239e-9256-4a7d-bbb6-956e529b5361": {"__data__": {"id_": "7af4239e-9256-4a7d-bbb6-956e529b5361", "embedding": null, "metadata": {"window": "But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n", "original_text": "W e \ndon't really like to do that.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3e7894e-c5bb-4618-983e-62300724676c", "node_type": "1", "metadata": {"window": "So that's something that we feel really good about, that we talk to manufacturers all the time \nand can work with them in either way.   But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n ", "original_text": "So it's hard to specifically talk about any individual drugs.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aaa5993c02a543b2a76342cfbb3c4616d025ac6d82029e64d35869386c96c515", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8afc9909-5c74-45ec-8f38-aa4c27b715bb", "node_type": "1", "metadata": {"window": "And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n ", "original_text": "But in terms of having the capabilities, I'm confident that we can do that anywhere.  "}, "hash": "fbfe30952adf03b6e1764b1531da2698c0f2fcb57a50736aec1589afbafc27e1", "class_name": "RelatedNodeInfo"}}, "text": "W e \ndon't really like to do that.  \n \n ", "start_char_idx": 1267, "end_char_idx": 1307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8afc9909-5c74-45ec-8f38-aa4c27b715bb": {"__data__": {"id_": "8afc9909-5c74-45ec-8f38-aa4c27b715bb", "embedding": null, "metadata": {"window": "And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n ", "original_text": "But in terms of having the capabilities, I'm confident that we can do that anywhere.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7af4239e-9256-4a7d-bbb6-956e529b5361", "node_type": "1", "metadata": {"window": "But a lot of manufacturers, you know, it depends on who the \nultimate customer is and who they're trying to reach, which one they may choose.  \n \n  And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n", "original_text": "W e \ndon't really like to do that.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "393a5fde390053d86b5899ec1ac594c246d96d5277035eb30ea3436c8a82863e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7fc55fe-912e-47ae-b2b2-05ccfd456e01", "node_type": "1", "metadata": {"window": "So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.  ", "original_text": "Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n "}, "hash": "32492a97fb1f8ebb846c1f1907109af84c578b79612df015f9384e738fca7dad", "class_name": "RelatedNodeInfo"}}, "text": "But in terms of having the capabilities, I'm confident that we can do that anywhere.  ", "start_char_idx": 1307, "end_char_idx": 1393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7fc55fe-912e-47ae-b2b2-05ccfd456e01": {"__data__": {"id_": "e7fc55fe-912e-47ae-b2b2-05ccfd456e01", "embedding": null, "metadata": {"window": "So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.  ", "original_text": "Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8afc9909-5c74-45ec-8f38-aa4c27b715bb", "node_type": "1", "metadata": {"window": "And sometimes they'll choose both, you know, depending on certain customers will go one \nway and other ones will go the other.   So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n ", "original_text": "But in terms of having the capabilities, I'm confident that we can do that anywhere.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49a3298ed5713c8403bb94a8ea88862dc3048cb60a7425f0de65bf0bee6a8eea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c83701-b19d-4b12-8c10-5aed890b9c97", "node_type": "1", "metadata": {"window": "W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n ", "original_text": "The third party logistics business we have is performing incredibly well in our specialty space.  \n"}, "hash": "f615fad9e8287029e48e1ed0e91bd92b995db65cd1000769c73cff5383f4d0d7", "class_name": "RelatedNodeInfo"}}, "text": "Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n ", "start_char_idx": 1393, "end_char_idx": 1536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2c83701-b19d-4b12-8c10-5aed890b9c97": {"__data__": {"id_": "a2c83701-b19d-4b12-8c10-5aed890b9c97", "embedding": null, "metadata": {"window": "W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n ", "original_text": "The third party logistics business we have is performing incredibly well in our specialty space.  \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7fc55fe-912e-47ae-b2b2-05ccfd456e01", "node_type": "1", "metadata": {"window": "So it's hard to specifically talk about any individual drugs.   W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.  ", "original_text": "Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e549f966524b61935bbbaf038f5c87a034db44f31a6dc74b4bc87eba358c6685", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "260a3118-dc2c-455a-a5f2-210a33b4d8d7", "node_type": "1", "metadata": {"window": "But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.  ", "original_text": "So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n "}, "hash": "4f684b940b876eeca117d3f89fa5fecf0915147196b2294b452c7d8ba51bdec9", "class_name": "RelatedNodeInfo"}}, "text": "The third party logistics business we have is performing incredibly well in our specialty space.  \n", "start_char_idx": 1536, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "260a3118-dc2c-455a-a5f2-210a33b4d8d7": {"__data__": {"id_": "260a3118-dc2c-455a-a5f2-210a33b4d8d7", "embedding": null, "metadata": {"window": "But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.  ", "original_text": "So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c83701-b19d-4b12-8c10-5aed890b9c97", "node_type": "1", "metadata": {"window": "W e \ndon't really like to do that.  \n \n  But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n ", "original_text": "The third party logistics business we have is performing incredibly well in our specialty space.  \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45bf0b9f7cad991a7ff0107a4e14f73203990566926accb0ae01a42994005e11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b9adfc2-b39d-4c39-b4b5-7c62b6d6bdde", "node_type": "1", "metadata": {"window": "Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.  ", "original_text": "As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.  "}, "hash": "b8a3d21451d2304d615e57af46732a4a4861f8c5722c9ec4959de7c86afd534b", "class_name": "RelatedNodeInfo"}}, "text": "So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n ", "start_char_idx": 1635, "end_char_idx": 1743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b9adfc2-b39d-4c39-b4b5-7c62b6d6bdde": {"__data__": {"id_": "6b9adfc2-b39d-4c39-b4b5-7c62b6d6bdde", "embedding": null, "metadata": {"window": "Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.  ", "original_text": "As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "260a3118-dc2c-455a-a5f2-210a33b4d8d7", "node_type": "1", "metadata": {"window": "But in terms of having the capabilities, I'm confident that we can do that anywhere.   Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.  ", "original_text": "So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f24a64a0b1ea5e49c417c731ba2115fb63366e9a0aed6147cc7aeae283771261", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b74a88a-cca3-4cbb-85eb-06f6c4316cbf", "node_type": "1", "metadata": {"window": "The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n ", "original_text": "We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n "}, "hash": "bd8411d99a597f6fb4018f3b4f76bb9aa8b6e0cf24a354b57ff102a44ad7f858", "class_name": "RelatedNodeInfo"}}, "text": "As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.  ", "start_char_idx": 1743, "end_char_idx": 1877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b74a88a-cca3-4cbb-85eb-06f6c4316cbf": {"__data__": {"id_": "7b74a88a-cca3-4cbb-85eb-06f6c4316cbf", "embedding": null, "metadata": {"window": "The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n ", "original_text": "We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b9adfc2-b39d-4c39-b4b5-7c62b6d6bdde", "node_type": "1", "metadata": {"window": "Even up to \nand including if it's a smaller company that's launching a drug and needs services all the way from, \nyou know, soup to nuts.  \n \n  The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.  ", "original_text": "As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b2e3d138c9e95d20fbc50a138f9b18b4b1a6ee9a4bffdbe3ba34ab462edce77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc16f267-bf77-44ba-9e59-52f8b0928acc", "node_type": "1", "metadata": {"window": "So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.  ", "original_text": "We have the absolute capabilities to do it.  "}, "hash": "788641ff4aae6439178d68cd3e4b1baaf2f06e033258ae1ec0dc974f4af6e0f3", "class_name": "RelatedNodeInfo"}}, "text": "We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n ", "start_char_idx": 1877, "end_char_idx": 1981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc16f267-bf77-44ba-9e59-52f8b0928acc": {"__data__": {"id_": "cc16f267-bf77-44ba-9e59-52f8b0928acc", "embedding": null, "metadata": {"window": "So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.  ", "original_text": "We have the absolute capabilities to do it.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b74a88a-cca3-4cbb-85eb-06f6c4316cbf", "node_type": "1", "metadata": {"window": "The third party logistics business we have is performing incredibly well in our specialty space.  \n So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n ", "original_text": "We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57667b39ad185feae69838ba720c9928210337bf183832a93c76eb0a0cb174af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ee013b2-7c03-4616-badc-ff1cb982eddb", "node_type": "1", "metadata": {"window": "As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n", "original_text": "We've been shipping many di fferent types of \nvaccines for years.  "}, "hash": "077fdea6a41593318240347017b35d019e684c63a58150196f1efffb8a8b5aeb", "class_name": "RelatedNodeInfo"}}, "text": "We have the absolute capabilities to do it.  ", "start_char_idx": 1981, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ee013b2-7c03-4616-badc-ff1cb982eddb": {"__data__": {"id_": "0ee013b2-7c03-4616-badc-ff1cb982eddb", "embedding": null, "metadata": {"window": "As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n", "original_text": "We've been shipping many di fferent types of \nvaccines for years.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc16f267-bf77-44ba-9e59-52f8b0928acc", "node_type": "1", "metadata": {"window": "So someone that needs customer service, shipping, billing, collections, et cetera, we can do that too.  \n \n  As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.  ", "original_text": "We have the absolute capabilities to do it.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06736fe4cb05c1ad9ade0a21163e76253d2406cd2278ba9535b8880d4d370530", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d820e2a-b586-4d27-a57f-16a4ed67b4f1", "node_type": "1", "metadata": {"window": "We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n "}, "hash": "8009cc3f52420081ad4abc932bd729a2c892dc35850513da5f6623fde2f10c4a", "class_name": "RelatedNodeInfo"}}, "text": "We've been shipping many di fferent types of \nvaccines for years.  ", "start_char_idx": 2026, "end_char_idx": 2093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d820e2a-b586-4d27-a57f-16a4ed67b4f1": {"__data__": {"id_": "3d820e2a-b586-4d27-a57f-16a4ed67b4f1", "embedding": null, "metadata": {"window": "We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ee013b2-7c03-4616-badc-ff1cb982eddb", "node_type": "1", "metadata": {"window": "As far as the COVID vaccine, as you know, as far as Phase 1 has been, one of our \ncompetitors has been chosen to do that in Phase 1.   We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n", "original_text": "We've been shipping many di fferent types of \nvaccines for years.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b48cd75fd98f5959ed8c9f6fbe59f704bce91bcb24cac4531d5820039148e76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6edf15ac-bdd7-4131-914a-77c6a9d9c2a3", "node_type": "1", "metadata": {"window": "We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.  "}, "hash": "8de5471ccd7856b237ff300c835053c6dd508179d610846b67941a1ff444d0c8", "class_name": "RelatedNodeInfo"}}, "text": "So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n ", "start_char_idx": 2093, "end_char_idx": 2197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6edf15ac-bdd7-4131-914a-77c6a9d9c2a3": {"__data__": {"id_": "6edf15ac-bdd7-4131-914a-77c6a9d9c2a3", "embedding": null, "metadata": {"window": "We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d820e2a-b586-4d27-a57f-16a4ed67b4f1", "node_type": "1", "metadata": {"window": "We continue to have daily conversations with the \nfolks in the government around being part of it.  \n \n  We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc3d7d7df137515350e098e7fd31e657edba8354d9a9faec38c79043c812cc41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7382c5d5-17de-42e3-88ab-b3719eba1438", "node_type": "1", "metadata": {"window": "We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "And we stand ready to do that, when that \nhappens.  \n \n"}, "hash": "b4690d8711e79bac39ffd68de998c70007a30bf3c8d6181c49a53637afa2fda5", "class_name": "RelatedNodeInfo"}}, "text": "And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.  ", "start_char_idx": 2197, "end_char_idx": 2553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7382c5d5-17de-42e3-88ab-b3719eba1438": {"__data__": {"id_": "7382c5d5-17de-42e3-88ab-b3719eba1438", "embedding": null, "metadata": {"window": "We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "And we stand ready to do that, when that \nhappens.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6edf15ac-bdd7-4131-914a-77c6a9d9c2a3", "node_type": "1", "metadata": {"window": "We have the absolute capabilities to do it.   We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.  ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22d170dea4a123690f4e4a3692c2b665562d3ab2d7f966b01853d0e98deb1a42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c9b445c-1b4c-4ff2-a1c1-6b0f53dcd228", "node_type": "1", "metadata": {"window": "So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "Ricky Goldwasser:  Thank you.  \n "}, "hash": "d309c8c5264ebca45a22a93b9ea6199d10518eb13850dde790ae1d3fe2ea4066", "class_name": "RelatedNodeInfo"}}, "text": "And we stand ready to do that, when that \nhappens.  \n \n", "start_char_idx": 2553, "end_char_idx": 2608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c9b445c-1b4c-4ff2-a1c1-6b0f53dcd228": {"__data__": {"id_": "4c9b445c-1b4c-4ff2-a1c1-6b0f53dcd228", "embedding": null, "metadata": {"window": "So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "Ricky Goldwasser:  Thank you.  \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e5d7d494-e527-4934-afb4-d787af208173", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c411d198c9f5a1e6ddb30bb2835a71feca835eae01a965e80394095608dc2ac5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7382c5d5-17de-42e3-88ab-b3719eba1438", "node_type": "1", "metadata": {"window": "We've been shipping many di fferent types of \nvaccines for years.   So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "And we stand ready to do that, when that \nhappens.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e844b204fc27ee37055596f4b3d0926c8706920a366ba31dffdcb7e81baf055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46c1e1fd-836c-4441-a991-25777f6a5147", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.  ", "original_text": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n"}, "hash": "ed6126183b6ffbdfa62fd57216d5edcda9f251cd4b6eb5b8f26e4235664e55dc", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Thank you.  \n ", "start_char_idx": 2608, "end_char_idx": 2641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46c1e1fd-836c-4441-a991-25777f6a5147": {"__data__": {"id_": "46c1e1fd-836c-4441-a991-25777f6a5147", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.  ", "original_text": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c9b445c-1b4c-4ff2-a1c1-6b0f53dcd228", "node_type": "1", "metadata": {"window": "So we have both ambient and cold chain storage capabilities and shipping \ncapabilities to do that.  \n \n  And my belief at least from what I think is probably best for making sure that the product is \navailable for our custom ers and the fact that we're going to our customers every day is that down the \nline, I think it would make the most sense for all the key distributors to be part of the Phase 2 of this \nwhen the products become more readily available.   And we stand ready to do that, when that \nhappens.  \n \n Ricky Goldwasser:  Thank you.  \n ", "original_text": "Ricky Goldwasser:  Thank you.  \n ", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a1764001353f50c5ebfbb72f93d99e2a1dad3e3eeb0bd922a8557d94b896c75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "441b655d-de18-4cd5-8c8e-a5ab1ed9394c", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n ", "original_text": "Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n"}, "hash": "9fd1b78efe70c7fc895d6676eb4ca434edb4da20a038e726aecb16d1ddc94faf", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n", "start_char_idx": 0, "end_char_idx": 54, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "441b655d-de18-4cd5-8c8e-a5ab1ed9394c": {"__data__": {"id_": "441b655d-de18-4cd5-8c8e-a5ab1ed9394c", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n ", "original_text": "Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46c1e1fd-836c-4441-a991-25777f6a5147", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.  ", "original_text": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "709c62334251059e57ee0cfc273a86677668ae9c918ba35aa1ebdfbee133edc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "948d3f28-1168-4b69-9576-91be5603d3e6", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?   ", "original_text": "George Hill:  Hey, good morning guys.  "}, "hash": "7a07dc622f0fb44204b853f3c13450347f71e0a7d85c5223b00dc0201bb0ab5b", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n", "start_char_idx": 54, "end_char_idx": 144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "948d3f28-1168-4b69-9576-91be5603d3e6": {"__data__": {"id_": "948d3f28-1168-4b69-9576-91be5603d3e6", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?   ", "original_text": "George Hill:  Hey, good morning guys.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "441b655d-de18-4cd5-8c8e-a5ab1ed9394c", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n ", "original_text": "Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79f72c3c2613d8e670785d71a589ae70f30282a95ecbb3ea46a8d791bda47ced", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1caf2ea7-a042-4f4a-95f7-a64efd44b451", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n", "original_text": "Thanks for sneaking me in.  "}, "hash": "16a3cb10c585e3baf21a2c467ae124f16bd43ebaba0c8ccf413e6d0b3406c618", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Hey, good morning guys.  ", "start_char_idx": 144, "end_char_idx": 183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1caf2ea7-a042-4f4a-95f7-a64efd44b451": {"__data__": {"id_": "1caf2ea7-a042-4f4a-95f7-a64efd44b451", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n", "original_text": "Thanks for sneaking me in.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "948d3f28-1168-4b69-9576-91be5603d3e6", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?   ", "original_text": "George Hill:  Hey, good morning guys.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "762443c66f581fd2014a98a2d768ab1d324998efa9c020f431f201470054dfdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2de3c250-0902-4016-a502-55df04f9a4d7", "node_type": "1", "metadata": {"window": "Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.  ", "original_text": "And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n "}, "hash": "292b6c7f61353cd8e5fe56f942e34ec40ac25936ad209fa4b9ee20b22844a057", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for sneaking me in.  ", "start_char_idx": 183, "end_char_idx": 211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2de3c250-0902-4016-a502-55df04f9a4d7": {"__data__": {"id_": "2de3c250-0902-4016-a502-55df04f9a4d7", "embedding": null, "metadata": {"window": "Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.  ", "original_text": "And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1caf2ea7-a042-4f4a-95f7-a64efd44b451", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n", "original_text": "Thanks for sneaking me in.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a95abfade70c338c25705464359d75ba8f4004f7898bafb0934c1700e7ea1e59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe8d1e64-5e02-4334-b873-ffc1168334c1", "node_type": "1", "metadata": {"window": "George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.  ", "original_text": "Like is the - I guess, does the guidance assume that we get 95% back, 98% back?   "}, "hash": "4ea8d4429f16e9838c43ffbd1abd5f6511d3834ccd7775d42d76514184f03f44", "class_name": "RelatedNodeInfo"}}, "text": "And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n ", "start_char_idx": 211, "end_char_idx": 484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe8d1e64-5e02-4334-b873-ffc1168334c1": {"__data__": {"id_": "fe8d1e64-5e02-4334-b873-ffc1168334c1", "embedding": null, "metadata": {"window": "George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.  ", "original_text": "Like is the - I guess, does the guidance assume that we get 95% back, 98% back?   ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2de3c250-0902-4016-a502-55df04f9a4d7", "node_type": "1", "metadata": {"window": "Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.  ", "original_text": "And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34207a40b711ebbdc126cf8ae091c0163e75d89ee8daaf1d6220ff814aeedcaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e669c7e-689e-4161-a566-b58a1fbbef7d", "node_type": "1", "metadata": {"window": "Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n ", "original_text": "I would \njust be interested on any color you can provide around that.  \n \n"}, "hash": "52631a9d10476de201cffa304780009761bd70db4405d2f019f521e4f420cf84", "class_name": "RelatedNodeInfo"}}, "text": "Like is the - I guess, does the guidance assume that we get 95% back, 98% back?   ", "start_char_idx": 484, "end_char_idx": 566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e669c7e-689e-4161-a566-b58a1fbbef7d": {"__data__": {"id_": "8e669c7e-689e-4161-a566-b58a1fbbef7d", "embedding": null, "metadata": {"window": "Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n ", "original_text": "I would \njust be interested on any color you can provide around that.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe8d1e64-5e02-4334-b873-ffc1168334c1", "node_type": "1", "metadata": {"window": "George Hill:  Hey, good morning guys.   Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.  ", "original_text": "Like is the - I guess, does the guidance assume that we get 95% back, 98% back?   ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f18200bd3ae9351adfd27947d1dae53396ea84b9d4de10252fbd4fddafc6b478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cf68cad-2b10-4e71-8c41-e46c52b7b78a", "node_type": "1", "metadata": {"window": "And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.  ", "original_text": "Mike Kaufmann:  Well I can talk specifically to pharma.  "}, "hash": "414d2d8140b547c098ad9f9b91e1e82abc96b3cca6fc152ee15aa8377defc99a", "class_name": "RelatedNodeInfo"}}, "text": "I would \njust be interested on any color you can provide around that.  \n \n", "start_char_idx": 566, "end_char_idx": 640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cf68cad-2b10-4e71-8c41-e46c52b7b78a": {"__data__": {"id_": "7cf68cad-2b10-4e71-8c41-e46c52b7b78a", "embedding": null, "metadata": {"window": "And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.  ", "original_text": "Mike Kaufmann:  Well I can talk specifically to pharma.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e669c7e-689e-4161-a566-b58a1fbbef7d", "node_type": "1", "metadata": {"window": "Thanks for sneaking me in.   And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n ", "original_text": "I would \njust be interested on any color you can provide around that.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa12e6cd551228fa07d24da3ab816277f19a7a77457df785e0fcd9d4888ae0d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23cedf18-59ad-47a2-ab40-cadddd6b6f69", "node_type": "1", "metadata": {"window": "Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.  ", "original_text": "We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.  "}, "hash": "57ca57f7459a9a7c09c4b63f19e8b3e5e17f7820453d6e81674b70ed020c414f", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Well I can talk specifically to pharma.  ", "start_char_idx": 640, "end_char_idx": 697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23cedf18-59ad-47a2-ab40-cadddd6b6f69": {"__data__": {"id_": "23cedf18-59ad-47a2-ab40-cadddd6b6f69", "embedding": null, "metadata": {"window": "Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.  ", "original_text": "We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cf68cad-2b10-4e71-8c41-e46c52b7b78a", "node_type": "1", "metadata": {"window": "And, Mike,  I'll apologize if you \ntouched on this already, but as you think about the guidance for the balance of this fiscal year, can \nyou quantify what your guidance implies in the core drugs business, I guess, as a percent of return to \nbaseline from pre -COVID?  \n \n  Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.  ", "original_text": "Mike Kaufmann:  Well I can talk specifically to pharma.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4bcc428507b32b71fe2991a809ef8855940b377bc5133555c368388776795d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46ee6961-c57f-483b-958e-7506b0c43ac7", "node_type": "1", "metadata": {"window": "I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n", "original_text": "Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n "}, "hash": "7b02701a9938e1fa7945f09423d28aa22e49346b0bb2f5ed61ad22996c9fbc5d", "class_name": "RelatedNodeInfo"}}, "text": "We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.  ", "start_char_idx": 697, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46ee6961-c57f-483b-958e-7506b0c43ac7": {"__data__": {"id_": "46ee6961-c57f-483b-958e-7506b0c43ac7", "embedding": null, "metadata": {"window": "I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n", "original_text": "Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23cedf18-59ad-47a2-ab40-cadddd6b6f69", "node_type": "1", "metadata": {"window": "Like is the - I guess, does the guidance assume that we get 95% back, 98% back?    I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.  ", "original_text": "We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "446747ddbc9de4b7449142d94a08aafd8d41764984c8cb5e1fe4b2615ab5160e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d43823e6-b0cc-475c-bfad-1b0a1b32003b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.  ", "original_text": "And so that's kind of how we would see it progressing over the next three quarters.  "}, "hash": "fc1ea6909801245ae5beaf2662dd59b1b501409a7fffdba60860c184ae932c92", "class_name": "RelatedNodeInfo"}}, "text": "Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n ", "start_char_idx": 784, "end_char_idx": 895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d43823e6-b0cc-475c-bfad-1b0a1b32003b": {"__data__": {"id_": "d43823e6-b0cc-475c-bfad-1b0a1b32003b", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.  ", "original_text": "And so that's kind of how we would see it progressing over the next three quarters.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46ee6961-c57f-483b-958e-7506b0c43ac7", "node_type": "1", "metadata": {"window": "I would \njust be interested on any color you can provide around that.  \n \n Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n", "original_text": "Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64342a5bef2dc283e1bb68951bfc3ddac05e710c7b84b5f93d92c9d52914009d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9a1bd12-0adc-4fa1-8a83-271f79b51b00", "node_type": "1", "metadata": {"window": "We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.  ", "original_text": "Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.  "}, "hash": "ce3e50706ccaf0b7f96702600cdda8885bd4036230d2546a0f6b21171963d560", "class_name": "RelatedNodeInfo"}}, "text": "And so that's kind of how we would see it progressing over the next three quarters.  ", "start_char_idx": 895, "end_char_idx": 980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9a1bd12-0adc-4fa1-8a83-271f79b51b00": {"__data__": {"id_": "f9a1bd12-0adc-4fa1-8a83-271f79b51b00", "embedding": null, "metadata": {"window": "We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.  ", "original_text": "Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d43823e6-b0cc-475c-bfad-1b0a1b32003b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Well I can talk specifically to pharma.   We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.  ", "original_text": "And so that's kind of how we would see it progressing over the next three quarters.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7af1a1c65bf514030c6aaefefc3b7bdd04bcdf50c4e4c34296cd6359cf2f50d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91766bf2-4259-4daf-ad53-5819439c1fda", "node_type": "1", "metadata": {"window": "Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.  ", "original_text": "Did that \nanswer your question, George?  \n \n"}, "hash": "e0ea0d6c9f1b63c7a9949662c6493e342beda615e0a20d4f4200159dedf20ec8", "class_name": "RelatedNodeInfo"}}, "text": "Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.  ", "start_char_idx": 980, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91766bf2-4259-4daf-ad53-5819439c1fda": {"__data__": {"id_": "91766bf2-4259-4daf-ad53-5819439c1fda", "embedding": null, "metadata": {"window": "Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.  ", "original_text": "Did that \nanswer your question, George?  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9a1bd12-0adc-4fa1-8a83-271f79b51b00", "node_type": "1", "metadata": {"window": "We really feel like we're tracking very similar \nto the IQVIA data and the Rx trends.   Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.  ", "original_text": "Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83c0c19c831349746591f0591a725e521c9c1352e4109d66ae2faf3da6fe5ca3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a4c68d3-30b1-4090-9c4c-702cf9de646e", "node_type": "1", "metadata": {"window": "And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?  ", "original_text": "George Hill:  Yes, it does.  "}, "hash": "4ecfffa368c19384b684ccd05f0937a117144ceb091896d151f722828e30e188", "class_name": "RelatedNodeInfo"}}, "text": "Did that \nanswer your question, George?  \n \n", "start_char_idx": 1080, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a4c68d3-30b1-4090-9c4c-702cf9de646e": {"__data__": {"id_": "8a4c68d3-30b1-4090-9c4c-702cf9de646e", "embedding": null, "metadata": {"window": "And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?  ", "original_text": "George Hill:  Yes, it does.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91766bf2-4259-4daf-ad53-5819439c1fda", "node_type": "1", "metadata": {"window": "Remember, our year end being June 30, would be at or near \npre-COVID levels by the time we exit the year.  \n \n  And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.  ", "original_text": "Did that \nanswer your question, George?  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce2b04b3c154ebfb7da37b04c88f7e4dcb8e04cdc019ddf50473177eede6df8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd45d807-0fca-41dd-bad3-f39c2559808d", "node_type": "1", "metadata": {"window": "Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n", "original_text": "And maybe if I could just do a quick follow -up.  "}, "hash": "f9056f07fd120b947d2cde1ce65cc12b9a685738f95f35d15a49659bf539329b", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Yes, it does.  ", "start_char_idx": 1124, "end_char_idx": 1153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd45d807-0fca-41dd-bad3-f39c2559808d": {"__data__": {"id_": "fd45d807-0fca-41dd-bad3-f39c2559808d", "embedding": null, "metadata": {"window": "Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n", "original_text": "And maybe if I could just do a quick follow -up.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a4c68d3-30b1-4090-9c4c-702cf9de646e", "node_type": "1", "metadata": {"window": "And so that's kind of how we would see it progressing over the next three quarters.   Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?  ", "original_text": "George Hill:  Yes, it does.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b688fe42596ee450e868793b9addffd89da07b0d5a40bb592a6aff2443ce91b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fe4bba2-560b-4661-acb0-e4c9d8bedaa0", "node_type": "1", "metadata": {"window": "Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.  ", "original_text": "One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.  "}, "hash": "645455520ed7f523a378c60c3c5cee3ed484557d81b8ba944ebbe2b26d2ea06e", "class_name": "RelatedNodeInfo"}}, "text": "And maybe if I could just do a quick follow -up.  ", "start_char_idx": 1153, "end_char_idx": 1203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fe4bba2-560b-4661-acb0-e4c9d8bedaa0": {"__data__": {"id_": "9fe4bba2-560b-4661-acb0-e4c9d8bedaa0", "embedding": null, "metadata": {"window": "Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.  ", "original_text": "One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd45d807-0fca-41dd-bad3-f39c2559808d", "node_type": "1", "metadata": {"window": "Again with \nthe caution of there being some potential lumpiness as things happen specific to RX\u2019s.   Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n", "original_text": "And maybe if I could just do a quick follow -up.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfb9ad0bd812564d97a3c7e51534e8947c80554a873b5b2696f8abccdf41a291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de3a6515-c093-48f1-9814-1d4e353c7eb9", "node_type": "1", "metadata": {"window": "George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.  ", "original_text": "I guess, have you \nguys participated in that?  "}, "hash": "c3503263883e4bf87eeffe3e8bf2df10ba97b3512dd05d01ba7404df6464213b", "class_name": "RelatedNodeInfo"}}, "text": "One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.  ", "start_char_idx": 1203, "end_char_idx": 1311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de3a6515-c093-48f1-9814-1d4e353c7eb9": {"__data__": {"id_": "de3a6515-c093-48f1-9814-1d4e353c7eb9", "embedding": null, "metadata": {"window": "George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.  ", "original_text": "I guess, have you \nguys participated in that?  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fe4bba2-560b-4661-acb0-e4c9d8bedaa0", "node_type": "1", "metadata": {"window": "Did that \nanswer your question, George?  \n \n George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.  ", "original_text": "One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75fc5dac70efd2f4f223b23f2c3eb1ef62ec6961fe755fb759f0585499979823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30f5ed19-d44f-4d13-8ef2-664a0b82baaa", "node_type": "1", "metadata": {"window": "And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n ", "original_text": "And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n"}, "hash": "e72af33acd51d2b18d1127fcfb420c691743322301300715b33e5edff1b4697a", "class_name": "RelatedNodeInfo"}}, "text": "I guess, have you \nguys participated in that?  ", "start_char_idx": 1311, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30f5ed19-d44f-4d13-8ef2-664a0b82baaa": {"__data__": {"id_": "30f5ed19-d44f-4d13-8ef2-664a0b82baaa", "embedding": null, "metadata": {"window": "And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n ", "original_text": "And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de3a6515-c093-48f1-9814-1d4e353c7eb9", "node_type": "1", "metadata": {"window": "George Hill:  Yes, it does.   And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.  ", "original_text": "I guess, have you \nguys participated in that?  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afa6105151069150a52f29b1bc3ff9bb14d5d5daf449d54ddfbc45c31234ed29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7deda3b4-a76d-4165-aba9-286567c99ab5", "node_type": "1", "metadata": {"window": "One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n ", "original_text": "Mike Kaufmann:  Yes, it's an interesting question.  "}, "hash": "88f78c196b2ec07878b63f9a130192bb9e03bfddfae318cef6bd572dfee7aee5", "class_name": "RelatedNodeInfo"}}, "text": "And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n", "start_char_idx": 1358, "end_char_idx": 1544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7deda3b4-a76d-4165-aba9-286567c99ab5": {"__data__": {"id_": "7deda3b4-a76d-4165-aba9-286567c99ab5", "embedding": null, "metadata": {"window": "One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n ", "original_text": "Mike Kaufmann:  Yes, it's an interesting question.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30f5ed19-d44f-4d13-8ef2-664a0b82baaa", "node_type": "1", "metadata": {"window": "And maybe if I could just do a quick follow -up.   One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n ", "original_text": "And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a4460e5890d2638f142e0f16ae98e1f3a4611689f2139ec76d87c81f2bd30b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1523910-8893-4a92-99d9-a5a54afe7af0", "node_type": "1", "metadata": {"window": "I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.  ", "original_text": "Flu vaccines have been significantly up this year, \nand we do distribute those.  "}, "hash": "b9a4c2de3bcc383bdb5e0c2754b3c75c3ea029240b7154b40ccc4a02dae4528e", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, it's an interesting question.  ", "start_char_idx": 1544, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1523910-8893-4a92-99d9-a5a54afe7af0": {"__data__": {"id_": "e1523910-8893-4a92-99d9-a5a54afe7af0", "embedding": null, "metadata": {"window": "I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.  ", "original_text": "Flu vaccines have been significantly up this year, \nand we do distribute those.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7deda3b4-a76d-4165-aba9-286567c99ab5", "node_type": "1", "metadata": {"window": "One of the things that \nwe've also seen from the IQVIA data is tha t flu vaccine volumes have been strong.   I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n ", "original_text": "Mike Kaufmann:  Yes, it's an interesting question.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4bc476790e5649c0ab65f8de0a6da0ff023ce282bd7d523f256bdaa4f6a7f9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e096a3f7-27a8-443f-947e-73bce4e0b0d7", "node_type": "1", "metadata": {"window": "And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.  ", "original_text": "And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n "}, "hash": "8f4c8b83cf76f9f11d287c43c4d9dc54d139c2aca63a4e32c5a86b7d1e8a4054", "class_name": "RelatedNodeInfo"}}, "text": "Flu vaccines have been significantly up this year, \nand we do distribute those.  ", "start_char_idx": 1596, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e096a3f7-27a8-443f-947e-73bce4e0b0d7": {"__data__": {"id_": "e096a3f7-27a8-443f-947e-73bce4e0b0d7", "embedding": null, "metadata": {"window": "And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.  ", "original_text": "And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1523910-8893-4a92-99d9-a5a54afe7af0", "node_type": "1", "metadata": {"window": "I guess, have you \nguys participated in that?   And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.  ", "original_text": "Flu vaccines have been significantly up this year, \nand we do distribute those.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45dc7ca32bba77350a7514558b2259b8038817596dea3043d2f1224478edb57c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f6a0483-cc54-49f8-9e9f-11b697bffc08", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.  ", "original_text": "Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n "}, "hash": "654d6294fdebd37a1ae51648b5f666101e9f252f3df042e94cb18f50651b11b1", "class_name": "RelatedNodeInfo"}}, "text": "And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n ", "start_char_idx": 1677, "end_char_idx": 1781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f6a0483-cc54-49f8-9e9f-11b697bffc08": {"__data__": {"id_": "9f6a0483-cc54-49f8-9e9f-11b697bffc08", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.  ", "original_text": "Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e096a3f7-27a8-443f-947e-73bce4e0b0d7", "node_type": "1", "metadata": {"window": "And kind of the derivative thought there, have you seen any change in mix \nas we think about kind of what has been going on in the drug business over the last three to si x \nmonths?  \n \n Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.  ", "original_text": "And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf0e5c63fb6c19928d070b64985e01b86560236645610edd56ee5b2fd2b84fe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae854fa6-104f-45e0-98cb-4ae85c037624", "node_type": "1", "metadata": {"window": "Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n", "original_text": "But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.  "}, "hash": "8c76860a2e11b89b5c4e04838168e6cd14380f00967397418200207ece364b85", "class_name": "RelatedNodeInfo"}}, "text": "Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n ", "start_char_idx": 1781, "end_char_idx": 2023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae854fa6-104f-45e0-98cb-4ae85c037624": {"__data__": {"id_": "ae854fa6-104f-45e0-98cb-4ae85c037624", "embedding": null, "metadata": {"window": "Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n", "original_text": "But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f6a0483-cc54-49f8-9e9f-11b697bffc08", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, it's an interesting question.   Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.  ", "original_text": "Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98f49dacc6f7002255262d638da8229411c5d0bcb50eb3136d20b5b83b6e212f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f09a94bc-95c3-4a68-a90a-11c1d4f70fc1", "node_type": "1", "metadata": {"window": "And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.  ", "original_text": "But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.  "}, "hash": "c4d9adf422f2fc690697de724cc8f2ef44209a76ecca57521839f42f16005f96", "class_name": "RelatedNodeInfo"}}, "text": "But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.  ", "start_char_idx": 2023, "end_char_idx": 2124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f09a94bc-95c3-4a68-a90a-11c1d4f70fc1": {"__data__": {"id_": "f09a94bc-95c3-4a68-a90a-11c1d4f70fc1", "embedding": null, "metadata": {"window": "And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.  ", "original_text": "But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae854fa6-104f-45e0-98cb-4ae85c037624", "node_type": "1", "metadata": {"window": "Flu vaccines have been significantly up this year, \nand we do distribute those.   And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n", "original_text": "But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "848c000d98be30dfa0900e370dfdcfeaa7825ae59ff0b2d3b591850e5dc27e80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4deba78c-210e-4b97-9ff6-a12eac4cd50f", "node_type": "1", "metadata": {"window": "Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n", "original_text": "But again, I just keep focused on that word.  "}, "hash": "1d92036be83b5fdb74171593dd58cb1a99224b620eae4f917f1a359694e97b08", "class_name": "RelatedNodeInfo"}}, "text": "But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.  ", "start_char_idx": 2124, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4deba78c-210e-4b97-9ff6-a12eac4cd50f": {"__data__": {"id_": "4deba78c-210e-4b97-9ff6-a12eac4cd50f", "embedding": null, "metadata": {"window": "Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n", "original_text": "But again, I just keep focused on that word.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f09a94bc-95c3-4a68-a90a-11c1d4f70fc1", "node_type": "1", "metadata": {"window": "And we've distributed significantly more flu vaccines this year than we \nhave in historical years.  \n \n  Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.  ", "original_text": "But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d202fa487fe949b7cee0fd05eaad83d9a09504a93e43def6fb16ddac72a79a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b801413-9682-4ac4-8c50-7cc4b2ba89cf", "node_type": "1", "metadata": {"window": "But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.  ", "original_text": "We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n"}, "hash": "9c7f12652bda61c8e2a9b387200b60fea596e5c9822f5461a9d40f1b5cec6554", "class_name": "RelatedNodeInfo"}}, "text": "But again, I just keep focused on that word.  ", "start_char_idx": 2338, "end_char_idx": 2384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b801413-9682-4ac4-8c50-7cc4b2ba89cf": {"__data__": {"id_": "6b801413-9682-4ac4-8c50-7cc4b2ba89cf", "embedding": null, "metadata": {"window": "But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.  ", "original_text": "We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4deba78c-210e-4b97-9ff6-a12eac4cd50f", "node_type": "1", "metadata": {"window": "Probably, wit h the combination of the fact more people are getting vaccinated as well as, you \nknow, practicing distancing, wearing masks, washing hands et cetera, we would expect a much \nlighter flu season this year than historically.  \n \n  But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n", "original_text": "But again, I just keep focused on that word.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cebd8420edf067ac1e9d575d850d17d1e13e765f08ab5951d12421872b12a1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7df36e58-fc22-4a46-a005-51e33aeaf01d", "node_type": "1", "metadata": {"window": "But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "George Hill:  Helpful.  "}, "hash": "bd1e3650361a1ba8678a5ddb47261a987a62b1a3854a05ea59ccbbe041a5001a", "class_name": "RelatedNodeInfo"}}, "text": "We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n", "start_char_idx": 2384, "end_char_idx": 2470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7df36e58-fc22-4a46-a005-51e33aeaf01d": {"__data__": {"id_": "7df36e58-fc22-4a46-a005-51e33aeaf01d", "embedding": null, "metadata": {"window": "But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "George Hill:  Helpful.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b801413-9682-4ac4-8c50-7cc4b2ba89cf", "node_type": "1", "metadata": {"window": "But we're not seeing any big necessary mix changes in our, you know, pharma business at this \ntime.   But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.  ", "original_text": "We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a589279d41a1fa7acbf61265fe132a7d94c22b68137e350fe14831fedac44ded", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "285033ad-ae6d-44dd-8e13-9d5b23750b89", "node_type": "1", "metadata": {"window": "But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "Thanks, Mike.  \n \n"}, "hash": "c7ce268a8518be2de473948aec9f9c2aa4d7f54fa81122333f696d464bf0d98e", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Helpful.  ", "start_char_idx": 2470, "end_char_idx": 2494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "285033ad-ae6d-44dd-8e13-9d5b23750b89": {"__data__": {"id_": "285033ad-ae6d-44dd-8e13-9d5b23750b89", "embedding": null, "metadata": {"window": "But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "Thanks, Mike.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7df36e58-fc22-4a46-a005-51e33aeaf01d", "node_type": "1", "metadata": {"window": "But we are keeping an eye on it because, you know, as different physicians get back into work, \nand people start visiting them, we may see a little bit of mix but right now nothing I wou ld call out as \nmaterial.   But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "George Hill:  Helpful.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22189086efb13f39527b958429c686f723ad1561c3b11159366ccce3eff2c80a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b37932f1-29b1-4ddc-aabd-c3ebee267372", "node_type": "1", "metadata": {"window": "We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.  "}, "hash": "11e980f2520593b5d079cfc034317b331c62ddf3f210377d1b583cb4b80e8e13", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Mike.  \n \n", "start_char_idx": 2494, "end_char_idx": 2512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b37932f1-29b1-4ddc-aabd-c3ebee267372": {"__data__": {"id_": "b37932f1-29b1-4ddc-aabd-c3ebee267372", "embedding": null, "metadata": {"window": "We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "285033ad-ae6d-44dd-8e13-9d5b23750b89", "node_type": "1", "metadata": {"window": "But again, I just keep focused on that word.   We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "Thanks, Mike.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92e5fd15b503c8d94ccd9b982e4efdc4437a62b33a7969be09f09f0d0383fe2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "513c3172-109f-47d6-8c24-c6f674c746e6", "node_type": "1", "metadata": {"window": "George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n "}, "hash": "af475c05a6500434566b85b6bcf835f497e2494806cbcbfe8cdfb60eadce9b68", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.  ", "start_char_idx": 2512, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "513c3172-109f-47d6-8c24-c6f674c746e6": {"__data__": {"id_": "513c3172-109f-47d6-8c24-c6f674c746e6", "embedding": null, "metadata": {"window": "George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48da569c-0288-4ee9-9e1c-c413a5facf60", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42bcf3953d21340282247373ee234539cb8c5387416243ce345d0efdb3a94364", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b37932f1-29b1-4ddc-aabd-c3ebee267372", "node_type": "1", "metadata": {"window": "We do expect it to be non -linear, a little bit \nlumpy over the rest of the year.  \n \n George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.  ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76a03663c797221982da31d8138a73f403fa03534d5def20f5cdfd9b36a81993", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a708b81-a11b-499b-a286-74fd9b8df405", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.  ", "original_text": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.  "}, "hash": "67dadf97e471989b020a91c38eee1f7ece91efe708a9e00620af1a62549a4f66", "class_name": "RelatedNodeInfo"}}, "text": "I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "start_char_idx": 2605, "end_char_idx": 2680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a708b81-a11b-499b-a286-74fd9b8df405": {"__data__": {"id_": "1a708b81-a11b-499b-a286-74fd9b8df405", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.  ", "original_text": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07d3e18a-9dcf-4042-9746-9cda9da75453", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55d92229818fff31075cb6989670fed2a35a43049805d8d51e4ee2ea4d4f6f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "513c3172-109f-47d6-8c24-c6f674c746e6", "node_type": "1", "metadata": {"window": "George Hill:  Helpful.   Thanks, Mike.  \n \n Operator:  And ladies and gentlemen, this will conclude your que stion -and-answer session.   I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "original_text": "I'll turn \nthe call back over to Mike Kaufmann for any closing remarks.  \n ", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55d8bc1677e2b8b56d99e3ba7bdb1dc2be9375ef1f99f83871adafb9f4d5b78b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8271a98-7f07-4f43-be31-88734dfa1adb", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.  ", "original_text": "And we look forward to speaking to \nall of you sometime soon.  "}, "hash": "8580b447cb9a90c371ac51d350c5ce2d9efc09dcb519fcf41d2a6875ee41adb7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.  ", "start_char_idx": 0, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8271a98-7f07-4f43-be31-88734dfa1adb": {"__data__": {"id_": "e8271a98-7f07-4f43-be31-88734dfa1adb", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.  ", "original_text": "And we look forward to speaking to \nall of you sometime soon.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07d3e18a-9dcf-4042-9746-9cda9da75453", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55d92229818fff31075cb6989670fed2a35a43049805d8d51e4ee2ea4d4f6f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a708b81-a11b-499b-a286-74fd9b8df405", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.  ", "original_text": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df197ec400a4e3a274152e33585913b7be9351bf0c3d4f9732949ef22ff44120", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdec10bd-72fa-4b1b-ae48-cbb4f24ac20e", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "Take care.  \n \n"}, "hash": "b1951b2e7fcd8fdc9be06557e3b9ecf93da642e6b555a8b04f6c03bdbed94fe3", "class_name": "RelatedNodeInfo"}}, "text": "And we look forward to speaking to \nall of you sometime soon.  ", "start_char_idx": 193, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdec10bd-72fa-4b1b-ae48-cbb4f24ac20e": {"__data__": {"id_": "fdec10bd-72fa-4b1b-ae48-cbb4f24ac20e", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "Take care.  \n \n", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07d3e18a-9dcf-4042-9746-9cda9da75453", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55d92229818fff31075cb6989670fed2a35a43049805d8d51e4ee2ea4d4f6f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8271a98-7f07-4f43-be31-88734dfa1adb", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.  ", "original_text": "And we look forward to speaking to \nall of you sometime soon.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9ed6fb6929131372f4f079393b33731202a403b2c1b685643be31b8b50bd9fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8b46b99-bcf0-45f3-ad2d-47f3fe50e825", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "Operator:  Ladies and gentlemen, this will conclude your conference today.  "}, "hash": "8d4435a13813d0e794337c633a61947173b9a51bedbeba2617c9ab8df72bceec", "class_name": "RelatedNodeInfo"}}, "text": "Take care.  \n \n", "start_char_idx": 256, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8b46b99-bcf0-45f3-ad2d-47f3fe50e825": {"__data__": {"id_": "c8b46b99-bcf0-45f3-ad2d-47f3fe50e825", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "Operator:  Ladies and gentlemen, this will conclude your conference today.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07d3e18a-9dcf-4042-9746-9cda9da75453", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55d92229818fff31075cb6989670fed2a35a43049805d8d51e4ee2ea4d4f6f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdec10bd-72fa-4b1b-ae48-cbb4f24ac20e", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "Take care.  \n \n", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88d129cf9a90e56a9fc1627071a7a2496c4f5298a863d4e8d923f56e393fefee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52c5e7cf-498d-4370-ba86-41cde14a20ed", "node_type": "1", "metadata": {"window": "And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "We do thank you for your \nparticipation.  "}, "hash": "3ff0b743425c66801efb96cb2c572432bcb17cb510d492ae57baa82221870f02", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Ladies and gentlemen, this will conclude your conference today.  ", "start_char_idx": 271, "end_char_idx": 347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52c5e7cf-498d-4370-ba86-41cde14a20ed": {"__data__": {"id_": "52c5e7cf-498d-4370-ba86-41cde14a20ed", "embedding": null, "metadata": {"window": "And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "We do thank you for your \nparticipation.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07d3e18a-9dcf-4042-9746-9cda9da75453", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55d92229818fff31075cb6989670fed2a35a43049805d8d51e4ee2ea4d4f6f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8b46b99-bcf0-45f3-ad2d-47f3fe50e825", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "Operator:  Ladies and gentlemen, this will conclude your conference today.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0010f19b400760f909675598b9458352e3dc07b45281770c5ae4fc32cc006da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c40949d-f235-4954-bc79-4cd82a4c7375", "node_type": "1", "metadata": {"window": "Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "And you may now disconnect.  \n \n \n "}, "hash": "ad115972c6b50037709f20339621f26e9f5438fba0df71dca3057fddfb01b2b9", "class_name": "RelatedNodeInfo"}}, "text": "We do thank you for your \nparticipation.  ", "start_char_idx": 347, "end_char_idx": 389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c40949d-f235-4954-bc79-4cd82a4c7375": {"__data__": {"id_": "4c40949d-f235-4954-bc79-4cd82a4c7375", "embedding": null, "metadata": {"window": "Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "And you may now disconnect.  \n \n \n ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07d3e18a-9dcf-4042-9746-9cda9da75453", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55d92229818fff31075cb6989670fed2a35a43049805d8d51e4ee2ea4d4f6f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52c5e7cf-498d-4370-ba86-41cde14a20ed", "node_type": "1", "metadata": {"window": "And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.   We do thank you for your \nparticipation.   And you may now disconnect.  \n \n \n ", "original_text": "We do thank you for your \nparticipation.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9444edd293a27d01d942dfc98d19b14e340291794ce8524b0761e1ee78937a36", "class_name": "RelatedNodeInfo"}}, "text": "And you may now disconnect.  \n \n \n ", "start_char_idx": 389, "end_char_idx": 424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"2553057e-9a75-4883-a326-74d477110ea3": {"doc_hash": "207d60e4a1256a8492d8c05256c1a781f19960698aab2dfc5843adc45096b7de", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "3d177c2c-1f0b-4001-89b8-425faa236d85": {"doc_hash": "4058dd6b44c9c90aaca844dcf442444a69d2f59e7c3991e4edb2f4e3bd2161c3", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "2f13c8f6-b8d5-4c7f-bddd-d8388ca24d60": {"doc_hash": "a294ee47c4dbd51d6af0a40432bf8cfc56e2debc3e0b2e074e7d7c87fd873ad9", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "cb8cc38c-12a3-4cd5-be6d-9791abf746fc": {"doc_hash": "431ee8ca81a8b252db531c496f1a099f8ebaeca011fb665901f71a694b25ab84", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "2dc59d3a-6986-4cf2-bb92-90ad4e22ad05": {"doc_hash": "22ee7dbf0484be270c70d114e55ec1643bf1181e092a83f7a4d57c4136534a2c", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "332e3b3d-6b6b-4c16-a6d0-9d162aa8bdd0": {"doc_hash": "4ca9dd92625a55b48333149e561590c9a7adc2d681faaef2ea1fc8d0cb78dc41", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "94128a65-ab91-42ef-9478-f16acd98a297": {"doc_hash": "5930a104642c8ea7d23b65d3cc1fd9b3e0515c2dc2dd3b35c3839a2ba6df6460", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "81d63427-dfe2-4b92-891c-a8476aa1fb8a": {"doc_hash": "3eb199a9d905898382591c8a35268f2084a44b561546858cfa6f90d20de8f5c1", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "4f03a76e-2e72-467d-b8ce-bee41ab22fd2": {"doc_hash": "b3af61b2788e88c3b866d66815ef66d04707ac6c030c1164cd4cc9bc01b9360a", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "20cbafa4-e967-4467-9f0c-908a90f98eeb": {"doc_hash": "8ccfbfa6b89af552ec76034eb598abbac49f5f27e42e336e0d1acdb1221c8827", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "3d3540b0-c9c1-4ad6-892f-68f78f54cf04": {"doc_hash": "41285e36d8312c483fc3d818995df7eb3c2263e60b1f27c3b83bebd1c2ab612a", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "3dbf84d6-74ad-4feb-a47f-02332a62401f": {"doc_hash": "987072885fc006d479cb5426b562e6f626cd2ffd23b08a7641b9303db27fc8e4", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "c97c48db-2936-44da-8d31-f829ef3e63b0": {"doc_hash": "b8d0a32515716a3841c911d4ede2a2bd3ea80fb8a82a84919590754f4e41d3d9", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "0b2f1848-4dfe-4e86-84dc-13784103c386": {"doc_hash": "834b9eb0eff6a233821cbc16234d0d954ea1d047663e197847b6bacb9f7f7350", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "0520f4a0-408d-4ca0-a732-1e0b1b2ed924": {"doc_hash": "fa9e1c845009581667db1de852655ff6842b62fb2acd2e5b23aa6bb3a52351f3", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "04d5bcf0-b6de-4469-b155-bfdd4b861b40": {"doc_hash": "4baed72afc6b41150a9dd093efff3ffc8993b8b6c1bf2bca53267f2013108e45", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "13d355ca-64c0-4f55-8179-3bca87b26645": {"doc_hash": "dbafd9b017f75fba399ec54cf1a317ba9797748fb8825ee1e0a51d1a5aceef9e", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "468fcdd1-16cd-4d6d-9c82-01e191f8aead": {"doc_hash": "d9e7b32c32d2c5d74913b3cb45c41d4145f78a0ed70d5aed1fddba9b8f01bf03", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "d239d995-8b72-4d03-a34b-221645003780": {"doc_hash": "1bb1e196752a2b49d9410fad705927fc049dbfd029977bb06c21b47761fc240b", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "02555899-8709-4fc0-8e27-a904aef8bd82": {"doc_hash": "8ef059ea1f2494fc1c7358ea5a4eac18bea27f9f4ea8366e24f0bf795f9856f3", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "1cdbc185-6356-4814-ad8c-abf3719216b8": {"doc_hash": "1bc0e4d37bacc648d4ee8451181740aceec1d786fcc96f93ecc88f6c2bac8c54", "ref_doc_id": "bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb"}, "a4001bef-1faa-4490-8674-88dd49a058ee": {"doc_hash": "f656743964f17f192c383fcb40b270127604b2cb2bb30f5cfd7afb746364be88", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "4bae68ad-40da-40c5-a50c-ff447fdf5b5d": {"doc_hash": "86c229ba4e392433094c8a1ac92d7f4f2e69ca4497e72129ecd32992d372566e", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "cea47fce-df81-44ba-85ad-27b3b85abebd": {"doc_hash": "6b9405e266262ed64c146b74b6708a0fabc37bfc467736c9b44806529ce69e0c", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "f5a7d44d-9e44-43d9-8146-82fee1816dba": {"doc_hash": "e11eb725fc99dea2d7005ebe39f2aa29b295c826eb0e0718618ab6b8b99a77da", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "dc35820c-ce63-4d85-8e7f-e4ff0a423ffe": {"doc_hash": "f23b4b911d5446ae9b25b3f74b991275bbc84fd0fd25d285b0a9d9d5d2a61993", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "9e44a36e-1297-4f96-8b6d-3e6f61d48c38": {"doc_hash": "bd70ea17328345161b43bd03dc0ef1eeb1168add3cbc13cd85ee0c222b1a1bcf", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "8f7b168e-b369-4849-97b5-7cebb47a324b": {"doc_hash": "cef10485e31aebd0cd8b8e8a256c902889d28f8cb2c59b9d47f84e5d45fa44ba", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "2f052e21-65fa-435e-b8fc-448186084662": {"doc_hash": "83f8892f66412148eaeeaf6c6d9fb62ed70a4b2cca91bcebbbfd087d38d7471e", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "68f85312-726a-4673-9eb0-8ee2e5a2f79a": {"doc_hash": "807ef615b4894a915bd357d4d6fc7ca147c5cbf86c354782975f7872f014b4a0", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "341294fd-3e6b-498a-bca7-0fafb433c230": {"doc_hash": "3305cf7ac612e19c21a25d1bcb63e66d58e5f7ca581a8065f0d52c3d31437427", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "4faeab45-6e19-4a72-914e-dc0fb88a29db": {"doc_hash": "34166a0ce5e1b3158ad70eecd14587e93b646d60bde3fb8eab8006adea09e60d", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "f086f2e6-8f35-4133-96eb-ff626e854d5c": {"doc_hash": "c03a4f7c2a0d4795e7e00b8aa152122b4ee1c9dd438742e5e5f7948e8ce7f07f", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "be0914d9-88c9-4121-bb72-fc0ca44814fb": {"doc_hash": "268461b880ad2ba74914cd30e136f8fe262b782df9aa6b5f107f7d1739efccd8", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "cd18ae82-9dae-4137-86ab-f4bd0cb7753f": {"doc_hash": "a6a9311c0475e12816af6640d7a999f75252f6bf5a4ebee0632a0cae3c722aeb", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "81b5d8ce-4618-4ed6-82cf-46b5e92f96c2": {"doc_hash": "8b09ecbd41ceddb27e03a5e8251019bbe1443f51ea69e7d7dd7f2f2a65d37e1f", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "2ea71a39-231a-4a1a-8451-e77579c3cffe": {"doc_hash": "cded00b4dc33e29cf4d6c97cc3254fbd15f24746377e9b11136803bd9c89a485", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "8e286e1c-fa5f-4818-add4-7ab92b4a9a52": {"doc_hash": "f200422af00a6d003fd4cd38b844d7b5327f2ab98a43dd720e4318e0f27dc726", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "44ef3ae3-ec68-4e71-b2c9-9168b2053585": {"doc_hash": "a301e6b3d3cc39fa319b65bc3f12247003aca29de31051634b2eb1979e3abf1f", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "503cb4c3-a98e-486b-adda-e78d7df31eac": {"doc_hash": "f475d6e3314a665ffd75384f747f7ae14a5bf913ec252e7312f21397f1f30d07", "ref_doc_id": "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d"}, "5772d814-021c-450e-a227-77a126e8d8da": {"doc_hash": "b7ecd8f3dd83119226e6aab0b26f0d64e149f5b451f6ca096dedfad8cbfeb5c8", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "2ba668b2-e5a4-46c7-a048-d03b7902f02b": {"doc_hash": "729ade19c22332df472d7f4f63e4444571849e082aa8d227a3252adceb51164a", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "75b4ea6d-c196-4d82-8cdd-8ceb64e0353d": {"doc_hash": "76527b6db9672f1351e62994984079f8abec7d3e1201cc3754d1ea56485132f9", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "2db8bcdc-058f-4a34-95ef-d2d390139b0f": {"doc_hash": "504881a287201500bc9987e0c57d023a26e8020f92ac9e21ffa3817a7838c06d", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "9218e891-ef4f-4464-a3c3-6b30734bce56": {"doc_hash": "37df1f631a1c147abdd58ad4413056b1fe9160c489d0cf63a874599ec8140ba4", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "f9067a12-4afc-43c1-91a3-1fe484218092": {"doc_hash": "55b057656c275d6a0a56cd46949271d91baa88402f27c0839aaf9d2cfe7ca6d1", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "599e79dc-fa86-4c3a-883b-8ec7bedfe130": {"doc_hash": "3b05a05ddadd43ebbd5838a04175c2cbef763c554194a6eab66a2669f7623276", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "6e6e2578-5c88-404d-b637-e0267bcbc912": {"doc_hash": "ca1b13101b9a1c2dd64f1469535598c1ab7ea3faf201130ffbb1bb2d7f4f5b0c", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "6669fb65-e6e8-440b-9386-a7fd110a285f": {"doc_hash": "522ef0195e62e0123ecbb8d09ff3af762e7911abbab0bcce62ed3c1af566ee6e", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "5f76c634-2d95-467f-b0c5-73d513a6a56c": {"doc_hash": "958e4fd26277195305afc049b0f907ed4450a5f96e65c6fc2ac0637d5b633357", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "f8d6e949-0588-45fe-9046-940e60f06be1": {"doc_hash": "2395bbaa4fd72dcd4213391ff294d927313445001b7a44e151a873e17913fa81", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "43efa39c-4bb4-4c84-a578-7e5f924d4de9": {"doc_hash": "c31fb388b0449d7dcfe579ed28bfede38f31d35655dce0153cbe2939895c2ede", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "1aa968f2-515a-441c-8984-3bbe713f6ab2": {"doc_hash": "9bf5ac14b0e8c3d3ba8851afa5f7951520da08a81e657a2d166bbaa51636239e", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "5124f9db-9207-4f08-94ec-787470c1ec72": {"doc_hash": "290decee0d30be7bac09311688405b9b9f4ba638c2ae89aeda5296d616ba5396", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "1073cae1-05d4-4525-9991-9ee2519dc4ef": {"doc_hash": "3a90996fd50f70fba2d3c2cc5f6fe75855c6480702ba987732399bae3ee61396", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "e465efda-9c7c-4ac1-9ce9-c91e2e357642": {"doc_hash": "165aa8e27545ea1c8c80dcaaf67286301e5d3da2c1590772917961b18cd35cde", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "88e86fee-b6c9-4b70-9676-ffbb6fc3f95e": {"doc_hash": "d01a83f5cc4d3427543c944a2239719e6445a2bf700621504d6a143b30f36fda", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "f7e40522-8958-4b01-a792-990660fbc840": {"doc_hash": "60e52e651060b501d051dc6cfe2e8f0e5a6d82ea6662d8d8c124e7a61ef3880b", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "d6fa5d49-088d-4a7b-9976-bad1f278a594": {"doc_hash": "ef7c80c7169af6c2ac952e57e053971295f606316684c457583d50bcd181c365", "ref_doc_id": "1233a304-658b-4c6a-abdf-b127304b6fd0"}, "639bbde2-c738-444a-8dbe-d060890b320f": {"doc_hash": "97fae181c25a55c50dfd34610ce51437ed8f59b40b271069c2bbc9bfaab4cfd6", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "da12aa00-b95d-431b-a641-e05a502f0a2c": {"doc_hash": "ae4c4cfcff427211dcdc8df7e4b424010c675f9b80227134d5441c91c52d7c9f", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "7b94add0-aa17-476c-9fb1-b5c025f1288e": {"doc_hash": "a3b4e720c8529c32c1c99358db790f50e610c47489e745de8742e91c8d3539f5", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "bc57783d-41a1-4d40-a6da-0dcaaf8780df": {"doc_hash": "8003097df08c2967e059935c14c99900d79ba47bca0e40e0fbb0d47289fc0c19", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "09b52429-9f70-410e-a0b3-e304293a6976": {"doc_hash": "77fb2543f59688970445a54436322d7129f238fdff34b26f11585ee5406334d8", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "eeceb55f-9b49-49ae-97e5-9125a4c80952": {"doc_hash": "b49ca2bb1e7f1f55e84aee0cc0bb0758799f7ae3a5967ea85e0e0a2289cc03ef", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "e9e26fdb-d961-4e79-93e2-2ee6b912589a": {"doc_hash": "4c9a4ecb74ab6471f03d0c6709b538ca6a578aa84ba27c990361a154b86580c0", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "f3c4b89a-5b57-4986-ba77-6101a5268d57": {"doc_hash": "01c4ac0e0cea7e82867b64ac9389161cbcc2e0d0321e458ba38117485988bb33", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "29074658-658a-4ed6-a243-f37252aec5b0": {"doc_hash": "d090187c6dcad91060cce09cc5edcc642de9a9d3e87ec1ea0c6091556d01bade", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "f4efe0a6-d8de-4c76-80fc-ba2c79ffda42": {"doc_hash": "8bc729a083d287b9a3d9cfa70eae4729c1f86ce2aa45dd68e8f0cc0aadc6bb27", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "1e0b654d-999f-4ca8-bab7-a53669cd1168": {"doc_hash": "85582cf34a079d58decd2a029d416af71df563b67ad9e062f64710d04f0e44cc", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "4696571d-c8db-4c53-8996-e2254467a960": {"doc_hash": "085b308e4fd820f67b8fae4a6b771ca1321525c54188a124e426a3f0ad071166", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "19fe9cc0-06c8-4bc4-85a5-ae9dafbb85fd": {"doc_hash": "d88ea81c6045508e5fe93c281d09a97dd69bf7ca0e5aa5f2eb72f9f6abc4e167", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "2b8e61ee-24e1-4cf4-ab1c-ce15c08e14ae": {"doc_hash": "246b5e6ca819d606dcf9bbc1b78741a6fde1a3cf8a95fa72bc37f018aa5dc8fb", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "15033c9f-2366-4ec7-b1a3-6c887340c131": {"doc_hash": "9edafb21ad7ac7bb57f310f4f26fe150ea11892557957b726e0dda28c8c1292a", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "1244a6a7-fd05-4271-93da-8f7e57aa6190": {"doc_hash": "1ebf3cdd99618a6c0abf981e2c7a38d84b2a4293d1c8824d0fe22bff2cff2534", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "05af0c4b-f01a-499e-9661-2a5f38f5e3fe": {"doc_hash": "367ae7b52cc1b4a9c714f7115d1792f5a7e9d33ac08da6b98910357cf0c7f6cb", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "d6d19bd1-2b52-49ab-a90d-b9a75d799045": {"doc_hash": "05cb083d2107fd9f92415e222c004d43795a8e5ffab78ea187af9d6d29522c68", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "dfc0a792-4a27-444a-a581-9282deaa5413": {"doc_hash": "367ecb72c71ae530ebd54ab5f78f548f6791d01f8578ee5167fba3239763fa1c", "ref_doc_id": "95e67101-a75f-4bb1-90db-77c354a480c5"}, "cce90874-e40e-47f8-a1f8-12e6745124c1": {"doc_hash": "8d14bb1cf110e94bdd0e80edfb8735176abfc131ea5a8c1512f9b76383d3a883", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "4616da42-fb11-44c1-b33e-2bb6bf87d3c7": {"doc_hash": "e27b0cfc59f69b89f7f352caeb9e042b9c7d6c35d097a53b1d7c5bf6d23a9b28", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "0df23b67-9ffc-4cd4-a02d-fc5be94c2f34": {"doc_hash": "7f584aba97d9442fb0af24f1d0f8faf322f21ce43bcf3f3e390cd5e15b96f44e", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "b4e3b061-b484-48a8-beb6-e83237bf2f50": {"doc_hash": "cfb4de34c5e2137bb85d559306847a7886571760e47760375e1287c9d63c34ae", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "a6229201-76ea-43c4-88a1-ba8b12608d65": {"doc_hash": "2439672a114303c25c8624da6ad55cef7bd868e4b27d2f91fb64b0675b9c7e9c", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "96354ca1-349b-4d78-8f32-3024cb0584c4": {"doc_hash": "8745e5bedcfaaafcef737ced003bebbd3c511a734362f3efd371339c29d91117", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "fa6c671b-95da-45a3-bde0-6c83e7b67b6e": {"doc_hash": "d26c8b7d05de62466eea3aeaecec83d0908f6458b4da90203bfe2acda33704be", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "75b1952b-516d-42bc-9aae-ad8f1e5f2921": {"doc_hash": "49847ceccb11f6b68efc18ccf024764c529415f8670bbd0a328692368d62cd22", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "0ab87a29-63f5-417e-a8a2-b1de9946b30a": {"doc_hash": "82ed6134d9d08a9383e92e2752c36396eaf5cbfc697960487529a76e08960d19", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "8858d96c-ca77-4cfd-99ef-e7cf11a2c1d6": {"doc_hash": "e97904a216bc79679562fa820451f224cde2cf3ab95cc16b58ca8398433706b1", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "4b7d7afd-2966-49a7-ae61-8a2d7b1c14bb": {"doc_hash": "9581fb468ab91c30285e0471ea97e41e1826ac3f49f60a1d7915395e1bbe51af", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "8feeaceb-de1a-4400-ae08-0c8c0396ef8e": {"doc_hash": "0c4d037c4ae9c222983dadcf7e0c08cac89ad82a722c17376363cf31e7b5adfd", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "51d1da03-1880-41e4-870d-b4a29ddf729e": {"doc_hash": "8e2f4ef4842322821bdca23147c0904dbf34f0caf26e56ae206af5f89c35acd0", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "c1607c3e-9cca-4b95-b17f-7b1828a6cb8a": {"doc_hash": "23bc049177cc5d1d15eeb67567560da5fff15ee5b566dfbd5b97182e483b84e5", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "336749ed-4751-44d1-a990-724a6a4f1069": {"doc_hash": "f2707b0fa63615a2b592804ab362f3dadd02c9d76e0502752ab748aa5c6f6cc6", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "55bf3ded-e792-4123-9373-05e6ae4acdc8": {"doc_hash": "04fbf0ad265b1d626dae6e5d2e35e7526aeb2c2df9a3e5aef7971f14a7efe89d", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "ed9db687-2cf8-4819-890e-441b50527efc": {"doc_hash": "cb297bbb755928a355c19edc8386fe69b94fa89374f830c3e8d355c7d03f6b50", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "0991d865-ffa1-4532-9443-db7e8f0551eb": {"doc_hash": "f5dd2e65dbfe1e2cd1c8376bd686e999ea90568f6304dd2e45e22d6dcce993e8", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "46e20b61-5060-4c61-937f-4132ab6a7aae": {"doc_hash": "83887b37af0c28855110d78186e928df087aca641f8fcb0250e92c4b3c3d495a", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "8bf8b295-4777-494b-ae35-6d516ff38c94": {"doc_hash": "5e9e38f01393175bde3c460628aa137061d8805fac4335af94a2526d04462723", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "4a7d0677-cbd0-496b-8d1e-d9dd1c65e512": {"doc_hash": "a97ff069d6c1e3f9d8b97919e6d851a3d2e6e717777def6c8d3c49c22572dc6c", "ref_doc_id": "f38138c0-cde7-4d8d-aae7-0a83bc9c21da"}, "acf4c530-b1d3-40f7-bc8a-da910acd57a0": {"doc_hash": "094b0fab4fd2dc3b7a52c2cc093d848030c656c327d9a4acc83397586fc85ce7", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "e1c600cd-86a6-4fcd-86c6-a2cdf0c7b25d": {"doc_hash": "73b7960c0ec8d45b16d7328243261d56db075c2e4e768da19d8b8f3f3ad34c3f", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "b46bc18e-472a-4a77-b44b-999a852f1bfd": {"doc_hash": "f3d904af8fcf79aecaf57a9b62c0f07fda5125a0ead0c78a31246780e6456005", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "5cdca9ba-7e5a-49ce-ab60-caede40f68aa": {"doc_hash": "1737fd8f363aa7f979f826dbac33102c430bf5cf73af1753fab7522323e9ef40", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "980294e3-431b-44c3-b2ce-fe4807172267": {"doc_hash": "dd06d99640a1a6e083cfce1ee16b25ce4d8971ea8e4c7c63ef53b0f21155c218", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "87931d02-335c-42db-9601-06c551e37dee": {"doc_hash": "d23313b4218dc1c3ac695300081878901b89f20f9a21ae020f1ae70d586d57fe", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "66335f33-bc7d-4111-8a9a-847897b30481": {"doc_hash": "35ec91f5b3f09857fb2b60d8a3d791beb023da1d2e5a26d177823bc3ee5afbe6", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "e2f49dab-af55-4ada-b0e4-73415f0a6d41": {"doc_hash": "b5a0655182a5147f3ae4a5983c34b9a4653e7ed4adb66bc4956a69b83c392449", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "55503605-18c2-474d-aa20-a119f5e2eb46": {"doc_hash": "6daf854e56a68192a85b77503efdaaff8ab6accf9d4a855931ffcf158ad1aaf2", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "f6f76547-f46e-4e4e-ab6a-de53a1384069": {"doc_hash": "8a746ca738578f3baebcef20f10c6ffc030ac0cc3eb22b88a75ec4fe4c514313", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "dc09c02a-8256-4e3b-836c-d6d065c1e0d9": {"doc_hash": "a6caf7840d022d88db156556b4eba6cb990e6abecbcc4faf0dec032dd8cf6e6b", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "4b19c9f3-c3c5-4bb7-8e9c-c504a901d137": {"doc_hash": "5f83c54066e82813173ee69fec113dbc97da4d777781e838282ac84844ce3ab1", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "564ed94c-9e0c-4a66-9899-f6e9ab802976": {"doc_hash": "fc6e759d4cd65f1f38906e1e54d7a4f3d8fcec273460eb77f3d8a48032758d70", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "9f4d8b6a-9c71-4477-b1e8-48860c36a312": {"doc_hash": "35872ef6be3635796fa169bc83dad140e92d56e105dcde9797a2400fa5f0db7d", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "cd4d2f16-208e-47d5-af01-a64978644e09": {"doc_hash": "41e877239656e832cd287df7df1e371f5dbcca44a4db337cff9e6c9eaaa054f7", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "f5fb5d17-2c39-4173-a05b-7613b3bdc82e": {"doc_hash": "2547d7d30e02004e7cd6d6616bb25cfb1d5af56006cd0313567ef2eaff13dd58", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "1134da6e-4e18-4447-8859-a613f448b045": {"doc_hash": "50d8899e13c04ecee6b252c32516499043e8c8c17b1ec633e2b44a904d89a7b0", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "9aa5ec17-5700-4e74-a32a-eef33e9f8793": {"doc_hash": "5950f39aa10b551d2e46a818b9da5678bc2c88b50b2db00a41f485c97a41a822", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "14285215-cfa7-412d-8a0f-5fe857747f62": {"doc_hash": "72f20fb40727e3de2b1164d5e28bece772758dea738cfccfa4c0fd7d89009ad2", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "4015eeda-f065-428d-8a3c-26eb644e97be": {"doc_hash": "8282edb5e1aa05d41ae1e68a1bb740854f5cdb3787607c202f41e0e222993e6f", "ref_doc_id": "96878c1c-63fe-489a-a010-49bb089f92ba"}, "79e9e2fa-396c-4d1a-9dfc-5a98f2dbb278": {"doc_hash": "d3ec0ce90d53d12324e043d67259babf286bf391a037801705a05a8e9322a753", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "33e489ea-d46f-4ad9-96f5-cded31d34c49": {"doc_hash": "3d1c46c212b5d1fbc3cc2877f1462d7df64c95b53713445e23ca9d30fcb63079", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "5ddc3da3-19b0-4715-a592-fbdb832d2d2d": {"doc_hash": "55e095b1c1acdc8ab34f629577ba2d3038363a7c25c45f0b9fab40a9573c5f4c", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "6600a5c5-640d-4a28-b997-6dc9fac60f69": {"doc_hash": "59b84fdddcdeedc8b12f4e52e623999ec7382d3859c8400da3aaa59982aa963b", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "d6fe9835-ebdd-4107-b7f8-fff83e9f6907": {"doc_hash": "bd5f290e4d6f493925da11e998906be673d4d93b934e7212d8889294a94996e0", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "0095e074-aa17-4851-9bf0-16af8583a376": {"doc_hash": "0383557ada1d1aa0336a01926bfce44eddf16413767f70070ab9071c318c94dd", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "20292e99-b9e8-444b-87aa-4b7c6ef651c2": {"doc_hash": "301413225934af7739b164a760e7f5444e9c85ebb9f29ee31c9d01123b2fe7a9", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "afdc40a0-2acd-4f22-9eb4-23a9b59a0b30": {"doc_hash": "d018477daf912369c293cc1a3c027f90c6175268cde3ddc76dee04c285a8cdc8", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "fea7dfea-602d-42f0-a86a-3c67d71dcdb6": {"doc_hash": "8734ecdd25869372c77e19e9d9bbd6840b8205627bd9cd977be5ed4892272c64", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "4529007f-78a4-42a9-9e6a-1a65394f5383": {"doc_hash": "08946320f3201f25ab1b607858b947c812767e720c96c20a58686db0aa508250", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "01771693-41da-42cb-a7d7-eb8582cb6b77": {"doc_hash": "a5d6373c32350b92128c40ca3bc78dd59c0892002364bc91f7b111b71852d47d", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "5a21cfb1-3485-464f-a999-7d769f1c9c6b": {"doc_hash": "169657348de82ede0700c8e8255a0dbd659734e88cfe374084a01134e61a6e7d", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "919c2e7c-94fd-41f6-be0b-f5d74273931f": {"doc_hash": "70ce55d1c7eedfcb00516726f2e506339434e194962b4fb93f21c8570798f8c5", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "228d19a2-5ecd-4efc-aa3e-097bf17ab12f": {"doc_hash": "1dfc1b02dde0a65add2a99c7c41b9c66b1989426260818f74c647c9555a09175", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "107e9590-764a-4972-aaf0-0c5015acab24": {"doc_hash": "b05831ae505bcb923dc36694f3d989663f10ba25a0b04deeb4f5cb6b71de7894", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "38927753-5255-450b-9612-1d9165ba4a23": {"doc_hash": "5a0e72951a15f4fd102022dd20d22c3bb20c37fd647b71e1a8b58c8d1642a449", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "57aa9b66-6b57-401a-96e4-21bfa56d9d5a": {"doc_hash": "cf90af28145a81b685ab1d9407eb9a2b79fb82bdce351b6d9519b01fa977fb6d", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "22531a03-2104-485f-a2cd-3bb4e85c471e": {"doc_hash": "4196d804ddd2dc7fb2a0b235c6d7bc3a914bd2a0ce4b6f3596394f4a27beba03", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "0d85dbb8-1a5b-4913-af1b-9da406f36748": {"doc_hash": "f95dbdd1d500ac9452ba7a28006601509c8e91368bda5a6f2f497b1540941b93", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "5a77d7f2-9ecf-4b35-938c-ece5c879480a": {"doc_hash": "f1f96134f894b73574eeea74dcfd4430f11d7be6282078e047768c560563c40b", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "ee2de254-486f-4498-89ea-8c04c4229aea": {"doc_hash": "9eacadd3908c80e0b8eae760d1b72160a744b4a32ed580f4318a18ef74366eaa", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "d21b9620-cd26-4d34-8300-d7f018294301": {"doc_hash": "5f4a0e16a0d6a3c9b2adba9447ce295ff3ac3edf7605c150ad5ff94990a48506", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "168ce4c9-ba9d-4467-b16c-24c7fe96061b": {"doc_hash": "9e2200cebc43dd426e58b82b2c0c3a01b8c2cc836a7b56cdfb343ed9edab2ec9", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "7a713cb1-34c3-4137-8e6f-b7834a77db56": {"doc_hash": "2eaa099eae4bef80b8f68a7a6d4cd7d43a5ec5eb4c446b37a4b6718f51b0f96b", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "52706fb1-58f4-48f8-8a86-5d301d160f71": {"doc_hash": "62a22d5d660539d3f00dc3db0bb3956cbd463d036e1f13b23c801afe4ce22396", "ref_doc_id": "3442b7a3-9cc1-49ba-8462-1941aec0cd54"}, "2199d210-8890-4d09-9dc1-851ecb8fd171": {"doc_hash": "26bccef7a37c4fd1229ec4d184d46a1c143f0903cbe69bfe1e3616ab80b1b796", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "3fe48257-8615-4d1f-abd3-587290841f8d": {"doc_hash": "25a3f443307babda3f3e4779f3508e1b0a1ffd059d85515598878d88487061fe", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "326d4427-95cd-4dce-8022-c5bac9e9a803": {"doc_hash": "4c290ef8acdcb1d79dcfd4f163b06c5a477d535aed2562c0a4e26f3fd4e48ad3", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "7ff9b0d4-2927-4da0-b9dd-9098a1c6119c": {"doc_hash": "fb6d66aa992bec64ce68c8ce6b9238e3bbad97d72d5e1e9bd74e38c1e8ec4d11", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "782e5dd5-f2d5-4637-8d57-4484e5441752": {"doc_hash": "fdd8e557a6e198c0df33b233ccd1256a982d9d56a8ac9fec6f9aca2835d7f19c", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "e10fe546-f601-43e8-9547-8750e8f8f027": {"doc_hash": "71c42cbeaaaf9a91ba036b7f28f76dbab37b9e8b3c6a175f28f6e2df1428eeeb", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "3fc8e2b2-a762-4432-9e9c-bb36c16fa5ca": {"doc_hash": "71f5fb462f1394f6fccda79c1252b0506072a0fca713a71225fca6484e231709", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "05bac6d9-a8f9-4209-89a6-ee29542b71a8": {"doc_hash": "5cfc20c709803237d85b8832e9195e721f5ec70d42a3b903148072d717a77fc7", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "ce84c58b-6f24-48eb-bc91-ce4f5f7c48b2": {"doc_hash": "a28a4582c5f55e9e694bda8084d2c1be87baa28356595f3710c9b9dc732fdacc", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "400d773c-803d-4114-aa87-c24896bdd27d": {"doc_hash": "0b0a64d9949490b4f4026bdb0c2b40ce9de381be9261ea6c31f3145d3b245a5f", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "538d26ea-92f3-49ed-a9b3-779c672baf6e": {"doc_hash": "8025394cc4c670b3882b5ea9b397621ea2d8b2f5a1120b1e7e38b74a5b80eb0a", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "16edbd6e-2394-4d30-803a-ab4ee2310210": {"doc_hash": "9e41a47600542d76bde3896320342f07c55ceb9212ea9ebcb99c86bdaa52c615", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "73f0232a-1cd1-4529-af24-fd87eb8d0930": {"doc_hash": "be2e271ab97a7c5ec7430c733fa962f7eea656a5cc267678dc4c6b8391a5fa4e", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "fc6eea4a-1d86-434a-82a9-19632fdd8268": {"doc_hash": "a1a7f01f71cb53839519d25ae3d955ae1383e21e971987a877f6b85fcb334566", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "70a9db09-ee43-44c5-9203-70d08a7a7b49": {"doc_hash": "b77cd4b14242850f427d5aaa5ac133d096d23e3186819a9f32a02a4cfc9a3187", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "ffeb1023-396a-4cf0-8456-342887f55d31": {"doc_hash": "1fb63a3cdabf98bdc843b51af665a1266b071a3d4ff1feebabc22a718b425288", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "317d9bef-5324-4d5f-b672-b6c47f0b24b0": {"doc_hash": "14ccc69ffb1448bd6abe5607ea03bd834755ea1d8f63d03016f8761be7eca087", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "56f693a0-83d0-48dc-afec-7c090ccc97f6": {"doc_hash": "d85ab4f11eaaaecb577bc3b79c916cfa0a9c820c5f543ac34bec3813d02b0772", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "7513eb88-4a01-4ab6-93ac-e8e6929778bd": {"doc_hash": "d8bc597266d14bb8e8979cda54de39665f34c9068b8764fdf925fb3c8a57d834", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "3c201eb5-1bd0-45da-a406-2e9ad40fd25c": {"doc_hash": "06854cf69b3571198e2ea536c4d9e2d87bc33897abd479c72318bb842d20e5e9", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "ebff9453-7059-4503-8f62-3462f7b21d39": {"doc_hash": "144392d09f4e3203a852504d3b742cb9a3412b858bc712d41c27d9ce81415958", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "c4d5dfc9-c2f9-4196-9af1-9a1fd302e1b5": {"doc_hash": "569283658c779de8e2f60dbb393bb62b0a4c9b611dbae2a517f56a0fbc3bea76", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "aa0b1047-5dec-4da5-8339-ee88481e3820": {"doc_hash": "4097c83cfd1bbb615c5f0d54cfd1d0dd2092c73c8b437f3d44c8a88ec7b615d2", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "392c4f53-1e98-4bf5-99cd-8f88d5df46c8": {"doc_hash": "483a2e3c3cc4d8749a74467675ba0e2a7d9948562b313b2e098a550dd32b7297", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "81fdefd5-b0e0-46cb-95b5-7b48558c8f83": {"doc_hash": "d13064fda325dbde9a47a6043cc56a06bad10b0e2604ebe663ffa972184dbdb0", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "d4b47b46-cadc-4948-90a7-cee40b093446": {"doc_hash": "d787cea082e6fe3d930696e78231635bb7a1cf287826d6cda27ba4f1dee7d755", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "fd115ace-6499-4d0a-815e-f59d38d638b7": {"doc_hash": "e069f0e91212a339d7c502149354491d96ddbbf0eaf3111be0142c302d96bcbe", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "db60c987-a5d6-44b0-a4c9-1f964f1cc87c": {"doc_hash": "4887c97e86643b6418a1d422db3e89575be8b789d679e011151e787848aa108a", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "ab7bc12c-d297-498d-ab48-b22d197a6fe4": {"doc_hash": "8b5ba7ca2d56c9f86735ab47d2a8f840a2640f31f05e0f1b4eb712b49922bb3c", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "d4d7a7f5-53d5-41ad-a98e-4dafd2774f75": {"doc_hash": "f0bcb84f611b0cf114d37509cf29413ac23b0e05f1b689e21235e67f4967c058", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "e449cfb5-3cfb-4346-9dad-9de6703b4406": {"doc_hash": "f367fc6d30910720660d88d5215c8cf639975b5093340ce74b480d50a941dc77", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "bc7a5024-66d3-42a9-8db7-a868bb91a14d": {"doc_hash": "bec0f53c7394658ab4ceb4eb1100915fcdb9bc5e4810b126f96e5dae20d23614", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "e27533af-ac15-42ab-8cbe-33ae576c42a3": {"doc_hash": "3ee13d252577865ebcc207ee4dac3f6b0b8dc52e54a403ff5475466f78e8c832", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "5e80b2cf-30d8-4c13-9f30-b35eb9758340": {"doc_hash": "472c164a36caf372ec905564c4dd3b9b794c7db5ec6fdd0916aff4d2de457c6b", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "7b3cfbeb-1f5e-4b09-bdfa-7ce78c362b78": {"doc_hash": "77d0195398af76a36267d901b4efc4a02d5d3638e13efbee95915380fccf4886", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "152e0039-1537-4407-9554-331381edd576": {"doc_hash": "25f354d049e4c6886ffc5e831f6cdb972a7a4bb58ae4617249605f938cc0a07f", "ref_doc_id": "f15eb638-dc76-451b-b633-c7320a38a86b"}, "d1bf31ad-6172-4e89-aeaf-553592302a31": {"doc_hash": "b8b131e02e4725fc9a1aa0c8d528982a2229b2cb8ae24c96133b6ada9e3430ee", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "f1bcf065-b4dc-4ee3-b06b-807a0035f697": {"doc_hash": "ad46266012d3a6aef182fb84add37489e08187e2c44fd78310242a0286e34e3c", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "84a785eb-0e16-404e-868b-93870cb5dfd9": {"doc_hash": "bea8dc5c73a3f20406bc6f623ce76acf725fb7fc151d9d1580ef9254612477a2", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "08a6f515-ec1a-4d55-873a-87bdaefd3ac8": {"doc_hash": "49cb4af463f07c007a95a938b39318da966359e9e9aeebed7327e3584e559e4e", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "6feed95b-467a-4ea9-ac9b-2fc040103f82": {"doc_hash": "e379b322a766f10e34069c2667507202956be78160f4734cb63fcf3ac7777b08", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "87ee05bb-6279-45e8-be46-de6b28ecb920": {"doc_hash": "e581e717ddb25b8d64afb79140ac5c3df720f1d21291baa49eeb92d4c35a990f", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "f6a4cae3-b8a8-49ef-94ec-8f0a057e5768": {"doc_hash": "418a59eb3082a7f1e9c67880604eac0bcf3804e3242e54f996aafe5080486f7f", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "3d025279-9312-4c1d-8cf0-6f068f610076": {"doc_hash": "fdfee43d3eb25f04a5c30c5411db61bd87ec47044d6b7833ea9381184a058eb1", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "cfe39b14-d909-4995-8df5-32d01c8c8788": {"doc_hash": "d97c2a4d724c14fb87c53d8882837b4bcb97a84510b8852ab46c5eaa79175b34", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "706c6462-b6f0-47ab-9ed5-d4e67807c037": {"doc_hash": "cad352569db5c9414f33e4bb1361d595899a8d8fe22a29c009d70ccfe59573be", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "4fef52fe-6b92-47b4-8872-91498a17c889": {"doc_hash": "73e8fc2b5e95ceae615a7affe7a8af275cbe511211fdc9db114d3a50bff0dc13", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "b94e1883-c671-4d4a-a096-4df1c5a24d9a": {"doc_hash": "62bf2992118393ad8ffa921ba86194be7e671f209e5463916ab80acb7c0a5586", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "d3eb804f-0f21-4cdd-9756-e789f6d0b377": {"doc_hash": "614bef2eaa72fd4f4c04e457c421d53d85f026eec1db788dedf54097779d3eee", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "b8e57fd3-e2ea-442f-9242-ffb4a87d8a10": {"doc_hash": "ee8be7e2ee5be4768278974203b9c7ef3612d567de65b01754bd091167a917ab", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "cfc10a99-1064-4cc5-aad9-5a83ac42082e": {"doc_hash": "83da3f32149f4aee1a35596580c84ac602c5f774f471953b75cb1fecda1c5509", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "668f8cf4-6a69-479c-98cb-454e774545d0": {"doc_hash": "413558b700fdcd460f847494af13782acc92360b29602512346bb04d02fd85f2", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "08944901-1bbe-4797-bdfc-08ae5ed539c1": {"doc_hash": "b6dab837f781f6c9c5e06793e1c22f36fe9138079267b378ccafb86fd6657799", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "e9cd71c6-2b65-4880-a434-4985814d71a4": {"doc_hash": "5788ff34865b71dc7e56da17fb7cb24fa6f7510993db5836b80887fd701db5d9", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "75dc8694-6a23-402f-b53a-9e25f3f0a1f6": {"doc_hash": "972adb9d9c07543cc2dc110c1c9360faf6cbf5ee88b21992501e108e5963bce5", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "39911401-345e-4e20-8fde-3976e2e66029": {"doc_hash": "514e6f86bfac8352d87b7343d57ccaaad4a87e9ee6aabe9fe984e4ad5e9f95de", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "b7386ec5-7b42-4a29-801d-fb630a5850fd": {"doc_hash": "53840deb789393473f478d12c60a8bb2daafa87c867f3799ca99938fdf8d6edd", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "69614c16-e5e7-4757-9622-127a14aa5749": {"doc_hash": "07c4a1fa673a61d7b7f12edd9966986114f5ed85a48999994c3ae632ac30be74", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "75b5098c-adbf-4c4f-aa81-50e3270bca1c": {"doc_hash": "06d47da013030c5fad8bc1fd46c6245b0776daee2c54b8a4b4dcbe004da756ac", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "a5a1ef6d-4628-428f-a8a3-505cb49fcd2f": {"doc_hash": "47c902fc6f24eabd88189858aea97408d3bce5719b824451c090ada8e39fcf5f", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "175ad5f6-0682-4999-8c84-718741d462f5": {"doc_hash": "2676773d3c8b39135edf935c315d81c4c567e5ec7a372579517d783953e5ba31", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "ceca0f69-f08d-4f93-840e-6e0fcdd16557": {"doc_hash": "f013156b40e711aa93890f1475b29351faef8c335fe15a8c131c1d775aee68c5", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "8195483c-0a2f-48dd-a378-6eac470f0e72": {"doc_hash": "edb5ea8bc30bd6377c503b265455c689189df38f6984b3234618021011085711", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "41088301-30a4-481d-8b3d-8a522e567e85": {"doc_hash": "d44c3b909edea16125f3f295dd193180a60b22760b04466a392dc63c07ef1138", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "6009caef-dede-4a04-8d7a-a18fafa78785": {"doc_hash": "1e367be095d9487d20d46e57b15c49f92241d48e2d3aed555f0eaaf23e0b4218", "ref_doc_id": "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833"}, "5f4dca8e-d7e0-4067-930d-ef0b9b993ef5": {"doc_hash": "5b5d23466384ed7172518f244850077077ac1e19ceefba172acf6f5308aa3191", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "c5b30864-646c-4c4b-ac6d-960fd3ca5431": {"doc_hash": "9a6c6d8dd7b0aa5b5310d6c02553ffafc1a64b6cc9a732f9c4bb1a5ef9798aa3", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "734e0d3c-b8c4-451e-b2e4-37b56dee3b66": {"doc_hash": "bc13429d6d0ccddfc899e6af39d4cb2c7a8763e49f3c8d53e4d2488035bfc616", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "174fb136-eb98-43c3-a076-c1d801b8af87": {"doc_hash": "869c27e74aeae30d3190824616c2293ee55507b2b558c71c471c1349d616cb2d", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "4f729f5a-86dc-444c-bbe5-784d7fa77c02": {"doc_hash": "d9870676f5babf575ebc5e4f8718bc594fba1fa25bba5c29688280089e9f324b", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "93483ed4-6648-4019-a431-1cacf77dcf8a": {"doc_hash": "0274a0803b4b1c70bd80f00978b29e12922b3dc885e364b7a5b3b439dc2eebb2", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "142f5614-f5a8-4fc6-a814-927e814e87c3": {"doc_hash": "30990b8954f3586d20faa48751efeed1908e34eb83f4f61e0d6db23f5e7a1372", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "48eb11bb-9dd5-453d-a19e-e19924838840": {"doc_hash": "cb47bed4d7443306700fa01c418c0cb0d56a0647b553729637a81d87ec3e1dcf", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "2363fd63-c463-489f-88fc-3ee37a98b99f": {"doc_hash": "27f318ea7a585fe4d10e094a34e3fbf66b60ab67ec28cf644421254408f18f7d", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "005c668d-04e3-4614-87ee-a3a406b0b57d": {"doc_hash": "a4beeb9a94abc627161ae95eafab08b3a11ad4fbf3dedc13d30c0a6b012e3f7a", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "b8fe0524-dd80-42c1-9d61-ffc8158543f7": {"doc_hash": "9d5e0ab5734ce2f5fcaba6660bc680472b923cc8d83d2dc5106591cdce8e4b64", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "4dcb51e0-c35a-4905-981e-2839ba4a2ae2": {"doc_hash": "7c19f398613631e5a5c0a0f7aff41d5929ed686e78f4ad923a21ed2de8cf45f5", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "4eed7b2d-2550-4b33-bb59-c199653725ec": {"doc_hash": "27c7b8832ef13212cf9a0948f864bed3d85b52dfa9af19deb1302533454ea9d4", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "a468c4ad-8994-476f-8c49-ecd592f67e4d": {"doc_hash": "a072ec48cc17fc8093f2242a1da0d92d7c3e4262117a18be8588523b1cf49923", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "411062d7-8277-4cd2-b0d6-ff0b9ee9b9bb": {"doc_hash": "21075877c1fba612ce95f037ca01d69cea8b4ed3926373b22cd508bfec73c56d", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "d22ce52a-11c9-4755-b161-4b444c80858b": {"doc_hash": "b7bb95792a68a79d31269a01cda05738681dd0a474b468f25154841e886227a6", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "5c739590-7b2d-426b-8e27-811a82806ff9": {"doc_hash": "4f684c22aa3c0931adfca3d6f976182fca12ce70346230bea350d4b1774f2dc7", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "27043ca3-ae5c-4fd8-a517-5f507cf49092": {"doc_hash": "6860d6b17d904eeeef9c1bcc39d99e77b16b07a1e554f13a876ee557abde1ec4", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "f8b58df8-7408-467a-b0b3-2dff384fb988": {"doc_hash": "8f50a9a297b039b661049da2ed673fb6e33706c7fa43ae690ab98cf4f4351ab7", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "54dd4a26-8718-445f-abbc-6d0e5e1295e0": {"doc_hash": "e1e9745c38f08bfb088fa33038a9c39dcab3b9a6fed88aba814b5bc4ff14eb1d", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "9193c411-95c7-47c0-926f-4bfa80d95397": {"doc_hash": "2a8c9c5a1e53ceb52f0cbdbf2333d7aa3e3f97644f5f56f7b210ded7a5029f16", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "35faad6b-b88d-48fe-b996-4f6a814182ab": {"doc_hash": "76dfd81a63f70318fd35b139144e7396aa217809493a49b584ffd2e375a59481", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "a5b57186-1ac2-4771-a653-87604d5f5cde": {"doc_hash": "09dd36a956817ff44ac71e4a4ed4fbcb2fc7d72407537e9f32435a186ad66960", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "bde680a8-eaef-46fb-a72e-9c818966ae87": {"doc_hash": "f62b220afcfa6bb76871274a66d036df36bd54633a91e137427c1f4e0292cd10", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "28ccd561-e427-4571-8f71-752e516aed31": {"doc_hash": "db4fffee97fd708fbf38f427931d6e80931ca566430c0e91e8c64ad695c4c1df", "ref_doc_id": "efd6bb26-986a-4d51-93b1-55e299b81335"}, "10fd6086-9752-4af2-82e1-2e332da96d37": {"doc_hash": "3853f4fe7f75cb9c207566513b42a6e7661f2256c9a5f0fb6d5054e95c3a880c", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "18a65ffb-1d13-4747-9cfd-bcc09e065f5d": {"doc_hash": "32711e5765500b277be666dc459e3c7e88a1c13f70afd91ecfb9df0d6e300892", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "1bd89c31-1d87-415a-8839-e0b3047fe935": {"doc_hash": "24d197e2812a1381b3af89bd43621ff1df55944222968204aad8e152a8ce8738", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "848bd998-e467-4627-ac0c-971702f44b46": {"doc_hash": "6070c02623b9883cc2bd3b4dad3ceeb3159750c102fa4f59f87c9bfef0aab53c", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "502e7132-aef7-4bdd-8884-52a33d324d5c": {"doc_hash": "e5bd38851b08a5facb1a216e98e0aa60b53dad98ab667f0d4d9d931160ea268d", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "e837febb-4dcb-4667-b7b8-3ddb0ac4b6c3": {"doc_hash": "adf53365579c7ab0ada7c41eba3af154ccb7d5907f7df2156ea15a1d695849d2", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "79d43d4f-88dd-4937-bd49-375e14da41c8": {"doc_hash": "ff98ede025ce1efe3664e9781950852faa6c11a5f21767ec335e50c7a169b3ca", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "7a9f75b5-8358-4079-8913-424c15398830": {"doc_hash": "e2aa0a33d9861aac9b9b6be059a7bc7f988deaab32902ff59db5088dad331420", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "67e5a6b9-1c1c-41b6-8d04-8fb08548e6d0": {"doc_hash": "39780b00aa994bf9ee9882f2fdb7c37323b4600be7b6a7b7f92c70e385bbec3f", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "a8ba5e9e-6d9b-41de-818a-b9ce34591aa8": {"doc_hash": "6d763426b546cbe89b9d37529b883d20a6733cb86b5cd3f1c5149bcd0579c131", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "0b3e8dfc-e836-442b-aa1b-cb5bdf4ea61d": {"doc_hash": "aa4ec92b41d836bea6a0ce29bfe10abb3cba733bbc10be84371ebc85d6ed0ca5", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "cb8c48d5-8487-405c-a893-0ca7e709574b": {"doc_hash": "2f651f91022ae3d3d1814513feed5d23fe27c7992e3be0b607c58595ca1fe38b", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "5ae81690-6ec1-42ee-b7f1-60f1179e2c97": {"doc_hash": "0b390d0a2f7ef51a8646d7057f07f34716b64a07265b2b0b8321f47897ebed74", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "4ce21810-6094-4ba7-b893-b11e34ba19ae": {"doc_hash": "39ba428b1a365b634e0be0be00385294c554cb8edc8da917fcdfbf5de129c8a2", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "a7351732-92aa-4f52-b2af-c5d5a6f0f09e": {"doc_hash": "d5a85e9f181538066bc9794bf80a0968dad132fba5210920b7bf215f7a8a591c", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "55830972-b324-414a-92ae-1fac08b87b79": {"doc_hash": "87df49dc4608f65592542257bbf410e6675f30f3490b6252372445c714d03f3b", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "64fab53c-d357-48f0-b1f3-bb97ec60938d": {"doc_hash": "446729fb53d672fa0fb661a92f03d84b132123bbc95cea3c79019cc6ef72b180", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "cf5d5949-48ac-41e4-a4d2-5fda32eef62d": {"doc_hash": "4c0d8f4a1e20b776374884a77326889b8228bdeede6d6324dd1285ee34c6ab27", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "492db601-eb30-4567-a79c-d9581c409918": {"doc_hash": "d40d2f052a152a74810842109b400693b378c83a0c8c2181c3d6522631f3693f", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "c74f8374-2175-4ffd-88d2-54bd55eba4e2": {"doc_hash": "6f0ac4c3bff4d1734bcb9d95cc9d0964960085031a5bc9944c3338d0993fc8c2", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "f24601ce-4d23-4700-9217-c1d5ad57e9c9": {"doc_hash": "1150aa63d47cdc6acfbba43861beb4d329257a9503ca026ab8231c793ee94629", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "e2e3c825-ab7c-4192-81a3-e0b5046bfdb5": {"doc_hash": "1228ccf77285215e595415b36583c6de059c0a2109ed09fb519f468486665340", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "5f7264cb-2c85-46ac-915f-d762756803f2": {"doc_hash": "891501d6499abbb4c28cc250161faad18dc217c63f0b4e0f56d2c0560cfed6c6", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "a3b1a0be-9159-4138-8dbd-d7282373e7f0": {"doc_hash": "0ea7a4544be54a72635dfa0f4ba69c3940f84fe50ded8c939ddffec0bde67288", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "1d1bf75c-d5ef-4dc4-b837-cde6de64ecd8": {"doc_hash": "debf9b37d664b841dedecea13fe3a68250e95d4d8fbd9397bbb6ff8c1ae5c269", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "6fe5ba65-8aea-43f7-b5d4-3e2f28d3a852": {"doc_hash": "ca3e9bffe90c46841a3c6255e49c19de078a29e801ae879a644ea79d25e7ffcb", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "33b6c668-803e-4aeb-9bb5-6770b2c31dc2": {"doc_hash": "8b340b15a82ef2c25604864d6ef4e05653f7404d04fc177b7e7c1407f21dc483", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "08521c34-9876-4e5e-9e80-4482df39a9fa": {"doc_hash": "dc4c316734d1ccefbe45939ff27f2a08f35d9ac97e0a122e0a0b0024ac1e46a1", "ref_doc_id": "0c9c9e66-2829-404b-ab52-860dfd1160ab"}, "c187c0d5-e62f-498b-a8ef-213e6dcb606f": {"doc_hash": "20bb6c429f87657b4a5270929fe23df2afbd66398e3ca43753e80c789cefb874", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "ee780fef-b232-4dfa-9a0d-e3a961aad3ae": {"doc_hash": "34b216f7c7af605ee0b7ebc58cacb9e676acd7d844d779a6206f8ab3d6b8d297", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "a142a726-ded1-4aa4-966c-b75ae8e61fed": {"doc_hash": "43b3922c579db19647abc60f02c2482d88b7bd2b97215cfee30ea60a737c5aa6", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "e3d3e48b-7fde-43da-a46d-d4452d92ce37": {"doc_hash": "e103f6289ea639618d81deea4a71facbc41960c60b5cdc07caee84497335b50a", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "b03c4c3a-c305-469d-b285-e90f3cfdc9c7": {"doc_hash": "b0d364ccfcdfd1cc627241b7855a7a1952629b89c5fde368456cdf344e1a7ae4", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "7b026a08-23ef-4c5a-b80e-d49b6052ae91": {"doc_hash": "543c3c323806c0960363340c38c6df3cfd3014bb04caaf9b40c90078f46085f9", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "09cc708e-d13a-4de8-bd10-96c99e6c8108": {"doc_hash": "1b9cf39cdeded322777d1c46f7e6156272571a1c5299f1c846c2d6337c218ad6", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "ce7b62b2-cb0c-4d7c-8648-3964b20f3b5e": {"doc_hash": "1f8d137de60aa7d2021d9af897d818d3f98117cd1dc3bb7039ba9e1a727bbf9f", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "540d116c-9002-4f50-a8f3-b1e7215c18bd": {"doc_hash": "9fbe63f5a508034542e5bae76926fb51847e542d27e71aeb4182adb670e6c163", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "f432debc-bb6c-42c7-bcef-61ec1dc82a57": {"doc_hash": "038128b871c6fc323114c4da2d5d6bb49b821011bcad4602f1b561a20b2e656e", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "4a02e310-14cc-4f49-bbf7-8642082b9cd4": {"doc_hash": "8b1e0d998f2fd418a4d7b5cb8cbda5a1fd4c96cb7502d3e18893b6bc3754c108", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "9a3a3fd8-3062-4ea1-af3f-30ba2766bf53": {"doc_hash": "42babc6d2c93fb9d73328e11c0467ac41ec2a1004d766c67536d3fb9d55c05e8", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "c788372c-36a7-41d8-b831-ce95355cbdf6": {"doc_hash": "0eaf99b34ccef80d6547aef2480d2c68ead61d37602be66fc5dc4d6f6c475bac", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "5f617382-29a9-4b9e-94fc-0aacdb11b9a3": {"doc_hash": "8d01942ad39c1f024ae4914cdaf102939855ca8c784178a3eb3746c12ef179e3", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "c0d18af2-1d3b-4aad-8506-16a4c1fa0011": {"doc_hash": "921cdddca941fcd8f6b60d6e102842f21a59e38f9dc7a6a7bdc669ff1ebca356", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "fdbc3545-6f63-4a65-8344-289f47dbe258": {"doc_hash": "17ec0534c5ccc379c6dd7904a6c100a6789986260bf8d3795dbc3e5529807cb4", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "7eb0c9d3-129a-48f2-ac23-af546a9f7262": {"doc_hash": "df39712536aa74ab00c1881d60dd2f146d09fe0a20819b702c955332b9c95aa7", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "cf1a0140-3885-451d-b242-438a8a09342e": {"doc_hash": "d9797f09bdbe703732e3dad0c639a20f317146425d33574e375cc6caf3e3502c", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "25fa851c-5ec9-42b5-b3dc-ec119d4f3d4b": {"doc_hash": "efb9976b8cf0b7d55051974595fbf1c3f7fe80fc26a0810a3b51063596e5faa6", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "6f45261b-47d8-4e28-a337-814f48f8c627": {"doc_hash": "088e2e45c75f803cb9af5035467ff1fcbefef4a9cd1a5bee58cb2d278fcd5ad0", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "242da652-62b2-4400-92de-126d0250dba1": {"doc_hash": "b787d4cdca8f08874c29fcbd5a5754572078b4da7d99ba76828cdd25dbaf8faf", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "7984f3f0-af84-49e7-8070-f4341885acd2": {"doc_hash": "ac0200e6ac386bdaa3cfa5b353ffc30d9aa5fa215b60fd63a949ff051bee6d1e", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "14372b84-8d5f-48ac-bf61-429c93925862": {"doc_hash": "4e13e458046a96278464d29e608681368c5a03462464836dc03b1183d445fe2e", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "e03289af-e433-4d24-8a18-247c4e819448": {"doc_hash": "7f1d0a987f05411afdbc8056bb451cc93e2036e987c127cdd5515894a5a914fa", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "a5d9a8bb-faec-45ef-b2b3-2696fc41d0ad": {"doc_hash": "c2a28ab287b7eec7cb77d81997b4c01e4442f7169d3b445482c4a0adbc1ec2ee", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "93b5a1a2-c705-4553-a85b-59612dcbe693": {"doc_hash": "9c612f72f4335eacd41b86f08679ab92758d09e3c7cd4ae621a929b268e4a0c5", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "d41eac65-9e1e-4da6-8d93-97039f0c0847": {"doc_hash": "102ebaefcbc730c2d96c3399fafb56d913e5d7c7abaf024bbcb0ed60f4a1004c", "ref_doc_id": "5f435ce2-0de2-4f6e-9572-496e2ac0eb21"}, "dc53abef-a3bc-4379-8dd1-b0e7625931d1": {"doc_hash": "41a8175053f81ea18bdebddc199c3c3e9da9433899eb555e29a65e0298be7d90", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "bc74bd7a-4e9f-4ec2-8ba2-22fb337f9b17": {"doc_hash": "f5e1f742975fe72c2dbdd42df5d990aebf373ef725a925a2564b1ccd7e27dd94", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "fb3b6212-de9e-4b65-afcc-bb9788f8a451": {"doc_hash": "0277a48c8915f523427af7ee1f5aee3fec9eb22ca23fc27f974c2892e35ecc0c", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "8cbd1d7b-4570-4f80-a4e4-926f42d0d9c4": {"doc_hash": "cd7563ef96dd49b62daeb18368b0f54cb102eff3e09cac00c22dbaba8687d396", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "bbe5ad37-a5cb-4788-940e-ca985e9f0b9d": {"doc_hash": "65864f0b25150ccf8520d270a5a4e387b4ab765d81a31bb04b85517b8ccef3ed", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "12e26e5b-c053-4ba5-b502-b2a808524502": {"doc_hash": "892c411ba9a4f7b2ce8d9df15b9a365688eed3894c3d529a8945e75e95099deb", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "d970352b-ccf0-464e-85e0-08bf99c5025f": {"doc_hash": "f32cec265e2bac4ed79f45c323a52867d342de1225cabe4ef9fc8e84f38052bf", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "a2e1ec62-cf91-47e4-b82b-7d78ccf75ba4": {"doc_hash": "7a4d6bf0fb5bc17ee72604c197bfcfcdd67cc91f47a3ec5e9df3572462abe462", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "f2624fe0-c463-4dc3-a606-c4c4f7ec96de": {"doc_hash": "060848ec00687fc6753080b3d717ab9b1c133715b271b04c7141dd6936ed81ec", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "80f22916-2dca-40ce-92bd-6d1a17dd0b10": {"doc_hash": "02435b31a374e00b806046002d656c64ea5839408d20d54ff5753cedd2554be1", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "98938a9c-f69f-4cdd-903f-71983353c915": {"doc_hash": "fad794ef72f28e04b356fd2ff33cdf3eeb553d1d96b5ba16c33984c3b95fe6c1", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "115e4179-db99-48b1-ba27-b04a6d612c0c": {"doc_hash": "b6e163da9ee5cb47bcf4fe0543a4fb20ae01582e855c6cb97242694d49323df8", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "18de233e-14c1-4cbd-ad8f-744beb1ebe04": {"doc_hash": "6b95f1953e80fd6931ce104f693753bf3fd7db2ff6afcc9363202174b5c2ca54", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "1149bad5-2953-42e2-a5d2-09a40ac2c984": {"doc_hash": "30e799122cec80b03ca27f0f7f1c7a8be5e3be06b1d69f2ed7847c05d8d43ccd", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "29904156-561d-48b8-9c7d-14e7504edb68": {"doc_hash": "0ceff69ab9a9c9cf905577d8486180abdd045e495ab790f083ba2b96157691c7", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "ebec3a23-144c-4acb-98f8-1fc11c4a4d52": {"doc_hash": "128a33ae2681c99a458de7e41c53014f57a435324246cf5c4ef21b4a369ce8b1", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "8b050892-1e27-4c26-8861-e3777de8cfb5": {"doc_hash": "f5e1b85f48cc52b26b349d7e9d6be5c119c27e1155008fb05ab3b9c1aa93ceff", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "314ff37f-7ddf-4457-8937-4cc7d653527b": {"doc_hash": "d9b779872bc55e055ee05382d07dd4cef2cf506af4f6695572d461cbb9715237", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "7d8311d5-a03d-40e2-8f19-18247d794a5b": {"doc_hash": "61b7591c0d759a14292af66264801f3ea3626b1b87092623592a2504077c014a", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "63621525-573d-4bea-a05c-916450909efd": {"doc_hash": "6ccb9c83c89c19f8169e61c5e651041cf85cf005fdf43ab5b41780c731dfb13c", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "cdc5a6fe-9499-47fe-8886-47f2aa41e0d6": {"doc_hash": "419dfbf6ca6e62d81079f6db848a34cc79e2ab3c384e9d009f53591e2fab2382", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "1b6d8d9f-4c6c-498f-9f85-70b4f61d977c": {"doc_hash": "03e390333931511e18baa7be4bb4b334a47cf03371b5a0c656623aaad3df79c9", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "95433123-6936-498f-aa23-a05612bf5201": {"doc_hash": "8c1fa8786fe9453bd7101c21c6c26d486f0183c849c52c3418f998941ce12f07", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "8f3b0fbc-c0b5-45e9-9dbd-fc9bfc66a179": {"doc_hash": "05b8be10d9c0d57570fbe521d45e50070385bb76eae3eb7872cd7cdaf47d016b", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "651a79aa-2cef-42c9-9b33-fa963e44c334": {"doc_hash": "41b60a195fd537d3cc366398bd98b1601043973152be56f08b3aa2adaf7294c5", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "91ced30c-7e09-4605-a889-7b04923895be": {"doc_hash": "94760e65f51079c2f415396b9644c31102c9b142e865e3a7b85f6727ae07f185", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "6e6a7616-1852-4887-8062-7379ded08ed5": {"doc_hash": "cd0ddb494df6e4038778a306124a6f091b2880489192a85f5cf2da58a17de625", "ref_doc_id": "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0"}, "60fc38f5-5a2f-45d3-994b-a1aa8a049333": {"doc_hash": "4eae3b3ddbcab4c39fd0c83426ff913a223c3a23ee34f76b25bacec7e6c9099b", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "1f97dd12-6204-4427-a1dd-745ed9bfb51a": {"doc_hash": "19a19f79a56faf27038368e2a0b0ce9d69e74c5346977fa89084cc1ba4e1c569", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "7417b4fd-2cdf-46e5-afb5-dfce19501216": {"doc_hash": "30953eca4ad453927a66feaa1e68be8fbb95beddc1015e9b9a5b7e38c8f36be1", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "a2687cd5-ed96-4490-b7d5-e1538c79f191": {"doc_hash": "5ea100894d07f0371ba118bc1cdb4f9674dedc676cd5bc3d300b412f31b2817e", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "9c8e036d-6e84-4b0f-8f9d-c04af802b870": {"doc_hash": "14261a190c2e2b41fd6e6b67e1f871b866e9e9d5a2fc0bde0478ef774b87226b", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "7ffe1cad-101e-4862-a245-278db58af059": {"doc_hash": "1a3d7f210b67ecd40f68421e476ef196ae1b78b54134a2f6790b6867b83ff3a7", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "4aa8a53f-814d-4298-ac6e-f4c02776d0b3": {"doc_hash": "640c64fdf58a41eb2b3c95fdc0356d8844fa96fdd48e30c2d5a6ef37bdc2588e", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "55e7830e-5902-4dd5-88d0-ca0e325e43b6": {"doc_hash": "2579c86650148c4d4efdeb93971cdc33d3bcbd33ac5c8f3f2833ef04d93dd46b", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "b9e63d24-244a-4836-a2fa-e01cc2f54c2f": {"doc_hash": "400a13df51c6a0ed49c4dac333efb85c780f487951b941b5f0d257e3c97531ce", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "5afa2743-a110-45f4-b65b-33f3a7ae48f4": {"doc_hash": "e1795a6606e39da361cbc4f47ee6ff8b8378bd3ff77d86a58725ecba031f44de", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "c8631960-1ab0-463a-9142-3f38c23f8243": {"doc_hash": "c357fb3224568ce0c515a4ab862fb40c15985f61dfca314a35f58b83268434fb", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "f3e7894e-c5bb-4618-983e-62300724676c": {"doc_hash": "aaa5993c02a543b2a76342cfbb3c4616d025ac6d82029e64d35869386c96c515", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "7af4239e-9256-4a7d-bbb6-956e529b5361": {"doc_hash": "393a5fde390053d86b5899ec1ac594c246d96d5277035eb30ea3436c8a82863e", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "8afc9909-5c74-45ec-8f38-aa4c27b715bb": {"doc_hash": "49a3298ed5713c8403bb94a8ea88862dc3048cb60a7425f0de65bf0bee6a8eea", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "e7fc55fe-912e-47ae-b2b2-05ccfd456e01": {"doc_hash": "e549f966524b61935bbbaf038f5c87a034db44f31a6dc74b4bc87eba358c6685", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "a2c83701-b19d-4b12-8c10-5aed890b9c97": {"doc_hash": "45bf0b9f7cad991a7ff0107a4e14f73203990566926accb0ae01a42994005e11", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "260a3118-dc2c-455a-a5f2-210a33b4d8d7": {"doc_hash": "f24a64a0b1ea5e49c417c731ba2115fb63366e9a0aed6147cc7aeae283771261", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "6b9adfc2-b39d-4c39-b4b5-7c62b6d6bdde": {"doc_hash": "5b2e3d138c9e95d20fbc50a138f9b18b4b1a6ee9a4bffdbe3ba34ab462edce77", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "7b74a88a-cca3-4cbb-85eb-06f6c4316cbf": {"doc_hash": "57667b39ad185feae69838ba720c9928210337bf183832a93c76eb0a0cb174af", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "cc16f267-bf77-44ba-9e59-52f8b0928acc": {"doc_hash": "06736fe4cb05c1ad9ade0a21163e76253d2406cd2278ba9535b8880d4d370530", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "0ee013b2-7c03-4616-badc-ff1cb982eddb": {"doc_hash": "3b48cd75fd98f5959ed8c9f6fbe59f704bce91bcb24cac4531d5820039148e76", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "3d820e2a-b586-4d27-a57f-16a4ed67b4f1": {"doc_hash": "bc3d7d7df137515350e098e7fd31e657edba8354d9a9faec38c79043c812cc41", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "6edf15ac-bdd7-4131-914a-77c6a9d9c2a3": {"doc_hash": "22d170dea4a123690f4e4a3692c2b665562d3ab2d7f966b01853d0e98deb1a42", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "7382c5d5-17de-42e3-88ab-b3719eba1438": {"doc_hash": "9e844b204fc27ee37055596f4b3d0926c8706920a366ba31dffdcb7e81baf055", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "4c9b445c-1b4c-4ff2-a1c1-6b0f53dcd228": {"doc_hash": "1a1764001353f50c5ebfbb72f93d99e2a1dad3e3eeb0bd922a8557d94b896c75", "ref_doc_id": "e5d7d494-e527-4934-afb4-d787af208173"}, "46c1e1fd-836c-4441-a991-25777f6a5147": {"doc_hash": "709c62334251059e57ee0cfc273a86677668ae9c918ba35aa1ebdfbee133edc3", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "441b655d-de18-4cd5-8c8e-a5ab1ed9394c": {"doc_hash": "79f72c3c2613d8e670785d71a589ae70f30282a95ecbb3ea46a8d791bda47ced", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "948d3f28-1168-4b69-9576-91be5603d3e6": {"doc_hash": "762443c66f581fd2014a98a2d768ab1d324998efa9c020f431f201470054dfdf", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "1caf2ea7-a042-4f4a-95f7-a64efd44b451": {"doc_hash": "a95abfade70c338c25705464359d75ba8f4004f7898bafb0934c1700e7ea1e59", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "2de3c250-0902-4016-a502-55df04f9a4d7": {"doc_hash": "34207a40b711ebbdc126cf8ae091c0163e75d89ee8daaf1d6220ff814aeedcaf", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "fe8d1e64-5e02-4334-b873-ffc1168334c1": {"doc_hash": "f18200bd3ae9351adfd27947d1dae53396ea84b9d4de10252fbd4fddafc6b478", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "8e669c7e-689e-4161-a566-b58a1fbbef7d": {"doc_hash": "fa12e6cd551228fa07d24da3ab816277f19a7a77457df785e0fcd9d4888ae0d0", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "7cf68cad-2b10-4e71-8c41-e46c52b7b78a": {"doc_hash": "c4bcc428507b32b71fe2991a809ef8855940b377bc5133555c368388776795d2", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "23cedf18-59ad-47a2-ab40-cadddd6b6f69": {"doc_hash": "446747ddbc9de4b7449142d94a08aafd8d41764984c8cb5e1fe4b2615ab5160e", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "46ee6961-c57f-483b-958e-7506b0c43ac7": {"doc_hash": "64342a5bef2dc283e1bb68951bfc3ddac05e710c7b84b5f93d92c9d52914009d", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "d43823e6-b0cc-475c-bfad-1b0a1b32003b": {"doc_hash": "7af1a1c65bf514030c6aaefefc3b7bdd04bcdf50c4e4c34296cd6359cf2f50d8", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "f9a1bd12-0adc-4fa1-8a83-271f79b51b00": {"doc_hash": "83c0c19c831349746591f0591a725e521c9c1352e4109d66ae2faf3da6fe5ca3", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "91766bf2-4259-4daf-ad53-5819439c1fda": {"doc_hash": "ce2b04b3c154ebfb7da37b04c88f7e4dcb8e04cdc019ddf50473177eede6df8b", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "8a4c68d3-30b1-4090-9c4c-702cf9de646e": {"doc_hash": "b688fe42596ee450e868793b9addffd89da07b0d5a40bb592a6aff2443ce91b2", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "fd45d807-0fca-41dd-bad3-f39c2559808d": {"doc_hash": "dfb9ad0bd812564d97a3c7e51534e8947c80554a873b5b2696f8abccdf41a291", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "9fe4bba2-560b-4661-acb0-e4c9d8bedaa0": {"doc_hash": "75fc5dac70efd2f4f223b23f2c3eb1ef62ec6961fe755fb759f0585499979823", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "de3a6515-c093-48f1-9814-1d4e353c7eb9": {"doc_hash": "afa6105151069150a52f29b1bc3ff9bb14d5d5daf449d54ddfbc45c31234ed29", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "30f5ed19-d44f-4d13-8ef2-664a0b82baaa": {"doc_hash": "f6a4460e5890d2638f142e0f16ae98e1f3a4611689f2139ec76d87c81f2bd30b", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "7deda3b4-a76d-4165-aba9-286567c99ab5": {"doc_hash": "b4bc476790e5649c0ab65f8de0a6da0ff023ce282bd7d523f256bdaa4f6a7f9c", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "e1523910-8893-4a92-99d9-a5a54afe7af0": {"doc_hash": "45dc7ca32bba77350a7514558b2259b8038817596dea3043d2f1224478edb57c", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "e096a3f7-27a8-443f-947e-73bce4e0b0d7": {"doc_hash": "cf0e5c63fb6c19928d070b64985e01b86560236645610edd56ee5b2fd2b84fe7", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "9f6a0483-cc54-49f8-9e9f-11b697bffc08": {"doc_hash": "98f49dacc6f7002255262d638da8229411c5d0bcb50eb3136d20b5b83b6e212f", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "ae854fa6-104f-45e0-98cb-4ae85c037624": {"doc_hash": "848c000d98be30dfa0900e370dfdcfeaa7825ae59ff0b2d3b591850e5dc27e80", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "f09a94bc-95c3-4a68-a90a-11c1d4f70fc1": {"doc_hash": "9d202fa487fe949b7cee0fd05eaad83d9a09504a93e43def6fb16ddac72a79a3", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "4deba78c-210e-4b97-9ff6-a12eac4cd50f": {"doc_hash": "9cebd8420edf067ac1e9d575d850d17d1e13e765f08ab5951d12421872b12a1d", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "6b801413-9682-4ac4-8c50-7cc4b2ba89cf": {"doc_hash": "a589279d41a1fa7acbf61265fe132a7d94c22b68137e350fe14831fedac44ded", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "7df36e58-fc22-4a46-a005-51e33aeaf01d": {"doc_hash": "22189086efb13f39527b958429c686f723ad1561c3b11159366ccce3eff2c80a", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "285033ad-ae6d-44dd-8e13-9d5b23750b89": {"doc_hash": "92e5fd15b503c8d94ccd9b982e4efdc4437a62b33a7969be09f09f0d0383fe2b", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "b37932f1-29b1-4ddc-aabd-c3ebee267372": {"doc_hash": "76a03663c797221982da31d8138a73f403fa03534d5def20f5cdfd9b36a81993", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "513c3172-109f-47d6-8c24-c6f674c746e6": {"doc_hash": "55d8bc1677e2b8b56d99e3ba7bdb1dc2be9375ef1f99f83871adafb9f4d5b78b", "ref_doc_id": "48da569c-0288-4ee9-9e1c-c413a5facf60"}, "1a708b81-a11b-499b-a286-74fd9b8df405": {"doc_hash": "df197ec400a4e3a274152e33585913b7be9351bf0c3d4f9732949ef22ff44120", "ref_doc_id": "07d3e18a-9dcf-4042-9746-9cda9da75453"}, "e8271a98-7f07-4f43-be31-88734dfa1adb": {"doc_hash": "f9ed6fb6929131372f4f079393b33731202a403b2c1b685643be31b8b50bd9fd", "ref_doc_id": "07d3e18a-9dcf-4042-9746-9cda9da75453"}, "fdec10bd-72fa-4b1b-ae48-cbb4f24ac20e": {"doc_hash": "88d129cf9a90e56a9fc1627071a7a2496c4f5298a863d4e8d923f56e393fefee", "ref_doc_id": "07d3e18a-9dcf-4042-9746-9cda9da75453"}, "c8b46b99-bcf0-45f3-ad2d-47f3fe50e825": {"doc_hash": "c0010f19b400760f909675598b9458352e3dc07b45281770c5ae4fc32cc006da", "ref_doc_id": "07d3e18a-9dcf-4042-9746-9cda9da75453"}, "52c5e7cf-498d-4370-ba86-41cde14a20ed": {"doc_hash": "9444edd293a27d01d942dfc98d19b14e340291794ce8524b0761e1ee78937a36", "ref_doc_id": "07d3e18a-9dcf-4042-9746-9cda9da75453"}, "4c40949d-f235-4954-bc79-4cd82a4c7375": {"doc_hash": "182d2043fd8fab12f3e771246f6d2bc0102ff9e0b2508538920287a5549d282a", "ref_doc_id": "07d3e18a-9dcf-4042-9746-9cda9da75453"}}, "docstore/ref_doc_info": {"bc0f5e3f-cbc6-4a59-bda2-7ce8289a5beb": {"node_ids": ["2553057e-9a75-4883-a326-74d477110ea3", "3d177c2c-1f0b-4001-89b8-425faa236d85", "2f13c8f6-b8d5-4c7f-bddd-d8388ca24d60", "cb8cc38c-12a3-4cd5-be6d-9791abf746fc", "2dc59d3a-6986-4cf2-bb92-90ad4e22ad05", "332e3b3d-6b6b-4c16-a6d0-9d162aa8bdd0", "94128a65-ab91-42ef-9478-f16acd98a297", "81d63427-dfe2-4b92-891c-a8476aa1fb8a", "4f03a76e-2e72-467d-b8ce-bee41ab22fd2", "20cbafa4-e967-4467-9f0c-908a90f98eeb", "3d3540b0-c9c1-4ad6-892f-68f78f54cf04", "3dbf84d6-74ad-4feb-a47f-02332a62401f", "c97c48db-2936-44da-8d31-f829ef3e63b0", "0b2f1848-4dfe-4e86-84dc-13784103c386", "0520f4a0-408d-4ca0-a732-1e0b1b2ed924", "04d5bcf0-b6de-4469-b155-bfdd4b861b40", "13d355ca-64c0-4f55-8179-3bca87b26645", "468fcdd1-16cd-4d6d-9c82-01e191f8aead", "d239d995-8b72-4d03-a34b-221645003780", "02555899-8709-4fc0-8e27-a904aef8bd82", "1cdbc185-6356-4814-ad8c-abf3719216b8"], "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember  5th, 2020 8:30AM Eastern  \n \nKevin Moran:  Good morning.   This is Kevin Moran, Vice President of Investor Relations.  Today we \nwill discuss Cardinal Health's first quarter fiscal 2021 results along with an update to our outlook.  \n \n ", "original_text": " \nPage 1 of 16 \n \nQ1 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e74e24cd-a9c0-4c59-bd87-4af1219bbf0d": {"node_ids": ["a4001bef-1faa-4490-8674-88dd49a058ee", "4bae68ad-40da-40c5-a50c-ff447fdf5b5d", "cea47fce-df81-44ba-85ad-27b3b85abebd", "f5a7d44d-9e44-43d9-8146-82fee1816dba", "dc35820c-ce63-4d85-8e7f-e4ff0a423ffe", "9e44a36e-1297-4f96-8b6d-3e6f61d48c38", "8f7b168e-b369-4849-97b5-7cebb47a324b", "2f052e21-65fa-435e-b8fc-448186084662", "68f85312-726a-4673-9eb0-8ee2e5a2f79a", "341294fd-3e6b-498a-bca7-0fafb433c230", "4faeab45-6e19-4a72-914e-dc0fb88a29db", "f086f2e6-8f35-4133-96eb-ff626e854d5c", "be0914d9-88c9-4121-bb72-fc0ca44814fb", "cd18ae82-9dae-4137-86ab-f4bd0cb7753f", "81b5d8ce-4618-4ed6-82cf-46b5e92f96c2", "2ea71a39-231a-4a1a-8451-e77579c3cffe", "8e286e1c-fa5f-4818-add4-7ab92b4a9a52", "44ef3ae3-ec68-4e71-b2c9-9168b2053585", "503cb4c3-a98e-486b-adda-e78d7df31eac"], "metadata": {"window": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.   Overall we \nremain focused on serving our customers and their patients as we optimize our core businesses and \ninvest for growth to fulfill  our critical role in healthcare now and into the future.  \n \n  With that, I'll now turn it over to Jason.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  ", "original_text": " \nPage 2 of 16 \n \n As a result of the strong start to our fiscal year, we have increased confidence in the full year \nand we are raising both our EPS guidance range and our medical segment outlook.  ", "page_label": "2", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1233a304-658b-4c6a-abdf-b127304b6fd0": {"node_ids": ["5772d814-021c-450e-a227-77a126e8d8da", "2ba668b2-e5a4-46c7-a048-d03b7902f02b", "75b4ea6d-c196-4d82-8cdd-8ceb64e0353d", "2db8bcdc-058f-4a34-95ef-d2d390139b0f", "9218e891-ef4f-4464-a3c3-6b30734bce56", "f9067a12-4afc-43c1-91a3-1fe484218092", "599e79dc-fa86-4c3a-883b-8ec7bedfe130", "6e6e2578-5c88-404d-b637-e0267bcbc912", "6669fb65-e6e8-440b-9386-a7fd110a285f", "5f76c634-2d95-467f-b0c5-73d513a6a56c", "f8d6e949-0588-45fe-9046-940e60f06be1", "43efa39c-4bb4-4c84-a578-7e5f924d4de9", "1aa968f2-515a-441c-8984-3bbe713f6ab2", "5124f9db-9207-4f08-94ec-787470c1ec72", "1073cae1-05d4-4525-9991-9ee2519dc4ef", "e465efda-9c7c-4ac1-9ce9-c91e2e357642", "88e86fee-b6c9-4b70-9676-ffbb6fc3f95e", "f7e40522-8958-4b01-a792-990660fbc840", "d6fa5d49-088d-4a7b-9976-bad1f278a594"], "metadata": {"window": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n First, while elective procedure volumes were still below prior year levels, they ramped -up more \nquickly tha n expected.  \n \n  Given our portfolio's general orientation around the OR, this volume improvement resulted in \nincreased demand for many of our higher margin offerings, including our custom surgical kits and \npatient recovery products.  \n \n  Second, our lab busines s, which has grown consistently over the past few years to product \nportfolio expansion and favorable market trends, experienced a tailwind from increased demand for \nCOVID -19 testing products.  \n \n ", "original_text": " \nPage 3 of 16 \n \n The following factors contributed to first quarter medical performance above our expectations.  \n", "page_label": "3", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "95e67101-a75f-4bb1-90db-77c354a480c5": {"node_ids": ["639bbde2-c738-444a-8dbe-d060890b320f", "da12aa00-b95d-431b-a641-e05a502f0a2c", "7b94add0-aa17-476c-9fb1-b5c025f1288e", "bc57783d-41a1-4d40-a6da-0dcaaf8780df", "09b52429-9f70-410e-a0b3-e304293a6976", "eeceb55f-9b49-49ae-97e5-9125a4c80952", "e9e26fdb-d961-4e79-93e2-2ee6b912589a", "f3c4b89a-5b57-4986-ba77-6101a5268d57", "29074658-658a-4ed6-a243-f37252aec5b0", "f4efe0a6-d8de-4c76-80fc-ba2c79ffda42", "1e0b654d-999f-4ca8-bab7-a53669cd1168", "4696571d-c8db-4c53-8996-e2254467a960", "19fe9cc0-06c8-4bc4-85a5-ae9dafbb85fd", "2b8e61ee-24e1-4cf4-ab1c-ce15c08e14ae", "15033c9f-2366-4ec7-b1a3-6c887340c131", "1244a6a7-fd05-4271-93da-8f7e57aa6190", "05af0c4b-f01a-499e-9661-2a5f38f5e3fe", "d6d19bd1-2b52-49ab-a90d-b9a75d799045", "dfc0a792-4a27-444a-a581-9282deaa5413"], "metadata": {"window": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n  Next, on Slide 8, I wil l move to our updated fiscal '21 outlook.   As a result of our strong first \nquarter performance, we are raising our earnings guidance range to $5.65 to $5.95 per share, which \nat the midpoint represents 6% EPS growth from the prior year.   We are reaffirming the guidance \nranges for each of our other corporate assumptions.  \n \n ", "original_text": " \nPage 4 of 16 \n \ndynamics within our generics program which, excluding the impact of COVID -19, was a net tailwind in \nthe quarter.  \n \n ", "page_label": "4", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f38138c0-cde7-4d8d-aae7-0a83bc9c21da": {"node_ids": ["cce90874-e40e-47f8-a1f8-12e6745124c1", "4616da42-fb11-44c1-b33e-2bb6bf87d3c7", "0df23b67-9ffc-4cd4-a02d-fc5be94c2f34", "b4e3b061-b484-48a8-beb6-e83237bf2f50", "a6229201-76ea-43c4-88a1-ba8b12608d65", "96354ca1-349b-4d78-8f32-3024cb0584c4", "fa6c671b-95da-45a3-bde0-6c83e7b67b6e", "75b1952b-516d-42bc-9aae-ad8f1e5f2921", "0ab87a29-63f5-417e-a8a2-b1de9946b30a", "8858d96c-ca77-4cfd-99ef-e7cf11a2c1d6", "4b7d7afd-2966-49a7-ae61-8a2d7b1c14bb", "8feeaceb-de1a-4400-ae08-0c8c0396ef8e", "51d1da03-1880-41e4-870d-b4a29ddf729e", "c1607c3e-9cca-4b95-b17f-7b1828a6cb8a", "336749ed-4751-44d1-a990-724a6a4f1069", "55bf3ded-e792-4123-9373-05e6ae4acdc8", "ed9db687-2cf8-4819-890e-441b50527efc", "0991d865-ffa1-4532-9443-db7e8f0551eb", "46e20b61-5060-4c61-937f-4132ab6a7aae", "8bf8b295-4777-494b-ae35-6d516ff38c94", "4a7d0677-cbd0-496b-8d1e-d9dd1c65e512"], "metadata": {"window": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.   The estimated total \ncash component for Cardinal Health would be $6.6 billion, with the majority currently expected to be \npaid over a period of 18 years.  \n \n  Considering this accrual update in the dynamic global environment, let me remind you of our \ncapital allocation approach, which we are prioritizing in the following manner.  \n \n  First, we are investing in key areas of our business to enable our strong pipeline of organic \ngrowth opportunities.  ", "original_text": " \nPage 5 of 16 \n \n While the definitive terms for settlement continue to be negotiated with better visibility into a \npotential outcome, we accrued an additional $1 billion pre -tax in the quarter.  ", "page_label": "5", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "96878c1c-63fe-489a-a010-49bb089f92ba": {"node_ids": ["acf4c530-b1d3-40f7-bc8a-da910acd57a0", "e1c600cd-86a6-4fcd-86c6-a2cdf0c7b25d", "b46bc18e-472a-4a77-b44b-999a852f1bfd", "5cdca9ba-7e5a-49ce-ab60-caede40f68aa", "980294e3-431b-44c3-b2ce-fe4807172267", "87931d02-335c-42db-9601-06c551e37dee", "66335f33-bc7d-4111-8a9a-847897b30481", "e2f49dab-af55-4ada-b0e4-73415f0a6d41", "55503605-18c2-474d-aa20-a119f5e2eb46", "f6f76547-f46e-4e4e-ab6a-de53a1384069", "dc09c02a-8256-4e3b-836c-d6d065c1e0d9", "4b19c9f3-c3c5-4bb7-8e9c-c504a901d137", "564ed94c-9e0c-4a66-9899-f6e9ab802976", "9f4d8b6a-9c71-4477-b1e8-48860c36a312", "cd4d2f16-208e-47d5-af01-a64978644e09", "f5fb5d17-2c39-4173-a05b-7613b3bdc82e", "1134da6e-4e18-4447-8859-a613f448b045", "9aa5ec17-5700-4e74-a32a-eef33e9f8793", "14285215-cfa7-412d-8a0f-5fe857747f62", "4015eeda-f065-428d-8a3c-26eb644e97be"], "metadata": {"window": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n  We are deepening partnerships with patients, payers and manufacturers to meet their evolving \nneeds and expand our capabilities.   We are also investing in our operating systems and digital \ncommercialization capabilities with a pipeline of AI initiatives to lower our cost to  serve and provide \nfully integrated medical and pharmacy billing solutions for our customers.  \n \n  These work streams will make us uniquely positioned to lead in the developing, interconnected \nhealth -at-home space.  ", "original_text": " \nPage 6 of 16 \n \n In our at -Home Solutions business, as trends and technologies accelerate in the increasingly \nvirtual world of the pandemic, we are focused on optimizing our product portfolio and enhancing the \ncustomer experience.  \n \n ", "page_label": "6", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3442b7a3-9cc1-49ba-8462-1941aec0cd54": {"node_ids": ["79e9e2fa-396c-4d1a-9dfc-5a98f2dbb278", "33e489ea-d46f-4ad9-96f5-cded31d34c49", "5ddc3da3-19b0-4715-a592-fbdb832d2d2d", "6600a5c5-640d-4a28-b997-6dc9fac60f69", "d6fe9835-ebdd-4107-b7f8-fff83e9f6907", "0095e074-aa17-4851-9bf0-16af8583a376", "20292e99-b9e8-444b-87aa-4b7c6ef651c2", "afdc40a0-2acd-4f22-9eb4-23a9b59a0b30", "fea7dfea-602d-42f0-a86a-3c67d71dcdb6", "4529007f-78a4-42a9-9e6a-1a65394f5383", "01771693-41da-42cb-a7d7-eb8582cb6b77", "5a21cfb1-3485-464f-a999-7d769f1c9c6b", "919c2e7c-94fd-41f6-be0b-f5d74273931f", "228d19a2-5ecd-4efc-aa3e-097bf17ab12f", "107e9590-764a-4972-aaf0-0c5015acab24", "38927753-5255-450b-9612-1d9165ba4a23", "57aa9b66-6b57-401a-96e4-21bfa56d9d5a", "22531a03-2104-485f-a2cd-3bb4e85c471e", "0d85dbb8-1a5b-4913-af1b-9da406f36748", "5a77d7f2-9ecf-4b35-938c-ece5c879480a", "ee2de254-486f-4498-89ea-8c04c4229aea", "d21b9620-cd26-4d34-8300-d7f018294301", "168ce4c9-ba9d-4467-b16c-24c7fe96061b", "7a713cb1-34c3-4137-8e6f-b7834a77db56", "52706fb1-58f4-48f8-8a86-5d301d160f71"], "metadata": {"window": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n Mike Kaufmann:  Yes, thanks for the question.   I'll start and then I'll turn it over to Jason.   First of all, I \nwould just emphasize, we are really excited about the efforts we're seeing in ou r medical segment.  \n \n ", "original_text": " \nPage 7 of 16 \n \nmost sources for potential upside -downside or  what I guess maybe on the downside are the most \nconcerning or the most risky in terms of  how to achieve the various levels of that profit expectation?  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f15eb638-dc76-451b-b633-c7320a38a86b": {"node_ids": ["2199d210-8890-4d09-9dc1-851ecb8fd171", "3fe48257-8615-4d1f-abd3-587290841f8d", "326d4427-95cd-4dce-8022-c5bac9e9a803", "7ff9b0d4-2927-4da0-b9dd-9098a1c6119c", "782e5dd5-f2d5-4637-8d57-4484e5441752", "e10fe546-f601-43e8-9547-8750e8f8f027", "3fc8e2b2-a762-4432-9e9c-bb36c16fa5ca", "05bac6d9-a8f9-4209-89a6-ee29542b71a8", "ce84c58b-6f24-48eb-bc91-ce4f5f7c48b2", "400d773c-803d-4114-aa87-c24896bdd27d", "538d26ea-92f3-49ed-a9b3-779c672baf6e", "16edbd6e-2394-4d30-803a-ab4ee2310210", "73f0232a-1cd1-4529-af24-fd87eb8d0930", "fc6eea4a-1d86-434a-82a9-19632fdd8268", "70a9db09-ee43-44c5-9203-70d08a7a7b49", "ffeb1023-396a-4cf0-8456-342887f55d31", "317d9bef-5324-4d5f-b672-b6c47f0b24b0", "56f693a0-83d0-48dc-afec-7c090ccc97f6", "7513eb88-4a01-4ab6-93ac-e8e6929778bd", "3c201eb5-1bd0-45da-a406-2e9ad40fd25c", "ebff9453-7059-4503-8f62-3462f7b21d39", "c4d5dfc9-c2f9-4196-9af1-9a1fd302e1b5", "aa0b1047-5dec-4da5-8339-ee88481e3820", "392c4f53-1e98-4bf5-99cd-8f88d5df46c8", "81fdefd5-b0e0-46cb-95b5-7b48558c8f83", "d4b47b46-cadc-4948-90a7-cee40b093446", "fd115ace-6499-4d0a-815e-f59d38d638b7", "db60c987-a5d6-44b0-a4c9-1f964f1cc87c", "ab7bc12c-d297-498d-ab48-b22d197a6fe4", "d4d7a7f5-53d5-41ad-a98e-4dafd2774f75", "e449cfb5-3cfb-4346-9dad-9de6703b4406", "bc7a5024-66d3-42a9-8db7-a868bb91a14d", "e27533af-ac15-42ab-8cbe-33ae576c42a3", "5e80b2cf-30d8-4c13-9f30-b35eb9758340", "7b3cfbeb-1f5e-4b09-bdfa-7ce78c362b78", "152e0039-1537-4407-9554-331381edd576"], "metadata": {"window": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n  We have procured these higher cost PPE inven tory items, but it's in transit.   A lot of that \nvolume is in transit.   So we know that we will be incurring those costs.  ", "original_text": " \nPage 8 of 16 \n \n Going back to PPE as it relates to the rest of the year, that is the one area that we do \nanticipate having higher net costs in the second quarter, versus the first quarter and that's just due to \nthe timing.  \n \n ", "page_label": "8", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8d0837d8-364f-4e9e-b9b9-e5f77dcb5833": {"node_ids": ["d1bf31ad-6172-4e89-aeaf-553592302a31", "f1bcf065-b4dc-4ee3-b06b-807a0035f697", "84a785eb-0e16-404e-868b-93870cb5dfd9", "08a6f515-ec1a-4d55-873a-87bdaefd3ac8", "6feed95b-467a-4ea9-ac9b-2fc040103f82", "87ee05bb-6279-45e8-be46-de6b28ecb920", "f6a4cae3-b8a8-49ef-94ec-8f0a057e5768", "3d025279-9312-4c1d-8cf0-6f068f610076", "cfe39b14-d909-4995-8df5-32d01c8c8788", "706c6462-b6f0-47ab-9ed5-d4e67807c037", "4fef52fe-6b92-47b4-8872-91498a17c889", "b94e1883-c671-4d4a-a096-4df1c5a24d9a", "d3eb804f-0f21-4cdd-9756-e789f6d0b377", "b8e57fd3-e2ea-442f-9242-ffb4a87d8a10", "cfc10a99-1064-4cc5-aad9-5a83ac42082e", "668f8cf4-6a69-479c-98cb-454e774545d0", "08944901-1bbe-4797-bdfc-08ae5ed539c1", "e9cd71c6-2b65-4880-a434-4985814d71a4", "75dc8694-6a23-402f-b53a-9e25f3f0a1f6", "39911401-345e-4e20-8fde-3976e2e66029", "b7386ec5-7b42-4a29-801d-fb630a5850fd", "69614c16-e5e7-4757-9622-127a14aa5749", "75b5098c-adbf-4c4f-aa81-50e3270bca1c", "a5a1ef6d-4628-428f-a8a3-505cb49fcd2f", "175ad5f6-0682-4999-8c84-718741d462f5", "ceca0f69-f08d-4f93-840e-6e0fcdd16557", "8195483c-0a2f-48dd-a378-6eac470f0e72", "41088301-30a4-481d-8b3d-8a522e567e85", "6009caef-dede-4a04-8d7a-a18fafa78785"], "metadata": {"window": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.   But for the other elements, you know, we continue to see relatively \nconsistent types of dynamics there.  \n \n  And then as I also mentioned, and Mike touched on as well, you know, as it relates to the \nunderlying cost controls, we feel really good about our performance in the first quarter.  \n \n  Some of those were absolutely permanent and a part of those structural cost reductions that \nwe've been putting into place for the last several years.  ", "original_text": " \nPage 9 of 16 \n \nJason Hollar:  Yes, I don't think there is too much more to add than what I just went through where \nagain from a Q1 to Q2 perspective, we definitely anticipate there being a gre ater headwind related to \nthe PPE recognition of that cost.  ", "page_label": "9", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "efd6bb26-986a-4d51-93b1-55e299b81335": {"node_ids": ["5f4dca8e-d7e0-4067-930d-ef0b9b993ef5", "c5b30864-646c-4c4b-ac6d-960fd3ca5431", "734e0d3c-b8c4-451e-b2e4-37b56dee3b66", "174fb136-eb98-43c3-a076-c1d801b8af87", "4f729f5a-86dc-444c-bbe5-784d7fa77c02", "93483ed4-6648-4019-a431-1cacf77dcf8a", "142f5614-f5a8-4fc6-a814-927e814e87c3", "48eb11bb-9dd5-453d-a19e-e19924838840", "2363fd63-c463-489f-88fc-3ee37a98b99f", "005c668d-04e3-4614-87ee-a3a406b0b57d", "b8fe0524-dd80-42c1-9d61-ffc8158543f7", "4dcb51e0-c35a-4905-981e-2839ba4a2ae2", "4eed7b2d-2550-4b33-bb59-c199653725ec", "a468c4ad-8994-476f-8c49-ecd592f67e4d", "411062d7-8277-4cd2-b0d6-ff0b9ee9b9bb", "d22ce52a-11c9-4755-b161-4b444c80858b", "5c739590-7b2d-426b-8e27-811a82806ff9", "27043ca3-ae5c-4fd8-a517-5f507cf49092", "f8b58df8-7408-467a-b0b3-2dff384fb988", "54dd4a26-8718-445f-abbc-6d0e5e1295e0", "9193c411-95c7-47c0-926f-4bfa80d95397", "35faad6b-b88d-48fe-b996-4f6a814182ab", "a5b57186-1ac2-4771-a653-87604d5f5cde", "bde680a8-eaef-46fb-a72e-9c818966ae87", "28ccd561-e427-4571-8f71-752e516aed31"], "metadata": {"window": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n  That is just the timing of some discrete items that were all anticipated when we established our \nguidan ce range.   So we'll continue to have some fluctuations there.   But that does look like, you \nknow, an impact in the first quarter that we would expect to revert more to the mean by the time we \nget to the end of the year.  \n \n", "original_text": " \nPage 10 of 16 \n \n \nJason Hollar:  And one other item, maybe just to make sure we reference this, is our tax rate for the \nfirst quarter was a couple hundred basis points lower than the midpoint and lower than the range that \nwe have.  \n \n ", "page_label": "10", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0c9c9e66-2829-404b-ab52-860dfd1160ab": {"node_ids": ["10fd6086-9752-4af2-82e1-2e332da96d37", "18a65ffb-1d13-4747-9cfd-bcc09e065f5d", "1bd89c31-1d87-415a-8839-e0b3047fe935", "848bd998-e467-4627-ac0c-971702f44b46", "502e7132-aef7-4bdd-8884-52a33d324d5c", "e837febb-4dcb-4667-b7b8-3ddb0ac4b6c3", "79d43d4f-88dd-4937-bd49-375e14da41c8", "7a9f75b5-8358-4079-8913-424c15398830", "67e5a6b9-1c1c-41b6-8d04-8fb08548e6d0", "a8ba5e9e-6d9b-41de-818a-b9ce34591aa8", "0b3e8dfc-e836-442b-aa1b-cb5bdf4ea61d", "cb8c48d5-8487-405c-a893-0ca7e709574b", "5ae81690-6ec1-42ee-b7f1-60f1179e2c97", "4ce21810-6094-4ba7-b893-b11e34ba19ae", "a7351732-92aa-4f52-b2af-c5d5a6f0f09e", "55830972-b324-414a-92ae-1fac08b87b79", "64fab53c-d357-48f0-b1f3-bb97ec60938d", "cf5d5949-48ac-41e4-a4d2-5fda32eef62d", "492db601-eb30-4567-a79c-d9581c409918", "c74f8374-2175-4ffd-88d2-54bd55eba4e2", "f24601ce-4d23-4700-9217-c1d5ad57e9c9", "e2e3c825-ab7c-4192-81a3-e0b5046bfdb5", "5f7264cb-2c85-46ac-915f-d762756803f2", "a3b1a0be-9159-4138-8dbd-d7282373e7f0", "1d1bf75c-d5ef-4dc4-b837-cde6de64ecd8", "6fe5ba65-8aea-43f7-b5d4-3e2f28d3a852", "33b6c668-803e-4aeb-9bb5-6770b2c31dc2", "08521c34-9876-4e5e-9e80-4482df39a9fa"], "metadata": {"window": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.   I think the first thing I think we all need to keep in mind is, \nit will probably be very choppy over the next 6 to 12 months.   It's hard to know how long, but I do think \nit will be choppy.  \n \n  We are even seeing small shutdowns here and there in US and obviously potentially in Europe \nin different spots.  ", "original_text": " \nPage 11 of 16 \n \nMike Kaufmann:  Yes, it' s a great question.  ", "page_label": "11", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5f435ce2-0de2-4f6e-9572-496e2ac0eb21": {"node_ids": ["c187c0d5-e62f-498b-a8ef-213e6dcb606f", "ee780fef-b232-4dfa-9a0d-e3a961aad3ae", "a142a726-ded1-4aa4-966c-b75ae8e61fed", "e3d3e48b-7fde-43da-a46d-d4452d92ce37", "b03c4c3a-c305-469d-b285-e90f3cfdc9c7", "7b026a08-23ef-4c5a-b80e-d49b6052ae91", "09cc708e-d13a-4de8-bd10-96c99e6c8108", "ce7b62b2-cb0c-4d7c-8648-3964b20f3b5e", "540d116c-9002-4f50-a8f3-b1e7215c18bd", "f432debc-bb6c-42c7-bcef-61ec1dc82a57", "4a02e310-14cc-4f49-bbf7-8642082b9cd4", "9a3a3fd8-3062-4ea1-af3f-30ba2766bf53", "c788372c-36a7-41d8-b831-ce95355cbdf6", "5f617382-29a9-4b9e-94fc-0aacdb11b9a3", "c0d18af2-1d3b-4aad-8506-16a4c1fa0011", "fdbc3545-6f63-4a65-8344-289f47dbe258", "7eb0c9d3-129a-48f2-ac23-af546a9f7262", "cf1a0140-3885-451d-b242-438a8a09342e", "25fa851c-5ec9-42b5-b3dc-ec119d4f3d4b", "6f45261b-47d8-4e28-a337-814f48f8c627", "242da652-62b2-4400-92de-126d0250dba1", "7984f3f0-af84-49e7-8070-f4341885acd2", "14372b84-8d5f-48ac-bf61-429c93925862", "e03289af-e433-4d24-8a18-247c4e819448", "a5d9a8bb-faec-45ef-b2b3-2696fc41d0ad", "93b5a1a2-c705-4553-a85b-59612dcbe693", "d41eac65-9e1e-4da6-8d93-97039f0c0847"], "metadata": {"window": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.   Generally biosimilar margins are similar to branded margins.  \n It depends on the individual supplier and the product.  \n \n  There are some opportunities when you are able to move share through your GPOs and stuff \nto make some potential extra margins on that.  ", "original_text": " \nPage 12 of 16 \n \n We think we're really well positioned to distribute and provide services, both upstream and \ndownstream, to the biosimilar players.  ", "page_label": "12", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2971b259-64b9-4cb3-a289-ac9f4c7e3ed0": {"node_ids": ["dc53abef-a3bc-4379-8dd1-b0e7625931d1", "bc74bd7a-4e9f-4ec2-8ba2-22fb337f9b17", "fb3b6212-de9e-4b65-afcc-bb9788f8a451", "8cbd1d7b-4570-4f80-a4e4-926f42d0d9c4", "bbe5ad37-a5cb-4788-940e-ca985e9f0b9d", "12e26e5b-c053-4ba5-b502-b2a808524502", "d970352b-ccf0-464e-85e0-08bf99c5025f", "a2e1ec62-cf91-47e4-b82b-7d78ccf75ba4", "f2624fe0-c463-4dc3-a606-c4c4f7ec96de", "80f22916-2dca-40ce-92bd-6d1a17dd0b10", "98938a9c-f69f-4cdd-903f-71983353c915", "115e4179-db99-48b1-ba27-b04a6d612c0c", "18de233e-14c1-4cbd-ad8f-744beb1ebe04", "1149bad5-2953-42e2-a5d2-09a40ac2c984", "29904156-561d-48b8-9c7d-14e7504edb68", "ebec3a23-144c-4acb-98f8-1fc11c4a4d52", "8b050892-1e27-4c26-8861-e3777de8cfb5", "314ff37f-7ddf-4457-8937-4cc7d653527b", "7d8311d5-a03d-40e2-8f19-18247d794a5b", "63621525-573d-4bea-a05c-916450909efd", "cdc5a6fe-9499-47fe-8886-47f2aa41e0d6", "1b6d8d9f-4c6c-498f-9f85-70b4f61d977c", "95433123-6936-498f-aa23-a05612bf5201", "8f3b0fbc-c0b5-45e9-9dbd-fc9bfc66a179", "651a79aa-2cef-42c9-9b33-fa963e44c334", "91ced30c-7e09-4605-a889-7b04923895be", "6e6a7616-1852-4887-8062-7379ded08ed5"], "metadata": {"window": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.   And we'll hear from Eric Percher with Nephron \nResearch.  \n \n Eric Percher:  Thank you.   I wanted to ask fo r a little bit more detail on the nuclear business.  ", "original_text": " \nPage 13 of 16 \n \n \nOperator:  We will now move to our next question.  ", "page_label": "13", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e5d7d494-e527-4934-afb4-d787af208173": {"node_ids": ["60fc38f5-5a2f-45d3-994b-a1aa8a049333", "1f97dd12-6204-4427-a1dd-745ed9bfb51a", "7417b4fd-2cdf-46e5-afb5-dfce19501216", "a2687cd5-ed96-4490-b7d5-e1538c79f191", "9c8e036d-6e84-4b0f-8f9d-c04af802b870", "7ffe1cad-101e-4862-a245-278db58af059", "4aa8a53f-814d-4298-ac6e-f4c02776d0b3", "55e7830e-5902-4dd5-88d0-ca0e325e43b6", "b9e63d24-244a-4836-a2fa-e01cc2f54c2f", "5afa2743-a110-45f4-b65b-33f3a7ae48f4", "c8631960-1ab0-463a-9142-3f38c23f8243", "f3e7894e-c5bb-4618-983e-62300724676c", "7af4239e-9256-4a7d-bbb6-956e529b5361", "8afc9909-5c74-45ec-8f38-aa4c27b715bb", "e7fc55fe-912e-47ae-b2b2-05ccfd456e01", "a2c83701-b19d-4b12-8c10-5aed890b9c97", "260a3118-dc2c-455a-a5f2-210a33b4d8d7", "6b9adfc2-b39d-4c39-b4b5-7c62b6d6bdde", "7b74a88a-cca3-4cbb-85eb-06f6c4316cbf", "cc16f267-bf77-44ba-9e59-52f8b0928acc", "0ee013b2-7c03-4616-badc-ff1cb982eddb", "3d820e2a-b586-4d27-a57f-16a4ed67b4f1", "6edf15ac-bdd7-4131-914a-77c6a9d9c2a3", "7382c5d5-17de-42e3-88ab-b3719eba1438", "4c9b445c-1b4c-4ff2-a1c1-6b0f53dcd228"], "metadata": {"window": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n Mike Kaufmann:  Yes.   As far as the specialty products , I would say is this.   What I really like about \nour position is we can manage both.  \n \n ", "original_text": " \nPage 14 of 16 \n \n And then also any thoughts about a potential role for Cardinal in distribution of COVID vaccine \nonce it's available for the general population?  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "48da569c-0288-4ee9-9e1c-c413a5facf60": {"node_ids": ["46c1e1fd-836c-4441-a991-25777f6a5147", "441b655d-de18-4cd5-8c8e-a5ab1ed9394c", "948d3f28-1168-4b69-9576-91be5603d3e6", "1caf2ea7-a042-4f4a-95f7-a64efd44b451", "2de3c250-0902-4016-a502-55df04f9a4d7", "fe8d1e64-5e02-4334-b873-ffc1168334c1", "8e669c7e-689e-4161-a566-b58a1fbbef7d", "7cf68cad-2b10-4e71-8c41-e46c52b7b78a", "23cedf18-59ad-47a2-ab40-cadddd6b6f69", "46ee6961-c57f-483b-958e-7506b0c43ac7", "d43823e6-b0cc-475c-bfad-1b0a1b32003b", "f9a1bd12-0adc-4fa1-8a83-271f79b51b00", "91766bf2-4259-4daf-ad53-5819439c1fda", "8a4c68d3-30b1-4090-9c4c-702cf9de646e", "fd45d807-0fca-41dd-bad3-f39c2559808d", "9fe4bba2-560b-4661-acb0-e4c9d8bedaa0", "de3a6515-c093-48f1-9814-1d4e353c7eb9", "30f5ed19-d44f-4d13-8ef2-664a0b82baaa", "7deda3b4-a76d-4165-aba9-286567c99ab5", "e1523910-8893-4a92-99d9-a5a54afe7af0", "e096a3f7-27a8-443f-947e-73bce4e0b0d7", "9f6a0483-cc54-49f8-9e9f-11b697bffc08", "ae854fa6-104f-45e0-98cb-4ae85c037624", "f09a94bc-95c3-4a68-a90a-11c1d4f70fc1", "4deba78c-210e-4b97-9ff6-a12eac4cd50f", "6b801413-9682-4ac4-8c50-7cc4b2ba89cf", "7df36e58-fc22-4a46-a005-51e33aeaf01d", "285033ad-ae6d-44dd-8e13-9d5b23750b89", "b37932f1-29b1-4ddc-aabd-c3ebee267372", "513c3172-109f-47d6-8c24-c6f674c746e6"], "metadata": {"window": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n Operator:  And our last question today will come from George Hill with Deutsche Bank.  \n \n George Hill:  Hey, good morning guys.   Thanks for sneaking me in.  ", "original_text": " \nPage 15 of 16 \n \nMike Kaufmann:  Next question.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "07d3e18a-9dcf-4042-9746-9cda9da75453": {"node_ids": ["1a708b81-a11b-499b-a286-74fd9b8df405", "e8271a98-7f07-4f43-be31-88734dfa1adb", "fdec10bd-72fa-4b1b-ae48-cbb4f24ac20e", "c8b46b99-bcf0-45f3-ad2d-47f3fe50e825", "52c5e7cf-498d-4370-ba86-41cde14a20ed", "4c40949d-f235-4954-bc79-4cd82a4c7375"], "metadata": {"window": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.   And we look forward to speaking to \nall of you sometime soon.   Take care.  \n \n Operator:  Ladies and gentlemen, this will conclude your conference today.  ", "original_text": " \nPage 16 of 16 \n \nMike Kaufmann:  Yes, I want to thank all of you for joining us this morning and on behalf of all of us at \nCardinal Health, I hope you and your families stay safe and well.  ", "page_label": "16", "file_name": "CAH-Q1-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 180802, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}